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 This report describes the synthesis, chemical derivation, and pharmacological and 
behavioral characterization of several unique classes of opioid receptor modulators. In chapter 
one, a general overview of opioid receptor history, signaling biology, and therapeutic 
applications is provided. Also reviewed are several topics of high current interest, including, 
biased signaling, opioid receptor splice variants/heteromers, and applications of opioid 
modulators in the treatment of mood disorders. This introduction aims to frame the work that 
follows, and emphasize to the reader the untapped potential of the opioid receptor system, 
particularly in the realm of therapeutics development. 
 Chapter two discusses the development of several new C-H activation reactions to 
provide rapid access to the core molecular scaffold of alkaloids from Tabernanthe iboga. The 
methods described permit the expedient construction of structurally diverse ibogamine analogs 
via a modular approach. In chapter three, this work is extended by applying the new reaction 
methodologies to explore a novel class of oxaibogamine analogs, which act as opioid receptor 
agonists and antagonists. The thorough exploration of structure-activity relationships within this 
skeleton is described, along with the pharmacological characterization of several select analogs 
as biased agonists at both the kappa- and mu-opioid receptors. This section concludes with a 
discussion of potential therapeutic applications for the synthesized compounds as new analgesics 
and antidepressants, and future goals and plans for this structural class. 
 
 In chapter four, the isolation and pharmacological study of several alkaloids of Mitragyna 
speciosa is presented. Mitragynine, the primary natural alkaloid in this plant, is isolated, along 
with several naturally occurring analogs, and the modulatory activity of these compounds at the 
opioid receptors is fully characterized. Further, preliminary results are presented suggesting 
activity of these alkaloids at several other classes of central nervous system targets, including 
serotonin and adrenergic receptors. Also discussed are the preparations of semi-synthetic and 
fully synthetic mitragynine derivatives, including a total synthesis of mitragynine itself. These 
novel analogs are applied to explore key structure-activity relationships in this unusual opioid-
active scaffold. Again, potential applications of Mitragyna alkaloid analogs in the treatment of 
pain and depression are discussed. 
 In the final chapter, I describe our discovery that tianeptine, a clinically used atypical 
antidepressant of previously unknown mechanism of action, acts as an agonist of both the mu- 
and delta-opioid receptors. Activation of the mu-opioid receptor is thus proposed as the initial 
molecular-level event responsible for eliciting the beneficial therapeutic effects of this agent. 
This hypothesis is integrated with the large body of literature describing this compound, and 
mechanistic theories connecting the opioid activity of tianeptine to previous observations are 
described, with a particular emphasis on indirect modulation of glutamate signaling. Behavioral 
studies in mice employing both genetic knockout and pharmacological inhibition are then used to 
confirm the involvement of the opioid receptors in tianeptine's mechanism of action. Also 
described are thorough explorations of opioid structure-activity relationships within the 
tianeptine scaffold, and the design and synthesis of novel analogs having improved 
pharmacokinetic properties. It is hoped that these derivatives may one day serve as new 
therapeutic options for patients suffering from treatment-resistant depression. 
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An Introduction to the Opioid Receptor System 
















 The psychoactive and medicinal properties of the opium poppy, Papaver somniferum 
(Figure 1A), have been known for thousands of years. Written descriptions of the opium poppy 
and its use are known from many ancient cultures, including those of Egypt, Greece, and 
Mesopotamia. In fact, the plant is believed to have been actively cultivated in these areas, first by 
the Sumerians, who referred to it as the "plant of joy".
1,2
 Raw opium is obtained by lancing of the 
poppy seed pod to produce a white exudate, which soon hardens to a brown solid. Consumption 
of opium by smoking or orally produces potent analgesic effects, along with pronounced 
euphoria and sedation at high doses. Accordingly, opium has a high abuse potential, and 
addiction to the substance has also been known and described since at least the middle ages.
1
  
 The primary active constituent of 
opium was first isolated by Friedrich Sertürner 
in 1806, who named the compound morphine, 
after the Greek god of dreams, Morpheus 
(Figure 1B).
3
 This was also the first pure 
alkaloid to be isolated from a plant and the 
first time that the pure substance responsible 
for the effects of a medicinal plant had been 
identified. Subsequently, the medicinal use of 
opiates expanded dramatically, but continued 
to be plagued by issues of addiction and 
dependence. The introduction of the semi-
synthetic opioid analog diacetylmorphine 
Figure 1. (A) The opium poppy, (B) Structures of 
principle natural opiates, (C) Structures of several 
early synthetic and semi-synthetic opioids. 
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(Figure 1C), or heroin, at the turn of the 20th century, promised to alleviate these shortcomings, 
a claim that in hindsight, was clearly misguided.
4
 The development of synthetic opioids 
continued in the following decades. Pethidine (Figure 1C), the first fully synthetic opiate, was 
discovered in 1939 and soon introduced to the medical practice, again amidst unfounded claims 
of improved safety and addiction liability.
1,5
 Many other synthetic opioids soon followed, 
including methadone in 1946.
1,6
 Around this time, the first opioid antagonist, nalorphine, was 
also discovered, and showed the ability to reverse morphine induced respiratory depression and 
to precipitate withdrawal symptoms in addicts.
1,7
 
 By mid-century, there was a growing consensus that the actions of opioids were likely 
mediated by specific, chemically defined, and stereoselective receptors in the body.
1,8
 However, 
clear biochemical demonstration of these suspicions, namely, the development of assays to probe 
the molecular level interactions of opioid drugs with their receptors, did not occur until the 1970s 
and later. The opioid receptors were a promising target for such efforts, as the physiological 
effects of their activation and inhibition were well characterized and a large number of small 
molecule agonists and antagonists were available. In a seminal study, Goldstein suggested that 
radiolabeled (typically with tritium) drugs might be used to label receptor binding sites in a 
specific manner.
9
 However, key to the success of such a strategy is the use of high potency 
compounds with high specific radioactivity, thereby allowing binding and detection at the low 
concentrations required to reduce off-target and non-specific binding. Unfortunately, the specific 
activity of the [
3
H]levorphanol used by Goldstein was too low to provide decent signal-to-noise, 
and these first results were not entirely convincing. However, this strategy was soon improved by 
Snyder and Pert using [
3
H]naloxone having high specific activity.
10
 This work demonstrated 
strong, stereoselective binding to opioid receptors in both rat brain homogenates and guinea pig 
 4 
intestinal ileum. Further, this radioligand binding could be competed by other non-labeled opioid 
agonists and antagonists, in a manner paralleling their in vivo potency. Following this convincing 
demonstration of a specific opioid binding site, similar studies rapidly followed with 
radiolabeled drugs targeting other receptor binding sites in the brain, including those specific for 
dopamine, serotonin, acetylcholine, and epinephrine.
8
 
 Additional studies of opioid receptor character, function, and structure continued to build 
upon this initial work. It was soon realized that the introduction of sodium cations (Na
+
) in 
binding assays could be used to differentiate agonists and antagonists, with the binding affinity 
of agonists being decreased in the presence of Na
+
, while that of antagonists was unaffected.
11
  
Thus, a simple ex vivo functional assay became available for the initial assessment of novel 
opioid ligands without the need to resort to in vivo studies. However, it would be many years 
before the actual downstream signal transduction pathways mediated by opioid and other protein 
receptors were understood (see below, Molecular Signaling of Opioid Receptors). Around the 
same time, the localization of opioid receptors to various brain regions was also demonstrated, 
suggesting neurostructural factors were involved in the behavioral effects of opioids.
12
  
 Due to the demonstrated existence of specific opioid receptors, it became evident that 
there were likely to be endogenous ligands for these receptors. This was first suggested 
experimentally by the ability of protein-free brain extracts to displace opioid radioligands from 
their receptors.
13
 Two of the specific molecules responsible for this activity were soon identified 
as pentapeptides, and named met- and leu-enkephalin.
14
 The identification of many other 





 The existence of a large variety of endogenous ligands suggested that there might be 
more than one type of opioid receptor. Based on the differing behavioral and physiological 
responses in dogs observed after administration of morphine and ketocyclazocine, Martin 
suggested the existence of distinct kappa- (KOR) and mu-opioid (MOR) receptors.
15
 A third 
class of receptor, the delta-opioid receptor (DOR), was also soon identified by tissue functional 
assays. Specifically, the endogenous leu-enkephalin was shown to be relatively more potent at 
inhibiting the electrically stimulated contractions of mouse vas deferens than morphine and 
conversely, less potent in the guinea pig ileum contraction assay as compared to morphine.
16
 
Similarly, the potencies of various drugs in the vas deferens assay correlated to their ability to 
displace radiolabeled enkephalin. The existence of opioid receptor subtypes was further 
demonstrated by the ability of different opioid ligands to protect distinct receptor populations 
from degradation by the alkylating agent phenoxybenzamine.
17
 The existence of the MOR, KOR, 
and DOR has since been confirmed by the cloning of each receptor in the early 1990s.
8
 Around 
this time, a fourth opioid related receptor, the nociceptin receptor (NOP) was discovered by 
cloning techniques.
18
 NOP shares high sequence homology with the other opioid receptors, but 
displays a distinct pharmacological and physiological profile, and will not be discussed in detail 
here. More recently, x-ray crystal structures of the three primary opioid receptors, and also NOP, 
have been obtained, opening new avenues of exploration in our efforts to understand the 
structure and function of these receptors at the molecular level.
19-22
 
 Despite decades of careful and dedicated research on the opioid receptor system, major 
challenges remain, and a complete understanding of the molecular-, cellular-, and systems-level 
actions of opioid receptors is far from being achieved. What follows here is an overview of our 
current understanding of the opioid receptor system, as well as discussion regarding topics of 
 6 
particularly high interest in the recent literature and areas where research is only in the nascent 
stages. In this context, the renewed interest in novel opioid-modulating therapeutics is also 
discussed, with a particular emphasis on both the development of analgesics with reduced 
addiction liability and on treatment of depression, anxiety, and other mood disorders. The topics 
briefly surveyed here have been extensively reviewed elsewhere, and the reader is referred to 
these works as appropriate, for more detailed description of the current state of the art. 
 
Current Understanding 
 The opioid receptors are all members of the inhibitory G protein-coupled receptor 
(GPCR) family and share approximately 60% sequence identity.
23
 Agonist binding to opioid 
receptors causes a conformational change that elicits myriad downstream effects, both direct and 
indirect. Although there are subtle differences in the molecular signaling pathways activated by 
the different opioid receptor subtypes, the general trends and coupling partners involved are 
largely similar. 
 Endogenous Ligands. The three classical opioid receptor subtypes as well as NOP are 
known to be activated by endogenous peptide ligands with varying selectivity for each subtype. 
In mammals, the primary endogenous DOR ligands are the pentapeptides met- and leu-
enkephalin (Tyr-Gly-Gly-Phe-Met and Tyr-Gly-Gly-Phe-Leu, respectively), which display 
agonist activity at both DOR and MOR, with some selectivity for the former. Similarly, peptide 
ligands selective for MOR and KOR are also known, with the 31 amino acid peptide β-endorphin 
being a major MOR ligand, and the 13 amino acid peptides dynorphin A and B primarily 
activating KOR. It should be noted however, that the endogenous peptide ligands are not highly 
selective amongst the subtypes, with selectivity typically less than 1 order of magnitude. Each of 
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these opioid peptides is derived from the longer, precursor peptides proenkephalin, 
proopioimelanocortin, and prodynorphin via proteolytic cleavage. This post-translational 
processing also gives rise to additional opioid-active peptides (at least 20), the significance of 
which are not known.
1
 Furthermore, many details of the localization, connectivity, and control 
mechanisms of opioid releasing neurons remain unknown. 
 Molecular Signaling of Opioid Receptors: G Protein-Mediated. As inhibitory GPCRs, 
opioid receptors couple to the Gαi, Gαo, and Gαz G protein subtypes. Receptor activation results in 
exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the alpha 
subunit of the receptor-bound heterotrimeric G protein complex. Subsequently, this exchange 
causes dissociation of the Gαi (or Gαo, Gαz) and Gβγ subunits, each of which in turn modulate 
additional downstream effector proteins and second messengers. Specifically, Gαi inhibits the 
activity of adenylate cyclases (AC), the enzymes responsible for the production of cyclic 
adenosine monophosphate (cAMP). Reduction of this second messenger can in turn modulate the 
activity of other effector proteins, for example, by depressing activity of protein kinase A (PKA), 
an important cAMP-dependent serine/threonine kinase. Likewise, the dissociated, dimeric Gβγ 
subunit interacts with its own downstream effectors. These effects include, most notably, 
activation of G protein-coupled inwardly-rectifying potassium channels (GIRKs) and inhibition 
of voltage gated calcium channels (Cav). Collectively, these effects generally result in decreased 
neuronal excitability in cells expressing opioid receptors through decreased Ca
2+
-dependent 
neurotransmitter release, and pre- and post-synaptic hyperpolarization, which resists depolarizing 
action potentials. Lastly, opioid receptors have been shown to activate protein kinase C (PKC), 
an effect which is purported to also be dependent directly on G protein signaling, likely via 
activation of phospholipase C isoforms by the Gβγ subunits.
24-26
 (Figure 2) 
 8 
 Molecular Signaling of Opioid Receptors: G Protein-Independent. Opioid receptors 
are also capable of activating several intracellular effectors independent of G protein activation. 
The most important among these alternative signaling pathways is receptor phosphorylation and 
the subsequent recruitment of β-arrestins, a process which is closely linked to receptor 
internalization and recycling.  In this process, agonist activated receptors are phosphorylated at 
one or more serine and threonine residues near the c-terminus. This phosphorylation of opioid 
receptors is primarily mediated by G protein-coupled receptor kinases (GRKs), most 
importantly, the GRK2 and GRK3 subtypes. However, other kinases, including both PKA and 
Figure 2. When activated by an agonist, opioid receptors activate a variety of signaling pathways. Some of these 
are dependent on G proteins and others are not (e.g. β-arrestin signaling). Abbreviations are described in the text 
except for CREB = cAMP response element-binding protein.  
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PKC, are also known to be capable of phosphorylating opioid receptors. Phosphorylation 
increases the affinity of the receptor for the scaffolding proteins β-arrestin-1 and β-arrestin-2 
(also known as arrestin-2 and arrestin-3 respectively). Binding of β-arrestin blocks further G 
protein signaling by preventing re-association of the G protein complex with the receptor. 
Further, it targets the receptor for internalization into endosomes via association with additional 
adapter proteins (the adaptin complex AP2) and clathrin. Following internalization, opioid 
receptors may be re-sensitized by dephosphorylation and returned to the cell surface, or degraded 
entirely (Figure 2). Hence, β-arrestin recruitment and receptor internalization are thought to play 
important roles in the development of opioid analgesic tolerance, physical dependence, and other 
adaptive changes resulting from prolonged opioid receptor activation.
24,25
 For example, β-
arrestin-2 knockout mice have been shown to resist the development of morphine tolerance, 
implying that receptor desensitization plays a key role in this process.
27 
 Although association with β-arrestin terminates G protein-dependent signaling, it also 
activates alternative signaling pathways of the mitogen-activated protein kinase (MAPK) family. 
This activation may in turn activate a wide variety of downstream targets, including transcription 
factors, over longer time scales (minutes to hours). β-arrestin is known to act as a scaffold for 
extracellular signal-regulated kinases 1 and 2 (ERK 1/2) and the stress related kinases c-Jun N-
terminal kinase (JNK) and p38 mitogen-activated protein kinases (p38 MAPK) (Figure 2).  
However, the activation of these kinase pathways is not always β-arrestin dependent and in fact, 
in some cases has been shown to be mediated through G proteins. Interestingly, MAPK pathways 
have also been shown to be activated by opioid receptor antagonists. For example, the KOR 
antagonists norbinaltorphimine (nor-BNI) and JDTic effectively antagonize KOR mediated 
analgesia for several weeks following a single administration, despite being non-covalent 
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binders. This long-lasting effect has been shown to depend on activation of JNK.
28
 The 
downstream targets of these signaling pathways are diverse and complex and accordingly, are 
not well understood in the context of opioid receptor activation. However, given the ability of 
MAPKs to modulate gene expression and the resulting long-term cellular adaptations, it is likely 
that MAPK signaling is involved in the development of opioid analgesic tolerance and physical 
dependence.
24,25 
 Distribution and Circuit-Level Effects. Opioid receptors are widely distributed in the 
central nervous system and peripheral tissues. In fact, most brain regions contain all three types 
of opioid receptor expressed to varying degrees, and areas expressing only a single subtype are 
uncommon.
29
 Accordingly, the circuit-level and physiological effects mediated by their 
molecular signaling pathways are diverse and variable in different brain regions and tissues. The 
circuit-level effects of opioid receptor activation can best be understood in terms of both direct 
inhibitory effects (through hyperpolarization), and indirect disinhibitory effects (mediated by 
depression of activity in inhibitory GABAergic interneurons). The interplay of these competing 
influences hence governs the specific activity in different populations of neurons dependent upon 
relative expression levels and the interconnectivity between different cell types. Further, given 
their similar molecular- and cellular-level signaling effects, the varying neuroanatomical 
distribution of the different opioid receptor subtypes and their circuit-level effects must play key 
roles in mediating the distinct physiological and behavioral effects of each subtype. 
 Perhaps the best understood circuit-level effects of opioid receptors are those mediating 
their analgesic properties in the spinal cord and brainstem. Activation of both MOR and KOR 
has been shown to elicit analgesia in vivo. Similarly, DOR activation produces analgesic effects, 
but only in certain types of pain (e.g. inflammatory and neuropathic pain). In simple animal pain 
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models like the hot-plate assay and 
writhing test, DOR agonists are 
ineffective, but in hyperalgesic 
inflammatory pain models, show high 
efficacy. This phenomenon is believed to 
be due to sequestration of DORs in 
intracellular vesicles in resting state 
neurons, where they are inaccessible to 
agonists. Only after inflammation 
mediated signaling are significant 
quantities of DOR trafficked to the 
surface. Interestingly, there is also 
evidence that this translocation of DOR 
requires MOR.
30 
 At the molecular level, the 
antinociceptive effects of opioids are 
primarily due to G protein-dependent 
modulation of Cav and GIRK channels, which produces pre- and post-synaptic hyperpolarization 
in cells expressing opioid receptors, and hence, a reduction of neurotransmitter release and 
excitability in these cells (as discussed above). This inhibitory effect on ascending first-order A 
delta and C fibers in the dorsal horn of the spinal cord reduces release of glutamate and 
substance P respectively, thereby reducing the signal passed to the brain via the spinothalamic 



















Figure 3. Pain signals carried by ascending glutamatergic 
fibers are inhibited in the dorsal horn of the spinal cord by 
opioid receptor activation. Opioids also inhibit the activity of 
GABAergic interneurons in the periaqueductal grey (PAG), 
resulting in disinhibition of descending modulatory neurons, 
which in turn activate endogenous opioid releasing 
interneurons at the spinal level. 
 12 
descending pathways from the periaqueductal grey (PAG). Activation of opioid receptors on 
inhibitory GABAergic interneurons reduces GABA release, thus disinhibiting descending 
monoaminergic fibers from the PAG which ultimately results (via the nucleus raphe magnus) in 
release of enkephalins and dynorphins from interneurons in the spinal cord, further inhibiting 
ascending pain signals in A delta and C fibers. This descending feedback pathway is also the 
primary route by which the endogenous opioids exert their analgesic effects in response to 
noxious stimuli (Figure 3).
31-33 
 The modulation of dopaminergic reward pathways by MOR in the mesolimbic system, 
specifically the ventral tegmental area (VTA) and nucleus accumbens (NAc), is also well 
Figure 4. Mesolimbic circuits involved in reward response. Activation of MOR on GABAergic VTA 
interneurons results in their inhibition, thus disinhibiting dopamine (DA) release in the NAc. Elevated DA in the 
NAc can activate inhibitory D2 receptors, decreasing the activity of D2 MSNs and producing a reward response. 
MOR or DOR expressed on MSNs may also inhibit their activity directly, or may modulate the excitatory 
influence of afferent glutamatergic terminals from the PFC, hippocampus, or amygdala. Activation of D1 MSNs 
via stimulatory D1 receptors may promote dynorphin release at feedback terminals on VTA DA neurons, thus 









































understood in a general sense. In the classical model, activation of MOR on GABAergic VTA  
interneurons inhibits GABA release at synapses with dopaminergic VTA cell bodies. This in turn  
disinhibits dopamine release from VTA neurons projecting into the NAc. The resulting increase 
in NAc dopamine is associated with a reward response (Figure 4). The existence and 
functionality of this dopamine-dependent reward pathway is supported by a variety of 
experimental findings: 1) rodents self-administer MOR agonists directly into the VTA, 2) MOR 
in the VTA is primarily expressed on inhibitory interneuron axonal terminals, but not on 
dopaminergic cell bodies, 3) MOR agonists hyperpolarize these GABAergic interneurons but do 
not directly influence the dopaminergic neurons, 4) MOR agonists in the VTA increase the firing 
rate of dopamine neurons and increase release of dopamine in the NAc, 5) dopamine release in 




 Although this mesolimbic dopamine pathway represents a simple and elegant explanation 
for MOR agonist induced reward, it has become clear that it is overly simplistic and that other 
factors contribute to the rewarding properties of opioid agonists. For example, rodents also learn 
to self-administer MOR agonists directly into the NAc, but this effect is not dependent on 
dopamine increases in the NAc and is only partially blocked by dopamine receptor antagonists or 
lesion of dopamine neurons in the NAc.
29, 34-36
 Instead, the rewarding effects of intra-NAc MOR 
agonists may be mediated by inactivation of dopamine receptor D2 (an inhibitory GPCR) 
expressing GABAergic medium spiny neurons (MSNs) in the NAc. Such an effect might be 
produced either directly via the activation of MORs expressed on these neurons, or indirectly, by 
opioid inhibition of afferent glutamatergic synapses projecting from other brain regions, 
including the prefrontal cortex (PFC), hippocampus, and amygdala.
36
 However, the details of 
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these more complex reward mechanisms remain unclear. The same mesolimbic circuits are also 
involved in mediating the aversive and dysphoric effects of KOR agonists. For example, direct 
injection of KOR agonists into the NAc produces a conditioned place aversion in rodents.
29
 It is 
believed that opposing MOR and KOR systems are present in the mesolimbic system that 
account for the opposing behavioral effects of agonist activity at these receptors (for a more 
detailed discussion see below, Antidepressant Mechanisms: The Mesolimbic System and 
Endogenous Opioids). Further, other brain regions are known to contribute to the rewarding 
effects of exogenous opioids. In the ventral pallidum, microinjection of morphine produces 
conditioned place preference (CPP). In contrast, rodents will self-administer morphine to the 
amygdala, but such injections do not produce CPP. Rodents can also be trained to self-administer 
morphine to other brain regions including the hippocampus, hypothalamus, and PAG.
29
 Clearly, 
the cell types and signaling circuits involved in the rewarding actions of opiates are more 
complex than once realized, and further study is necessary before full understanding of opioid 
reward pathways is obtained at the cellular and neuroanatomical level. 
 Gross Physiological Effects and Clinical Properties. The systemic physiological and 
behavioral effects produced by activation of opioid receptors have been thoroughly described in 
a variety of animals and humans. The effects of MOR activation have the longest history of 
study in humans and are the most well precedented. Most notably, their activation produces 
strong analgesic effects and hence, MOR agonists like morphine remain the gold standard of 
pain therapy. Unfortunately, acute MOR activation is also associated with serious side effects, 
including respiratory depression, constipation, sedation, nausea, and itching. At sufficiently high 
doses, the evoked respiratory depression can be severe enough to cause death. Further, the 
pronounced euphoria produced by MOR agonists makes them major recreational drugs of abuse. 
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These properties have made overdose from prescription opioid analgesics a leading cause of 
accidental death in the United States, killing more than 15,000 people in 2013.
37
 Another severe 
shortcoming of MOR agonists is the rapid development of tolerance to their analgesic effects. 
Thus, continuing escalation of dose is required to maintain an equivalent level of pain 
management. Similarly, in recreational users, tolerance is also rapidly developed, so doses must 
be increased to obtain the same level of perceived euphoria. Thus in either case, chronic use can 
result in severe physical dependence on MOR agonists due to cellular- and circuit-level 
adaptations to continuous receptor stimulation. Tolerance to the sedative and respiratory 
depressant effects of MOR agonists also develops rapidly, but in contrast, can be considered 
beneficial in most therapeutic settings. Curiously, tolerance to the side effect of constipation 
develops only very slowly by comparison to analgesic tolerance, and the molecular- and tissue-
level mechanisms responsible for this distinction are not known.  
 Withdrawal of MOR agonists in a dependent individual rapidly induces physical 
symptoms of withdrawal that progress as the last dose of the drug is eliminated. In the early 
stages, symptoms typically include anxiety, restlessness, temperature sensitivity, sweating, 
salivation, lacrimation, and rhinorrhea. As withdrawal progresses, prominent nausea, vomiting, 
abdominal cramps, and insomnia are also common. Such symptoms typically peak in intensity 
after 1-3 days, depending on the elimination half-life of the drug which has been withdrawn. 
Similarly, withdrawal can be precipitated immediately by administration of an MOR antagonist. 
It is important to distinguish physical dependence and the associated withdrawal symptoms, from 
psychological dependence (addiction). A psychological addiction is characterized by strong 
cravings and compulsive drug-seeking behavior, and typically results in a concomitant physical 
dependence. However, an individual may be physically dependent to opioids without being 
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considered psychologically addicted. In fact, development of psychological dependence is 
uncommon when MOR agonists are used in the medical setting.
38
 
 In contrast to MOR agonists, the physiological and behavioral effects produced by KOR 
agonists are quite different. Like MOR agonists, KOR agonists produce notable analgesic 
effects, but their effects on other behaviors, notably the reward pathways, have been shown to be 
largely opposite to those induced by MOR agonists. Early enthusiasm for a non-addictive opioid 
analgesic acting through KOR was soon tempered by the observation that, although they produce 
strong analgesic effects, KOR agonists are characterized by concomitant and dose-limiting 
dissociative, hallucinogenic, and dysphoric effects. In animal models these effects are clearly 
apparent in a variety of conditioned aversion models and have also been documented in human 
clinical trials.
30,39
 The potent, naturally occurring hallucinogen salvinorin A is also known to 
elicit its effects through activation of the KOR.
40
 Such aversive effects of KOR agonists are 
likely related to their ability to inhibit dopamine release in the mesolimbic circuits (see above).
41
 
Accordingly, no pure KOR agonists have reached the market as analgesics agents, despite their 
early promise.  
 In contrast, several mixed MOR/KOR agonists have been approved for pain, for example 
pentazocine and nalbuphine, both of which act as partial agonists at both the MOR and KOR. 
However, clinical use of these agents is also characterized by dose-dependent incidence of 
psychotomimetic side effects. Notably however, such side effects are much less severe with 
nalbuphine as compared to pentazocine, the reasons for which are not clear.
42
 Positively, mixed 
MOR/KOR agonists show a ceiling level for respiratory depression and have lower abuse 
potential (presumably due to their aversive KOR component).
38
 Thus, there may still be potential 
in a polyopioid approach to safer, less addictive opioid analgesics. Another curious property of 
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mixed MOR/KOR agents is an apparent gender-dependent variability in their effects. 
Pentazocine has been shown to be a more effective analgesic in women than in men, suggesting 
a gender-dependent distribution of KOR in the CNS.
43
 
 As a result of their distinct effects, modulators of KOR have also been pursued as 
potential treatments for other conditions, notably depression and addiction.
39,44
 As can be 
expected from the aversive and dysphoric effects of KOR agonists, antagonists of this receptor 
are antidepressant in animal models.
45
 Further, KOR antagonists oppose a variety of stress-
related responses that are believed to be mediated through the endogenous KOR agonists, 
dynorphins.
46,47
 For example, KOR antagonists prevent stress-induced potentiation of cocaine 
CPP.
48
 Beneficial effects of KOR antagonists have also been found in drug-seeking behaviors 
mediated by other drugs of abuse, including ethanol and nicotine.
49,50
 Such results have 
generated considerable interest in KOR antagonists for the treatment of depression and drug 
abuse, and various agents have entered clinical trials for both conditions.
51
 
 KOR agonists have also been pursued for the treatment of pruritus (itch) and the KOR 
agonist nalfurafine (TRK-820) is approved in Japan for this condition.
52
 This application is 
notable, as it represents another incidence of the opposing effects of the KOR and MOR systems. 
A well known side effect of MOR agonists is pruritus
53
, and KOR agonists have been shown to 
inhibit this effect induced by morphine.
54
 Further, nalfurafine is the only clinically approved 
selective KOR agonist to date, and is especially notable for its lack of psychotomimetic and 
aversive effects at therapeutic doses.
55
 Excitingly, this suggests that the beneficial effects of 
KOR agonists may not be inherently associated with negative side effects. The molecular 
mechanisms responsible for this improved therapeutic profile have not been explored, but could 
potentially derive from biased agonism of the KOR (see below, Functional Bias at KOR). 
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 The behavioral and physiological effects of DOR agonists are the least studied and 
understood, especially in humans, as no selective DOR agonists have yet been approved for any 
condition. Activation of DOR has been most thoroughly explored for the treatment of pain.
56,57
 
In contrast to MOR and KOR agonists, DOR agonists show only weak analgesic effects in 
animal models of acute pain. However, they are much more effective in models of chronic pain 
and allodynia, for example those related to inflammation or neuropathy. As discussed briefly 
above, this distinction is believed to be related to the intracellular sequestration of DORs in the 
quiescent state, requiring prolonged stimulation or other signaling pathways to bring the 
receptors to the cell surface, where they may mediate an analgesic response. The 
neuroanatomical expression of DOR is also distinct from MOR, and mid-brain and brainstem 
areas important in mediating the analgesic properties of MOR agonists (e.g. the PAG and raphe 
magnus) show very low expression of DOR. In sum, the available data indicates that the DOR 
system may represent the primary endogenous mechanism for the control of chronic pain. 
Considering the often poor efficacy of MOR agonists in managing inflammatory and neuropathic 
pain, and the rapid development of tolerance to their effects, DOR agonists have attracted 
considerable attention as a complimentary approach to pain management. Indeed, several 
selective DOR agonists have entered clinical trials for chronic pain. However, as of this writing, 
none have progressed beyond phase II trials, as efficacy in several pain models has not proven 
significant versus placebo.
57
 For example, the DOR agonists ALD5859 and ALD5747 were 
ineffective in osteoarthritic knee pain.
57
 Therefore, the potential clinical benefits of DOR 
agonists in analgesia remain unclear. 
 The other notable result of DOR activation is antidepressant and anxiolytic effects. In 
animal models of depression and anxiety (e.g. forced swim test, elevated plus maze, etc.), DOR 
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agonists show robust and rapid effects, with magnitudes similar to well known antidepressants 
and anxiolytics, for example selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines 
respectively.
56,57
 Further, in depression and anxiety tests, DOR knockout mice are prodepressive 
and anxiogenic, phenotypes that are not observed with genetic deletion of MOR or KOR (for 
more detailed mechanistic discussion, see below, Antidepressant Mechanisms: The 
Mesolimbic System and Endogenous Opioids).
58
 Accordingly, DOR agonists have been 
pursued for the treatment of these mood disorders, and the compound AZD2327 has been 
evaluated in a phase II clinical trial for major depressive disorder. Although the full results of 
this trial have not been published, the publicly available data indicate that only modest efficacy 
trends were observed, and clinical development of this compound appears to have been 
abandoned at this time. Thus, as in chronic pain, the promise of DOR agonists for the treatment 
of mood disorders has not been realized at this time. 
 The present clinical failure of DOR agonists may be related to insufficient dosing, due to 
concerns of convulsive side effects. Many DOR agonists are known to produce convulsive or 
seizurogenic side effects in a variety of animal species at some dose level.
56
 Unfortunately, this 
side effect is mediated by DOR itself, being absent in DOR knockout mice and blocked by DOR 
antagonists (e.g. naltrindole).
59
 Positively, the induced convulsions, although tonic-clonic, are 
typically short-lived, self-limiting, and invariably non-lethal. Furthermore, many of the known 
delta agonists only elicit convulsive effects at doses significantly above their therapeutic dose 
ranges in animals, or do not exhibit any convulsive side effects at all. For example the recently 
reported DOR agonist KNT-127 does not produce convulsions even at a dose of 100 mg/kg, a 
level 100-fold higher than the dose required for robust antidepressant activity.
60
 The underlying 
mechanisms for this variability in proconvulsive activity are not known at this time, but could be 
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related to biased agonism (see below, Functional Bias at DOR). Nevertheless, it seems possible 
to dissociate positive therapeutic benefits from this key side effect, such that it should not 
represent a limiting factor in future clinical progress with DOR agonists. 
 Notably, the abuse potential and tolerance building properties of DOR agonists are not 
well characterized and show variability across the literature. Unlike MOR agonists, where there 
is a long history of human use and abuse, there is no such data to draw on for DOR agonists, and 
potential recreationally attractive effects in humans (e.g. euphoria) that might encourage abuse 
are not known. In animal models of reward, results are decidedly mixed. For example, the 
peptide DOR agonist DPDPE is self-administered by rodents, whereas several small molecule 
DOR agonists, including the prototypical agent SNC-80, are not.
61
 However, SNC-80 is also 
known to support a CPP.
62
 In drug discrimination studies, DOR agonists generally do not 
substitute for known drugs of abuse, although there are exceptions.
63,64
 Reports regarding the rate 
of tolerance development to various DOR mediated behavioral effects are also varied, and appear 
to depend on the DOR agonist examined and the experimental conditions.
61,65,66
 It seems clear 
however, that chronic DOR agonist administration does not produce a strong physical 
dependence, as no overt withdrawal symptoms are manifested on discontinuation.
63,67
 Lastly, 
DOR modulation also appears to affect the rewarding properties of other drugs, as DOR 
antagonists diminish the rewarding properties of morphine and cocaine.
56,68
 In sum, there appears 
to be a clear connection between the DOR system and reward behaviors, but the extent and 
details of that connection, as well as its relevance to abuse potential and therapeutic tolerance, 




Biased Agonism: A New Frontier for Opioids  
 With increasing understanding of the molecular signaling partners and pathways 
controlled by opioid receptor activation, has come the realization that downstream signaling may 
be selectively biased towards one or more pathways dependent upon the agonist employed, a 
phenomenon that is now known to occur for multiple GPCRs.
69-72
 In the last decade, this has 
become one of the most active areas of opioid research, and significant work remains to be done 
to answer several key questions: 1) What are the theoretical aspects governing ligand bias at the 
molecular level? 2) What tools can be used to study ligand bias and how can such bias be 
quantified and ranked? 3) What are the behavioral and physiological consequences of biased 
agonism in whole organisms? In opioid research, there is particular promise in biased ligands, as 
it has been postulated, and in some cases demonstrated, that selective control of downstream 
signaling may provide a means to dissociate the beneficial effects of opioids (e.g. analgesia) 
from their negative side effects (e.g. dependence or respiratory depression for MOR agonists). 
 Theory. A functionally biased agonist is capable of selectively activating one signaling 
pathway over another by interaction with the same receptor. Similarly, a biased agonist may have 
differential effects on other processes related to downstream signaling, for example, receptor 
internalization, trafficking, and downregulation. In the case of the opioid receptors, a ligand may 
selectively activate either of the two main signaling pathways, the G protein pathway, or the β-
arrestin pathway.  
 Bias can perhaps be most simply understood by dividing the phenomenon into two 
categories, efficacy bias and potency bias. In both cases, bias can only be quantified relative to 
the efficacy and potency of a reference agonist (for additional discussion, see below, 
Quantifying Bias). In efficacy bias, the intrinsic activity (Emax) of the test agonist is lower or 
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higher than the intrinsic activity of another reference agonist, in a functional assay system 
specific to a particular downstream signaling pathway. For example, consider two hypothetical 
opioid agonists A and B, with A being the reference agonist. Both A and B may show equal 
maximum intrinsic activity in an assay measuring G protein activation, while in a second assay 
assessing β-arrestin recruitment, agonist B may display only partial activity relative to the 
maximal activity of reference agonist A. In such a case, the test agonist B could be said to be 
efficacy-biased towards G protein activation (Figure 5A). The reverse case of efficacy bias in 
the direction of β-arrestin signaling is also possible. Such efficacy bias can be most simply 
explained by variations in the active receptor conformations sampled by a particular agonist. A 
receptor can be imagined to have more than two discrete conformational states (active and 
inactive). In fact, multiple, stable, active and inactive conformations (multiple state model) or a 
conformational continuum (n state model) are likely to exist, each coupling with lower or higher 
efficiency to disparate downstream effectors. The ability of a particular agonist to influence the 
thermodynamic equilibrium between these states is therefore a key mechanism in functional 





























G protein activation = Agonist A (reference) = red
Agonist B (test) = blue
A/ B/ C/
Figure 5. Different types of biased agonism for hypothetical opioid receptor agonists. (A) Efficacy Bias: Test agonist 
B shows lower Emax for β-arrestin recruitment than the reference agonist A. (B) Potency Bias: Test agonist B shows a 
larger shift to lower potency (EC50) than the reference agonist A when moving from the G protein to β-arrestin assay. 
(C) Mixed Bias: Combinations of potency and efficacy bias are most commonly observed. 
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particular agonist.  
 In potency bias, the ratio of potencies between two assays assessing coupling to 
alternative downstream effectors is different when calculated for two different agonists. It is 
important to note that the EC50 (concentration producing half maximal signal) determined in one 
or both assays may be different from the equilibrium binding constant (Ki) for the agonist. Such 
discrepancies between receptor occupancy (as determined by Ki) and potency in a functional 
assay can occur due to a variety of assay-dependent factors, including potential receptor reserve 
and signal amplification in assays where activity is measured at a downstream target. 
Accordingly, it is inappropriate to quantify potency bias by a direct comparison of EC50 between 
two assays, which may differ in inherent sensitivity. The potency ratio of a reference agonist 
must be used as a point of comparison in quantification (Figure 5B). As an example, again 
consider two hypothetical opioid agonists A and B, with A being the reference agonist. Agonist 
A may show an EC50 of 10 nM in a G protein coupling assay, and 100 nM in a β-arrestin 
recruitment assay. Therefore, giving a functional potency ratio between the two assays of 1:10. 
In contrast, agonist B may show a potency ratio of 1:100, thus displaying a potency bias towards 
G protein signaling (Figure 5B). Simply stated, the rank order of agonist potencies may not be 
conserved between different assays. It is also important to consider that the intrinsic activities of 
the two agonists in each assay may differ concomitantly with potency. In other words, there may 
be an overlying efficacy bias as well, and in fact, ligands displaying some degree of bias in both 
Emax and EC50 are the most commonly observed (Figure 5C).  
 Potential Kinetic Effects on Functional Selectivity. In examining ligand bias, the 
kinetics of binding are a potential influencing factor that has largely been ignored in the 
literature. In assay systems not at equilibrium, the potential effects of kinetics on the observed 
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maximal signal and potency are potentially very large. Two agonists may share identical 
equilibrium dissociation constants (Kd), but at the same time, have completely different on/off 
rates (kon and koff). Therefore, the equilibrium ratio between active and inactive receptor 
conformations in the presence of a given concentration of two such agonists may be the same, 
while the mean time spent in each conformation may be vastly different. It is reasonable to 
assume that coupling to certain downstream effectors (e.g. β-arrestin) is more strongly dependent 
on mean occupancy time at the receptor (a kinetic phenomenon) rather than equilibrium percent 
occupancy (thermodynamic phenomenon). Consider the specific case of β-arrestin recruitment, 
which depends largely on receptor phosphorylation. A chemical reaction like phosphorylation is 
expected to have a slower forward rate constant than that governing the conformational change 
involved in G protein dissociation. Therefore, it is plausible that only agonists with a slow on/off 
rate occupy the receptor for long enough time periods on average to allow phosphorylation and 
β-arrestin recruitment. For agonists with fast on/off rates, much higher ligand concentrations 
(and hence occupancy) would be required to increase occupancy time sufficiently to allow 
receptor-effector processes with slower forward rate constants to occur. In contrast, given the 
higher rate constant for G protein dissociation (a conformational change), the on/off kinetics of a 
given agonist are expected to have a much smaller influence on probability of activation, which 
would instead depend mostly on the conformational equilibrium ratio (occupancy) induced by 
agonist binding (Figure 6). 
 Kinetic effects are expected to be further exaggerated in assays where the signal readout 
is based on molecular events significantly downstream of the receptor and thus, where the kinetic 
effects of multiple effector-effector interactions are involved, and where equilibrium may take a 
long time to be established. Similarly, assays measuring an accumulative readout, for example 
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transcription based assays, are also expected to have the potential to exist in non-equilibrium 
states for long periods of time, thus being susceptible to the influence of signaling kinetics. It can 
be imagined that certain receptor regulated intra and intercellular processes, particularly those 
involving gene regulation or structural changes (e.g. receptor internalization or synaptogenesis) 
may take minutes, hours, or even days to reach a steady state under the influence of a receptor-
level signaling event. Synaptic concentrations of neurotransmitters are also known to decay 
rapidly following a signaling event (seconds), meaning that in many cases, equilibrium is never 
achieved, and non-equilibrium signaling will be important. For example, it has recently been 
shown that the potency of norepinephrine to induce G protein activation via α2A-adrenergic 
receptors varies by an order of magnitude over several seconds.
73
 In such situations, functional 
signaling bias induced by variation in binding kinetics is likely to be physiologically relevant. It 
is also known that drug binding kinetics are important in modulating the pharmacokinetic 
properties and temporal selectivity of some known drugs, but no correlations to molecular level 
signaling bias have been demonstrated.
74




























Figure 6. Potential kinetic effects on signaling bias in non-equilibrium systems. For an agonist with fast on/off 
kinetics, mean occupancy time is low, and the rate of receptor phosphorylation, as governed by kphos, may be too low 
to compete with the off rate of the ligand at the receptor, koff. For an agonist with slow on/off kinetics, mean 
occupancy time is increased, and the rate of phosphorylation may compete with koff, resulting in phosphorylation and 
β-arresin recruitment. 
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between binding kinetics and functional bias may prove enlightening. The influence of on/off 
rate on receptor-effector coupling efficiency, if any, is not known. Ligand binding kinetics are 
easily determined in radioligand displacement assays and the activity of various signaling 
pathways can be easily studied by the methods described below (see Studying Bias: Assay 
Design). Hence, an examination of potential kinetic effects on ligand bias is well within the 
realm of current experimental capabilities. 
 Studying Bias: Assay Design. A large number of membrane- and cell-based assays can, 
and have, been employed to study the functional activation of disparate signaling partners by 
opioid receptors in vitro.
69-72
 The key property is the dependence of the assay readout on a single 
downstream pathway, namely the G protein pathway or the β-arrestin pathway. A classic assay 
for assessing G protein activation is by measuring binding of the radiolabeled, no-hydrolyzable 
GTP analog, [
35
S]GTPγS to the membrane. An increase in membrane radioactivity is indicative 
of GTP recruitment, and thus, G protein activation. The dissociation of Gαi and Gβγ subunits, 
which occurs on receptor activation, can also be monitored by fluorescence resonance energy 
transfer (FRET) or bioluminescence resonance energy transfer (BRET) methods, assuming 
receptor and/or G proteins appropriately tagged with fluorescent or bio/chemiluminescent 
functionalities are employed.
75
  Another common assay for measuring G protein activation is by 
monitoring cAMP accumulation. As opioids are coupled to inhibitory G proteins, their activation 
leads to an inhibition of adenylate cyclase, and a concomitant decrease in cAMP concentration. 
Changes in cAMP concentration can be monitored by a variety of readily available fluorescent 
and bioluminescent methods. For example, the cAMP BRET sensor CAMYEL features a 
fragment of the cAMP binding guanine nucleotide exchange factor Epac1, sandwiched between 
a luciferase and yellow fluorescent protein (YFP) BRET donor-acceptor pair.
76
 With cAMP 
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bound, the donor and acceptor are held apart, giving a low BRET signal. On activation of opioid 
receptors, cAMP would be expected to decrease, resulting in dissociation from CAMYEL, and a 
concomitant increase in BRET signal. A related technology, the GloSensor
TM
 from Promega, 
employs an engineered luciferase, which increases in bioluminescence on cAMP binding, thus 
producing a declining signal with opioid receptor activation.
77 
 A variety of assays are also available to examine activation of the β-arrestin pathway. In a 
simple qualitative or semi-quantitative assay, cells expressing the receptor and a fluorophore 
tagged β-arrestin can be observed by microscopy, in which case, localization of fluorescence 
near the membrane is an obvious indication of arrestin recruitment.
78
 For a more quantitative 
approach, other assays are available. Fluorescent/bioluminescent tagging of the receptor C-
terminus, or of other membrane associated proteins, in addition to β-arrestin, creates a BRET 
donor-acceptor pair, which permits quantitative measurement of arrestin recruitment.
75,79
 
Enzyme complementation strategies have also been employed to measure arrestin recruitment. 
For example, in the PathHunter
TM
 assay by DiscoveRx, both β-arrestin and the receptor are fused 
to complementary, but inactive, fragments of a β-galactosidase enzyme.
78
 On arrestin 
recruitment, an active enzyme is reconstituted, the activity of which can be detected with 
chemiluminescent reagents. A third strategy for monitoring arrestin activation is via a 
transcriptional assay. In the Tango assay design, a protease-arrestin fusion protein is recruited on 
receptor activation, where it cleaves a transcription factor tethered to the C-terminus of the 
receptor, which can then activate the expression of a reporter gene (e.g. luciferase).
80
 
 Quantifying Bias. Once the potency and efficacy of a set of agonists has been assessed 
in both G protein and β-arrestin assays, the data obtained may be used to rank and quantify bias. 
Both efficacy and potency bias are easily ranked independently, in a qualitative sense, within a 
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particular assay system. However, a comparison of bias ratios determined in different assay 
systems, or where both efficacy and potency bias is observed simultaneously, is more 
complicated. In such cases a means of quantifying the bias ratio is essential for a rigorous 
treatment. Perhaps the most rigorous methods for calculating bias factors are those which have 
been described by Kenakin and others applying the Black-Leff operational model of 
pharmacological agonism.
81-85
 In this model, the response of the assay system can be shown to 
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In this equation, the maximum response of the system is defined as Emax and the agonist 
concentration as [A]. The factor n describes the transducer slope for the function describing 
agonist response in terms of agonist concentration. Although n is not identical to the more 
commonly encountered Hill slope, the two factors are closely related. Further, systems with a 
Hill slope of 1, also result in n=1, introducing certain simplifications to this model that will be 
discussed below. The parameter KA is defined as the equilibrium dissociation constant, and is a 
measure of the affinity of the agonist for the receptor, with the important caveat that this affinity 
is conditional on the specific system. In other words, the conditional affinity described by KA 
takes into effect the allosteric modulatory effects of any bound effector proteins (e.g. G proteins 
or β-arrestin), and is therefore likely to vary between different cell systems and also from the Ki 
of the naked receptor (as determined, for example, in radioligand binding experiments). In fact, 
this suspicion has been confirmed experimentally, as the Ki values determined for binding of 
several agonists, to fusion proteins of angiotensin II type 1 receptor (AT1R) and the transducers 
Gq and β-arrestin 2, differed according to the fused transducer.
86
 Moreover, this variation in 
binding affinity was shown to correlate to the functional bias observed in cell-based functional 
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assays. Accordingly, it is not appropriate to substitute a single independently determined Ki for 
KA when applying the operational model to analyze activity in different assays systems. The final 
key parameter of the operational model is the τ factor, which incorporates terms describing both 
the receptor density, [Rt], and the intrinsic activity or efficacy of receptor-effector coupling in a 
particular system, KE.  
τ = [Rt]/KE 
Thus, τ conveniently accounts for all system/pathway and ligand specific factors affecting 
signaling efficacy. By combining both the measure of efficacy, τ, and the measure of conditional 
potency, KA, a "transduction coefficient" specific to the ligand and signaling pathway can be 
obtained. 
transduction coefficient = τ/KA 
Transduction coefficients have been shown to remain stable at varying receptor densities, and 
thus represent a convenient method for simultaneously evaluating the potency and efficacy of a 
particular ligand to induce a specific functional effect. Further, they can be determined for each 
test agonist and assay combination by the fitting of functional data to the operational model. 
These factors mean that comparisons of transduction coefficients across pathways and ligands 
are one of the best methods for quantifying the bias of different agonists. Typically, a normalized 
logarithmic transduction coefficient, ∆log(τ/KA), is determined for each agonist as follows, 
∆log(τ/KA)test = log(τ/KA)test - log(τ/KA)ref 
where "test" and "ref" indicate the test agonist and reference agonist respectively. This is 
repeated in a second functional assay observing a different signaling pathway, and the 
normalized transduction coefficients compared to each other to determine a bias factor as shown 
below, 
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log bias = ∆∆log(τ/KA)test = ∆log(τ/KA)1 - ∆log(τ/KA)2 
where 1 and 2 indicate the two signaling pathways. As the log bias is measured on a logarithmic 
scale, a log bias factor of 1 represents a 10-fold preference for pathway 1, while a log bias factor 
of -1 represents a 10-fold bias in favor of pathway 2. A simple, non-logarithmic, bias factor can 
also be easily calculated from these values as an alternative representation. Therefore, fitting of 
data to the operational model, followed by determination of comparative transduction 
coefficients, represents a rigorous approach for the quantification of bias between two signaling 
pathways that should be independent of specific assay effects (as they are already normalized to 
the reference agonist). 
 A simpler method for quantifying bias is through the use of "relative activity" values, 
RA, defined as follows, 
RA = Emax/EC50 
where again, Emax is the maximum signaling efficacy of the particular assay, and EC50 is the half-
maximal effective concentration determined for the test agonist. Similar to above, logarithmic 
and normalized RA values can be determined for a test agonist in relation to a reference agonist, 
as described by the following equation 
∆log(RA)test = log(RA)test - log(RA)ref 
Once ∆log(RA)test has been determined in two different assays, the log bias factor for the test 
agonist can be calculated analogously to above, as follows, 
log bias = ∆∆log(RA)test = ∆log(RA)1 - ∆log(RA)2 
again with positive bias factors indicating a preference for pathway 1, and negative bias factors 
indicating a bias for pathway 2. A notable advantage of this method is the ease of calculation, as 
EC50 and relative Emax are obtained directly from the functional data without need for careful 
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fitting of the operational model. Further, for assay systems with Hill slopes close to 1, RA and 
τ/KA become equivalent, allowing bias factors to be calculated using the relative activity method 
without concern of variations due to receptor density. Hence, in most cases, this method 
represents the most convenient and easily applied method of calculating bias. 
 A further simplification is introduced into either of the previous methods when the 
agonists to be compared are both full agonists, showing the same maximal signaling efficacy. In 
such cases the efficacy related terms τ and Emax cancel in the above equations, and a direct 
comparison of potency, as quantified by KA or EC50 is sufficient to fully characterize the bias 
factor. However, considering that ligands showing the strongest bias factors are often partial 
agonists, this simple method is not typically applicable. 
 Complications can occur when one of the test agonists has extremely low Emax (e.g. 
<15%), for a particular assay. Depending on the signal-to-noise and dynamic range of the assay, 
such low efficacy can make potency, as well as the magnitude of Emax, difficult to determine 
accurately. Therefore, significant discrepancies in bias factors calculated from such data can 
result. Recently, an alternative method for quantifying the bias of very weak partial agonists has 
been described.
87
 In this method, competitive antagonism experiments between the test agonist 
and the high efficacy reference agonist are used to quantify the bias. This provides a much larger 
difference between the maximal and minimal signal, allowing for more accurate quantification of 
bias factors for highly efficacy-biased agonists. 
 Functional Bias at MOR. Given the potential promise of functional selectivity to 
separate therapeutic benefits from negative side effects, the study of agonist bias at the MOR is a 
very active area of research at present.
70-72
 Perhaps the most striking result of work in this area 
has been the realization that the prototypical small molecule MOR agonist, morphine, is a G 
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protein biased agonist, showing high efficacy for G protein activation, but little arrestin 
recruitment. It has been thoroughly demonstrated in a variety of cell lines, that morphine induces 
very little receptor phosphorylation, β-arrestin recruitment, and receptor internalization, when 
compared to other well known MOR agonists including methadone, fentanyl, etorphine, 
DAMGO, and met-enkephalin.
70,72,88-92
 Similar G protein bias has also been observed for the 
close structural relative oxymorphone, and the partial agonist buprenorphine.
90
 The weak arrestin 
signaling induced by morphine appears to depend on differential activation of receptor 
phosphorylation, as in cell lines overexpressing GRK, morphine is equally efficacious to other 
opioids in promoting receptor phosphorylation and arrestin recruitment.
88,92
 Further, multiple 
reports suggest that MOR phosphorylation induced by morphine is dependent on both GRK and 
PKC, whereas that induced by other agonists, for example DAMGO, is dependent on GRK 
alone.
93
 Curiously, genetic knockout, or siRNA knockdown, of β-arrestin-2 produces enhanced 
acute analgesia and reduced tolerance with morphine, as well as attenuation of key negative side 
effects, namely respiratory depression and constipation.
27,94-98
 Physical dependence on morphine, 
as measured by naloxone precipitated withdrawal signs, is also attenuated in β-arrestin-2 
knockout animals.
98
 Oddly, similar changes in the behavior of β-arrestin-2 knockout animals are 
not observed with other MOR agonists that show a greater efficacy for arrestin recruitment in 
vitro.
98
 This is surprising, as morphine would be expected to be less affected than other MOR 
agonists by the loss of β-arrestin, given its weak recruitment of this effector. The "morphine 
paradox" represents a clear complication in our attempts to understand the physiological and 
behavioral relevance of biased activation at MOR, and a challenge to claims that G protein 
biased MOR agonists will have improved therapeutic profiles and reduced side effects. 
 33 
 The situation is further convoluted when tolerance is considered. In the standard 
hypothesis relating MOR internalization to tolerance development, it is assumed that increased 
receptor trafficking will resist the development of tolerance, by allowing a natural control to the 
duration of signaling, while providing a means for the return of resensitized receptors to the cell 
surface. In contrast, weekly desensitizing and internalizing agonists like morphine would be 
expected to trap active receptors at the cell surface, where prolonged signaling would promote 
adaptive changes related to tolerance. Although morphine does elicit modestly increased 
tolerance compared to other opioids in rodents, these differences are not of clinical relevance in 
humans, where robustly internalizing agonists also effect rapid tolerance development.
98,99
 
Furthermore, the vast majority of studies reporting on biased signaling and trafficking at MOR, 
have been conducted in artificial in vitro systems, with little attempt to connect these molecular- 
and cellular-level effects, to systems-level physiological effects. In general, it is hard to envision 
a clear clinical benefit from a reduction of β-arrestin signaling when both morphine, a G protein 
biased agonist, and other well known MOR agonists that are not biased (e.g. fentanyl and 
methadone), show similar maximal efficacy, development of tolerance and physical dependence, 
abuse liability, and negative side effects in man. 
 The differential signaling properties and behavioral effects of morphine in comparison to 
other opioids appear to depend on a variety of factors other than the absolute bias observed in 
vitro, and the complexity of the system is understated by the simple understanding that morphine 
is G protein biased. For example, the decreased phosphorylation elicited by morphine as 
compared to DAMGO is observed in some MOR splice variants, but not in others.
100
 This fact is 
especially relevant, in that at least 26 splice variants of the mouse MOR have been observed, and 
show different regional expression patterns in the CNS.
70
 The specific residues phosphorylated 
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on morphine activation also differ from those phosphorylated in the presence of other 
agonists.
101,102
 Furthermore, the biased signaling of morphine is apparent in the recruitment of 
the two relevant arrestins. Morphine is not able to recruit β-arrestin-1 at all, as it has a lower 




 An additional complicating factor in understanding the effects of biased agonism on 
physiology and behavior is the temporal and spatial variation observed in the degree of MOR 
desensitization and G protein uncoupling resulting from prolonged agonist stimulation. For 
example, in MOR expressing HEK-293 cells, DAMGO treated cells are rapidly desensitized to G 
protein activation, but cells treated with morphine are not.
104
 However, in the same cell type, 
morphine produces a more rapid and greater desensitization to intracellular calcium release than 
does DAMGO.
105
 When morphine induced desensitization to [
35
S]GTPγS binding is observed in 
the rat brain, stark regional differences are also seen, with desensitization apparent in several 
brainstem regions, but absent in other areas including the striatum and thalamus.
106
 Such regional 
variability may depend on both the ability of the agonist to activate different phosphorylation 
pathways and on variable expression of different kinases. In cell culture, inhibition of GRK2 
reduces DAMGO-induced desensitization of GIRK channel activation, whereas inhibition of 
PKC attenuates morphine-induced desensitization of the same channels without affecting 
DAMGO-induced desensitization.
93,107
 As desensitization may be related to receptor 
internalization, it is unsurprising that differences in agonist-induced internalization have also 
been observed between morphine and other agonists, and that the degree of internalization varies 
by brain region. 
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 Recently, several novel G protein biased MOR agonists have been described. Of 
particular interest are aryl ester analogs of the potent KOR agonist and natural product Salvinorin 
A, of which, the compound herkinorin (Figure 7) is the prototypical example.
108,109
 The change 
from an acetate ester in Salvinorin A, to a benzoate ester in herkinorin, produces a selective 
MOR agonist that is a full agonist for G protein signaling. However, it elicits very little receptor 
phosphorylation and does not recruit β-arrestin or promote receptor internalization, even when 
GRK2 is overexpressed. Interestingly, replacement of the benzoate ester in herkinorin with a 
benzamide, yields an MOR selective agonist, which in contrast to the parent compound, induces 
robust β-arrestin recruitment and internalization.
109
 This demonstrates the dramatic effects that 
subtle structural changes may have on ligand bias. Although it has been suggested that the strong 
G protein bias of herkinorin and its analogs may yield a beneficial therapeutic profile, the 
evidence remains somewhat equivocal. In transfected cells, chronic herkinorin results in a 
decreased sensitivity to itself and DAMGO in [
35
S]GTPγS binding assays, and increased 
forskolin stimulated cAMP accumulation, both signs of tolerance.
110
 Conversely, herkinorin has 
demonstrated efficacy in the formalin test of inflammatory pain that is peripherally mediated, 
and tolerance is not developed after five days of treatment.
111
 However, in vivo results with this 
compound class should be taken with 
reservation, as their high lipophilicity, 
and susceptibility of the ester 
functionality to hydrolysis, indicate 
that they may have unusual 
pharmacokinetic properties. Another G 
protein biased MOR agonist, TRV130 
Figure 7. Notable biased agonists of MOR. 
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(Figure 7), has recently been described and has entered clinical trials for acute pain. In animal 
models, TRV130 shows higher maximum analgesia and less respiratory depression and 
constipation compared to morphine at equianalgesic doses.
112
 These benefits have now also been 
demonstrated in early clinical trials, indicating that there may in fact be promise in applying 
molecular-level functional selectivity to achieve an improved therapeutic profile.
113
 Lastly, the 
tetramer peptide endomorphin-2 has recently been reported to be a modestly β-arrestin biased 
agonist at MOR, but the behavioral and physiological consequences of bias in this direction are 
not known.
114 
 Functional Bias at KOR. Agonists of the KOR, although promising as non-addictive 
analgesics, also present serious side effects that have drastically limited their clinical application, 
namely dysphoria and psychotomimetic effects.
71
 Accordingly, potential biased agonists of the 
KOR are enticing, as they may allow the separation of the beneficial analgesic effect from these 
negative side effects.
39,115
 As with MOR, there has been some suggestion that the negative side 
effects of KOR activation may be associated largely with the β-arrestin signaling pathway. This 
possibility has been in part supported by recent findings of Chavkin and coworkers.
46,116,117
 In 
both transfected cells and primary striatal astrocytes and neurons, they have shown that the 
stress-related kinase p38 MAPK is activated by the prototypical and unbiased KOR agonist U-
50,488. This activation is dependent on KOR phosphorylation by GRK3 and β-arrestin 
recruitment, as mutation of a key serine residue to alanine, prevents receptor phosphorylation at 
this position, and in turn, β-arrestin recruitment and phosphorylation of p38 MAPK. Further, the 
activation of p38 MAPK is inhibited by the KOR antagonist nor-BNI and not observed in 
primary cells isolated from KOR or GRK3 knockout animals.
116
 It has also been shown that 
forced swim stress induces phosphorylation of p38 MAPK in several brain regions (including the 
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NAc) and that this effect is blocked by the KOR antagonist nor-BNI, or eliminated in KOR or 
GRK3 knockout animals. Similarly, this report also showed that U-50,488 produces a 
conditioned place aversion in rodents, and that this effect, as well as swim test immobility, is 
blocked in the presence of the p38 MAPK inhibitor SB203580.
117
 Importantly, this inhibition did 
not block the analgesic effects of U-50,488, suggesting that the analgesic and aversive effects of 
KOR agonists might be separable with an appropriately biased agonist. These results clearly 
implicate the dynorphin-KOR system in aversive responses to stressful stimuli, and this is likely 
the endogenous signaling system responsible for the dysphoric components of the stress response 
(as opposed to MOR signaling, which modulates reward).
46,117
 Interestingly, activation of p38 
MAPK is known to increase the cell surface expression and transport capacity of the serotonin 
transporter (SERT).
118
 Thus, by indirectly depleting synaptic serotonin through increased uptake, 
active p38 MAPK may oppose the actions of classical SSRI antidepressants, in agreement with 
the aversive properties of this signaling pathway. However, it should be noted that these findings 
have not yet been repeated by other laboratories, and the situation in fact appears to be more 
complex (see discussion of RB-64 and TRK-820 below). 
 Activation of p38 MAPK has also been postulated to be involved in hyperalgesia and 
allodynia, as it acts indirectly to phosphorylate GIRK channel Kir3.1, resulting in its 
desensitization. This produces depressed membrane polarization and increased neuronal 
excitability, thus resulting in enhanced pain sensitivity.
119
 Lastly, KOR internalization and 
desensitization mediated by β-arrestin may be involved in the development of tolerance to 
agonists at this receptor, in a manner similar to MOR.
120
 Although still controversial, this would 
suggest yet another benefit of functional selectivity in favor of G protein activation. 
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 The apparent association of KOR-activated arrestin signaling with the negative side 
effects of KOR agonists has stimulated the development of G protein biased agonists at this 
receptor, but such agents have only very recently become available. The first to be described was 
the naltrindole analog 6'-guanidinonaltrindole (6'-GNTI) (Figure 8).
75
 A potent partial agonist of 
the G protein pathway, 6'-GNTI does not induce significant β-arrestin-2 or β-arrestin-1 
recruitment, or receptor internalization, even when GRK3 is overexpressed. Further, it 
effectively antagonizes the arrestin recruitment and internalization elicited by ethylketazocine 
(EKC). The signaling bias of 6'-GNTI has also been observed in striatal neurons, where it 
selectively activates the Akt signaling pathway, but not ERK1/2, as phosphorylation of ERK1/2 
in this system is β-arrestin-dependent.
78
 However, this same study reported that in CHO cells 
expressing KOR, 6'-GNTI was effective for ERK1/2 phosphorylation, as in this system, this 
process was G protein-dependent. Accordingly, this work demonstrates the importance of the 
experimental system to the observed signaling bias and downstream effectors activated by 
agonists biased at the molecular-level, and emphasizes the need for in vivo studies to further 
clarify the relevance of functional selectivity in whole organisms. Unfortunately, 6'-GNTI does 
not cross the blood-brain barrier, placing limitations on in vivo and therapeutic applications of 
this agent. 
 Other G protein biased KOR agonists have now been identified, including novel triazole 
and isoquinolinone scaffolds, as well as analogs of Salvinorin A.
121-123
 Interestingly, the 
salvinorin analog RB-64 (Figure 8) has been evaluated in vivo and found to have a distinct 
profile compared to salvinorin A and the arylacetamide agonist U-69,593 (both unbiased 
agonists).
124
 It was found to be analgesic in the hot plate assay while producing less motor 
incoordination and sedation (as evaluated by rotarod and locomotion tests). In contrast, tests 
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evaluating aversive and anhedonic responses were mixed. RB-64 produced less anhedonic effect 
in an intracranial self-stimulation (ICSS) model, but produced conditioned place aversion similar 
to both salvinorin A and U-69,593, indicating that the aversive effects of KOR agonists are 
unlikely to be mediated entirely through arrestin and p38 MAPK, as previously suggested (by 
Chavkin and coworkers).  
 The behavioral effects of RB-64 are complicated by the fact that in the original report of 
this compound, it was found to reduce prepulse inhibition (PPI) in a manner similar to salvinorin 
A.
122
 As inhibition of PPI is known to be indicative of psychotomimetic effects, this result 
suggests that the G protein bias of RB-64 does not alleviate the well known hallucinogenic 
effects of the unbiased agonist salvinorin A. This report also presented evidence that RB-64 is a 
covalent agonist of KOR, a result that would certainly complicate the interpretation of any in 
vivo results. Although the most 
recent work on this compound 
indicates that this observation 
does not hold in vivo, supporting 
data have not been published, so 




reports also question the ability 
of G protein bias to eliminate 
psychotomimetic side effects. 
For example, the selective KOR 
agonist nalfurafine (TRK-820) 
Figure 8. Notable agonists of KOR (biased and unbiased). 
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(Figure 8), which is approved as an anti-itch treatment in Japan, is known to be an unbiased 
agonist, yet it shows effectively no hallucinogenic side effects or tolerance build-up in humans at 
therapeutic doses, and does not produce a conditioned place aversion in rodents at analgesic 
doses.
55,125,126
 Although most reports indicate that salvinorin A is not significantly biased 
towards either G protein or arrestin signaling in comparison to arylacetamides like U-50,488, one 
study has showed that salvinorin A was 40-fold less potent than U-50,488 in eliciting receptor 
internalization, implying an unexpected, large G protein bias (or a completely different 
mechanism).
126
 Clearly, more work needs to be done to fully understand the correlation between 
various molecular-level signaling events and different behavioral and physiological phenotypes. 
 Functional Bias at DOR. The study of biased agonism at DOR is less developed in 
comparison to the other opioid subtypes. However, it is expected to be of high relevance at this 
subtype, as receptor trafficking is known to be of particular importance in controlling the effects 
of DOR agonists. In some brain regions, the majority of DOR is known to be sequestered in 
intracellular reserves, where it is largely inaccessible to agonists. Further, the trafficking of these 
receptors to the cell surface appears to require or involve both MOR and β-arrestin.
30,127-129
 Also 
of note, internalization of DOR typically results in receptor degradation, as compared to MOR, 
where internalized receptor is rapidly translocated back to the cell surface.
130,131 
 Using BRET assays, Molinari characterized the potency and efficacy of several DOR 
agonists for both G protein and β-arrestin signaling.
90
 If this data is used to calculate bias factors 
based on relative activity values (as discussed above), it is found that the endogenous human 
peptide met-enkephalin, as well as several related DOR selective peptides (DPDPE, DADLE, 
and deltorphin I), are not significantly selective for one pathway over the other, in relation to 
each other (bias factors <~2). Similarly, the synthetic DOR agonist UFP-512 is also unbiased 
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relative to met-enkephalin. Surprisingly, SNC-121 (Figure 9), a close analog of the prototypical 
synthetic DOR agonist SNC-80 (Figure 9), is strongly selective for G protein coupling (bias 
factor >20).
90
 Another curious finding of this report is that diprenorphine, a reputed potent and 
nonselective opioid agonist, is actually a partial agonist at DOR with a strong G protein bias 
(>10). Lastly, morphine, although only weakly active at DOR, maintains the biased activity 
observed at MOR, showing partial efficacy for G protein signaling but no β-arrestin recruitment. 
This work appears to be the only available rigorous, molecular-level quantification of G protein 
and β-arrestin 
signaling for a large 
set of different DOR 
agonists to date. 
However, many 
other investigators 
have made more 
detailed studies of 
particular agonists, 
or qualitative 
observations of the 
relative potency and 
efficacy of various 
agonists to promote 
G protein activation 
or arrestin 
Figure 9. Selected agonists of DOR. Non-internalizing agonists are presumed to be 
biased towards G protein signaling, as internalization usually occurs concomitant with 
receptor phosphorylation and β-arrestin recruitment. However, only SNC-121 has 
been rigorously evaluated for receptor-level biased signaling. 
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recruitment and associated behaviors.
72,132-136
 For example, and in agreement with the BRET 
results described above, Zhang and coworkers previously showed in transfected cells that DOR 
activation by morphine fails to cause receptor phosphorylation, β-arrestin-2 recruitment, or 
receptor internalization in comparison to etorphine, which is efficacious in all tests.
132
 
Interestingly, GRK2 overexpression does not rescue the arrestin signaling of morphine at DOR, 
which stands in contrast to results observed with MOR. Functional selectivity for G protein 
activation over receptor internalization has also been demonstrated for other agonists. For 
example, TAN-67 (Figure 9) and oxymorphindole, while effective for G protein activation, have 
very low efficacy for DOR phosphorylation or internalization relative to other agonists (e.g. met-
enkephalin and other DOR agonist peptides).
133
 Similar lack of internalization has also been 
reported for DOR agonists ADL5747 (Figure 9), ADL5859, and SB235863.
134,135
 Another 
interesting observation in vitro has been that although DPDPE and SNC-80 promote similar 
levels of DOR internalization, recovery of receptors back to the surface after a rest period is 
much more robust with DPDPE. Moreover, this distinction appears to depend on different 
molecular-level interactions, as characterized by detailed BRET studies.
136
 In all, amongst the 
selective small molecule agonists known for DOR, weakly internalizing agonists actually appear 
to be more common than those promoting robust receptor internalization, and the prototypical 
DOR agonist SNC-80 is somewhat unique. 
 Correlations between DOR internalization and behavior have also been demonstrated in 
several instances. In striatal and hippocampal neurons isolated from mice expressing functional 
DOR-GFP fusion protein, robust internalization is observed on treatment with SNC-80, but not 
with AR-M100390 (Figure 9), while both agonists show similar potency and efficacy for 
[
35
S]GTPγS binding. More interestingly, in a model of allodynia, mice treated with SNC-80 
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show nearly complete tolerance development to analgesia after a single injection, whereas AR-
M100390 causes no tolerance. Furthermore, this tolerance development is paralleled by 
internalization of DOR as observed in ex vivo analysis.
137
 However, chronic administration of 
AR-M100390 also produces eventual tolerance in pain models despite continued surface 
expression of functional DOR. At the same time, tolerance development to AR-M100390 does 
not occur in models of anxiety or locomotor activity.
138
 The correlation between receptor 
internalization and acute tolerance development is not as clear as these studies would suggest 
however, as it has also been observed that the peptide DPDPE causes comparable internalization 
to SNC-80, but does not evoke rapid acute tolerance.
136
 Similarly, the agonist UFP-512 also 
causes robust internalization, but no tolerance develops in vivo to its antidepressant effects, a 
phenomenon that may be related to rapid trafficking of DOR back the surface, as observed with 
DPDPE.
139
 In sum, this body of work demonstrates fascinating ligand-specific differentiation of 
behavioral effects related to variable regulation of  receptor internalization and desensitization. 
 Unfortunately, very little data is available regarding potential correlation between 
molecular-level signaling bias at DOR and the most concerning side effect of this class, 
convulsions. The recently reported DOR agonist KNT-127 (Figure 9) is reported to be free of 
convulsive side effects in rodents at doses up to 100 mg/kg, and is also known to be a non-
internalizing agonist.
60,140
 Similarly, ADL5747 and ADL5859 do not cause internalization and 
are also reported to be free of convulsive side effects. In light of this apparent correlation, it is 
tempting to assume that DOR internalization is related to the production of convulsions, but this 
has not been rigorously demonstrated. It is also unclear what molecular- and circuit-level 
mechanisms are responsible for this side effect, so these observations may only be coincidentally 
related.  
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 Outlook. At this juncture, it appears clear that the development of functionally biased 
agonists for the various opioid receptors holds promise for the creation of new therapeutics with 
diminished side effects or unique therapeutic profiles. However, much more work needs to be 
done to fully understand the connections between functional selectivity at the molecular and 
cellular level, and the observation of various behavioral and physiological phenotypes. 
 
Opioid Receptor Splice Variants and Heteromers 
 There is clear variability in the systemic and tissue-specific effects of different opioid 
ligands, even when comparing agonists known to be highly selective for a particular type (MOR, 
KOR, or DOR). As discussed above, one potential explanation for such variability is agonist-
defined functional selectivity for different downstream signaling pathways. However, other 
factors may also be involved. One possibility is that additional opioid subtypes exist (e.g. µ1, µ2, 
µ3) beyond the three canonical receptor types, each with unique ligand specificities, downstream 
signaling pathways, and tissue distribution. In fact, a large body of research has 
pharmacologically defined several distinct subtypes within each of the primary opioid receptor 
types, based on the ability of different opioid ligands to variably agonize or antagonize certain in 
vivo, ex vivo, and in vitro effects.
141
 
 Three pharmacologically distinct MOR subtypes have been claimed, µ1, µ2, and µ3. Both 
the µ1 and µ2 appear to be involved in analgesia, with µ2 also being associated with the negative 
side effects of respiratory depression and constipation. The antagonist naloxonazine is known to 
differentiate µ1 and µ2, selectively antagonizing the µ1 subtype. The peptide TRIMU-5 is also 
purported to show differential activity at these subtypes, acting as an agonist at µ2 and an 
antagonist at µ1. A third subtype, µ3, has also been claimed, being insensitive to opioid peptides 
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but showing low affinity interactions with morphinoid alkaloids. The KOR has been divided into 
at least two subtypes, κ1 and κ2, as well as a third subtype, κ3, that is now believed to correspond 
to the NOP receptor. The KOR agonist U-69,593 has been reported to act as a selective agonist 
of κ1, and bremazocine as a selective agonist of κ2. Lastly, the DOR has been divided into two 
subtypes, δ1 and δ2, each being associated with specific antagonists. Both naltrindole-5'-
isothiocyanate and the benzofuran analog of naltrindole, naltriben, are reported to be selective 
antagonists of δ2 receptors, while 7-benzylidenenaltrexone serves as a selective antagonist of δ1 
receptors.
141 
 However, these additional divisions of the opioid receptors must necessarily be due to 
differential splicing or post-transcriptional modification, as only three opioid receptor genes 
(OPRM1, OPRK1, and OPRD1) are known, and full genetic disruption of any one of them 
results in loss of all function associated with that receptor. As such, the putative opioid receptor 
subtypes might represent pharmacologically distinct splice variants of these three genes. Indeed, 
at least 25 splice variants of the MOR are known.
70,100,142-144
 Although these splice variants show 
largely similar binding properties with various ligands, their downstream functional activities 
and propensities for desensitization and internalization are variable, particularly for variants with 
changes to the C-terminus. This is to be expected, as the C-terminus is an important region for 
phosphorylation and thus, control of related arrestin signaling. Further, the expression of mRNAs 
for different splice forms of MOR in mice is variable depending on both brain region and genetic 
strain.
70,145
 Differential expression has also been observed in specific cell populations, and even 
at the level of dendrites, cell bodies, and axon terminals.
146
 Accordingly, the apparent complexity 
of MOR splice variants and their varying functional activity, expression, and localization makes 
them an attractive rationalization for the observation of pharmacologically distinct MOR 
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subtypes in vivo. However, no particular splice variant has been convincingly correlated to the 
µ1, µ2, or µ3 subtypes. Furthermore, similar splice variants have not been reported for the KOR or 
DOR, so the functional and therapeutic relevance of opioid receptor splice variants remains 
unclear in the general sense. 
 An alternative potential explanation for the variable effects of different opioids is 
dimerization or oligomerization of two or more opioid receptors (of the same or different 
subtype) to form pharmacologically and functionally distinct signaling units. For the past two 
decades, a large amount of evidence has accumulated suggesting the existence of potential opioid 
homo or heteromers with unique pharmacology and associated behavioral effects.
141,147,148
 
Similar dimerization has also been suggested for a variety of other GPCRs and between opioid 
receptors and other classes of GPCR. The possible existence of opioid heteromers has been 
demonstrated using a variety of techniques, including most commonly co-immunoprecipitation 
of tagged receptors, resonance energy transfer studies (to demonstrate proximity), and 
modulation of the pharmacological properties of various ligands dependent upon coexpression of 
two receptor subtypes (e.g. allosteric modulation of the binding of a selective DOR ligand, by a 
selective MOR ligand when both receptors are present).  
 Perhaps the best studied of the purported opioid heteromers is the MOR-DOR dimer. 
This heteromer was first reported based on co-immunoprecipitation studies and the ability of 
ligands selective for one of the involved subtypes (MOR or DOR) to modulate the binding 
and/or signaling of ligands selective for the other subtype when the two receptors are 
coexpressed.
149,150
 A large number or follow-up studies have since reaffirmed and extended these 
early findings.
147
 For example, BRET studies have shown a close association of coexpressed 
MOR and DOR in the cell membrane.
152,153
 The MOR-DOR heteromer has also been implicated 
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in specific behavioral effects. For example, a fusion protein of the cell-penetrating TAT peptide 
and a peptide representing the first transmembrane segment of MOR has been claimed to disrupt 
MOR-DOR dimer formation in vivo in mice, where its coinjection with morphine results in 
increased analgesia and decreased tolerance development.
153
 Using a similar approach, it has 
been found that coadministration of a TAT-conjugate peptide mimicking the carboxyl tail of 
DOR alongside the DOR agonist UFP-512, completely antagonizes the antidepressant and 
anxiolytic effects of this agent in mice through presumed disruption of MOR-DOR 
heteromers.
154
 Ligands showing selective modulation of the MOR-DOR heteromer have also 
recently been reported. The novel compound CYM51010 has been claimed as a selective MOR-
DOR heteromer agonist, while the well known DOR antagonist, naltriben, is reported to stabilize 
functional MOR-DOR heteromers at the cell surface, preventing their endocytosis.
155,156
 Similar 
immunoprecipitation, pharmacological, and RET methods have also been used to characterize 




 Although opioid receptor heterodimerization represents an alluring explanation for the 
complexity of observed in vivo opioid effects, it has also generated considerable controversy, and 
several investigators have openly criticized the conclusions drawn from the available data as 
overly definitive.
160,161
 Indeed, a variety of arguments can be made that question the existence of 
GPCR heteromers. For one, the apparent interactions between heteromer partners appear to be 
both weak and transient. Heteromers are observed to be dissociated in detergent solutions, which 
is a behavior not observed for more well-precedented protein oligomers having strongly 
interacting surfaces. Further, recent single molecule imaging studies have demonstrated that 
although GPCRs interact in the membrane as apparent dimers, these interactions are transient, 
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with mean lifetimes of at most, several seconds.
162,163
 Likewise, the immobilization of a certain 
subset of receptors with antibodies appears to have no discernable effect on the mobility of 
unbound receptors, also suggestive of weak protein-protein interactions.
164
 In line with these 
apparently low affinity interactions, there is no consensus on the interacting domains of GPCRs, 
despite high structural homology amongst this class. This lack of an apparent conserved binding 
interface suggests that protein-protein interactions between GPCRs are likely to occur in random 
orientations. Likewise, RET data supporting the dimerization of GPCRs in the cell membrane is 
also inconsistent, as several studies have observed RET signals that show a positive correlation 
to receptor density, as would be expected from random transient interactions, not stable 
dimers.
165
 Indeed, a clear RET signal can be observed due to random proximity within a two-
dimensional membrane and does not necessarily demonstrate a true interaction.
166
 It is hard to 
imagine a reproducible and predictable influence of one receptor on the conformational 
equilibrium of another if there is no structurally defined and stable contact between them, 
otherwise interactions with any membrane protein might influence said receptor in a similar 
manner.  
 A further confounding factor is introduced by the potential for receptor crosstalk or 
interference at downstream effectors when examining functional variability of apparent 
heteromers. Such effects are only further exacerbated with in vivo studies, where cellular 
heterogeneity and circuit-level effects must also be taken into account. Accordingly, it is 
inappropriate to characterize potential heteromer interactions in more complex systems until they 
are first understood on a molecular level, at the receptors themselves. It should also be noted here 
that opioid receptors have been reported to be localized to lipid raft domains.
167
 It can be 
imagined that such local organization might influence heteromeric interactions, or produce 
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similar proximity-related functional modulation, without the necessity of stable receptor-receptor 
binding. Although the existence of functionally distinct opioid heteromers holds promise for the 
development of novel therapeutics with more specific behavioral or physiological effects, more 
detailed study is warranted before clear conclusions may be drawn. 
 
Depression and Anxiety: New Therapeutic Applications for Opioid Modulators 
 Although the primary interest in opioid receptors has stemmed from their well-known 
analgesic properties, there is both a historical, and a recently growing interest in modulating the 
opioid receptor system to treat depression, anxiey, and other mood disorders.
168,169
 Major 
depressive disorder (MDD) is a serious mental disorder characterized by a variety of emotional 
symptoms including feelings of sadness, hopelessness, worthlessness, anhedonia, or suicidal 
ideation which frequently occur simultaneously with physical symptoms, including fatigue, 
changes in appetite, or insomnia. Other mood-related disorders, including various anxiety and 
compulsive disorders, or other psychiatric conditions like bipolar disorder or schizophrenia, 
often occur comorbid with MDD.  
 In addition to psychotherapy, a variety of psychiatric medications are available to treat 
MDD, and by extension, other related mood disorders. The most commonly prescribed 
antidepressants can be divided into four major classes, in order of popularity: selective serotonin 
reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic 
antidepressants (TCAs), and monoamine oxidase inhibitors (MAOI). In almost all cases, an SSRI 
is used as the first line treatment for MDD, with fluoxetine (Prozac) being the prototypical agent 
in this class. Unfortunately, these drugs are associated with significant shortcomings including 
low response rate, slow onset of effects, and serious side effects.
170-172
 In fact, approximately 
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50% of patients fail to achieve an adequate response to initial monotherapy with an SSRI, and an 
even higher 60-70% fail to attain remission of symptoms. This situation is not always improved 
by switching medication, as in a clinical trial allowing patients staged access to up to 4 distinct 
therapeutic strategies, cumulative remission rate was still less than 70%.
172
 The drugs described 
above are also characterized by a slow onset of therapeutic benefit, typically requiring at least 
two weeks of therapy before sufficient control of symptoms is achieved. This clearly represents a 
major shortcoming with severely depressed or suicidal patients, where a rapid effect would be 
highly desirable. Intolerable side effects, perhaps most notably decreased libido,
173
 are also 
common with known antidepressants, occurring in at least 10-20% of patients, and often lead to 
the discontinuation of therapy. In sum, the prevalence of treatment resistant depression (TRD), as 
well as the poor temporal and side effects profiles of currently available drugs, clearly represent 
major challenges in psychiatry that might be addressed by novel therapeutics. 
 The Monoamine Hypothesis. The high observed rate of TRD is unsurprising, given that 
nearly all clinically available antidepressants act through the same initial molecular mechanism, 
the elevation of monoamine neurotransmitter levels (serotonin, norepinephrine, and to a lesser 
extent, dopamine). Through direct inhibition of the monoamine transporters (serotonin 
transporter, SERT; norepinephrine transporter, NET; dopamine transporter, DAT) or through 
inhibition of enzymatic monoamine degradation (as with MAOIs), the major classes of 
antidepressants effectively increase synaptic and extrasynaptic levels of the monoamines. This 
eventually leads to the clinical relief of symptoms, although the exact downstream mechanisms 
mediating the therapeutic benefits of increased monoamines are not clear. The monoamine 
hypothesis of depression
174
 appears to be overly simplistic, as for example, SSRIs acutely elevate 
brain serotonin levels within minutes or hours, but their mood elevating effects are chronic, and 
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do not become apparent for weeks. Accordingly, it is now well recognized that depression does 
not result from a simple deficiency of monoamine signaling, and that more complex adaptive 
changes are required, including transcriptional regulation and structural changes related to 
neuronal plasticity and synaptogenesis.
171,175-177
 
 Due to the obvious shortcomings of the monoamine hypothesis, a truly massive amount 
of research effort has been dedicated to better understanding and articulating the diverse 
molecular-, cellular-, and circuit-level mechanisms that mediate depression and related 
disorders.
171,175-177
 Interpretation and review of this work results in the formulation of three 
particularly compelling hypotheses, which are each independently supported by large bodies of 
evidence: 1) the BDNF hypothesis, 2) the glutamate hypothesis, and 3) the dopamine/opioid 
hypothesis. 
 Antidepressant Mechanisms: BDNF. Neurotrophic factors are small proteins 
responsible for regulating the growth, survival, differentiation, and synaptic plasticity of neurons 
in both the developing and adult brain. Brain-derived neurotrophic factor (BDNF) appears to be 
of particular importance in mediating the symptoms of depression and in eliciting the long term 
effects of well known antidepressants.
171,175-178
 Further, these modulatory effects appear to be 
most apparent in the hippocampus. Postmortem analysis in the brains of suicide victims has 
shown decreased levels of BDNF in both the hippocampus and prefrontal cortex, and serum 
BDNF levels of living depressed patients are also reported to be depressed.
179,180
 In rodent 
models, stress exposure also results in decreased hippocampal BDNF and dendritic atrophy.
181-
183
 Similarly, depressed humans also show decreased hippocampal volume.
184
 Complementing 
these observations in depressive states, treatment with nearly all known antidepressants increases 
BDNF expression in the hippocampi of both animals and humans.
185,186
 Similarly, infusion of 
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BDNF into the hippocampus produces antidepressant effects in animal models.
187
 Despite this 
seemingly clear connection between upregulation of BDNF and antidepressant effects, there is 
conflicting evidence. Not only have other studies failed to reproduce these effects, but in 
mesolimbic regions of the brain (e.g. NAc), an opposing relationship with BDNF is observed, as 
BDNF is elevated in response to stress, and injection of BDNF elicits prodepressive effects.
188-190
 
Additionally, the val66met BDNF polymorphism observed in a subpopulation of humans impairs 
hippocampal function and activity-evoked BDNF release, but is not associated with an increased 
susceptibility to MDD (but is associated with other psychiatric disorders).
191,192
 At this juncture, 
it seems that the BDNF hypothesis of depression is in need of further clarification. 
 Antidepressant Mechanisms: Glutamate and NMDAR. Modulation of the brain's 
primary excitatory neurotransmitter, glutamate, has also been proposed as a means to treat 
depression.
171,193,194
 This hypothesis is most strongly supported by the fact that antagonists of the 
glutamate gated ion channel, N-methyl D-aspartate receptor (NMDA-R), produce profound, 
rapid, and long-lasting antidepressant effects in both animals and humans after a single 
administation.
171,193-196
 Of these agents, ketamine is the most well documented, but similar 
clinical and preclinical effects have been observed with other NMDA-R antagonists. With 
ketamine, a single sub-anesthetic infusion in humans results in robust antidepressant efficacy 
within hours that persists for days, or even weeks, without further treatment. The fact that the 
onset of antidepressant effects is temporally separated from the transient psychotomimetic 
properties of ketamine, coupled with the long duration of this therapeutic benefit, indicates that 
long-lasting transcriptional and synaptic restructuring mechanisms must be involved in 
mediating these effects. However, the key modulations downstream of NMDA-R blockade 
remain unclear at this time. There is evidence that another ionotropic glutamate receptor, α-
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amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R), is involved, as the 
blockade of these channels eliminates the antidepressant effects of NMDA-R antagonists.
197
 
Furthermore, potentiators of AMPA-R are antidepressant themselves.
198
 There are also multiple 
indications that BDNF is involved in the antidepressant effects of glutamate modulators. For 
example, both ketamine and AMPA-R potentiators rapidly increase hippocampal BDNF mRNA 
and protein levels in rats.
199,200
 Also, the antidepressant properties of NMDA-R antagonists 
appear to depend on BDNF expression.
201
 The involvement of glutamatergic signaling in 
depression is yet further supported by observed NMDA-R and glutamate release abnormalities in 
response to stress, and by the ability of clinically used antidepressants to reverse or oppose these 
adaptations (indirectly).
202-205
 The importance of both AMPA-R and NMDA-R, as well as 
BDNF, in memory, learning, and synaptic plasticity, indicate that all three are likely to be 
involved in the antidepressant effects of glutamate modulation. In total, the available evidence 
indicates a clear involvement of glutamatergic pathways in depression, and their regulation as a 
promising approach for treating this condition, although the details remain to be clarified. 
 Antidepressant Mechanisms: The Mesolimbic System and Endogenous Opioids. 
Given their important role in modulating reward, pleasure, and motivation, the circuits of the 
mesolimbic pathway, and the endogenous opioid peptides that modulate them, are likely to be 
perturbed in MDD and related mood and anxiety disorders.
168,169,177,206-208
 Surprisingly, the 
relationship between dopaminergic pathways and depression has been understudied compared to 
the historic focus on the other monoamines (serotonin and norepinephrine) and other brain 
regions (e.g. the hippocampus). However, there is now growing interest in this area and 
accumulating evidence continues to indicate the importance of mesolimbic reward pathways, and 
their synaptic connections with related areas (e.g. prefrontal cortex, hippocampus, and 
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amygdala), in the pathology of mood disorders and as a possible approach to treatment (for a 
summary of relevant mesolimbic pathways see Figure 4). 
 The general hypothesis is that depressed individuals suffer from dysfunctional or 
underactive reward circuits, and thus display reduced ability to respond to natural rewards and/or 
diminished basal hedonic tone. This in turn suggests increasing activity in the mesolimbic 
pathway (e.g. with exogenous opioids) as a potential means of therapeutic intervention. Such 
depression and anxiety associated dysfunction is suggested by a variety of observations in both 
humans and animals. Using imaging methods (magnetic resonance imaging, MRI; functional 
MRI, fMRI; and positron emission tomography, PET), it has been shown that depressed patients 
exhibit decreased activity in the NAc and PFC, and increased activity in the amygdala (important 
for fear response), in addition to decreased prefrontal cortical volume.
209-212
 Unfortunately, the 
spatial resolution of these methods is low, so it is not known what cell types or connections 
(excitatory or inhibitory) are associated with these observations. Accordingly, more detailed 
animal studies have helped to better clarify our understanding. Much of this work has focused on 
the effects of stress on depressive states and mesolimbic activity. For example, several models of 
stress in rodents (chronic mild stress (CMS), forced swim test (FST), and inescapable shocks) 
elicit an anhedonic state showing reduced responses to subsequent rewarding stimuli (e.g. 
desirable food or drugs of abuse).
213,214
 Importantly, the depressive state produced by stress is 
believed to depend on dopamine modulation in the mesolimbic system, as stressed rodents show 
decreased dopamine levels in NAc, depressed dopamine release/accumulation in NAc in 
response to rewarding stimuli, and decreased phasic firing of VTA dopaminergic neurons 
projecting onto the NAc .
215-220
 Also interesting, is that the administration of clinically used 
antidepressants acts to normalize these responses.  
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 However, contradictory results are observed in some models. For example, in rodents 
exposed to chronic social defeat stress, increased NAc dopamine release and firing of VTA to 
NAc dopaminergic projections is observed.
221,222
 One potential rationalization, is that under more 
severe stress (e.g. social defeat), this activation of the reward circuits is an adaptive or 
compensatory response meant to counteract the negative aspects of the stimulus.  
 Complex and specific synaptic remodeling is also observed in reward-related brain 
regions in response to stress. For example, although changes in spine density and dendritic 
arborization are observed in the rat PFC after exposure to chronic stress, these modifications are 
region- and circuit-dependent.
223
 There is also evidence for genetic factors controlling 
mesolimbic basal activity and reward responsiveness, as rats can be generated by selective 
breeding that show concomitant reduced basal swimming in the FST and decreased 
responsiveness to amphetamine stimulation.
224
 In total, the available data suggests a clear 
correlation between mood disorders and mesolimbic modulation, which will become yet more 
clear as the role of opioids is discussed below. 
 Opioid Modulators as Antidepressants and Anxiolytics. The involvement of the 
mesolimbic system in depression and anxiety immediately suggests the importance of 
endogenous opioid peptides in regulating depressive symptoms, and more importantly, the 
potential use of exogenous opioids to appropriately activate this system, so as to provide 
antidepressant effects. In fact, the evidence connecting mood disorders and the reward circuits is 
further clarified when considered from the specific perspective of the opioid system.
168,169
   
 Firstly, the therapeutic effects of some clinically used antidepressants appear to involve 
the opioid receptors. For example, in rodent behavioral models of depression, the effects of the 
TCAs imipramine, desipramine, and clomipramine, and the SNRI venlafaxine, have all been 
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shown to be partially inhibited by the opioid antagonist naloxone.
225,226
 Some clinical 
antidepressants are also known to increase enkephalin protein and mRNA levels in several brain 
regions, including the reward circuits.
227,228
 Similarly, imipramine increases MOR expression in 
several areas.
229
 Taken together, these observations demonstrate a strong correlation between 
clinical antidepressants and the opioid system, although the exact mechanisms mediating these 
effects are not known. 
 More directly, MOR agonists are also known to be effective as antidepressants. Indeed, 
until the mid-20th century, low doses of opium itself were used to treat depression, and the so 
called "opium cure" was purportedly quite effective.
230
 With the advent of tricyclic 
antidepressants in the 1950s however, the psychiatric use of opiates rapidly fell out of favor and 
has been largely dormant since, likely due to negative medical and societal perceptions stemming 
from their abuse potential. However, there have been scattered clinical reports (both case studies 
and small controlled trials) since the 1970s indicating the effectiveness of MOR agonists in 
treating depression. The endogenous opioid peptide β-endorphin, as well as the small molecules 
oxycodone, oxymorphone, methadone, tramadol, and buprenorphine have all been reported to 
rapidly and robustly improve the symptoms of MDD and/or anxiety disorders in the clinical 
setting.
231-238
 These results have been recapitulated in rodent models, where a variety of MOR 
agonists, including morphine and the endogenous endomorphins, show antidepressant effects, 
which are blocked by naloxone.
239-242
 Most recently, our laboratory has found that the atypical 
antidepressant tianeptine, which has been used clinically for several decades, exerts its beneficial 
effects via direct agonism of MOR (see Chapter 5 for full discussion).
243
 When taken together, 
this body of work establishes a clear precedent for the effectiveness of MOR agonists in the 
treatment of depression and anxiety. It can be imagined that such compounds exert their 
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therapeutic benefit by compensating for an underactive endogenous opioid system, which may 
be the root cause of reduced basal hedonic tone and diminished natural reward response in 
depressed individuals. There is some evidence for populations afflicted with such dysfunctional 
reward circuits. For example, as monitored by a PET study with an MOR-selective tracer, 
untreated patients with MDD showed decreased endogenous opioid release, both in response to 
social rejection stress and after the rewarding stimulus of social acceptance.
244
 This implies that 
depressed individuals have a reduced ability to cope with stress through compensatory 
mesolimbic activation, and also a decreased ability to experience reward through the same 
pathway, mediated by endogenous opioids. 
 As discussed in earlier sections, DOR agonists also show robust antidepressant and 
anxiolytic action in animals, although human evidence remains limited at this time.
56-
58,60,65,139,245,246
 Further, DOR knockout mice show a prodepressive phenotype.
58
 The molecular- 
and circuit-level mechanisms involved in these effects are largely unknown, but may involve 
modulation of dopamine levels in the mesolimbic circuits and the ability of exogenous DOR 
agonists to substitute for endogenous DOR activating peptides (primarily met- and leu-
enkephalin). A number of reports suggest the importance of enkephalins in regulating mood. Pre-
proenkephalin knockout mice show an anxious phenotype, while proenkephalin knockouts do 
not display a naloxone conditioned place aversion.
247,248
 Similarly, both diminished basal 
enkephalin levels and lowered enkephalin release in response to reward are observed in rodents 
after CMS, while known antidepressants counteract these deficits.
227,249,250
 In contrast, 
enkephalinase inhibitors, that prevent the degradation of endogenous enkephalins, elicit 
antidepressant effects, which are blocked by the DOR antagonist naltrindole.
251,252
 Therefore, 
DOR agonists may be able to substitute for deficiencies in enkephalin signaling to exert their 
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beneficial effects on mood. Studies examining the effects of DOR agonists on mesolimbic 
dopamine release are less clear, as both increases and decreases have been observed.
62,253
 BDNF 
may also be involved in the antidepressant properties of DOR agonists, as both peptide and small 
molecule agonists increase BDNF mRNA expression in several brain regions, including the 
hippocampus (similar to known antidepressants).
65,254,255
 
 The effects of KOR modulation in the mesolimbic circuits are particularly interesting, as 
they generally oppose the actions of MOR and DOR. Both the endogenous dynorphin peptides 
and exogenous KOR agonists induce prodepressive and aversive effects, while KOR antagonists 
produce antidepressant and anxiolytic effects in animal models.
45-47,256,257
 These effects are also 
known from early studies of KOR agonists in humans.
258
 Similarly, KOR agonists appear to 
induce anhedonic states, as evidenced by reduced responses to rewarding stimuli, which appears 
to depend on depressed dopamine release in the NAc.
259-261
 Considering these observations, it is 
unsurprising that stress elevates dynorphin levels in the NAc and hippocampus, and that mice 
lacking prodynorphin show a stress resilient phenotype.
48,262
 Release of dynorphin in response to 
stress appears to be induced by activation of cAMP response element-binding protein (CREB) in 
the NAc. This is supported by several findings, namely: 1) FST stress elevates CREB activity in 
the NAc, 2) selective elevation of CREB activity in the NAc results in prodepressive effects, 
while its selective ablation induces antidepressant effects, and 3) CREB expression is colocalized 
with, and controls, prodynorphin expression in MSNs of the NAc.
263,264
 Accordingly, a feedback 
mechanism can be proposed, in which stress activates CREB in MSNs of the NAc, resulting in 
release of dynorphin both locally, and from reciprocal projections of these neurons synapsing 
onto dopaminergic cell bodies in the VTA (see Figure 4). This in turn activates KORs on these 
VTA neurons and inhibits dopamine release at their projections terminating in the NAc, thus 
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reducing the reward response and basal hedonic tone.
265,266
 This CREB-mediated pathway may 
also be involved in the observed prodepressive effects of BDNF in the NAc, as BDNF can 
activate CREB through the kinase TrkB and the ERK signaling pathway.
188-190,206
 Further, as 
BDNF expression can also result from CREB activation, potential positive feedback mechanisms 
are suggested.
267
 In total, the connection between KOR and mood regulating mechanisms seems 
clear, at least in relation to the mesolimbic circuits. However, as no KOR antagonists have yet 
reached the market for the treatment of depression or other mood disorders, the potential promise 
suggested by these animal studies remains to be realized. 
 Outlook. Given the extreme complexity of the brain, it seems highly likely that the 
depression-related mechanisms described above are interrelated and coincident in many cases. 
Each of these mechanistic systems is interconnected, and they may in turn modulate each other, 
via direct or indirect pathways, in an upstream or downstream fashion, depending on the specific 
molecular perturbations of the therapeutic agent. For example, there is considerable involvement 
of opioid receptors in the regulation of glutamate signaling (see Chapter 5 for detailed 
discussion).
35
 Further, it is not yet clear if any single molecular mechanism is capable of eliciting 
antidepressant effects in isolation. In fact, it is likely that more effective future antidepressants 
will need to modulate multiple neurotransmitter systems (perhaps including the opioid receptors) 
and circuits to exert maximal therapeutic effects that will be patient specific. 
  
Current Work 
  As described above, the study of the opioid receptor system is a highly active and 
growing area of research. Recent and ongoing developments in our understanding of opioid 
receptor pharmacology and the various behaviors and pathologies modulated by those receptors, 
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have opened abundant new opportunities to develop novel analgesics with improved therapeutic 
profiles, and to modulate opioid receptors to treat depression and anxiety. Accordingly, today 
more than ever, there is a compelling case to develop and study new small molecule modulators 
of the opioid system. The studies that follow here present chemical, pharmacological, and 
behavioral explorations surrounding three unusual opioid modulating molecular scaffolds: iboga 
alkaloids, mitragyna alkaloids, and tianeptine. Synthetic routes to each scaffold and methods of 
derivatization are described, along with exploration of structure-activity relationships (SAR) at 
the opioid and other brain receptors. Also discussed are mechanistic hypotheses based on the 
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 The iboga alkaloids, represented by the prototypical members ibogamine and ibogaine 
(Figure 1B), are a class of indole natural products isolated from Tabernanthe iboga (Figure 1A), 
a plant used in folk and ritualistic medicine in west Africa. Ibogaine has historically received 
significant attention in both the scientific community and popular media, due to widespread 
anecdotal reports of its remarkable ability to reverse, or markedly attenuate, drug addiction and 
dependence in humans.
1-4
 Reportedly, a single high dose (>1 gram) administration of ibogaine, 
known as "ibogaine reset", immediately results in a reduction or total loss of both drug 
withdrawal symptoms and cravings in 
addicted individuals. Further, this 
interruption of addictive behavior typically 
persists for long periods of time (weeks or 
months) following a single administration, 
although small maintenance doses are 
sometimes employed. These claims have 
been largely recapitulated in rodents, where 
ibogaine reduces self-administration and 
reinstatement of major drugs of abuse, 
including cocaine, morphine, alcohol, and 
nicotine.
1
 Unfortunately, the high doses of 
the compound used in addiction therapy, 
also elicit profound hallucinations and 
dissociative states in the patient, as well as 
Figure 1.  (A) Tabernanthe iboga; (B) Structure of iboga 
alkaloids; (C) The indicated disconnection unlocks a rapid 
and modular approach to ibogamine analogs. This key C-H 
functionalization is however highly challenging, as described 
here. 
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negative cardiovascular effects in some cases, side effects that make ibogaine a controversial 
clinical option. These hallucinogenic properties have also resulted in the prohibition of ibogaine 
in the United States, where it is a Schedule 1 controlled substance, a situation that has hindered 
fundamental and clinical studies with this potentially valuable substance. 
 Despite this substantial evidence for ibogaine's efficacy in both humans and animal 
models, the molecular mechanism(s) of action responsible for its anti-addictive properties is not 
clear. The in vitro pharmacological activity of ibogaine has been extensively studied and it is 
known to bind to, or show functional activity at, a variety of CNS receptors with micromolar 
potency.
1,5
 The complexity of ibogaine's pharmacological profile is further complicated by the 
high doses used in treatment and thus, the high brain concentrations achieved.
6
 Therefore, even 
targets of low binding affinity (>10 µM) may be activated at clinical doses and thus, be of 
significant importance in mediating ibogaine's gross behavioral effects. A particularly 
compelling hypothesis is that ibogaine is capable of increasing expression of glial cell line-
derived neurotrophic factor in the ventral tegmental area of the brain, and that this modulation is 
responsible for its anti-addictive properties.
7
 However, ibogaine also shows activity at a variety 
of other CNS targets, including the opioid receptors, N-methyl-D-aspartate receptor, the 
dopamine and serotonin transporters, sigma 2 receptor, 5-HT2a, acetylcholine receptors, and 




Synthesis of Iboga Alkaloids via C-H Functionalization. In light of their interesting 
pharmacological and clinical properties, the iboga alkaloids have attracted considerable interest 
from the synthetic community, with several total syntheses of the desmethoxy analog ibogamine 
(Figure 1B) reported in the literature.
9 
In the context of a research program studying the 
pharmacology and cell signaling biology of iboga alkaloids, we required a modular and robust 
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synthesis for the preparation of ibogamine and unnatural derivatives. Specifically, we wanted to 
explore structure-activity relationships (SAR) at several potential molecular targets, an effort that 
required access to numerous structurally varied analogs. Finding existing synthetic strategies 
poorly suited to this task, we endeavored to develop new synthetic methods providing a general, 
and easily varied approach, to the iboga skeleton.  
 For many years, we have been advancing “C-H bond functionalization” as a general 
concept in chemical synthesis.
10
 Viewing C-H bonds as ubiquitous functionalities leads to novel 
strategic opportunities in the construction of complex molecular skeletons, or in the late-stage 
diversification of existing frameworks. In the context of iboga alkaloid synthesis, we were 
interested in rapid construction of the polycyclic core structure by formation of the 7-membered 
ring, via C-H bond/alkene coupling, as the key strategic step (Figure 1C).  We viewed this as a 
powerful disconnection, which would enable modular and convergent synthesis of ibogamine 
analogs from a diverse set of readily available isoquinuclidines and bromoethylheteroarenes.  
 This approach was previously employed by Trost in the synthesis of ibogamine and 
related systems.
11-13 
Unfortunately, the original conditions reported for this cyclization suffer 
from several major disadvantages. Firstly, stoichiometric quantities of both palladium and silver 
are required, making the transformation quite costly. More importantly, we found the original 
procedure highly inconsistent and low yielding, and yields over 15% were never obtained despite 
extensive variation of the reaction conditions. Our results are in agreement with those of 
Hodgson, who also reported a low yield using this procedure.
14
 Therefore, we set out to 
systematically examine this powerful, but challenging, C-H functionalization step for cyclization 
of the iboga skeleton, with the main goal of developing new catalytic procedures to provide easy 
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access to iboga alkaloid analogs in support of our pharmacological explorations of this molecular 
scaffold. 
 
Results and Discussion 
 Synthesis of Cyclization Substrates: N-heteroarylalkylisoquinuclidines. To prepare 
for exploration of novel C-H activation-cyclization reactions, we first needed to prepare the 
necessary substrates for this work, namely, N-heteroarylalkylisoquinuclidines. We envisioned 
that these could be accessed by a modular approach, through alkylation of isoquinuclidine 
alkenes with various bromoalkylheteroarenes (Figure 1C). Accordingly, the first task at hand 
became the synthesis of these necessary building blocks. To prepare the isoquinuclidine 
fragments, exo- and endo-tosylhydrazones 1a and 1b were synthesized according to the Diels-
Alder strategy of Krow (Scheme 1).
15
 It should be noted that the stereochemistry of these 
products was incorrectly assigned in this original report, as noted and corrected by Hodgson 
based on crystallographic data.
14
 Similarly, we independently confirmed the corrected 
stereochemistry of both hydrazones based 
on NMR experiments. Finding the 
reported reduction procedures of the 
hydrazones to be low yielding, we 
developed alternative conditions. 
Interestingly, the two isomers required 
different reduction conditions, with the 
exo-isomer 1a being much more resistant 
to reduction. By our modified conditions, 
Scheme 1. Synthesis of isoquinuclidine fragments by 
Diels-Alder reaction. 
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both exo- and endo-7-ethylisoquinuclidines 2a and 2b were successfully obtained in moderate 
yields (Scheme 1). 
 With the required isoquinuclidine fragments in hand, we turned our attention to the 
synthesis of the necessary heteroarene fragments. As the electronic character of the heteroarene 
and the critical 2-position C-H bond were expected to be of significant importance in the success 
of potential C-H bond/alkene couplings, we wanted to prepare cyclization substrates bearing 
diverse heteroarenes, so as to provide a means for examining the scope of any new reactions 
developed. Therefore, in addition to the unsubstituted, commercially available 3-(2-















Scheme 2. Synthesis of bromoalkylheteroarenes. 
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as well as the analogous 
benzofuran (6c) and 
benzothiophene (6d) bromides 
(Scheme 2). To access a 
substrate which would provide 
an 8-membered ring on 
cyclization, we also prepared 
the propylbromide 6e. To obtain 
the N-heteroarylalkyl- 
isoquinuclidines required for the 
cyclization studies, 
isoquinuclidines 2a and 2b were 
then deprotected and alkylated 
with the bromides (6), to obtain a collection of heteroarene-alkene substrates (7) appropriate for 
potential C-H bond/alkene coupling (Scheme 3).  
 Indole C-H Bond Functionalization: Electrophilic Approach. As an initial approach 
to the key cyclization, it was hoped that a catalytic, electrophilic activation reaction could be 
developed under acidic conditions. Electrophilic palladium(II) species are known to activate 







 have shown that the intermediate alkyl-palladium 
species in these reactions can be reduced to afford a reductive coupling process. Therefore, it 
was hoped that in the iboga system, where oxidative cyclization is not feasible due to strain 
considerations, the intermediate alkyl-palladium cyclization product would be susceptible to 
Scheme 3. Synthesis of N-heteroarylalkylisoquinuclidines by alkylation. 
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protonolysis. In such a reaction, an 
electrophilic palladium (or other metal) 
species would activate the system either 
through direct metalation of indole, or through 
coordination to the olefin. Following C-C 
bond formation, protonative removal of the 
metal could regenerate the electrophilic 
catalyst (Figure 2). Unfortunately, a variety of 
Pd(II) salts under protic/acidic conditions 
failed to effect cyclization of the unsubstituted 
indole substrate 7a (Table 1). Although traces of product were observed under some conditions 
(by TLC and mass spectrometry), no isolable yields could be obtained and the conditions could 
not be optimized to obtain better results.  
 We also examined a large variety of other electrophilic transition metal conditions (Table 
2), including platinum and ruthenium catalysts effective for intramolecular indole-alkene 
hydroarylation reactions.
19,20
 Several gold-catalyzed conditions reported for indole-alkene 
coupling were also attempted, as well as the non-metallic electrophilic reagent N-
phenylselenophthalimide.
21-23
 Again however, in all cases, none or only a trace of the desired 
product was detected. A frequent problem in many trials was the rapid reduction and 
precipitation of the electrophilic metal species as the corresponding neutral metal (e.g. palladium 
black). We suspect that reduction by the tertiary amine present in the substrate is a primary 
driver of these difficulties. However, addition of a variety of oxidants did not successfully 
prevent reduction and precipitation of the metal in the case of palladium (Table 1, Entries 7-12). 
Figure 2. Proposed mechanistic rationale for an 
electrophilic, catalytic cyclization. ML represents the 



























Catalyst                                    
(Quantity, mol%)
Solvent                
(Quantity, mL)
Additive 1         
(Quantity, mol%)





1 0.1 Pd(OAc)2 (100) AcOH (1) - - 80
full conversion, no 
product
2 0.1 Pd(OAc)2 (10) AcOH (1) - - 80
low conversion, no 
product
3 0.1 Pd(OAc)2 (10) TFA (1) - - 80
low conversion, no 
product
4 0.1 Pd(OAc)2 (100) TFA (1) - - 80
full conversion, no 
product




low conversion, trace 
product




low conversion, trace 
product
7 0.1 Pd(OAc)2 (100)
dioxane:AcOH:H2O, 
65:17:17 (1)
benzoquinone (100) - 80
low conversion, trace 
product
8 0.1 Pd(OAc)2 (100)
dioxane:AcOH:H2O, 
65:17:17 (1)
Cu(OAc)2 •  H2O 
(100)
- 80
low conversion, trace 
product
9 0.1 Pd(OAc)2 (100)
dioxane:AcOH:H2O, 
65:17:17 (1)
AgOAc (100) - 80
low conversion, trace 
product
10 0.05 Pd(OAc)2 (100)
dioxane:AcOH:H2O, 
65:17:17 (0.50)
oxone (200) - 80
low conversion, no 
product






full conversion, no 
product
12 0.05 Pd(OAc)2 (100)
dioxane:AcOH:H2O, 
65:17:17 (0.50)
NMO • H2O (200) - 80
full conversion, no 
product




low conversion, trace 
product




low conversion, trace 
product




low conversion, no 
product
16 0.1 Pd(OAc)2 (10)
dioxane:AcOH, 65:35    
(1)
- - 80
low conversion, trace 
product




low conversion, trace 
product




low conversion, trace 
product
19 0.1 Pd(OAc)2 (10)
dioxane:AcOH:H2O, 
65:17:17 (1)
oxygen atmosphere - 80
high conversion, no 
product
20 0.1 PdCl2 (20) CH3CN (0.40) AgBF4 (40) HBF4 • H2O (150) 85
low conversion, no 
product
21 0.1 PdCl2 (20) CH3CN (0.40) AgBF4 (40) HOTf (150) 85
low conversion, no 
product
22 0.1 PdCl2 (20) CH3CN (0.40) AgOTf (40) HOTf (150) 85
low conversion, no 
product
23 0.1 PdCl2 (20) 1,2-DCE (0.40) AgOTf (40) HOTf (150) 85
full conversion, no 
product
24 0.1 PdCl2 (20) CH3CN (0.40) AgOTf (40) - 85
low conversion, no 
product




low conversion, trace 
product




low conversion, no 
product
























low conversion, no 
product












full conversion, no 
product




low conversion, trace 
product
34 0.05 Pd(CH3CN)4(BF4)2 (100) CH3CN:H2O, 65:17 (0.42) - - 80
low conversion, no 
product
35 0.05 Pd(CH3CN)4(BF4)2 (100)





36 0.05 Pd(CH3CN)4(BF4)2 (100) H2O (0.42) - - 80
medium conversion, 
trace product
37 0.05 Pd(CH3CN)4(BF4)2 (100)
DMSO:H2O, 65:17     
(0.42)
- - 80
low conversion, no 
product

























Table 2. Unsuccessful electrophilic metal conditions screened for cyclization of 7a. 
 
Entry Scale (mmol)
Catalyst               
(Quantity, mol%)
Solvent                   
(Quantity, mL)
Additive 1      
(Quantity, mol%)





1 0.25 (PPh3)AuCl (10) toluene (0.83) AgOTf (10) - 85 no conversion
2 0.25 (PPh3)AuCl (10) toluene (0.83) AgOTf (10) - 150 no conversion
3 0.1 RuCl3  xH2O (5) 1,2-DCE (0.50) AgOTf (10) - 60 no conversion
4 0.1 RhCl3 (5) 1,2-DCE (0.50) AgOTf (10) - 60 no conversion
5 0.1 IrCl4  xH2O (5) 1,2-DCE (0.50) AgOTf (10) - 60 no conversion
6 0.1 PtCl4 (5) 1,2-DCE (0.50) AgOTf (10) - 60 no conversion
7 0.1 Sc(OTf)3 (20) 1,2-DCE (0.50) - - 100 no conversion
8 0.1 Cu(OTf)2 (20) 1,2-DCE (0.50) - - 100
low conversion, no 
product








 (2.5) p-TsOH (5) - R.T. to 80
phenylselenide at 
indole 2-position
11 0.1 Hg(OTf)2 (120) CH2Cl2 (1.5) - - 80
slow conversion to tar, 
no product
12 0.1 Hg(OTf)2 (120) toluene (1.5) - - 80
slow conversion to tar, 
no product
13 0.1 Hg(OTf)2 (120) CH3CN (1.5) - - 80
slow conversion to tar, 
no product
14 0.05 PtCl4 (30) toluene (0.50) AgBF4 (120) - 80 insoluble tar
15 0.05 PtCl4 (30) 1,2-DCE (0.50) AgBF4 (120) - 80
medium conversion, 
trace product
16 0.05 PtCl4 (30)
dioxane:H2O, 4:1 
(0.50)
AgBF4 (120) - 80
low conversion, no 
product
17 0.05 RuCl3 (30) toluene (0.50) AgBF4 (90) - 80 insoluble tar
18 0.05 RuCl3 (30) 1,2-DCE (0.50) AgBF4 (90) - 80
medium conversion, 
trace product
19 0.05 RuCl3 (30)
dioxane:H2O, 4:1 
(0.50)
AgBF4 (90) - 80
low conversion, no 
product
20 0.05 AuCl3 (30) toluene (0.50) - - 80
low conversion, no 
product
21 0.05 AuCl3 (30) 1,2-DCE (0.50) - - 80
low conversion, no 
product






low conversion, no 
product
23 0.05 AuCl3 (30) toluene (0.50) AgBF4 (90) - 80 insoluble tar
24 0.05 AuCl3 (30) 1,2-DCE (0.50) AgBF4 (90) - 80
medium conversion, 
trace product







 (90) - 80
low conversion, no 
product
26 0.05 PtCl4 (30) 1,2-DCE (0.50) AgBF4 (120) - 50
medium conversion, no 
product
27 0.05 PtCl4 (100) 1,2-DCE (0.50) AgBF4 (400) - 80 insoluble tar
28 0.05 PtCl4 (30) 1,2-DCE (0.50) AgOTf (120) - 80
medium conversion, no 
product
29 0.05 PtCl4 (30) 1,2-DCE (0.50) AgSbF6 (120) - 80
medium conversion, 
trace product
30 0.05 PtCl4 (30) 1,2-DCE (0.50) - - 80
low conversion, trace 
product
31 0.1 PtCl4 (30) 1,2-DCE (1.0) AgSbF6 (90) - 80
low conversion, no 
product
32 0.1 PtCl4 (30) 1,2-DCE (1.0) AgSbF6 (60) - 80
low conversion, trace 
product
33 0.1 PtCl4 (30) 1,2-DCE (1.0) AgSbF6 (30) - 80
low conversion, trace 
product
34 0.1 PtCl4 (10) 1,2-DCE (1.0) AgSbF6 (40) - 80
low conversion, no 
product
35 0.1 PtI4 (30) 1,2-DCE (1.0) - - 80
low conversion, no 
product
36 0.1 PtCl2 (30) 1,2-DCE (1.0) AgSbF6 (60) - 80
low conversion, no 
product
37 0.1 PtCl2 (30) 1,2-DCE (1.0) - - 80
low conversion, no 
product
38 0.1 PtI2 (30) 1,2-DCE (1.0) AgSbF6 (60) - 80
low conversion, no 
product
39 0.1 PtI2 (30) 1,2-DCE (1.0) - - 80
low conversion, no 
product
40 0.1 [PtCl2(C2H4)]2 (5) dioxane (1.0) HCl (5) - 90
low conversion, no 
product
41 0.1 [PtCl2(C2H4)]2 (5) dioxane (1.0) HCl (105) - 90
low conversion, no 
product
42 0.1 [PtCl2(C2H4)]2 (5) dioxane (1.0) AgOTf (10) PPh3 (10) 90
low conversion, no 
product
43 0.1 [PtCl2(C2H4)]2 (5) dioxane (1.0) - PPh3 (10) 90
low conversion, no 
product
44 0.1 [PtCl2(C2H4)]2 (5) dioxane (1.0) - PPh3 (20) 90
low conversion, no 
product
45 0.1 [PtCl2(C2H4)]2 (5) dioxane (1.0) AgOTf (10) - 90
low conversion, no 
product
46 0.1 [PtCl2(C2H4)]2 (5) dioxane (1.0) - PPh3 (10) 120
full conversion, no 
product
47 0.05 - - - - 200
low conversion, no 
product
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 In contrast to these disappointing results, it was found that the original conditions
11-13
 
could be improved by a simple modification. When the pre-formed palladium tetrafluoroborate 
salt Pd(CH3CN)4(BF4)2 was used in 
place of a mixture of PdCl2(CH3CN)2 
and AgBF4, modest, but consistent 
yields of ibogamine were obtained 
following sodium borohydride 
reduction of the resulting 
organopalladium intermediate (Table 3, 
Entry 1). This result indicates that silver 
is not directly involved in electrophilic 
activation of the substrate and serves 
only to exchange chloride for non-
coordinating tetrafluoroborate, thus 
generating a more active electrophile. 
Indeed, a reagent system consisting of 
equimolar amounts of 
Pd(CH3CN)4(BF4)2 and AgBF4 
provided an identical yield to the 
palladium salt alone, thus confirming 
the likely role of silver as a simple 
halide scavenger. These modified 
conditions were applied with success to 
a
Reactions run at 0.250 mmol scale, 
b
Isolated yields from 
representative examples of 2 or more independent trials, NMR 
yields in parentheses, trial-to-trial variation typically <5%, 
c
Run at 0.100 mmol scale, 
d
Run at 0.060 mmol scale 
 




a variety of substrates (Table 3, Entries 2-5). As expected, lower yields were obtained when the 
heteroarene was more electron-poor, with both the fluoroindole 7b and benzofuran 7d providing 
significantly reduced yields. These substrates are evidently less amenable to electrophilic 
palladation, or alternatively, to nucleophilic attack on a palladium activated olefin. However, 
these conditions were not effective for the formation of the 8-membered ring analog when 
applied to substrate 7g (Table 3, Entry 6). 
 In all cases, the primary side products were the hydrogenated starting materials (olefin 
reduced), which were often observed in comparable yields to the desired products. Presumably, 
these byproducts result from residual starting material that is hydrogenated by liberated hydrogen 
during the sodium borohydride quench. Accordingly, it was found that extended reaction times 
reduced the amount of hydrogenated side product, but surprisingly, did not increase yields of the 
cyclized product. Using these conditions, an attempt was also made to probe the viability of a 
protic de-metalation catalytic cycle (Figure 2). After treatment of 7a with Pd(CH3CN)4(BF4)2 in 
the usual manner, tetrafluoroboric acid diethyl ether complex was added in place of the normal 
NaBH4 treatment. Unfortunately, no conversion of the intermediate organopalladium species to 
the product was observed under these conditions, either at room temperature or upon heating. 
Therefore, a strategy based on protonolysis to regenerate an active Pd(II) catalytic species does 
not appear to be feasible and thus, we were unable to overcome the need for stoichiometric 
palladium using this strategy. 
 Indole C-H Bond Functionalization: Bromination and Reductive Heck Coupling. 
Encountering such difficulties with the electrophilic activation strategy, and still desiring a 
catalytic route to the iboga scaffold, an alternative strategy was pursued employing traditional 
palladium chemistry. It was found that substrate 7a could be selectively brominated at the indole 
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2-position using trimethylphenylammonium tribromide in ~65% yield.
 
This aryl bromide 
intermediate was then cyclized by a reductive Heck reaction
24
 employing Pd(PPh3)4 as catalyst, 
with sodium formate as the hydride source (Table 4, entry 1). Although initial trials with this 
reaction were low-yielding, some optimization identified DMSO as the ideal solvent for this 
transformation, and with the optimized conditions, yields of ~65% were obtained with only trace 
quantities of 7a observed (resulting from competing aryl bromide reduction). Reduced catalyst 
loadings achieved complete conversion but provided lower yields of product. Likewise, formates 
with alternative counterions (potassium and ammonium) resulted in significantly reduced yields. 
Pleasingly, it was found that purification of the intermediate bromide was not required. The 
crude bromination mixture could simply be washed with aqueous ammonia in situ, concentrated, 
and used directly in the cyclization step. This protocol provided an overall yield of 42% over two 
steps, in agreement with the yields 
obtained when the two steps were run 
independently. The total synthesis of 
ibogamine was thus accomplished in 7 
steps from pyridine (6.4% overall yield). 
 Pleased with the success of the 
reductive Heck reaction for the efficient 
total synthesis of ibogamine, we attempted 
to apply the same procedure to related 
substrates (Table 4, Entries 2-6). 
Unfortunately, these efforts met with 
unsatisfactory results. With electron-poor 
Table 4. Preparation of ibogamine analogs via reductive 
Heck reaction. 
* ~65% yield for each individual step 
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indole substrate 7b, only a very small quantity of the desired product could be isolated and the 
product mixture was very complex, hindering purification. Further examination revealed that 
both the bromination step and the cyclization step (with pure bromide) were independently low 
yielding (<25%). Difficulty was also encountered with electron-rich substrate 7c, as bromination 
was selective for the indole 4-position, para to the benzyloxy group. When benzofuran (7d) and 
benzothiophene (7f) substrates were used, no bromination was observed. Lastly, substrate 7g was 
successfully brominated, but no cyclization occurred, only reduction of the aryl bromide back to 
the starting material 7g. Therefore, although effective for the synthesis of ibogamine itself, the 
reductive Heck procedure did not provide a general solution for the synthesis of ibogamine 
analogs varied at the aryl moiety. 
 Indole C-H Bond Functionalization: Low-Valent Metal Insertion Approach. At this 
time, we became interested in an alternative strategy employing a direct C-H insertion 
mechanism. It was envisioned that oxidative addition of a low-valent transition metal into the 2-
position heteroaryl C-H bond might provide a metal hydride species that could then add directly 
to the olefin, followed by reductive elimination to provide the cyclized product and regenerate 
the catalyst (Figure 3). In particular, we were interested by a recent report of intermolecular 
hydroheteroarylation of styrenes employing a 
nickel(0)/N-heterocyclic carbene (NHC) catalyst 
system.
25
 The substrate scope of this work 
included both electron-poor indoles (electron 
withdrawing group at 3-position) and benzofuran, 
as well as a single example demonstrating 
hydroheteroarylation of an aliphatic olefin. 
Figure 3. An alternative strategy for iboga 
cyclization relying on direct C-H insertion of a 
low-valent metal. ML represents the metal (M) 
attached to one or more ligands (L). 
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Therefore, it was hoped that this Ni(0) catalyst system might be employed intramolecularly, to 
afford cyclization yielding the iboga skeleton. 
 Applying 10 mol% Ni(COD)2 and 10 mol% IMes (1,3-Bis(2,4,6-trimethylphenyl)-1,3-
dihydro-2H-imidazol-2-ylidene) in toluene at 140 °C to benzofuran substrate 7d, low yields of 
the cyclized product 8d could be obtained, but with incomplete conversion (Table 5, entry 1). 
However, it was soon found that the switch to aliphatic hydrocarbon solvents provided much 
improved yields, with heptane being the optimal solvent (Table 5, Entry 2). Further 




Catalyst                   
(Quantity, mol%)
Solvent                   
(Quantity, mL)
Additive 1     
(Quantity, mol%)





1 0.1 Ni(COD)2 (10) toluene (0.50) IMes (10) - 140 12% NMR yield
2 0.1 Ni(COD)2 (10) heptane (0.50) IMes (10) - 140 41% NMR yield
3 0.1 Ni(COD)2 (10) hexane (0.50) IMes (10) - 140 30% NMR yield
4 0.1 Ni(COD)2 (10) dodecane (0.50) IMes (10) - 140 40% NMR yield
5 0.1 Ni(COD)2 (10) chlorobenzene (0.50) IMes (10) - 140
low conversion, trace 
product
6 0.1 Ni(COD)2 (10) THF (0.50) IMes (10) - 140
low conversion, trace 
product
7 0.1 Ni(COD)2 (20) heptane (0.50) IMes (20) - 140 65% NMR yield
8 0.1 Ni(COD)2 (10) heptane (0.50) IPr (10) - 140 8% NMR yield
9 0.1 Ni(COD)2 (10) heptane (0.50) IMes  HCl (10) NaOtBu (12) 140 20% NMR yield
10 0.1 Ni(COD)2 (10) heptane (0.50) IiPr  HCl (10) NaOtBu (12) 140
low conversion, trace 
product
11 0.1 Ni(COD)2 (10) heptane (0.50) IAd  HCl (10) NaOtBu (12) 140
low conversion, trace 
product
12 0.1 Ni(COD)2 (10) heptane (0.50) SIPr  HCl (10) NaOtBu (12) 140
low conversion, trace 
product
13 0.1 Ni(PPh3)2(CO)2 (10) heptane (0.50) IMes (12) - 130 10% NMR yield
14 0.1 Ni(PPh3)4 (10) heptane (0.50) IMes (12) - 130 10% NMR yield
15 0.1 Ni(acac)2 (10) heptane (0.50) IMes (10) - 140 no product
16 0.05 Ir(COD)2BF4 (20) heptane (0.25) - - 130 no conversion
17 0.05 Ir(COD)2BF4 (20) heptane (0.25) IMes (24) - 130 no conversion
18 0.05 Rh(COD)2BF4 (20) heptane (0.25) - - 130 no conversion
19 0.05 Rh(COD)2BF4 (20) heptane (0.25) IMes (24) - 130 no conversion
Table 5. Optimization of Ni(0)-catalyzed cyclization (partially performed by Dr. Souvik Rakshit). 
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complete conversion and significantly improved yield (Table 5, Entry 7). Unfortunately, yields 
for this transformation could not be further improved. The use of the alternative NHC ligand IPr 
did provide the desired product, but in lower yield, while other NHCs provided only traces of 
product (Table 5, Entries 8-12). Likewise, the use of different Ni(0) sources strongly inhibited 
product formation (Table 5, Entries 13-15). Other low-valent metals were also completely 
ineffective for this transformation, with (COD)2Ir(BF4) and (COD)2Rh(BF4) showing no 
conversion of starting material, both with and without IMes (Table 5, Entries 16-19). We also 
examined the analogous intermolecular reaction between isoquinuclidine 2b and 3-
methylbenzofuran, which was ineffective 
under these conditions, indicating that this 
reaction benefits from intramolecular 
entropic enhancement. 
 We then applied our optimized 
conditions to substrate 7d on a larger 
preparative scale, and an excellent isolated 
yield of the cyclized product was obtained 
(Table 6, Entry 1). Interestingly, yields 
with the endo-epimer substrate 7e were not 
as high (Table 6, entry 2). This disparity 
may result from a difference in steric 
shielding of the tertiary amine by the ethyl 
group between 7d and 7e, allowing for 
greater interference with the catalytic 
a
Reactions run at 0.500 mmol scale, 
b
Isolated yields from 
representative examples of 2 or more independent trials, 
NMR yields in parentheses, trial-to-trial variation 
typically <5%, 
c
Run at 0.250 mmol scale with 10 mol% 
Ni(COD)2 and 10 mol% IMes in toluene, 
d
Run at 0.250 
mmol scale in toluene 
 




species by the more exposed amine in endo-substrate 7e. Indeed, 7e was observed to be 
significantly more polar than 7d on silica, likely indicated greater exposure of the nitrogen lone 
pair for hydrogen bonding. Alternatively, the steric bulk of the exo-ethyl group in 7d may act to 
enrich the nitrogen atom configuration in which the heteroaryl substituent is constrained on the 
olefin side and thus, appropriately aligned for cyclization. 
 Building on these results, application of similar conditions to indole and benzothiophene 
substrates was attempted. Unfortunately, no conversion was observed in either case (Table 6, 



























inhibited by competing insertion into the more acidic N-H bond, or by the higher electron density 
of the heteroarene (compared to benzofuran). Therefore, we felt that protection of the indole 
nitrogen could remedy both of these potential difficulties by removing the problematic N-H bond 
while decreasing the electron-richness of the heteroarene (with electron withdrawing protecting 
groups). Unfortunately, analogs of 7a protected at the indole nitrogen with a tosyl, triflyl, acetyl, 
or [2-(trimethylsilyl)ethoxy]methyl group
26
 also failed in the cyclization (Scheme 4). Similarly, 
an attempt to use a pyridin-2-ylsulfonyl group on the indole nitrogen, to provide a directing 
effect to position 2, also met with failure (Scheme 4). Therefore, this remarkable Ni-mediated 
transformation appears to be limited to benzofuran substrates. A variety of alternative, low-
valent metal catalyst systems were also screened on the protected derivatives 7j and 7l, but no 
further effective conditions were identified (Table 7). 
 
 
        Table 7. Unsuccessful low-valent metal conditions for the cyclization of protected indole substrates. 
Entry
Substrate     
(Quantity, mmol)
Catalyst                     
(Quantity, mol %)





1 7j (0.050) RhCl(PPh3)3 (20) toluene (0.20) 130
low conversion, de-
acetylated starting mat.
2 7j (0.050) RuH2(CO)(PPh3)3 (20) toluene (0.20) 130
low conversion, de-
acetylated starting mat.
3 7l (0.050) RhCl(PPh3)3 (20) toluene (0.20) 130
low conversion, no 
product
4 7l (0.050) Rh(CO)2acac (20) toluene (0.20) 130
low conversion, no 
product
5 7l (0.050) RuH2(CO)(PPh3)3 (20) toluene (0.20) 130
low conversion, no 
product
6 7l (0.050) CpRu(PPh3)2Cl (20) toluene (0.20) 130
low conversion, no 
product
7 7l (0.050) [(COD)Ir(PMePh2)2]PF6 (20) toluene (0.20) 130
low conversion, no 
product
8 7l (0.050) [(COD)Ir(PPh3)2]BF4 (20) toluene (0.20) 130
low conversion, no 
product
9 7l (0.050) (PPh3)2Ni(CO)2 toluene (0.20) 130
low conversion, no 
product
10 7l (0.050) Ni[P(OPh)3]4 toluene (0.20) 130




 In the preceding work, the modular synthesis of the iboga alkaloid core via a strategy 
centered on a direct intramolecular cyclization was examined. This key C-H bond 
functionalization step proved unexpectedly difficult. Although there are a number of known 
catalytic systems that effect hydroarylation of unactivated alkenes, most of them failed in the 
specific context of this cyclization. We propose that the following structural features contribute 
to the difficulty of this transformation: 1) the substitution of the indole in the 3-position with an 
electron-donating group (that also sterically hinders indole metalation); 2) the isoquinuclidine’s 
basic amine (that deactivates and reduces transition metal catalysts); 3) the bicyclic nature of the 
isoquinuclidine (that prevents oxidative cyclization); and 4) formation of a medium-sized ring.  
 Nevertheless, a direct nickel-catalyzed cyclization was found for the benzofuran 
substrates, which provided novel oxaibogamine analogs in moderate to good yields. We also 
identified two palladium-based systems for the formation of the 7-membered ring in iboga 
alkaloids, one of which (the electrophilic method), was tolerant of variable heteroarenes. 
Unfortunately, all three procedures suffer from significant shortcomings, most notably low 
yields, high or stoichiometric catalyst loading, and/or poor substrate scope. However, in 
combination, the methods described here do indeed provide practical routes to several novel 
ibogamine analogs, and permit rapid access to a molecular scaffold of high pharmacological 
interest. The nickel cyclization proved to be of particular value in our own biological studies, as 
it facilitated rapid SAR exploration of a novel opioid receptor-active scaffold based on the iboga 
alkaloids, as will be discussed in Chapter 3. The difficulties encountered in this work serve to 
highlight the challenges of C-H bond functionalization methodology development within the 
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context of a complex substrate class, and the shortcomings of existing methodologies when 
applied to substrates with interfering functional groups and multiple structural features. 
 
Experimental 
 General Considerations. Reagents and solvents (including anhydrous solvents) were 
obtained from commercial sources and used without further purification unless otherwise stated. 
All compounds were prepared in racemic form. All reactions were performed in flame-dried 
glassware under an argon atmosphere unless otherwise stated, and monitored by TLC using 
solvent mixtures appropriate to each reaction. All column chromatography was performed on 
silica gel (40-63µm). For compounds containing a basic nitrogen, Et3N was often used in the 
mobile phase in order to provide better resolution. In these cases, TLC plates should be pre-
soaked in the Et3N containing solvent and then allowed to dry briefly before use in analysis, such 
that an accurate representation of Rf is obtained. Nuclear magnetic resonance spectra were 
recorded on Bruker 300, 400, or 500 MHz instruments as indicated. Chemical shifts are reported 
as δ values in ppm referenced to CDCl3 (
1
H NMR = 7.26 and 
13
C NMR = 77.16). Multiplicity is 
indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); p (pentet); h (heptet); dd 
(doublet of doublets); ddd (doublet of doublet of doublets); dt (doublet of triplets); td (triplet of 
doublets); m (multiplet); br (broad).  
 For those described compounds containing a carbamate group, complex spectra with split 
peaks are observed. This effect can be ascribed to the presence of conformers about the 
carbamate group. As a result of these effects, multiple peaks may correspond to the same proton 
group or carbon atom. When possible, this is indicated by an "and" joining two peaks or spectral 
regions. Furthermore, compounds containing fluorine are subject to F-C coupling, resulting in 
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splitting of some carbon peaks. In these cases, peaks are listed as doublets and the associated 
coupling constants are indicated. Alternatively, certain carbon peaks overlap and thus represent 
two carbons (indicated by (2C) designation in some cases). In all cases, the assignments of these 
complex peaks were determined by COSY, HSQC, and/or DEPT-135 experiments. All carbon 
peaks are rounded to one decimal place unless such rounding would cause two close peaks to 
become identical. In these cases, two decimal places are retained. High-resolution mass spectra 
(HRMS) were acquired on a high-resolution sector-type double-focusing mass spectrometer 
(ionization mode: FAB+). In calculated high resolution masses, the mass difference for loss of 
one electron has been taken into account for positive ions. Low-resolution mass spectra were 
recorded on a JEOL LCmate (ionization mode: APCI+). 
 exo-Methyl 7-(1-(2-tosylhydrazono)ethyl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate 
(1a) and endo-methyl 7-(1-(2-tosylhydrazono)ethyl)-2-azabicyclo[2.2.2]oct-5-ene-2-
carboxylate (1b). Exo-tosylhydrazone 1a and endo-tosylhydrazone 1b were prepared by the 
method of Krow.
15
 However, in contrast to the previous report, crystalline products were 
obtained for both stereoisomers. Further, the stereochemistry of 1a and 1b has been revised from 
the initial report
15
, as confirmed by 2D NMR experiments and by the reduction of 1a to exo-
product 2a, the structure of which has been previously assigned by Hodgson using x-ray 
crystallography.
14
 Also, isoquinuclidine 2a was converted to ibogamine, further confirming the 
exo stereochemistry of the 7-ethyl group.  
 For clarification, the preparation of 1a and 1b is described as follows. A mixture of 
exo/endo-methyl 7-acetyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate
27
 (60:40 exo:endo ratio, 
34.93 g, 167 mmol) and p-toluenesulfonhydrazide (31.10 g, 167 mmol) in anhydrous THF (136 
mL) was heated at 50 °C for 15 h, at which time a white precipitate had formed. The reaction 
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mixture was cooled to room temperature and the white precipitate was collected by filtration, 
washing 3x at the filter with ice-cold MeOH, to provide pure endo-tosylhydrazone 1b as a fine 
white powder (19.55 g, 31%). The filtrate and washings were combined and concentrated to a tan 
solid, which was recrystallized from MeOH to obtain the pure exo-tosylhydrazone 1a as white 
plates (33.14 g, 53%). 
1a. The exo-tosylhydrazone was prepared by separation of the exo/endo mixture as described 
above. The spectral data were in agreement with the epimer incorrectly assigned to the endo 
configuration by Krow.
15
 Mp 162-166 °C (inaccurate due to trapped MeOH);
 1
H NMR (400 
MHz, CDCl3) (spectrum complicated by conformers) δ 7.85 and 7.79 (d, J = 8.3 Hz, 2H), 7.35 – 
7.28 (m, 3H), 6.46 – 6.37 (m, 2H), 4.74 – 4.68 and 4.61 – 4.57 (m, 1H), 3.52 and 3.34 (s, 3H), 
3.02 and 2.94 (dd, J = 9.8, 2.2 Hz, 1H), 2.87 and 2.78 (dt, J = 9.8, 2.6 Hz, 1H), 2.73 – 2.67 (m, 
1H), 2.48 – 2.37 (m, 1H), 2.44 (s, 3H), 2.30 and 2.09 (ddd, J = 13.1, 4.4, 2.4 Hz, 1H), 1.89 and 




 378.15, found 
377.8. 
1b. The endo-tosylhydrazone was prepared by separation of the exo/endo mixture as described 
above. The spectral data were in agreement with the epimer incorrectly assigned to the exo 
configuration by Krow.
15
 Mp 181-184 °C; 
1
H NMR (400 MHz, CDCl3) (spectrum complicated 
by conformers) δ 7.81 (t, J = 7.4 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.12 (s, 1H), 6.19 (q, J = 7.5 
Hz, 1H), 6.02 (dd, J = 12.0, 5.6 Hz, 1H), 4.87 and 4.77 (d, J = 4.3 Hz, 1H), 3.69 and 3.66 (s, 
3H), 3.23 (d, J = 10.1 Hz, 1H), 3.01 - 2.85 (m, 2H), 2.74 (br s, 1H), 2.45 and 2.44 (s, 3H), 1.87 – 





 378.15, found 377.8. 
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 exo-Methyl 7-ethyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2a). exo-
tosylhydrazone 1a (33.02 g, 87.5 mmol), sodium cyanoborohydride (21.99 g, 350 mmol), and p-
toluenesulfonic acid monohydrate (1.40 g, 7.36 mmol) were combined in anhydrous THF (250 
mL) and refluxed for 21 h. At this time, additional p-TsOH  H2O (0.35 g, 1.84 mmol) was added 
and reflux was continued for an additional 4 h. The reaction mixture was then diluted with water 
(250 mL) and extracted with cyclohexane (3 x 100 mL). The combined organics were washed 
with water (250 mL), saturated aqueous NaHCO3 (250 mL), and water again (50 mL), dried over 
Na2SO4, and concentrated to provide a cloudy, pale-yellow oil. This was washed through a short 
silica column with 7:3 hexanes:EtOAc and the eluate was concentrated to yield pure exo-
isoquinuclidine 2a as a pale-yellow oil (10.12 g, 59%). The spectral data were in agreement with 
the epimer incorrectly assigned to the endo configuration by Krow and in agreement with the 




H NMR (400 MHz, CDCl3) δ 6.47 and 6.42 (br dd, J = 7 Hz, 
1H), 6.34 and 6.30 (br dd, J = 8 Hz, 1H), 4.59 and 4.44 (d, J = 6 Hz, 1H), 3.67 and 3.66 (s, 3H), 
3.20 (td, J = 10, 2 Hz, 1H), 2.98 and 2.94 (dt, J = 10, 3 Hz, 1H), 2.65 (m, 1H), 1.64 and 1.61 (dt, 
J = 10, 3 Hz, 1H), 1.38 (m, 3H), 1.00 (m, 1H), 0.95 and 0.92 (t, J = 7 Hz, 3H); 
13
C NMR (101 
MHz, CDCl3) δ 156.7 and 156.3, 133.8 and 133.7, 133.3 and 133.1, 52.2 and 52.1, 49.1 and 





 196.13, found 195.9. 
 endo-Methyl 7-ethyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2b). To a suspension 
of endo-tosylhydrazone 2b (3.50 g, 9.27 mmol) in MeOH (41 mL) was added a solution of 
sodium cyanoborohydride (833 mg, 13.26 mmol) and ZnCl2 (904 mg, 6.63 mmol) in MeOH (28 
mL) and the resulting mixture was refluxed for 3 h. The reaction was then quenched with 1% 
aqueous NaOH (200 mL) and extracted with cyclohexane (3 x 50 mL). The combined organics 
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were washed with water (50 mL) and brine (50 mL), dried over Na2SO4, and concentrated to 
provide a clear, colorless oil. This was washed through a short silica column with 1:1 
hexanes:EtOAc and the eluate was concentrated to yield pure endo-isoquinuclidine 2b as a 
colorless oil (1.11 g, 61%). The spectral data were in agreement with the epimer incorrectly 




H NMR (400 MHz, CDCl3) δ 6.31 (m, 2H), 4.66 
and 4.48 (s, 1H), 3.69 and 3.66 (s, 3H), 3.21 (m, 1H), 2.94 (m, 1H), 2.69 (m, 1H), 1.96 (m, 1H), 
1.81 (m, 1H), 1.19 (m, 1H), 1.01 - 0.84 (m, 5H); 
13
C NMR (101 MHz, CDCl3) δ 155.6 and 
155.2, 134.4 and 134.0, 130.6 and 130.0, 52.0 and 51.9, 49.3 and 48.9, 46.9 and 46.5, 40.7 and 






 Methyl 2-(7-(benzyloxy)-1H-indol-3-yl)-2-oxoacetate (3). To a solution of 7-
benzyloxyindole (4.91 g, 22.0 mmol) in anhydrous THF (65 mL) at 0 °C was added oxalyl 
chloride (2.49 mL, 28.6 mmol) dropwise over 5 min. and the resulting yellow-orange solution 
was stirred at 0 °C for 4 h. The reaction mixture was then concentrated in vacuo to yield the 
crude acyl chloride intermediate as a yellow-brown solid. To this material was added anhydrous 
MeOH (40 mL), the mixture was cooled in ice, and one neck of the flask was opened under a 
strong flow of argon to remove any evolved HCl gas as Et3N (3.99 mL, 28.6 mmol) was added 
dropwise over 3 min. The yellow mixture was then sealed again and refluxed for 2 h, then cooled 
to 0 °C and the solids collected by filtration, washing at the filter with several small portions of 
ice-cold MeOH. Glyoxylate ester 3 was thus obtained as yellow ochre crystals (5.67 g, 83%). 
Mp 175-178 °C; 
1
H NMR (400 MHz, CDCl3) δ 9.09 (br s, 1H), 8.41 (d, J = 3.3 Hz, 1H), 8.02 
(d, J = 8.0 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.44 – 7.34 (m, 3H), 7.25 (t, J = 8.0 Hz, 1H), 6.86 (d, J 
= 7.7 Hz, 1H), 5.21 (s, 2H), 3.94 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 177.9, 163.3, 145.4, 
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136.6, 135.7, 128.9, 128.6, 128.1, 127.8, 126.8, 124.4, 115.4, 115.0, 106.0, 70.7, 52.9; HRMS 
(FAB+) m/z: [M+H]
+
 Calcd for C18H16NO4
+
 310.1074; found 310.1079.  
 Ethyl 2-(benzofuran-3-yl)acetate (4). Compound 4 was prepared by a slight 
modification of the literature procedure.
28
 A solution of benzofuran-3(2H)-one (5.00 g, 37.3 
mmol) and (carbethoxymethylene)triphenylphosphorane (14.28 g, 41.0 mmol) in anhydrous 
toluene (125 mL) was refluxed for 87 h and then concentrated in vacuo. On standing, copious 
crystals formed in the dark-brown liquid. The mixture was diluted with 10:1 hexanes:EtOAc and 
the crystalline mass crushed thoroughly. The supernatant was then decanted, leaving behind as 
much of the solids as possible.  The residual crystalline solids were washed 3x with 10:1 
hexanes:EtOAc, removing and saving the supernatant each time. The combined washes were 
then purified directly by column chromatography (10:1 hexanes:EtOAc, large fractions 
collected) to yield the pure ester 4 as an orange oil (6.30 g, 83%). Spectral and physical 
properties were in agreement with those previously reported.
29 
 2-(5-Fluoro-1H-indol-3-yl)ethanol (5a). Compound 5a was prepared using the modified 
Fischer indole synthesis protocol described by Campos.
30
 4-fluorophenylhydrazine 
hydrochloride (8.13 g, 50.0 mmol) was dissolved in a mixture of DMAc (70 mL) and 4% m/m 
aqueous H2SO4 (70 mL) and heated to 100 °C. 2,3-dihydrofuran (3.78 mL, 50.0 mmol) was then 
added dropwise over 2 min. and the brown solution was stirred for 3 h at 100 °C. After cooling 
to room temperature, the mixture was extracted with EtOAc (3 x 50 mL, then 25 mL) and the 
combined organics were washed with water (3 x 50 mL), dried over Na2SO4, and concentrated to 
give a yellow-orange oil. This was purified by column chromatography (1:1 hexanes:EtOAc) to 
yield alcohol 5a as an orange-red oil (5.57 g, 62%). Spectral and physical properties were in 




 2-(7-(Benzyloxy)-1H-indol-3-yl)ethanol (5b). Glyoxylate ester 3 (5.64 g, 18.2 mmol) 
was carefully added to a suspension of LiAlH4 (2.08 g, 54.7 mmol) in anhydrous THF (90 mL) at 
room temperature and the resulting yellowish-gray mixture was refluxed for 5 h. After cooling in 
ice, the reaction was quenched by the successive addition of water (2.1 mL), 15% aqueous 
NaOH (2.1 mL), and water again (6.3 mL). The resulting mixture was stirred vigorously until the 
aluminum salts were white and loose and then filtered, washing the filter cake with Et2O (3 x 50 
mL). The combined filtrate and washings were concentrated to afford alcohol 5b as a cloudy, 
pale-brown oil that slowly crystallized to an off-white solid (4.86 g, 100%). Mp 70-72 °C; 
1
H 
NMR (400 MHz, CDCl3) δ 8.36 (br s, 1H), 7.49 (dd, J = 7.7, 1.1 Hz, 2H), 7.45 – 7.35 (m, 3H), 
7.26 (d, J = 8.0 Hz, 1H), 7.05 (t, J = 7.9 Hz, 1H), 7.02 (d, J = 2.3 Hz, 1H), 6.75 (d, J = 7.7 Hz, 
1H), 5.21 (s, 2H), 3.89 (br s, 2H), 3.02 (t, J = 6.4 Hz, 2H), 1.59 (br s, 1H); 
13
C NMR (101 MHz, 
CDCl3) δ 145.6, 137.2, 129.1, 128.8, 128.3, 128.0, 127.8, 122.3, 120.0, 112.8, 112.0, 103.4, 
70.4, 62.8, 29.0; HRMS (FAB+) m/z: [M]
+
 Calcd for C17H18NO2
+
 268.1332; found 268.1334. 
 2-(Benzofuran-3-yl)ethanol (5c). A solution of ester 4 (6.21 g, 30.4 mmol) in anhydrous 
THF (25 mL) was added dropwise to a suspension of LiAlH4 (3.00 g, 79.0 mmol) in anhydrous 
THF (80 mL) over 10 min. and the resulting mixture was then refluxed for 1 h. After cooling to 
room temperature the reaction was quenched by the successive addition of water (3 mL), 15% 
aqueous NaOH (3 mL), and water again (9 mL). The resulting mixture was stirred vigorously 
until the aluminum salts were white and loose and then filtered, washing the filter cake with Et2O 
(2 x 30 mL, then 2 x 50 mL). The combined filtrate and washings were concentrated to yield the 
pure alcohol 5c as a yellow oil (4.81 g, 98%). Spectral and physical properties were in agreement 




 2-(Benzo[b]thiophen-3-yl)ethanol (5d). Compound 5d was prepared via LiAlH4 
reduction of benzo[b]thiophene-3-acetic acid as previously described.
33
 The crude product was 
obtained as an orange oil of sufficient purity for the next step (895 mg, 97%). Spectral and 
physical properties were in agreement with those previously reported.
34
 
 3-(2-Bromoethyl)-5-fluoro-1H-indole (6a). To a solution of alcohol 5a (5.51 g, 30.75 
mmol) and carbon tetrabromide (14.28 g, 43.05 mmol) in anhydrous CH3CN (160 mL) at 0 °C 
was added triphenylphosphine (10.49 g, 39.98 mmol) in five equal portions over 10 min. and the 
resulting mixture was stirred for 20 min. at 0 °C. At this time, the reaction mixture was 
concentrated and the resulting dark-orange oil was dissolved in CH2Cl2 and washed through a 
silica plug, washing with CH2Cl2 until all product had passed through. The eluate was then 
concentrated and washed through a second silica plug, starting with 2:1 hexanes:CH2Cl2 until 
most of the upper bromoform impurity had been eluted and then with CH2Cl2 to finish elution of 
the product. The collected eluate containing product was again concentrated and purified by 
column chromatography (6:1 hexanes:EtOAc) to yield pure bromide 6a as a yellow oil which 
slowly solidified to a waxy yellow-brown solid (4.97 g, 67%). Spectral and physical properties 
were in agreement with those previously reported.
35
 
 7-(Benzyloxy)-3-(2-bromoethyl)-1H-indole (6b). To a solution of alcohol 5b (4.81 g, 
18.0 mmol) and carbon tetrabromide (8.95 g, 27.0 mmol) in anhydrous CH2Cl2 (36 mL) at room 
temperature was carefully added triphenylphosphine (7.08 g, 27.0 mmol) and the resulting 
mixture was stirred for 1 h. At this time, the reaction mixture was filtered through a silica plug, 
washing the plug with additional CH2Cl2 (225 mL). The filtrate was concentrated to afford a 
yellow oil that was further purified by column chromatography (hexanes, 2 column volumes → 
8:2 hexanes:Et2O, 3 column volumes) to yield the pure bromide 6b as a pale-yellow oil that 
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slowly crystallized to an off-white solid (3.78 g, 64%). Mp 65-67 °C; 
1
H NMR (500 MHz, 
CDCl3) δ 8.29 (br s, 1H), 7.48 (d, J = 7.1 Hz, 2H), 7.44 – 7.39 (m, 2H), 7.39 – 7.34 (m, 1H), 
7.22 (d, J = 8.0 Hz, 1H), 7.08 – 7.02 (m, 2H), 6.74 (d, J = 7.7 Hz, 1H), 5.21 (s, 2H), 3.64 (t, J = 
7.7 Hz, 2H), 3.33 (t, J = 7.7 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 145.6, 137.1, 128.8, 128.6, 
128.3, 128.0, 127.0, 122.0, 120.2, 114.1, 111.6, 103.4, 70.4, 33.1, 29.7; HRMS (FAB+) m/z: 
[M]
+




 330.0488; found 330.0483. 
 3-(2-Bromoethyl)benzofuran (6c). To a solution of alcohol 5c (4.76 g, 29.35 mmol) and 
carbon tetrabromide (14.60 g, 44.03 mmol) in anhydrous CH2Cl2 (60 mL) at room temperature 
was carefully added triphenylphosphine (11.55 g, 44.03 mmol) and the resulting dark orange-
brown mixture was left to stir for 30 min. At this time, the reaction mixture was filtered through 
a silica plug, washing the plug with additional CH2Cl2 (150 mL). The filtrate was concentrated to 
afford a yellow oil which was re-dissolved in CH2Cl2 (50 mL) and washed through a second 
silica plug, again washing the plug with additional CH2Cl2 (150 mL). The yellow oil obtained on 
concentration of the filtrate was then purified by column chromatography (hexanes, 2 column 
volumes → 20:1 hexanes:Et2O, 3 column volumes) to yield pure bromide 6c as a pale-yellow oil 




 3-(2-Bromoethyl)benzo[b]thiophene (6d). To a solution of alcohol 5d (895 mg, 5.02 
mmol) and carbon tetrabromide (2.50 g, 7.53 mmol) in anhydrous CH2Cl2 (10 mL) at room 
temperature was carefully added triphenylphosphine (1.98 g, 7.53 mmol) and the resulting dark 
red-brown mixture was stirred for 15 min. The reaction mixture was then concentrated and 
purified directly by column chromatography (6:1 hexanes:EtOAc) to yield pure bromide 6d as an 
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orange oil after thorough drying under high vacuum to remove bromoform impurity (1.14 g, 
94%). Spectral and physical properties were in agreement with those previously reported.
36
 
 3-(3-Bromopropyl)-1H-indole (6e). Alcohol 5e (3-(1H-indol-3-yl)propan-1-ol) was 
prepared starting from phenylhydrazine hydrochloride (2.17 g, 15.0 mmol) using a modified 
Fischer indole synthesis protocol as previously described.
30
 The crude alcohol was obtained as an 
orange oil containing solvent and other impurities (2.44 g). The whole of this material was 
dissolved in anhydrous CH2Cl2 (30 mL) along with carbon tetrabromide (6.93 g, 20.90 mmol) 
and triphenylphosphine (5.82 g, 20.90 mmol) was carefully added at room temperature. After 
stirring for 30 min., the reaction mixture was concentrated and purified directly by column 
chromatography (6:1 hexanes:EtOAc) to yield pure bromide 6e as a pale-yellow oil (1.81 g, 51% 
for 2 steps). Spectral and physical properties were in agreement with those previously reported.
37
 
 General Procedure for Preparation of N-heteroarylalkylisoquinuclidines (7a-g). To a 
solution of exo- or endo-isoquinuclidine 2a or 2b (1 equivalent) in anhydrous CH2Cl2 (0.125 M, 
based on 2) at 0 °C was added iodotrimethylsilane (4 equivalents) and the resulting mixture was 
stirred for 10 min. at 0 °C and then at room temperature until TLC indicated that no 2 remained 
(typically ~1 h). The reaction mixture was then concentrated to yield the deprotected 
isoquinuclidine hydroiodide salt in quantitative yield. To this material was added the appropriate 
bromoalkylheteroarene 6a-e (1 equivalent) and NaHCO3 (4 equivalents), followed by anhydrous 
CH3CN (0.208 M, based on 2), and the resulting mixture was refluxed until TLC indicated the 
disappearance of the bromide (typically 2-4 days). The reaction was then diluted with water, 
made strongly basic with aqueous NaOH, and extracted with CHCl3 (3x). The combined 
organics were washed with water, dried over Na2SO4, and concentrated to provide the crude 
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product, which was purified by column chromatography with an appropriate solvent mixture (as 
described below for each compound). 
 exo-2-(2-(1H-Indol-3-yl)ethyl)-7-ethyl-2-azabicyclo[2.2.2]oct-5-ene (7a). The product 
7a was prepared using commercially available 3-(2-bromoethyl)-1H-indole and purified by 
column chromatography (8:2 hexanes:EtOAc + 2% Et3N). It was obtained as a viscous yellow 




 endo-7-Ethyl-2-(2-(5-fluoro-1H-indol-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene (7b). 
The product 7b was purified by column chromatography (1:1 hexanes:EtOAc + 2% Et3N) and 
obtained as a tan solid (450 mg, 60%). Mp 140-143 °C; 
1
H NMR (400 MHz, CDCl3) δ 7.91 (br 
s, 1H), 7.26 – 7.20 (m, 2H), 7.05 (d, J = 2.2 Hz, 1H), 6.92 (td, J = 9.0, 2.5 Hz, 1H), 6.38 (t, J = 
6.9 Hz, 1H), 6.18 – 6.11 (m, 1H), 3.41 – 3.36 (m, 1H), 3.03 (dd, J = 9.7, 1.8 Hz, 1H), 2.95 – 2.76 
(m, 3H), 2.61 – 2.46 (m, 2H), 2.10 (dt, J = 9.7, 2.7 Hz, 1H), 2.07 – 1.98 (m, 1H), 1.79 (ddd, J = 
12.1, 9.2, 2.8 Hz, 1H), 1.24 – 1.11 (m, 1H), 1.07 – 0.94 (m, 1H), 0.86 (t, J = 7.3 Hz, 3H), 0.82 – 
0.74 (m, 1H); 
13
C NMR (101 MHz, CDCl3) (spectrum complicated by C-F coupling) δ 157.8 (d, 
JC-F = 235 Hz), 133.8, 132.9, 130.2, 128.1 (d, JC-F = 9.1 Hz), 123.5, 115.1 (d, JC-F = 5.1 Hz), 
111.7 (d, JC-F = 10.1 Hz), 110.3 (d, JC-F = 26.2 Hz), 103.9 (d, JC-F = 20.2 Hz), 58.9, 57.3, 54.5, 
40.6, 31.6, 30.8, 28.8, 24.6, 11.7; HRMS (FAB+) m/z: [M+H]
+





(7c). The product 7c was purified by column chromatography (9:1 hexanes:EtOAc, 3 column 
volumes → 9:1 hexanes:EtOAc + 2% Et3N, 5 column volumes) and obtained as a viscous yellow 
oil (70.3 mg, 36%). 
1
H NMR (500 MHz, CDCl3) δ 8.18 (br s, 1H), 7.48 (d, J = 7.1 Hz, 2H), 
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7.44 – 7.38 (m, 2H), 7.38 – 7.33 (m, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.04 – 6.98 (m, 2H), 6.71 (d, 
J = 7.7 Hz, 1H), 6.38 – 6.28 (m, 2H), 5.20 (s, 2H), 3.28 (s, 1H), 3.12 (d, J = 8.3 Hz, 1H), 2.93 – 
2.75 (m, 3H), 2.58 – 2.48 (m, 1H), 2.45 (s, 1H), 1.98 (d, J = 9.1 Hz, 1H), 1.69 – 1.53 (m, 2H), 
1.53 – 1.45 (m, 1H), 1.35 – 1.28 (m, 1H), 0.98 – 0.94 (m, 1H), 0.92 (t, J = 7.4 Hz, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 145.5, 137.4, 132.9 (2C), 129.3, 128.7, 128.2, 127.9, 126.9, 121.2, 
119.5, 115.7, 112.2, 103.1, 70.3, 59.2, 56.4, 56.1, 41.3, 31.8, 29.9, 27.3, 24.7, 12.7; HRMS 
(FAB+) m/z: [M+H]
+
 Calcd for C26H31N2O
+
 387.2431; found 387.2439.  
 exo-2-(2-(Benzofuran-3-yl)ethyl)-7-ethyl-2-azabicyclo[2.2.2]oct-5-ene (7d). The 
product 7d was purified by column chromatography (19:1 hexanes:EtOAc) and obtained as an 
orange-brown oil (940 mg, 46%). 
1
H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 7.3 Hz, 1H), 7.49 
(s, 1H), 7.47 – 7.41 (m, 1H), 7.30 – 7.25 (m, 1H), 7.22 (td, J = 7.4, 1.1 Hz, 1H), 6.38 – 6.27 (m, 
2H), 3.22 (d, J = 5.1 Hz, 1H), 3.09 (dd, J = 9.1, 2.1 Hz, 1H), 2.87 – 2.66 (m, 3H), 2.57 – 2.48 (m, 
1H), 2.44 (br s, 1H), 1.94 (dt, J = 9.0, 2.4 Hz, 1H), 1.64 – 1.42 (m, 3H), 1.35 – 1.24 (m, 1H), 
0.95 – 0.90 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 155.3, 141.7, 
133.1, 132.8, 128.6, 124.1, 122.2, 119.7, 119.1, 111.5, 57.9, 56.3, 56.2, 41.3, 31.8, 29.9, 27.4, 
23.0, 12.6; HRMS (FAB+) m/z: [M+H]
+
 Calcd for C19H24NO
+
 282.1853; found 282.1862.  
 endo-2-(2-(Benzofuran-3-yl)ethyl)-7-ethyl-2-azabicyclo[2.2.2]oct-5-ene (7e). The 
product 7e was purified by column chromatography (15:1 hexanes:EtOAc + 2% Et3N, 3 column 
volumes → 9:1 hexanes:EtOAc + 2% Et3N, 3 column volumes) and obtained as a pale-yellow oil 
(422 mg, 60%). 
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 7.3 Hz, 1H), 7.45 (s, 1H), 7.45 (d, J 
= 5.8 Hz, 1H), 7.30 – 7.25 (m, 1H), 7.25 – 7.20 (m, 1H), 6.39 (t, J = 7.3 Hz, 1H), 6.17 – 6.11 (m, 
1H), 3.41 – 3.34 (m, 1H), 3.03 (dd, J = 9.6, 1.8 Hz, 1H), 2.91 – 2.74 (m, 3H), 2.59 – 2.53 (m, 
1H), 2.53 – 2.47 (m, 1H), 2.07 (dt, J = 9.6, 2.7 Hz, 1H), 2.05 – 1.98 (m, 1H), 1.78 (ddd, J = 12.1, 
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9.2, 2.8 Hz, 1H), 1.23 – 1.13 (m, 1H), 1.06 – 0.96 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H), 0.82 – 0.76 
(m, 1H); 
13
C NMR (75 MHz, CDCl3) δ 155.3, 141.5, 133.7, 130.2, 128.5, 124.2, 122.3, 119.8, 





 282.1853; found 282.1864.  
 endo-2-(2-(Benzo[b]thiophen-3-yl)ethyl)-7-ethyl-2-azabicyclo[2.2.2]oct-5-ene (7f). 
The product 7f was purified by column chromatography (9:1 hexanes:EtOAc, 3 column volumes 
→ 9:1 hexanes:EtOAc + 2% Et3N, 3 column volumes) and obtained as a yellow oil (150 mg, 
40%). 
1
H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.41 – 
7.36 (m, 1H), 7.36 – 7.30 (m, 1H), 7.13 (s, 1H), 6.40 (t, J = 7.2 Hz, 1H), 6.17 – 6.12 (m, 1H), 
3.44 – 3.39 (m, 1H), 3.08 – 2.97 (m, 3H), 2.97 – 2.88 (m, 1H), 2.66 – 2.57 (m, 1H), 2.55 – 2.49 
(m, 1H), 2.11 (dt, J = 9.7, 2.7 Hz, 1H), 2.09 – 2.01 (m, 1H), 1.80 (ddd, J = 12.1, 9.2, 2.8 Hz, 1H), 
1.24 – 1.14 (m, 1H), 1.07 – 0.96 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H), 0.83 – 0.77 (m, 1H); 
13
C 
NMR (101 MHz, CDCl3) δ 140.5, 139.2, 135.1, 133.8, 130.2, 124.2, 124.0, 123.0, 121.8, 121.7, 
58.0, 57.5, 54.4, 40.6, 31.6, 30.7, 28.8, 27.9, 11.7; HRMS (FAB+) m/z: [M+H]
+
 Calcd for 
C19H24NS
+
 298.1624; found 298.1625. 
 exo-2-(3-(1H-Indol-3-yl)propyl)-7-ethyl-2-azabicyclo[2.2.2]oct-5-ene (7g). The 
product 7g was purified by column chromatography (15% EtOAc in hexanes + 2% Et3N, 3 
column volumes → 20% EtOAc in hexanes + 2% Et3N) and obtained as a viscous, pale-yellow 
oil (86 mg, 58%). 
1
H NMR (400 MHz, CDCl3) δ 7.88 (bs s, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.35 
(d, J = 8.1 Hz, 1H), 7.21 – 7.15 (m, 1H), 7.13 – 7.08 (m, 1H), 6.99 – 6.96 (m, 1H), 6.34 – 6.23 
(m, 2H), 3.19 – 3.16 (m, 1H), 3.05 (dd, J = 9.1, 2.3 Hz, 1H), 2.88 – 2.71 (m, 2H), 2.51 (dt, J = 
11.8, 7.4 Hz, 1H), 2.43 – 2.37 (m, 1H), 2.30 – 2.21 (m, 1H), 1.87 – 1.69 (m, 3H), 1.68 – 1.53 (m, 




NMR (126 MHz, CDCl3) δ 136.5, 132.9 (2C), 127.8, 121.9, 121.3, 119.20, 119.16, 117.2, 





 295.2169; found 295.2182. 
 exo-7-Ethyl-2-(2-(1-tosyl-1H-indol-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene (7h). To a 
solution of 7a (140 mg, 0.500 mmol), p-toluenesulfonyl chloride (167 mg, 0.875 mmol), and 
tetrabutylammonium hydrogensulfate (17.0 mg, 0.0500 mmol) in CH2Cl2 (2.5 mL) was added 
50% m/m aqueous NaOH (0.25 mL) and the resulting mixture was stirred vigorously at room 
temperature for 12 h. The reaction was then diluted with water (5 mL) and extracted with CH2Cl2 
(3 x 5 mL). The combined organics were washed with water (2 x 5 mL) and brine (5 mL), dried 
over Na2SO4 and concentrated to yield an off-white solid (245 mg). This crude product was 
purified by column chromatography (9:1 hexanes:EtOAc + 2% Et3N) to provide a tan solid (203 
mg). This material was dissolved in 1:1 CH2Cl2:hexanes and concentrated, resulting in the 
formation of white crystals. These crystals were washed 3x with cold Et2O and dried to provide 
the pure product 7h as white crystals (177 mg, 81%). 
1
H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 
8.2 Hz, 1H), 7.77 – 7.71 (m, 2H), 7.46 (d, J = 7.6 Hz, 1H), 7.40 (s, 1H), 7.32 – 7.26 (m, 1H), 
7.24 – 7.16 (m, 3H), 6.37 – 6.26 (m, 2H), 3.20 (dd, J = 3.5, 1.8 Hz, 1H), 3.04 (dd, J = 9.0, 2.2 
Hz, 1H), 2.84 – 2.63 (m, 3H), 2.53 – 2.45 (m, 1H), 2.45 – 2.40 (br m, 1H), 2.33 (s, 3H), 1.90 (dt, 
J = 9.0, 2.5 Hz, 1H), 1.58 – 1.42 (m, 3H), 1.33 – 1.23 (m, 1H), 0.93 – 0.88 (m, 1H), 0.86 (t, J = 
7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 144.7, 135.7, 135.3, 133.1, 132.7, 131.5, 129.9 
(2C), 126.9 (2C), 124.5, 123.2, 123.0, 121.9, 119.6, 113.8, 57.7, 56.3, 56.2, 41.3, 31.7, 29.8, 
27.4, 24.2, 21.6, 12.6. 
 exo-7-Ethyl-2-(2-(1-((trifluoromethyl)sulfonyl)-1H-indol-3-yl)ethyl)-2-
azabicyclo[2.2.2]oct-5-ene (7i). To a solution of 7a (280 mg, 1.00 mmol) in anhydrous THF (16 
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mL) at -78 °C was added n-BuLi (2.5 M in hexanes, 0.42 mL, 1.05 mmol) and the mixture was 
stirred for 20 min. Trifluoromethanesulfonic anhydride (190 µL, 319 mg, 1.13 mmol) was then 
added dropwise over several minutes and the reaction was stirred for 2 h at -78 °C. At this time, 
water (3 drops) was added and the mixture was allowed to warm to room temperature, poured 
into 2% aqueous NaHCO3 (16 mL), and extracted with Et2O (3 x 15 mL). The combined 
organics were washed with water (20 mL) and brine (20 mL), dried over Na2SO4, and 
concentrated to  provide a transparent yellow oil (417 mg). This material was purified by column 
chromatography (9:1 hexanes:EtOAc) to provide the product 7i as a pale-yellow oil (278 mg, 
67%). 
1
H NMR (400 MHz, CDCl3) δ 7.92 – 7.85 (m, 1H), 7.60 – 7.53 (m, 1H), 7.42 – 7.33 (m, 
2H), 7.30 (s, 1H), 6.38 – 6.27 (m, 2H), 3.22 – 3.17 (m, 1H), 3.05 (dd, J = 9.0, 2.2 Hz, 1H), 2.88 – 
2.80 (m, 1H), 2.80 – 2.69 (m, 2H), 2.54 (ddd, J = 10.3, 8.1, 5.4 Hz, 1H), 2.45 (dd, J = 3.9, 2.2 
Hz, 1H), 1.92 (dt, J = 9.0, 2.5 Hz, 1H), 1.56 – 1.42 (m, 3H), 1.34 – 1.24 (m, 1H), 0.90 (ddd, J = 





413.15, found 412.83. 
 exo-7-Ethyl-2-(2-(1-acetyl-1H-indol-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene (7j). 
Powdered KOH (56.0 mg, 1.00 mmol) was suspended in anhydrous DMSO (2.0 mL) and the 
mixture was stirred for 5 min. at room temperature. Compound 7a (140 mg, 0.500 mmol) was 
then added, followed acetic anhydride (104 µL, 113 mg, 1.10 mmol) 5 min. later. The resulting 
mixture was stirred for 1 h and then quenched with water (10 mL) and extracted with Et2O (3 x 
10 mL). The combined organics were washed with water (3 x 10 mL) and brine (10 mL), dried 
over Na2SO4, and concentrated to yield a viscous yellow oil (106 mg). This material was purified 
by column chromatography (9:1 hexanes:EtOAc + 2% Et3N) to provide the product 7j as a 




NMR (400 MHz, CDCl3) δ 8.43 (br d, J = 5.8 Hz, 1H), 7.51 (d, J = 7.4 Hz, 1H), 7.37 – 7.31 (m, 
2H), 7.28 (dt, J = 7.4, 1.5 Hz, 1H), 6.40 – 6.27 (m, 2H), 3.24 (br s, 1H), 3.09 (d, J = 8.5 Hz, 1H), 
2.87 – 2.69 (m, 3H), 2.60 (s, 3H), 2.59 – 2.51 (m, 1H), 2.46 (br s, 1H), 1.95 (dt, J = 6.7, 2.4 Hz, 
1H), 1.65 – 1.54 (m, 2H), 1.54 – 1.45 (m, 1H), 1.37 – 1.27 (m, 1H), 0.97 – 0.91 (m, 1H), 0.90 (t, 
J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 168.56, 135.85, 133.11, 132.69, 131.11, 
125.18, 123.43, 122.43, 121.75, 118.91, 116.78, 57.82, 56.43, 56.03, 41.25, 31.68, 29.84, 27.56, 




 323.21, found 323.35. 
 exo-7-Ethyl-2-(2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-3-yl)ethyl)-2-
azabicyclo[2.2.2]oct-5-ene (7k). To a suspension of NaH (60% in oil, 23.0 mg, 0.575 mmol) in 
anhydrous DMF (0.60 mL) and anhydrous DMSO (0.30 mL) at 0 °C was added a solution of 7a 
(140 mg, 0.500 mmol) in anhydrous DMF (0.60 mL) dropwise over 10 min. The resulting 
mixture was allowed to stir for 5 min. at 0 °C and 15 min. at room temperature. It was then 
cooled back to 0 °C, 2-(trimethylsilyl)ethoxymethyl chloride (97.0 µL, 91.7 mg, 0.550 mmol) 
was added, and the mixture was allowed to warm to room temperature and stirred for 3 h. At this 
time, the reaction was quenched with water (15 mL) and extracted with Et2O (3 x 10 mL). The 
combined organics were washed with water (2 x 10 mL) and brine (10 mL), dried over Na2SO4, 
and concentrated to give a yellow oil (189 mg). This material was purified by column 
chromatography (20:1 hexanes:EtOAc + 1% Et3N, 1 column volume → +1.5% Et3N, 2 column 
volumes → +2% Et3N, 2 column volumes) to provide the product 7k as a pale-yellow oil (49.5 
mg, 24%). Note: The bulk of the product could not be separated from a close eluting impurity. 
1
H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 7.8 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.25 – 7.20 
(m, 1H), 7.17 – 7.10 (m, 1H), 7.03 (s, 1H), 6.38 – 6.28 (m, 2H), 5.43 (s, 2H), 3.50 – 3.43 (m, 
2H), 3.29 (br s, 1H), 3.12 (d, J = 8.6 Hz, 1H), 2.94 – 2.75 (m, 3H), 2.60 – 2.50 (m, 1H), 2.46 (br 
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s, 1H), 2.01 – 1.93 (m, 1H), 1.70 – 1.54 (m, 2H), 1.54 – 1.46 (m, 1H), 1.38 – 1.28 (m, 1H), 0.98 
– 0.86 (m, 6H), -0.04 (s, 9H); 
13
C NMR (101 MHz, CDCl3) δ 136.8, 133.0, 132.9, 129.0, 125.6, 
122.0, 119.5, 119.2, 115.1, 109.9, 75.5, 65.8, 59.0, 56.3, 56.1, 41.3, 31.8, 29.9, 27.4, 24.3, 17.9, 




 411.28, found 411.44. 
 exo-7-Ethyl-2-(2-(1-(pyridin-2-ylsulfonyl)-1H-indol-3-yl)ethyl)-2-
azabicyclo[2.2.2]oct-5-ene (7l). To a solution of 7a (1.12 g, 4.00 mmol), pyridine-2-sulfonyl 
chloride (1.24g, 7.00 mmol, freshly prepared according to literature procedure
38
), and 
tetrabutylammonium hydrogensulfate (136 mg, 0.400 mmol) in CH2Cl2 (20 mL) was added 50% 
m/m aqueous NaOH (2.0 mL) and the mixture was stirred vigorously for 26 h at room 
temperature, adding additional portions of pyridine-2-sulfonyl chloride (0.53 g and 0.36 g at 19 h 
and 22 h respectively). The reaction was then diluted with water (40 mL) and extracted with 
CH2Cl2 (3 x 20 mL). The combined organics were washed with water (2 x 20 mL) and brine (20 
mL), dried over Na2SO4, and concentrated to give a brown oil (1.82 g). This material was 
purified by column chromatography (9:1 hexanes:EtOAc + 2% Et3N, 2 column volumes → 8:2 
hexanes:EtOAc + 2% Et3N, 2 column volumes) to provide the product 7l as a yellow-orange oil 
that slowly crystallized into a waxy, yellow-orange solid (1.26 g, 75%). 
1
H NMR (400 MHz, 
CDCl3) δ 8.59 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 8.07 (dt, J = 7.9, 0.9 Hz, 1H), 8.01 – 7.95 (m, 1H), 
7.85 (td, J = 7.8, 1.7 Hz, 1H), 7.51 – 7.45 (m, 2H), 7.42 (ddd, J = 7.7, 4.7, 1.1 Hz, 1H), 7.31 – 
7.19 (m, 2H), 6.37 – 6.25 (m, 2H), 3.20 (d, J = 5.2 Hz, 1H), 3.06 (dd, J = 9.0, 2.1 Hz, 1H), 2.85 – 
2.66 (m, 3H), 2.56 – 2.47 (m, 1H), 2.43 (br s, 1H), 1.91 (dt, J = 9.0, 2.4 Hz, 1H), 1.59 – 1.41 (m, 





 422.19, found 422.00. 
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 General Procedure for Preparation of Iboga Alkaloids by Pd(CH3CN)4(BF4)2 
Mediated Cyclization (8a-f). In a glovebox, a Schlenk flask was charged with 
Pd(CH3CN)4(BF4)2 (144 mg, 0.325 mmol). It was then sealed and removed from the glovebox 
and anhydrous CH3CN (3.5 mL) was added to form a yellow solution. To this solution was 
added a solution of the substrate 7a-g (0.250 mmol) in anhydrous CH3CN (9.0 mL) resulting in a 
color change (ranging from orange to deep-red depending on substrate). The reaction mixture 
was stirred for 2 h at room temperature and then warmed to 70 °C and stirred for a further 16 h. 
At this time, the reaction was cooled to 0 °C and anhydrous MeOH (2.25 mL) was added 
followed by NaBH4 (30.3 mg, 0.800 mmol), causing the immediate precipitation of palladium 
black. The resulting black mixture was stirred for 20 min. at 0 °C, then diluted with Et2O (50 
mL), filtered through celite, and the filter cake washed with additional Et2O (4 x 10 mL). The 
combined filtrate and washings were concentrated to afford the crude product. The NMR yield 
was then determined using mesitylene (10 µL) as an internal standard and the product was 
purified by column chromatography with an appropriate solvent mixture (as described below for 
each compound).  
 rac-Ibogamine (8a). The product 8a was purified by column chromatography (9:1 
hexanes:EtOAc + 2% Et3N) and obtained as a colorless oil that slowly crystallized to a waxy 





H NMR (500 MHz, CDCl3) δ 7.61 (br s, 1H), 7.51 – 7.46 (m, 1H), 7.28 
– 7.24 (m, 1H), 7.15 – 7.07 (m, 2H), 3.44 – 3.33 (m, 2H), 3.21 – 3.12 (m, 1H), 3.09 (dt, J = 9.2, 
2.0 Hz, 1H), 3.00 (d, J = 9.1 Hz, 1H), 2.93 (ddd, J = 11.6, 4.0, 1.7 Hz, 1H), 2.88 (s, 1H), 2.75 – 
2.64 (m, 1H), 2.11 – 2.01 (m, 1H), 1.89 – 1.78 (m, 2H), 1.66 (ddd, J = 13.2, 6.7, 3.5 Hz, 1H), 




NMR (126 MHz, CDCl3) δ 142.0, 134.8, 129.9, 121.1, 119.3, 118.1, 110.2, 109.4, 57.7, 54.3, 
50.1, 42.1, 41.6, 34.3, 32.3, 28.0, 26.7, 20.8, 12.1. 
 rac-12-Fluoro-4-epi-ibogamine (8b).  The product 8b was purified by column 
chromatography (7:3 hexanes:EtOAc + 2% Et3N) and obtained as an amorphous, off-white solid 
(8.3 mg, 11%). 
1
H NMR (400 MHz, CDCl3) δ 7.73 (br s, 1H), 7.15 (dd, J = 8.7, 4.4 Hz, 1H), 
7.10 (dd, J = 9.8, 2.4 Hz, 1H), 6.84 (td, J = 9.1, 2.5 Hz, 1H), 3.44 – 3.23 (m, 3H), 3.20 – 3.09 (m, 
2H), 3.05 (dd, J = 11.6, 5.3 Hz, 1H), 2.89 (s, 1H), 2.63 – 2.51 (m, 1H), 2.09 – 1.94 (m, 3H), 1.90 
(s, 1H), 1.70 – 1.61 (m, 1H), 1.38 (p, J = 7.2 Hz, 2H), 1.13 – 1.03 (m, 1H), 0.93 (t, J = 7.4 Hz, 
3H); 
13
C NMR (101 MHz, CDCl3) (spectrum complicated by C-F coupling) δ 158.1 (d, JC-F = 
235 Hz), 144.0, 130.9, 130.2 (d, JC-F = 10.1 Hz), 110.9 (d, JC-F = 10.1 Hz), 110.5 (d, JC-F = 5.1 
Hz), 109.2 (d, JC-F = 26.3 Hz), 103.0 (d, JC-F = 24.2 Hz), 57.3, 54.7, 49.7, 42.0, 35.1, 34.4, 31.7, 
28.5, 26.3, 20.3, 12.2; HRMS (FAB+) m/z: [M+H]
+
 Calcd for C19H24FN2
+
 299.1919; found 
299.1924.  
 rac-14-(Benzyloxy)ibogamine (8c). The reaction was run on 0.100 mmol scale. The 
product 8c was purified by column chromatography (20:1 hexanes:EtOAc + 2% Et3N) and 
obtained as a pale-yellow glass (8.8 mg, 23%). 
1
H NMR (400 MHz, CDCl3) δ 7.87 (br s, 1H), 
7.51 – 7.45 (m, 2H), 7.44 – 7.33 (m, 3H), 7.11 (d, J = 7.9 Hz, 1H), 6.99 (t, J = 7.8 Hz, 1H), 6.67 
(d, J = 7.7 Hz, 1H), 5.19 (s, 2H), 3.42 – 3.31 (m, 2H), 3.20 – 3.05 (m, 2H), 3.01 – 2.88 (m, 2H), 
2.85 (s, 1H), 2.69 – 2.60 (m, 1H), 2.03 (t, J = 12.4 Hz, 1H), 1.87 – 1.75 (m, 2H), 1.65 (dd, J = 
13.1, 3.1 Hz, 1H), 1.60 – 1.39 (m, 3H), 1.25 – 1.17 (m, 1H), 0.90 (t, J = 7.0 Hz, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 144.9, 141.8, 137.4, 131.3, 128.7, 128.2, 128.0, 125.0, 119.6, 111.3, 109.9, 
102.7, 70.4, 57.7, 54.4, 50.2, 42.1, 41.6, 34.4, 32.3, 28.0, 26.7, 21.0, 12.1; HRMS (FAB+) m/z: 
[M+H]
+
 Calcd for C26H31N2O
+
 387.2431; found 387.2438. 
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 rac-16-Oxaibogamine (8d). The product was not isolated due to low yield. NMR yield 
was calculated as 11% in two independent trials. For spectral data, see Ni-catalyzed preparation 
below. 
 rac-16-Thia-4-epi-ibogamine (8f). The reaction was run on 0.060 mmol scale. The 
product 8f was purified by column chromatography (9:1 hexanes:EtOAc + 2% Et3N, 4 column 
volumes → 8:2 hexanes:EtOAc + 2% Et3N, 2 column volumes) and obtained as a pale-yellow oil 
(6.0 mg, 34%). 
1
H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.9 Hz, 1H), 7.62 (d, J = 8.1 Hz, 1H), 
7.35 (t, J = 7.6 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H), 3.46 – 3.30 (m, 3H), 3.28 – 3.18 (m, 1H), 3.18 
– 3.09 (m, 2H), 2.92 (s, 1H), 2.82 (d, J = 14.7 Hz, 1H), 2.13 (t, J = 12.5 Hz, 1H), 2.02 – 1.90 (m, 
3H), 1.75 (dd, J = 13.4, 6.6 Hz, 1H), 1.46 – 1.36 (m, 2H), 1.11 – 1.00 (m, 1H), 0.94 (t, J = 7.4 
Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 145.3, 141.6, 138.2, 131.0, 124.0, 123.5, 122.2, 120.9, 





 298.1624; found 298.1620.  
 General Procedure for Preparation of Iboga Alkaloids by Reductive Heck Reaction 
(8a-b). To a solution of the substrate (7a or 7b) (0.100 mmol) in anhydrous CH2Cl2 (0.90 mL) 
was added a solution of trimethylphenylammonium tribromide (41.4 mg, 0.110 mmol) in 
anhydrous CH2Cl2 (0.50 mL) dropwise at room temperature over 20 min. The resulting dark-red 
solution was stirred until TLC showed no starting material (~10 min.) and then quenched with 
water (2.0 mL), basified with saturated NH4OH (0.25 mL), and the aqueous layer removed. The 
remaining organic layer was then washed with water (1.0 mL) and concentrated in vacuo to 
provide the crude bromide as a viscous brown oil (Note: If desired, the bromide intermediate 
may be purified by column chromatography: 9:1 hexanes:EtOAc + 2% Et3N for bromide from 
7a; 8:2 hexanes:EtOAc + 2% Et3N for bromide from 7b). To the crude bromide was added 
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tetrakis(triphenylphosphine)palladium(0) (11.6 mg, 0.010 mmol) and sodium formate (27.2 mg, 
0.400 mmol, powdered and dried with gentle heating under vacuum before use), followed by 
anhydrous DMSO (0.40 mL) and the resulting mixture was heated to 130 °C for 1 h (gas 
evolution occurs). The reaction was then diluted with water (1 mL) and extracted with CH2Cl2 (3 
x 1 mL) (Note: On larger scale, the use of Et2O is recommended to avoid excessive DMSO in 
the organic extracts). The combined organics were dried over Na2SO4 and concentrated to afford 
the crude product. The NMR yield was then determined using mesitylene (10 µL) as an internal 
standard and the product was purified by column chromatography with an appropriate solvent 
mixture (as described below for each compound). 
 rac-Ibogamine (8a). The reaction was run on 0.100 mmol scale. The product 8a was 
purified by column chromatography (9:1 hexanes:EtOAc + 2% Et3N) and obtained as a colorless 
oil that slowly crystallized to a waxy white solid (11.9 mg, 42%). Spectral and physical 
properties were in agreement with those previously reported
14
 and with those of the material 
obtained from the electrophilic Pd procedure (see above). 
 rac-12-Fluoro-4-epi-ibogamine (8b). The reaction was run on 0.500 mmol scale. The 
product 8b was purified by repeated column chromatography on both silica (8:2 hexanes:EtOAc 
+ 2% Et3N, 2 column volumes → 7:3 hexanes:EtOAc + 2% Et3N, 2 column volumes → 6:4 
hexanes:EtOAc + 2% Et3N, until product eluted) and ethyltrichlorosilane treated silica (see 
below for preparation) (Column 1: 20:1 → 10:1 → 5:1 CH2Cl2:MeOH; Column 2: 20:1 
CH2Cl2:MeOH, 3 column volumes → 20:1 CH2Cl2:MeOH + 2% Et3N) and obtained as an 
amorphous off-white solid (5.1 mg, 3%). Spectral and physical properties were in agreement 
with those of the material obtained from the electrophilic Pd procedure (see above). 
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 General Procedure for Preparation of Oxaibogamine Analogs by Ni(0) C-H 
Insertion (8d-e). In a glovebox, a vial was charged with Ni(COD)2 (27.5 mg, 0.100 mmol) and 
1,3-Bis(2,4,6-trimethylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene (IMes, 36.5 mg, 0.120 
mmol), followed by anhydrous heptane (1.0 mL) and the resulting black solution was stirred at 
room temperature for 15 min. To this mixture was then added a solution of the benzofuran 
substrate (7d or 7e) (141 mg, 0.500 mmol) in anhydorus heptane (1.5 mL) and the reaction 
vessel was sealed, removed from the glovebox, and heated at 130 °C for 3 h. After cooling to 
room temperature, the reaction mixture was purified directly by a combination of column 
chromatography and preparative TLC (as described below for each compound). 
 rac-16-Oxaibogamine (8d). The crude reaction mixture was purified directly by column 
chromatography (40:1 hexanes:EtOAc + 2% Et3N) to yield several fractions as viscous, pale-
yellow oils. The central fractions provided pure product (20.3 mg) while the early (96.1 mg) and 
later (26.1 mg) fractions were contaminated with co-eluting impurities. The later fractions were 
purified on a second chromatography column (hexanes + 4% Et3N) to provide a colorless oil 
(14.2 mg). This material was combined with the early fractions from the first column and the 
whole was purified by preparative TLC (20 x 20 cm plate, 1 mm silica layer, 80:1 
hexanes:EtOAc + 2% Et3N) to provide a second portion of pure product as a viscous, nearly 
colorless oil (83.8 mg). Overall yield of pure product 8d was 104 mg (74%). 
1
H NMR (500 
MHz, CDCl3) δ 7.43 – 7.39 (m, 1H), 7.39 – 7.35 (m, 1H), 7.24 – 7.18 (m, 2H), 3.47 – 3.39 (m, 
1H), 3.28 – 3.13 (m, 3H), 3.02 – 2.92 (m, 2H), 2.82 (s, 1H), 2.54 (d, J = 15.7 Hz, 1H), 2.05 (t, J 
= 12.4 Hz, 1H), 1.90 – 1.77 (m, 2H), 1.66 (ddd, J = 13.3, 6.4, 3.1 Hz, 1H), 1.62 – 1.43 (m, 3H), 
1.25 – 1.17 (m, 1H), 0.92 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 160.0, 153.7, 
 125 
130.9, 123.3, 122.1, 118.7, 111.6, 110.6, 57.3, 53.3, 49.7, 41.5, 41.1, 33.0, 32.3, 27.5, 26.5, 19.5, 
11.9; HRMS (FAB+) m/z: [M]
+
 Calcd for C19H23NO
+
 281.1775; found 281.1772.  
 rac-16-Oxa-4-epi-ibogamine (8e). The crude reaction mixture was purified directly by 
column chromatography (9:1 hexanes:EtOAc + 2% Et3N) to yield a viscous, orange-brown oil 
contaminated with a co-eluting impurity. The NMR yield of product contained in this material 
(42%) was determined using mesitylene (10 µL) as an internal standard and it was then further 
purified by preparative TLC (20 x 20 cm plate, 1 mm silica layer, Et2O + 1% Et3N) to provide 
the pure product 8e as a viscous, pale-yellow oil (53.3 mg, 38%). 
1
H NMR (500 MHz, CDCl3) δ 
7.43 – 7.39 (m, 1H), 7.38 – 7.34 (m, 1H), 7.24 – 7.18 (m, 2H), 3.44 (ddd, J = 13.8, 4.7, 2.3 Hz, 
1H), 3.38 – 3.29 (m, 2H), 3.25 (ddd, J = 17.0, 12.3, 4.7 Hz, 1H), 3.12 – 3.02 (m, 2H), 2.88 (s, 
1H), 2.57 – 2.49 (m, 1H), 2.09 – 1.94 (m, 3H), 1.92 – 1.85 (m, 1H), 1.62 (ddd, J = 13.3, 6.0, 3.7 
Hz, 1H), 1.47 – 1.34 (m, 2H), 1.18 – 1.09 (m, 1H), 0.95 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 
MHz, CDCl3) δ 160.7, 153.4, 130.7, 123.3, 122.2, 118.6, 112.1, 110.7, 56.5, 53.5, 49.1, 41.9, 
34.3, 34.1, 31.6, 28.5, 26.4, 18.9, 12.3; HRMS (FAB+) m/z: [M+H]
+
 Calcd for C19H24NO
+
 
282.1853; found 282.1859.  
 Ethyltrichlorosilane Treated Silica Gel. Deactivated silica was prepared as follows. To 
a suspension of silica gel (40-63µm, 50 g) in CH2Cl2 (200 mL) was added ethyltrichlorosilane 
(4.0 mL) (gas evolution occurs) and the resulting mixture was stirred for 15 min. At this time the 
treated silica was collected by filtration, washed with CH2Cl2 (2 x 100 mL) and MeOH (3 x 100 
mL), and dried in vacuo with gentle warming. Treated TLC plates were prepared in the same 
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Oxaibogamine Analogs:  
















 In Chapter 2, we described our development of several novel C-H activation methods for 
synthesis of the iboga alkaloid skeleton. With this chemistry in place, we were in a position to 
rapidly explore the structure-activity relationships (SAR) of this molecular scaffold at selected 
CNS receptor targets. In particular, and in line with a growing interest in the opioid receptor 
system in our lab at the time, we became interested in the potential opioid activity of the iboga 
alkaloids. 
 In multiple reports, ibogaine, and its primary metabolite, noribogaine
1,2
 (Figure 1A) have 
been reported to bind to both kappa- and mu-opioid receptors (KOR and MOR).
3-8
 Although the 
reported binding affinities show variability between reports, and also appear to be species 
dependent, noribogaine is consistently 
observed to be more potent than 
ibogaine itself. In fact, at least three 
investigations have demonstrated 
nanomolar binding by noribogaine at 
KOR, MOR, or both (Figure 1B). 
Further, one report has shown the 
ability of noribogaine to activate MOR 
using [
35




 Given ibogaine's ability to 
interrupt psychological and physical 





Species KOR MOR DOR Reference
bovine 2.08 ± 0.23 >100 >100 Deecher, 1992
bovine 3.77 ± 0.81 11.04 ± 0.66 >100 Pearl, 1995
bovine 2.2 ± 0.10 2.0 ± 0.15 >10 Glick, 2001
rat - 3.76 ± 0.223 - Pablo, 1998
rat 29.8 ± 8.3 - - Layer, 1996
mouse 13.8 ± 0.60 - - Layer, 1996
not reported 3.16 - - Repke, 1994
Noribogaine
Ki (µM)
Species KOR MOR DOR Reference
bovine 0.96 ± 0.080 2.66 ± 0.62 24.72 ± 2.26 Pearl, 1995
bovine 0.61 ± 0.015 0.68 ± 0.016 5.2 ± 0.64 Glick, 2001
rat - 0.16 ± 0.012 - Pablo, 1998
rat 0.28 ± 0.11 - - Layer, 1996
mouse 1.2 ± 0.10 - - Layer, 1996
Figure 1. (A) Demethylation of ibogaine yields noribogaine,  a 
compound with higher opioid binding affinity. (B) Both 
ibogaine and noribogaine are reported to bind to the opioid 




agonists, we found this potential agonist activity at these same receptors intriguing. We reasoned 
that at the high doses used in treatment, sufficiently high brain concentrations of ibogaine and 
noribogaine might be achieved to activate the opioid receptors, thus acting as a temporary 
substitute for the opioid drug of abuse, and attenuating withdrawal symptoms. This possibility is 
supported by multiple pharmacokinetic studies in both rodents and humans, where ibogaine has 
been shown to reach micromolar concentrations in both blood and brain tissue.
1,2,9-12
 
Furthermore, these reports indicate that the major metabolite, noribogaine, has a much longer 
biological half-life than ibogaine itself, being detectable in significant concentrations even 24 h 
post dosing. Accordingly, it can be postulated that a slowly declining concentration of 
noribogaine might act to gradually taper the level of opioid receptor activation, thus easing the 
worst withdrawal symptoms in dependent individuals. 
 Although the potential of ibogaine to act, through its more potent metabolite noribogaine, 
as a direct substitute for opioid drugs of abuse represents a simple and compelling explanation 
for this agent's therapeutic benefits, there is also conflicting evidence. Most notably, in one 
recent study, both ibogaine and noribogaine failed to show any significant agonist activity at 
MOR in several distinct functional assays employing both transfected cells and rodent brain 
isolates.
13
 In fact, both alkaloids were found to be low potency antagonists in one assay (rat 
thalamic membranes). Unfortunately, the functional activity of iboga alkaloids at KOR, where 
their binding is better documented, had not been rigorously evaluated at the time we first became 
interested in these compounds (and remains unstudied by others).  
 Accordingly, we felt that the opioid pharamcology of the iboga alkaloids was worthy of 
further examination, and thus, we set out to use the new synthetic tools we had developed to 
access this scaffold, to make new explorations in this area. What follows here is an account of 
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our opioid receptor SAR studies of novel ibogamine analogs, in particular, contrasting the potent 
opioid agonist activity of oxaibogamine analogs, with the inactivity of the natural compound 
ibogamine and the key metabolite of ibogaine, noribogaine. 
 
Results and Discussion 
 Initial Explorations. In early radioligand binding studies of some of our iboga alkaloid 
synthetic intermediates, we had noted tantalizing activity at the KOR. Accordingly, we screened 
a variety of ibogamine-related compounds at the opioid receptors using bioluminescence 
resonance energy transfer (BRET) functional assays, using HEK cells transfected with human 
opioid receptors. Specifically, we used a G protein based assay, where the Gα subunit is fused 
with a luciferase donor, and the Gγ subunit is fused with a yellow fluorescent protein acceptor. 
Thus, on receptor activation, the G protein subunits dissociate and the observed BRET signal 
decreases. All functional assays were performed by Madalee Gassaway (graduate student, Sames 
Lab) with the aid of our collaborators in 
the Jonathan Javitch laboratory at 
Columbia University Medical Center. 
 These initial studies showed that 
ibogamine (racemic) was completely 
inactive at the human opioid receptors, 
showing no activation of hKOR, hMOR, 
or human delta-opioid receptor (hDOR), 
even at 100 µM concentration. However, 
it was found that the oxaibogamine 
Figure 2. Activity of initial lead compounds (racemic) and 
design strategy for increasing opioid potency. 
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analogs 1a and 1b (racemic), where the indole moiety was replaced with a benzofuran, were low 
potency partial agonists at hKOR (Figure 2 and Figure 3A). Although the activity of these 
compounds was very weak, we found the ability of a single atom substitution (indole NH to 
benzofuran O) to turn on this activity at opioid receptors intriguing. Therefore, we decided to 
further explore the SAR of this novel oxaibogamine scaffold at the opioid receptors. 
 Molecular Design: Introducing a Hydroxy Group. In designing more potent analogs of 
our oxaibogamines, we turned to the structure of noribogaine, as well as those of other known 
opioid scaffolds, for inspiration. Given the well precedented and moderate high affinity of 
noribogaine for both KOR and MOR, as well as its significantly higher affinity compared to 
ibogaine (Figure 1), we reasoned that the phenolic hydroxyl group in this structure might be 
critical for opioid binding. This would not be surprising considering the vital importance of the 
phenol for activity in classical opioids, for example the morphinans and benzomorphans, as well 
as in peptidic endogenous opioids, which contain a key tyrosine residue.
14,15
 In these molecular 
scaffolds, the phenol is believed to form a hydrogen bonding network with a histidine residue in 
the binding pocket, mediated by several receptor associated water molecules.
16
 Accordingly, we 
imagined that installation of a hydroxyl group at postition 12 of the oxaibogamine scaffold 
would yield structures with enhanced potency at the opioid receptors (Figure 2). 
 Synthesis of Initial Phenolic Analogs. To probe this hypothesis, we synthesized the 
phenolic analogs of 1a and 1b, bearing a hydroxy group at the appropriate position, employing 
the modular synthetic approach previously developed in Chapter 2. The required isoquinuclidine 
fragments 2a and 2b were accessed via a Diels-Alder route starting from a protected 
















fragment, 4-methoxyphenol was treated with chloroacetonitrile in the presence of BCl3 and 
AlCl3, a known process which effects selective alpha chloroacetylation.
17
 After refluxing the 
resulting product in the presence of sodium acetate, benzofuranone 3a was obtained. A Wittig 
reaction, followed by reduction and bromination, then provided the necessary bromide 6a 
(Scheme 1B). This material was used to alkylate isoquinuclidines 2a and 2b, to obtain the 
cyclization 
substrates 7a and 
7b (Scheme 1C). 
These 
Scheme 1. Synthesis of building blocks en route to iboga analogs 9a and 9b. 
Scheme 2. Cyclization and demethylation to provide phenolic analogs 9a and 9b. 
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intermediates were then succcessfully cyclized using the Ni(0) C-H activation conditions 
developed previously (Chapter 2), to provide methoxy analogs 8a and 8b. Similar to the 
analogous reactions yielding the unsubstituted products 1a and 1b, the cyclization was much 
more successful with the exo-substrate than the endo-substrate. As the final step in the sequence, 
both compounds were demethylated under nucleophilic conditions to yield the desired phenolic 
analogs 9a and 9b (Scheme 2). 
 12-Hydroxy Analogs are 
Potent Opioid Agonists. We 
evaluated phenolic compounds 9a 
and 9b in our BRET assays and 
were pleased to find that they both 
displayed potent agonist activity at 
the opioid receptors (Figure 3). The 
exo-analog 9a was a full agonist at 
all three opioid receptor subtypes, 
with submicromolar potency at both 
hKOR and hMOR, and weaker 
activity at hDOR. In contrast, the 
endo-analog 9b showed increased 
potency and full efficacy at hKOR, 
while it was only a partial agonist at 
both hMOR and hDOR. Therefore, 





 EC50 ± SEM (µM) (Emax%) 
Compound hKOR hMOR hDOR 
9a 0.66 ± 0.13 (100%) 0.98 ± 0.14 (100%) 4.5 ± 1.2 (100%) 
9b 0.20 ± 0.076 (100%) 0.98 ± 0.15 (78%) 3.3 ± 1.9 (29%) 
 
Figure 3. The 12-hydroxy analogs 9a and 9b are agonists at all three 
opioid receptor subtypes, while the unsubstituted analogs 1a and 1b 
are only weakly active at hKOR. Curves and EC50 values represent 
the average of two or more independent experiments in the G protein 
activation assay. (A) Agonist activity at hKOR, positive control = U-
50,488; (B) Agonist activity at hMOR, positive control = [D-Ala2, 
N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO); (C) Agonist activity at 
hDOR, positive control = [D-Pen(2,5)]enkephalin (DPDPE); (D) 
EC50 values ± SEM (Emax%). Data collected by Madalee Gassaway. 
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ethyl group was observed to play an important role in subtype selectivity. Pleased with these 
initial results, and with a potent, opioid-active structural motif in hand, we synthesized additional 
analogs to further define the SAR of this new scaffold, with the hope of identifying structural 
modifications that would allow better control and tuning of subtype selectivity, as required for 
different therapeutic applications (e.g. pain or mood disorders). 
 Exploring SAR in the Oxaibogamine Scaffold: Strategy. In mapping the SAR of the 
oxaibogamines, several key functionalities needed to be explored (Figure 4). In the aromatic 
region, the phenolic hydroxy group was clearly of primary importance. Accordingly, we wanted 
to examine the effect of its translocation to other ring positions, in the hopes of finding an even 
more favorable location. Similarly, probing the effect of disubstitution on the ring was important 
to map the steric tolerance of the scaffold in this region, which was expected to be limited due to 
probable close contact between the phenol and the binding pocket. It was hoped however, that 
electron withdrawing or donating groups might be tolerated adjacent to the phenol, allowing for 
tuning of the pKa and hydrogen bonding capacity of this functionality, factors assumed to be 
critical for binding.  
 Comparing ibogamine and the simple oxaibogamine 1a, it also appeared that the ring 
heteroatom at position 16 might be critical for opioid activity. Accordingly, we wanted to 
explore the ability of alternative heteroarenes, namely benzothiophene and benzimidazole, to 
substitute for the benzofuran in this 
scaffold. Further, comparison to the 
natural metabolite noribogaine, was 
important to fully quantify the 
significance of the benzofuran Figure 4. SAR exploration strategy. 
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substitution, and to confirm the prior reports of opioid activity with this compound. 
 In the aliphatic region, we chose to explore two substituent positions that were expected 
to have a strong modulatory effect on the opioid activity. From the initial results with exo- and 
endo-epimers 9a and 9b (Figure 3), it was clear that the stereochemistry (and likely size) of 
substituents at the 4-position would have a significant effect on subtype selectivity. Through 
examination of the binding pockets of the three opioid receptors as determined by recent x-ray 
crystallographic studies
16,18,19
, we developed a qualitative understanding of probable binding 
orientations of the iboga alkaloids, which indicated that substituents at the 4-position were likely 
to be facing towards the outside of the pocket. Therefore, we expected there to be significant 
steric tolerance at this position, and chose to explore several derivatives with substituents larger 
than the ethyl group found in the initial lead compounds. However, it was also desirable to 
prepare the derivative lacking a substituent at this position, so as to confirm the true importance 
of this functionality for opioid binding. Position 4 was also enticing from the synthetic 
viewpoint, as a variety of substituents were expected to be easily installed at this position 
through diverse isoquinuclidine building blocks (accesed by Diels-Alder route).  
 It is also known in the classical morphinan opioids that varying the alkyl substituent on 
the basic nitrogen exerts a dramatic effect on both potency and efficacy. In fact, the appropriate 
substituent at this position can switch the morphinan scaffold from agonist to antagonist. For 
example, replacing the N-methyl substituent in the opioid agonist oxymorphone, with an allyl 
substituent, results in the pure opioid antagonist naloxone. Given the potential antidepressant 
activity of KOR antagonists, and the ongoing interest of our lab in developing new treatments for 
mood disorders, we were particularly interested in applying this knowledge to potentially 
develop selective KOR antagonists within the iboga scaffold. Unfortunately, in the case of the 
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iboga alkaloids, no directly analogous position exists, as all the nitrogen substituents are tied 
back in the core ring system. However, we imagined that alkyl substituents introduced on the 
central bridge, alpha to the key nitrogen, might act as reasonable surrogates for N-alkyl 
substituents in the morphinans, and this position 7 was thus selected as a key locant for 
exploration. 
 Synthesis of Diverse Iboga Analogs. To explore the SAR of the features described 
above, we prepared a large collection of ibogamine analogs by the same modular route used to 
prepare 9a and 9b. This effort required the preparation of diverse isoquinuclidine and 
heteroarene buiding blocks, their coupling to provide N-heteroarylethylisoquinuclidines, and 
finally, cyclization of these intermediates to provide the final iboga analogs. It should be noted 
here that in practice, the following studies were largely conducted in an iterative fashion, with 
new analogs continuously tested in opioid functional assays as available, and the resulting data 
used to guide further design and synthesis efforts. However, in the interest of clarity, the 
synthesis of the analog library, and the biological evaluation of those analogs, have been divided, 
such that the reader may more easily consider the available data as a whole. 
 Synthesis of Isoquinuclidine Building Blocks. To investigate the importance of 
isoquinuclidine substituents, we prepared a collection of isoquinuclidine building blocks bearing 
different alkyl and aryl groups at position 7 (position 4 in final compounds). Diels-Alder reaction 
between a protected dihydropyridine and ethyl acrylate provided isoquinuclidine 10 as a mixture 
of exo- and endo-isomers. This material was hydrolyzed and converted to Weinreb amide 12, 
which acted as a versatile intermediate for the synthesis of several different isoquinuclidines. 
Reaction with ethyl Grignard provided mixed exo- and endo-7-propanoylisoquinuclidines 13, 
which were then epimerized and converted to the mixed tosylhydrazones. In contrast to the 
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tosylhydrazones of the 7-aceytlisoquinuclidines prepared on route to 2a and 2b (see Chapter 2), 
hydrazones 14a and 14b were not easily separated by crystallization and instead, 
chromatographic separation was necessary. Following separation, reduction of the hydrazones 
provided 7-propylisoquinuclidines 2c and 2d (Scheme 3). 
 Amide 12 was also coverted to the mixed exo- and endo-7-benzoylisoquinuclidines 15. 
Unforunately, the tosylhydrazone derivatives of these compounds proved extremely resistant to 
Scheme 3. Synthesis of 7-propyl and 7-benzylisoquinuclidine building blocks. 
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reduction, so it was necessary to resort to alternative 
deoxygenation methods. After considerable 
experimentation, it was found that the toluate ester 
derivatives 18 could be reduced with samarium iodide. 
Unforunately, this approach provided exclusively the 
endo-product 2f, despite complete conversion of 
starting material. Evidently, the exo-toluate ester 
produces a radical intermediate that decays more 
rapidly to alternative products, and not to the desired simple reduction product. As an alternative, 
it was found that iodides 17 could be reduced with NaBH4 in the pyrimidinone solvent DMPU, 
to provide both exo- and endo-products, from which the exo-product 2e could be separated by 
chromatography (Scheme 3). Unfortunately, this reaction suffered from competing elimination 
to an olefin byproduct, which was difficult to separate from 2e/f. It was found that rigorously 
anhydrous conditions largely suppressed elimination, but it could not be entirely prevented. 
Nonetheless, sufficient quantities of the 7-benzylisoquinuclidines were obtained for initial analog 
synthesis. 
 We also prepared the unsubstituted isoquinuclidine 2g, as well as the rigid, bulky, mixed 
exo- and endo-7-phenylisoquinuclidines 2h. These were both obtained via Diels-Alder reactions, 
according to literature procedures (Scheme 4).
20,21
 
 Synthesis of Heteroarene Building Blocks. A collection of haloethylheteroarenes was 
also prepared (Schemes 5 and 6). The substituted bromoethylbenzofurans 6b-f were prepared 
starting from their corresponding benzofuranones, via Wittig reaction to provide esters 4b-f, 
reduction to the alcohols 5b-f, and finally, bromination to provide the products. In some cases,  
Scheme 4. Synthesis of 7-unsubstituted 
and 7-phenylisoquinuclidine building 
blocks. 
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the required benzofuranones were commercially available, but several also had to be prepared. In 
two cases, this was accomplished by alpha chloroacetylation of the appropriate phenol, followed 
by cyclization (as described for 3a, see above). However, synthesis of benzofuranone 3d 
required an alternative approach, namely, decarboxylative condensation of the appropriately 
substituted dicarboxylic acid 20 (Scheme 5). 
 Other haloethylheteroarenes were also synthesized. To prepare the benzothiophene 
building block, 4-methoxythiophenol was alkylated with ethyl 4-chloroacetoacetate and then 
cyclized under Friedel-Crafts conditionds to provide an ester. This was reduced and brominated 
in the same manner as the benzofurans, to provide the required building block 22. For the 
benzimidazole analog, aminoalcohol 24 was prepared in a two step sequence according to 
previously described procedures.
22
 This material was condensed with formic acid to form the 
imidazole ring, and then chlorinated to provide chloroethylbenzimidazole 26. Lastly, we  
Scheme 5. Synthesis of diverse bromoethylbenzofurans. 
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prepared the bromoethylindole building block 28, required for the synthesis of noribogaine, via 
reduction of the corresponding carboxylic acid, followed by bromination (Scheme 6). 
 Synthesis of Cyclization Substrates: N-benzofuranylethylisoquinuclidines. To 
provide a collection of benzofuran substrates suitable for the impending Ni(0)-catalyzed 
cyclization, isoquinuclidines 2a-h were deprotected and alkylated with the 
bromethylbenzofurans 6a-f, to provide benzofuran-alkene substrate 7a-n (Scheme 7A). We were 
not able to prepare the 6-methoxybenzofuran substrate 7j via the alkylation route, as the 
necessary bromide building block was found to be highly unstable. As an alternative approach, 
isoquinuclidine 2a was used to form amide 29, which was then reduced to provide the desired 
product (Scheme 7B).  
 Synthesis of Oxaibogamine Analogs. To complete the synthesis of benzofuran analogs, 
substrates 7a-n were first subjected to the previously developed Ni(0)-catalyzed cyclization 
reaction (Chapter 2), to provide fully cyclized analogs of type 8 (Scheme 8). Pleasingly, this 
work confirmed the broad scope of the nickel cyclization within this structural class, as all 
substrates were successfully cyclized in modest to good yields. As had been previously observed 
(Chapter 2), the yields obtained with exo-substrates were significantly higher than those  





















obtained with endo-substrates. Furthermore, the depressed yields observed for endo-substrates 
were worsened with increasing steric bulk of the endo-substituent (compare 8b and 8d to 8f). 
 However, the mechanistic explanation for these observations remains uncertain. 
Originally, we had postulated that exo-substituents provided improved yields by one of two  













possible mechanisms: 1) hindrance of the nitrogen lone pair, resulting in less potential 
interference with the catalytic system, or 2) enrichment of the N-atom configuration positioning 
the heteroarene on the same side as the olefin and thus, enhancing the rate of cyclization. 
However, the fact that the unsubstituted isoquinuclidine product, 8h, was obtained in similar 
yield to those products bearing exo-substituents, argues against either of these possibilities. 
Instead, an alternative explanation can be envisioned, in which re-hybridization of the olefinic C-
H bond at position 5 of the isoquinuclidine during metal insertion/C-C bond formation, results in 
increased pseudo-1,3-diaxial strain between this hydrogen and the endo-substituent at position 7. 
Scheme 8. Ni(0)-catalyzed cyclization of benzofuran substrates. 
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 Thus, increasing bulk in the endo-7-position 
would result in unfavorable energetics 
during cyclization (Figure 5). 
 As the final transformation to 
provide potentially opioid-active hydroxybenzofuran analogs, the methoxybenzofuran analogs of 
type 8 were demethylated under nucleophilic conditions (Scheme 9). Thus were obtained a large 
set of oxaibogamine analogs, 9a-n, bearing a phenolic moiety and varied at either the aryl 
substituents or the position 4 substituents. Accordingly, detailed SAR studies of these two key 














Figure 5. Pseudo-1,3-diaxial strain during cyclization of 
endo-substrates 










 Synthesis of α-Methyl Analogs. To explore the effect of alkyl substitution in the vicinity 
of the basic nitrogen, we synthesized oxaibogamine analogs with a methyl group adjacent to this 
functionality. The required ketone 30 was first prepared from benzofuranone 3a via Wittig 
reaction (Scheme 10A). This was then used in a reductive amination reaction with deprotected 
isoquinuclidines 2a and 2b, to provide the four possible diastereomers, α-exo- and α-endo-7o, 
and α-exo- and α-endo-7p (Scheme 10B). In this case, the terms "α-endo" and "α-exo" are used 
to refer not to the stereochemistry of the isoquinuclidine 
7-position substitutent, but to the stereochemistry of the 
alpha-methyl group, with the meanings defined in 
Scheme 10. Interesting diastereoselectivity was 
observed in this reaction, with isoquinuclidine 2a 
showing a strong selectivity for the α-endo-product, and 
isoquinuclidine 2b resulting in a nearly equal ratio of 
the two. This can be rationalized by considering the 
Scheme 10. Synthesis of α-methyl starting materials. 
Figure 6. Facial selectivity during 
reductive amination is governed by 7-
position stereochemistry. 
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steric hindrance to hydride attack on the iminium intermediate presented by the 7-position ethyl 
group, which is much larger with 2a than with 2b, resulting in greater facial selectivity (Figure 
6). 
 The four benzofuran-alkene substrates were then subjected to the Ni cyclization, resulting 
in the four cyclized analogs α-exo/endo-8o and α-exo/endo-8p, which were in turn demethylated 
by the standard conditions to provide the corresponding phenolic analogs of type 9 (Scheme 11). 
In all cases, the relative stereochemistry of the products was assigned by NOESY NMR 
experiments. Interestingly, the stereochemistry of the α-methyl group had a strong effect on the 
yields obtained in the cyclization reaction. Both α-endo-8o and α-endo-8p were obtained in ~2-














Scheme 11. Synthesis of α-methyl oxaibogamine analogs. 
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between exo- and endo-epimers at the isoquinclidine 7-position. Unfortunately, this selectivity 
cannot be easily rationalized based on steric arguments, and it remains an unexplained 
phenomenon at this time. 
 Synthesis of Heteroaryl Analogs and Noribogaine. As the final group of analogs for 
SAR screening, we prepared benzothiophene and benzimidazole analogs, as well as the reference 
compound noribogaine, to probe the importance of the heteroatom at position 16. Isoquinuclidine 
2a was deprotected and alkylated with the haloethylheteroarenes 22, 26, and 28 to provide the 
corresponding cyclization substrates. Pleasingly, the benzimidazole substrate 34 was 
successfully cyclized using the Ni(0)-catalyzed conditions, further expanding the scope of this 
reaction. However, the benzothiophene and indole substrates 31 and 37 required use of the 
electrophilic palladium salt Pd(CH3CN)4(BF4)2 (see Chapter 2 for discussion). The phenolic 
benzothiophene and benzimidazole analogs were then obtained by nucleophilic demethylation of 
the methoxy-substituted precursors, while noribogaine was obtained by hydrogenation of the 
benzyloxy intermediate (Scheme 12). 
Scheme 12. Synthesis of other heteroaryl ibogamine analogs including noribogaine. 
 149 
 Opioid SAR of the Oxaibogamine Scaffold. With a variety of iboga alkaloid analogs 
displaying variability at all the key positions in hand, we were in a position to identify important 
SAR trends within this molecular skeleton. Thus, the derivatives synthesized above were 
screened for functional activity at the three human opioid receptors using the G protein BRET 
assay (Table 1, see above for assay description). 
 SAR of the 4-Position. Moving from ethyl (9a/b), to the slighly larger propyl (9c/d) 
substitutent at the 4-position, had little effect at hMOR, while producing a modest loss of 
potency at hKOR. Results at hDOR were mixed, as the ethyl-propyl substitution had no effect 
with the exo stereochemistry, but decreased potency and increased efficacy when in the endo 
position. Moving to the bulky phenyl substituents at this position produced a dramatic loss of 
activity, in terms of both potency and efficacy, at all receptor subtypes, although the endo 
stereochemistry was more tolerant to this large substituent, and 9f retained some activity at all 
three receptors. Interestingly, an exo-benzyl group at this position (9g) was significantly better 
tolerated, and this analog was much more active than the corresponding exo-phenyl derivative 
9e, particularly at the hMOR. Presumably, this difference results from the greater conformational 
flexibility of the benzyl group, which allows it to appropriately position its steric bulk so as to 
avoid steric clashes. In contrast, eliminating the substituent at position 4 (9h) produced an 
increase in hKOR selectivity. This analog maintained nearly identical hKOR potency to the 
endo-ethyl analog 9b, while showing decreased efficacy at hMOR, and a complete loss of 
agonist activity at hDOR.  
 As a whole, these results suggest several important points regarding SAR at this position. 
Most notably, there does in fact, appear to be significant available space in this region of the 








However, this tolerance is constrained by substituent flexibility, as the rigid phenyl analogs were 
much less active. This suggests that substituents at position 4 remain in close contact with the 
Table 1. Agonist activity of iboga analogs (racemic) at human opioid receptors as determined in the G protein 
BRET assay. All data represents mean EC50 ± SEM (µM) of at least 2 independent experiments, or EC50 from a 
single experiment if no error is indicated; Emax in parentheses; "X" indicates inactive or EC50  >100 µM in 
agonist mode; when available, IC50 determined in antagonist mode is indicated in parentheses. All compounds 
are benzofuran analogs except 33, 36, and noribogaine. Data collected by Madalee Gassaway.  
 
SAR Locant Compound Key Functionality hKOR hMOR hDOR 
9a exo-ethyl 0.66 ± 0.13 (100%) 0.98 ± 0.14 (100%) 4.5 ± 1.2 (100%) 
9c exo-propyl 2.1 ± 1.2 (100%) 0.95 ± 0.069 (100%) 4.4 ± 2.0 (100%) 
9e exo-phenyl X 43 (44%) X 
9g exo-benzyl 11 ± 1.1 (16%) 2.8 ± 0.10 (86%) 7.6 ± 1.6 (58%) 
9b endo-ethyl 0.20 ± 0.076 (100%) 0.98 ± 0.15 (78%) 3.3 ± 1.9 (29%) 
9d endo-propyl 0.30 ± 0.30 (87%) 0.92 ± 0.28 (70%) 5.7 ± 5.1 (63%) 
9f endo-phenyl 1.3 (18%) 5.2 (52%) 6.6 (42%) 
4-position 
substituent 
9h unsubstituted 0.21 ± 0.056 (100%) 1.2 ± 0.80 (68%) X 
8i 12-F 42 ± 19 (55%) X X 
9l 11-OH X 36 (79%) X 
9j 13-OH 2.1 ± 0.30 (87%) 3.4 ± 0.70 (31%) X 
8j 13-OMe 1.1 ± 0.008 (83%) 3.3 ± 1.0 (40%) X 
9k 14-OH 2.3 ± 1.6 (28%) X X 
9m 13-F-12-OH 18 (76%) 11 (73%) X 
benzofuran 
substituents 
9n 12-OH-13-Me 2.3 (89%) 4.8 (77%) 40 (85%) 
α-endo-9o α-endo-Me-exo-Et 2.4 ± 0.190 (26%) 29 ± 30 (24%) X 
α-exo-9o α-exo-Me-exo-Et 0.44 ± 0.059 (88%) 0.40 ± 0.056 (98%) 4.2 ± 0.67 (98%) 
α-endo-9p α-endo-Me-endo-Et 0.12 ± 0.014 (47%) X (IC50 = 11) X (IC50 = 21) 
α-methyl 
α-exo-9p α-exo-Me-endo-Et 0.14 ± 0.006 (72%) 0.48 ± 0.20 (50%) X 
33 benzothiophene 8.3 (70%) 10 (46%) X 
36 benzimidazole 29 (51%) X X heteroarene 
noribogaine indole X 42 (44%) X 
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receptor surface. However, substitution at this position is not required for opioid activity at 
hKOR or hMOR, as the unsubstituted analog 9h retained activity at both of these receptors. 
 SAR of the Benzofuran Substituents. As expected, the benzofuran substituents proved 
very sensitive to modification (Table 1). Substitution of the key hydroxy group with a fluorine 
(8i) almost completely abolished opioid activity, confirming the need for a hydrogen bond 
acceptor/donor at this position. Likewise, moving the hydroxy group from position 12, to either 
position 11 or 14 (9l and 9k), resulted in a nearly complete loss of activity at all three opioid 
subtypes. In contrast, analog 9j, with the hydroxy group at the 13-position, retained some activity 
at both hKOR and hMOR. Interestingly, the methoxy precursor of this compound, 8j, was more 
potent and efficacious for activation of both receptors. This result stands in sharp contrast to the 
methoxy analogs at the other ring positions, which are almost entirely inactive. We thus reasoned 
that position 13 might be tolerant of some steric bulk, and selected this locant for introduction of 
a second substituent (in addition to the key 12-OH). It was hoped that it might be possible to 
modulate the hydrogen bonding capacity of the 12-position hydroxy group by introducing 
adjacent electron withdrawing or donating substituents at position 13. However, the disubstituted 
analogs 9m and 9n were only weakly active, suggesting that altering the pKa of the phenolic 
hydrogen is undesirable for binding. Alternatively, 9a may take on a slightly different binding 
pose than 8/9j, one that eliminates any steric tolerance at this position. Considering these results, 
it can be concluded that a 12-position hydroxy group is likely to be the ideal aryl substituent in 
this scaffold. 
 SAR of α-Methyl Analogs. Perhaps the most interesting SAR observed in the iboga 
scaffold was found by introduction of a methyl group at the 7-position, alpha to the basic 
nitrogen (Table 1). In the α-methyl analogs of 9a, bearing an exo-ethyl group (9o), the two 
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potential orientations of the methyl group resulted in starkly different opioid activity. With the 
major diastereomer α-endo-9o, having α-endo configuration of the α-methyl group, opioid 
activity was significantly reduced. In contrast, the α-exo-epimer, α-exo-9o, displayed modestly 
increased potency at both hKOR and hMOR in comparison to 9a, while activity at hDOR was 
unchanged. It can be postulated that the poor activity of α-endo-9o results from steric shielding 
of the nitrogen lone pair by the α-methyl group, hindering formation of a probable salt bridge 
interaction between these electrons and a key aspartic acid residue in the binding pocket of the 
opioid receptors, which is known to be critical for the activity of many opioid scaffolds. This is 
supported by the large polarity difference observed between this compound and its α-exo-epimer, 
α-exo-9o. The inactive α-endo-compound was significantly less retained on silica columns and 
TLC plates, likely indicating steric shielding of the nitrogen lone pair, which would be expected 
to prevent hydrogen bonding interactions with OH groups on the silica gel surface, thus reducing 
retention. 
 The observed SAR with the α-methyl analogs of 9b, bearing an endo-ethyl group (9p), 
was somewhat different, but did help to support our suspicions regarding the importance of the 
nitrogen lone pair. Similar to α-exo-9o in the exo-ethyl series, the α-exo-diastereomer in this 
endo-ethyl series, α-exo-9p, showed modestly increased potency at both hKOR and hMOR in 
comparison to 9b, while activity at hDOR was eliminated. In contrast to α-endo-9o, which was 
inactive, the α-endo-epimer in this series, α-endo-9p, was found to be a potent, partial agonist at 
hKOR, with no agonist activity at hMOR or hDOR (Figure 7). Apparently, the additional 
shielding of the nitrogen lone pair introduced by an α-endo-oriented methyl group can be 
sufficiently compensated by the competing reduction in shielding obtained when the 4-position 


























Figure 7. Compound α-endo-9p (racemic) is a selective partial agonist at hKOR. The BRET G protein activation 
assay was used in agonist mode (left panels), or in antagonist mode (right panels) measuring competitive inhibition of 
a standard agonist (5x EC50 concentration). (A) Structure of α-endo-9p; (B) Agonist and antagonist activity at hKOR, 
control agonist = U-50,488, control antagonist = nor-binaltorphimine (nor-BNI); (C) Agonist and antagonist activity 
at hMOR, control agonist = DAMGO, control antagonist = cyprodime; (D) Agonist and antagonist activity at hDOR, 
control agonist = DPDPE, control antagonist = TIPP-psi. All curves represent the mean of two or more independent 
experiments. Data collected by Madalee Gassaway. 
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sufficiently exposed to mediate binding and activation of hKOR, but not of the other receptor 
subtypes. 
 Considering the apparent selectivity of α-endo-9p for hKOR in the agonists assays, we  
also evaluated this compound in antagonist experiments, so as to fully define its selectivity. We 
found that α-endo-9p acted as a competitive antagonist at both hMOR and hDOR, indicating that 
the compound also binds to these receptors to some degree (Figure 7). However, this activity 
was quite weak (IC50 > 10µM), so α-endo-9p does appear to show some genuine selectivity for 
hKOR. Unfortunately, we have found that IC50 as determined under the conditions used in our 
BRET assays, does not correspond well to Ki as determined in radioligand displacement 
experiments. In fact, the actual Ki typically indicates much stronger binding than would be 
expected from the IC50 value, even when appropriately corrected using the Cheng-Prusoff 
equation. Therefore, the KOR-selectivity of α-endo-9p as indicated by these functional 
experiments may be overestimated, and a full determination of its selectivity would require 
binding experiments at each receptor, work which has not been completed as of this writing. 
 SAR of Heteroaryl Analogs. We had initially unlocked opioid activity in the iboga 
molecular scaffold by substituting oxygen for nitrogen in the heteroarene (i.e. 1a versus 
ibogamine). Accordingly, we were particularly interested in assessing the effect of other 
heteroaryl substitutions (Table 1). Fascinatingly, we found that the benzothiophene analog 33 
was only weakly active at the opioid receptors. This data appears to indicate that a hydrogen 
bond acceptor at this position is required for potent opioid activity. Given this apparent 
constraint, we imagined that the benzimidazole analog 36 might represent a better substitution, 
as this compound hosts an sp
2
-hybridized lone pair on nitrogen, at the appropriate position to act 
as a hydrogen bond acceptor. Surprisingly however, we found this derivative to be almost 
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completely inactive at the opioid receptors. On further consideration, one potential explanation 
for this discrepancy may result from the basicity of the benzimidazole nitrogen, the conjugate 
acid of which, would be expected to have a pKa in the range of 6-7. Therefore, significant 
protonation might occur in the phosphate buffered saline (pH ~7.4) used during the BRET 
assays, which would produce a charged species unable to bind the receptor. Alternatively, the 
more basic character of the benzimidazole lone pair, as compared to benzofuran, might simply 
render it unsuitable for the appropriate hydrogen bonding interaction. 
 Lastly, we investigated the opioid activity of the purported metabolite of ibogaine, 
noribogaine (39). Once again, we were surprised to find that this compound possesed no activity 
at hKOR/hDOR (EC50/IC50 = >100 µM), and was only a weak partial agonist at hMOR (EC50 = 
44 µM). This result stands in direct contrast to several prior reports of both opioid binding and 
functional activity with this compound. However, it is in agreement with a more recent 
collaborative report between several laboratories, which showed that noribogaine was inactive, 
or only very weakly active, in several in vitro and ex vivo functional assays at MOR, including 
the classic [
35
S]GTPγS binding assay in cell lines transfected with MOR.
13
 Thus, the available 
data appears to contradict a potential opioid mechanism of action for ibogaine. Further, the 
inactivity of noribogaine again highlights the unique character of the oxaibogamine analogs 
described here, and the necessity of an oxygen atom substitution at position 16. 
 Oxaibogamine Analogs are Uniquely Biased Agonists. Having completed a thorough 
SAR study of the oxaibogamine scaffold at the opioid receptors, we initiated more detailed 
studies of several of the more pharmacologically interesting compounds. Specifically, we wanted 
to check for possible biased agonism at the opioid receptors. Functionally selective agonists of 
the opioid receptors, which preferentially activate only certain downstream signaling pathways, 
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hold promise as potential analgesics with reduced side effects. In particular, some evidence 
indicates that MOR agonists biased towards G protein signaling over β-arrestin signaling display 
less respiratory depression and constipation, while remaining potent analgesics. Similarly, at 
KOR, some prior work suggests that the dysphoric and psychotomimetic side effects of agonists 
at this receptor may be mediated through the β-arrestin signaling pathway (for detailed 
discussion, see Chapter 1). Thus, a selective KOR, or mixed KOR/MOR agonist, eliciting 
functionally biased receptor activation might represent a lead for improved opioid analgesics.  
 To assess the level of β-arrestin recruitment induced by our novel opioid active 
compounds, we employed two recently described BRET assays in transfected HEK cells.
23,24
 In 
the first assay, which was used for hMOR and hDOR, the unlabeled receptor is transfected 
alongside β-arrestin-2 (arrestin-3), fused with luciferase and an SH3 binding domain (Sp1), and 
the membrane protein GAP43, fused with a yellow fluorescent protein (YFP) and an SH3 
domain. Accordingly, when an agonist induces β-arrestin recruitment to the receptor, the Sp1 on 
arrestin is brought into proximity with the membrane-localized SH3 domain, and binding occurs. 
This results in concomitant association of the luciferase donor and YFP acceptor, and a BRET 
signal is observed.
23
 Unfortunately, we could not obtain an acceptable signal-to-noise ratio when 
this assay design was applied to hKOR. Therefore, for this receptor an alternative assay was 
used, employing hKOR fused with the luciferase BRET donor, and β-arrestin-2 fused with the 
BRET acceptor YFP. Thus, recruitment of arrestin by the receptor results in close proximity of 
the donor-acceptor pair, and a BRET signal is observed.
24 
 As an initial assesment of potential biased signaling by the oxaibogamine analogs, the 
initial lead compounds 9a and 9b, as well as the potentially selective KOR agonist α-endo-9p, 
were evaluated for arrestin recruitment ability using the assays described above, resulting in 
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several interesting preliminary 
observations. As a general trend, 
the oxaibogamine analogs were 
much less efficacious in 
recruitment of β-arrestin than the 
reference agonists, even in the 
presence of G protein-coupled 
receptor kinase 2 or 3 (GRK2 or 
GRK3), which enhance the 
efficacy and potency of coupling 
to β-arrestin  (Figure 8 and 
Figure 9).  
 With compounds 9a and 
9b, an interesting relationship 
was observed between the ethyl group stereochemistry, and the observed functional selectivity at 
hMOR. The exo-epimer, 9a, was effective for coupling to arrestin at this receptor (although low 
efficacy), while the endo-epimer, 9b, was not (Figure 8A). Interestingly however, when we 
calculated the bias factor for 9a, using the relative activity (RA) method (see Chapter 1 for 
details), it was found to be significantly biased towards β-arrestin signaling, with a negative log 
bias factor of -0.625. This was surprising considering the lower efficacy of 9a for arrestin 
recruitment compared to the reference agonist [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin 
(DAMGO), but can be rationalized by the lower interassay potency shift observed for 9a as 
compared to DAMGO. This is apparent when the log bias factor is separated into its log potency 
A/
B/







DAMGO 2.07 ± 1.21 (100%) 98.3 ± 0.60 (100%) 0 0 0 
9a 979 ± 138 (100%) 4,300 ± 1,600 (39%) -1.03 0.41 -0.625 
9b 978 ± 150 (78%) <8% - - - 
 
Figure 8. To measure β-arrestin recruitment induced by MOR 
activation, HEK cells were transfected with hMOR, RLuc8-arrestin3-
Sp1, mem-linker-citrine-SH3, and GRK2. Under these conditions, an 
increase in BRET signal indicates β-arrestin recruitment. (A) The 
endo-epimer, 9b, is less efficacious for arrestin recruitment than the 
exo-epimer, 9a. Curves represent the average of two independent 
experiments. (B) EC50 ± SEM (nM), Emax (%), and calculated log 
potency bias, log efficacy bias, and combined log bias factors (RA 
method) are also provided for each compound. Data collected by 
Madalee Gassaway. 
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bias and log efficacy bias components. In the relative activity model, these values can be 
calculated via the following equations, 
 
log potency bias = [-log(EC50)test + log(EC50)ref]G protein - [-log(EC50)test + log(EC50)ref]β-arrestin 
log efficacy bias = [log(Emax)test - log(Emax)ref]G protein - [log(Emax)test - log(Emax)ref] β-arrestin 
log bias factor = log potency bias + log efficacy bias 
 
where "test" and "ref" indicate the values for the test and reference agonists, respectively, and 
positive values indicate a bias towards G protein signaling. Considering the values obtained for 
9a, it can be seen that this compound shows a strong potency bias towards β-arrestin, and a lesser 
efficacy bias towards G protein (Figure 8B). Taken together, these values result in a combined 
log bias factor that remains negative. Unfortunately, the stronger apparent bias of the endo-
epimer, 9b, could not be quantified, as the Emax for arrestin recruitment was too low to be 
reliably determined (best trial only 8%). Thus, the efficacy bias of 9b can only be considered in a 
qualitative sense. 
 We also evaluated the selective KOR agonist, α-endo-9p, for functional selectivity at this 
receptor. Similar to the endo-ethyl analog 9b at hMOR, α-endo-9p displayed only very low 
efficacy for β-arrestin recruitment at hKOR, in comparison to the standard small molecule 
agonist U-50,488 (Figure 9A). Several other well-known KOR agonists were also evaluated for 
comparison, namely, the endogenous peptide dynorphin A, the hallucinogenic compound 
salvinorin A, and the previously reported G protein-biased agonist 6'-guanidinonaltrindole (6'-
GNTI). The resulting data was then used to calculate log bias factors for each compound, using 
dynorphin A as the reference agonist (Figure 9B). As expected, U-50,488 and salvinorin A were 
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found to be unbiased agonists, while 6'-GNTI was strongly selective for G protein signaling. 
However, according to the calculated log bias factor, α-endo-9p was found to be unbiased, a 
surprising observation given its weak arrestin recruitment in comparison to the other unbiased 
agonists. It should be noted that this unexpected finding may simply be due to an inaccurate 
estimation of EC50 due to the very low Emax, and thus high noise, observed in the arrestin assay 
with this compound. However, if this preliminary data is accepted as accurate, then interesting 
behavior again emerges when the log bias factor is separated into its log potency bias and log 
efficacy bias components (Figure 9B). Similar to the results with 9a at hMOR, it can be seen 
























Dynorphin A 9.8 ± 10.1 nM (100%) 80.3 ± 47.8 nM(100%) 0.000 0 0 
U-50,488 53.1 ± 21.4 nM (100%) 660 ± 497 nM (100%) 0.181 0 0.181 
Salvinorin A 7.4 ± 2.1 nM (100%) 56.3 ± 25.8 nM (100%) -0.032 0 -0.032 
6'-GNTI 1.3 ± 0.9 nM (73%) 61.4 ± 31.8 nM (17%) 0.761 0.633 1.39 
α-endo-9p 110 ± 36 nM (49%) 385 ± 252 nM (19%) -0.369 0.411 0.042 
Figure 9. To measure β-arrestin recruitment induced by KOR activation, HEK 
cells were transfected with hKOR-Rluc8, arrestin3-mVenus, and GRK3. Under 
these conditions, an increase in BRET signal indicates β-arrestin recruitment. 
(A) The compound α-endo-9p shows very low efficacy for arrestin recruitment 
compared to U-50,488. Curves represent the average of two or more 
independent experiments. (B) EC50 ± SEM, Emax (%), and calculated log 
potency bias, log efficacy bias, and combined log bias factors (RA method) are 
also provided for each compound, as well for additional reference agonists, 





biased potency component. In contrast, 6'-GNTI shows a positive bias factor in terms of both 
efficacy and potency. 
 The observation of two compounds, 9a and α-endo-9p, displaying competing, mixed bias 
was surprising, as it differed from the expectation that compounds having efficacy bias towards 
one pathway would necessarily display potency bias towards that same pathway. However, the 
situation appears to be more complex, and opioid agonists cannot be simply classified as G 
protein selective or β-arrestin selective. Instead, based on our preliminary data, it may be 
expected that there will be multiple distinct classes of functionally biased agonists at a given 
receptor. This can be clearly visualized by plotting the log potency bias and log efficacy bias 
factors of the tested KOR agonists as a two dimensional plot (Figure 10). Generally speaking, 
the bias of an agonist in such a plot can be considered as a vector quantity, with the magnitude of 
functional selectivity quantified by measuring the distance of displacement from the origin 
(location of the reference agonist), and the specific nature/type of bias determined by the 
direction of that displacement, with distinct directions defining different classes of biased 
agonism. In this treatment, α-endo-9p can be clearly seen to plot in a different region (quadrant 
II) than the reference unbiased agonists (dynorphin A, U-50,488, and salvinorin A), which plot 
near the origin. Likewise, it can be clearly understood that in an analogous analysis for MOR, 
compound 9a would also plot in quadrant II, thus potentially indicating a general trend towards a 
unique type of biased signaling induced by compounds in this molecular scaffold. In contrast, 6'-
GNTI is found in a distinct region (quadrant I), both from the reference unbiased agonists, and 
from α-endo-9p. It is also probable that an agonist may signal in such a way so as to plot in 
quadrant III or IV, however, no such compounds were identified in the present work. Thus, 
















 However, the relevance of specific types of biased agonism, and in fact, of biased activity 
in general, to gross physiological or behavioral effects remains uncertain. Further, the unusual 
mixed bias observed for both α-endo-9p (at KOR) and 9a (at MOR) will need to be confirmed in 
additional experiments, due to the potentially unreliable data obtained in our funtional assays at 
very low Emax. Although it is tempting to consider such low efficacy signaling as non-relevant, 
and therefore claim α-endo-9p as a fully G protein-biased agonist, this is inappropriate 









































Figure 10. When the efficacy (Log Efficacy Bias) and potency (Log Potency Bias) components of 
the log bias factor are separated and plotted individually in two dimensions, distinct functional 
selectivity profiles are visualized, which may be divided by quadrant. The reference agonists 
dynorphin A, U-50,488, and Salvinorin A are unbiased and cluster near the origin. The known biased 
KOR agonist 6'-GNTI shows both efficacy and potency bias towards G protein, and plots in quadrant 
I. The iboga analog α-endo-9p shows mixed bias, with efficacy bias towards G protein, and potency 
bias towards β-arrestin, thus plotting in quadrant II. Biased agonists plotting in quadrants III and IV 
may also potentially exist, but were not identified in the present study. 
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 Potential Therapeutic Applications. The failure of noribogaine to activate any of the 
opioid receptor subtypes at reasonable concentrations suggests that these receptors are not 
involved in the antiaddictive effects of this compound, or of the parent compound ibogaine. 
Further, our results directly contradict a prior report demonstrating agonist activity for 
noribogaine at MOR
7
, and are in agreement with a more recent study in this regard.
13
 Thus, the 
novel analogs described here are not likely to be relevant for the development of more effective 
treatments for drug addiction acting through the same receptor systems as ibogaine itself. 
 However, the oxaibogamine analogs represent a new class of opioid agonists having 
unique subtype and functional selectivity profiles. Accordingly, they may serve as leads for the 
development of new analgesic drugs with improved therapeutic profile. For example, the KOR-
selective compound α-endo-9p, which displays distinct biased signaling activity, may be an 
effective analgesic with less incidence of the dysphoric and psychotomimetic side effects that 
plague traditional KOR agonists (see Chapter 1 for discussion). However, additional studies, 
both in vitro and in animals, are needed to better understand the potentially unique downstream 
signaling and behavioral effects of this compound compared to other KOR agonists (both biased 
and unbiased). Similarly, given the partial agonist activity of α-endo-9p, it may act as a useful 
starting point for developing new KOR antagonists, which are of interest in the treatment of 
depression and related mood disorders (see Chapter 1 for discussion). In fact, the α-ethyl analog 
of α-endo-9p has also recently been synthesized, and in initial studies, has been found to act as a 
selective KOR antagonist, highlighting a potential structural modification to obtain pure opioid 
antagonists within the iboga alkaloid structural space. 
 The oxaibogamine compounds described here are also potentially enabling of an opioid 
polypharmacology approach for the treatment of several conditions, where the low subtype 
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selectivity of this scaffold would be harnessed as an asset. In particular, the agonist acivity at 
hKOR and hMOR is well balanced. For example, the analog α-exo-9o is a nearly full efficacy 
agonist at both hKOR and hMOR, with equivalent submicromolar potency at both receptors. 
Similarly, the epimer α-exo-9p is a potent partial agonist at these two receptor subtypes (Table 
1). There is reason to believe that such dual KOR/MOR agonists will possess an improved side 
effect profile compared to pure KOR or MOR agonists. The known and clinically used opioid 
agonist nalbuphine, possesses a similar opioid profile to these compounds, as it acts as a partial 
agonist of both KOR and MOR with almost equal potency.
25
 Notably, this compound induces 
significantly less respiratory depression than more selective MOR agonists (e.g. morphine), and 
such effects are restricted by a ceiling.
26,27
 Likewise, psychotomimetic and dysphoric effects are 
rarely observed with nalbuphine at therapeutic doses, unlike with other clinically used opioids 
acting through the KOR (e.g. pentazocine).
26
 This improved therapeutic profile may be the result 
of several factors, which remain to be elucidated, namely, 1) partial, as opposed to full, agonist 
activity, 2) potentially beneficial circuit-level crosstalk between the two receptor subtypes, 3) 
potentially biased downstream signaling. In any case, the oxaibogamine analogs displaying dual 
KOR/MOR activity are likely to benefit from similar factors, and therefore represent potential 
leads for improved analgesics acting via a polypharmacological approach. 
 Concomitant modulation of both KOR and MOR is also expected to be beneficial in the 
treatment of depression. Both KOR antagonists and MOR agonists are known to be effective 
therapies for mood disorders, both in animals, and in the case of MOR, humans (see Chapter 1 
for discussion). Thus, a dual KOR antagonist and MOR agonist would be expected to be an 
effective antidepressant and/or anxiolytic. The combined KOR/MOR activity of the 
oxaibogamine analogs suggests that they may serve as a suitable starting point for the 
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development of such compounds, providing additional SAR studies were to be successful in 
switching the KOR component to antagonism. 
 As therapeutics, the compounds described here also have the advantage of derivation 
from a known natural product with a long history of safe human use. It is thus to be expected that 
the oxaibogamines will have an acceptable safety profile and less potential for idiosyncratic 
toxicity issues, as compared to lesser known compounds. 
 
Conclusion 
 In this chapter, we have described the identification and thorough pharmacological 
characterization of a new class of opioid receptor modulators, the oxaibogamines, derived from 
the natural iboga alkaloids. The SAR studies presented above establish two structural features 
essential for opioid activity in this molecular scaffold, namely, a free hydroxy group at position 
12, and the subsitution of oxygen for nitrogen at position 16, to obtain benzofuran derivatives. 
Notably, we also found that the purported major active metabolite of ibogaine, noribogaine, is 
inactive as an opioid agonist. Thus, it is unlikely that the opioid receptor system is the direct 
molecular-level mechanism through which ibogaine mediates its antiaddictive effects. 
 Several of the novel oxaibogamine analogs described here also displayed unique 
signaling bias in preliminary studies. For example, the G protein/β-arrestin signaling profile of 
the KOR-selective analog α-endo-9p, was found to be distinct, both from reference unbiased 
agonists (including the endogenous peptide dynorphin A), and from the previously reported G 
protein-biased agonist 6'-GNTI. Thus, this compound may represent a useful tool for elucidating 
the downstream and systems-level effects of signaling bias at the molecular level, and the 
relevance of such bias to potential therapeutic applications. In particular, the interesting 
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pharmacological profiles of α-endo-9p and the other α-methyl substituted congeners, suggest the 
further exploration of SAR at this locant, as well as at the other unexplored positions adjacent to 
the nitrogen. Such efforts may reveal additional analogs with therapeutically desirable 
pharmacological profiles (e.g. a selective KOR antagonist or a mixed KOR antagonist/MOR 
agonist). 
 From the perspective of chemistry, perhaps the most interesting aspect of the studies 
described here, was their enablement by the novel synthetic methodologies developed in Chapter 
2. The key Ni(0)-catalyzed cyclization proved essential in the expedient construction of a large 
number of oxaibogamine analogs and the rapid exploration of this complex structural space, an 
effort that would not have been possible with alternative approaches to this molecular scaffold. 
Thus, our work here serves to highlight the tremendous value of new, robust reaction 
methodologies in attacking problems in chemical biology and medicinal chemistry, particularly 
when they may be applied to highly complex molecular scaffolds. 
 
Experimental 
 General Considerations: Chemistry. Reagents and solvents (including anhydrous 
solvents) were obtained from commercial sources and used without further purification unless 
otherwise stated. All compounds were prepared in racemic form. All reactions were performed in 
flame-dried glassware under an argon atmosphere unless otherwise stated, and monitored by 
TLC using solvent mixtures appropriate to each reaction. All column chromatography was 
performed on silica gel (40-63µm). Preparative TLC was performed on 20 x 20 cm plates with a 
1 mm silica layer. For compounds containing a basic nitrogen, Et3N was often used in the mobile 
phase in order to provide better resolution. In these cases, TLC plates should be pre-soaked in the 
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Et3N containing solvent and then allowed to dry briefly before use in analysis, such that an 
accurate representation of Rf is obtained. Nuclear magnetic resonance spectra were recorded on 
Bruker 300, 400, or 500 MHz instruments as indicated. Chemical shifts are reported as δ values 
in ppm referenced to CDCl3 (
1
H NMR = 7.26 and 
13
C NMR = 77.16) or DMSO-d6 (
1
H NMR = 
2.50 and 
13
C NMR = 39.52). Multiplicity is indicated as follows: s (singlet); d (doublet); t 
(triplet); q (quartet); p (pentet); h (heptet); dd (doublet of doublets); ddd (doublet of doublet of 
doublets); dt (doublet of triplets); td (triplet of doublets); ddt (doublet of doublet of triplets); tdd 
(triplet of doublet of doublets); m (multiplet); br (broad).  
 For those described compounds containing a carbamate group, complex spectra with split 
peaks are observed. This effect can be ascribed to the presence of conformers about the 
carbamate group. As a result of these effects, multiple peaks may correspond to the same proton 
group or carbon atom. Furthermore, compounds containing fluorine are subject to F-C coupling, 
resulting in splitting of some carbon peaks. When possible, such peaks are indicated by an "and" 
joining two peaks or spectral regions. Alternatively, certain carbon peaks overlap and thus 
represent two carbons (indicated by (2C) designation in some cases). All carbon peaks are 
rounded to one decimal place unless such rounding would cause two close peaks to become 
identical. In these cases, two decimal places are retained. High-resolution mass spectra (HRMS) 
were acquired on a high-resolution sector-type double-focusing mass spectrometer (ionization 
mode: FAB+). In calculated high resolution masses, the mass difference for loss of one electron 
has been taken into account for positive ions. Low-resolution mass spectra were recorded on a 




Preparation of Isoquinuclidine Building Blocks 
 exo- and endo-Methyl 7-ethyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2a and 
2b). For preparation of 2a and 2b see Chapter 2. 
 exo-Methyl 7-propyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2c). Exo-
tosylhydrazone 14a (1.64 g, 4.19 mmol), sodium cyanoborohydride (1.05 g, 16.8 mmol), and p-
toluenesulfonic acid monohydrate (67.0 mg, 0.352 mmol) were combined in anhydrous THF (17 
mL), and the mixture was refluxed for 13 h. At this time an additional portion of p-TsOH  H2O 
(17 mg, 0.088 mmol) was added, and reflux was continued for an additional 5 h. After cooling to 
room temperature, the reaction mixture was extracted with cyclohexane (3 x 20 mL). The 
combined organics were washed with water (20 mL), saturated aqueous NaHCO3 (20 mL), and 
water again (20 mL), dried over Na2SO4, and concentrated to yield a cloudy yellow oil. This 
material was purified by column chromatography (7:1 hexanes:EtOAc) to yield exo-
isoquinuclidine 2c as a thin, pale-yellow oil (460 mg, 52% yield).
 1
H NMR (400 MHz, CDCl3) 
(spectrum complicated by conformers) δ 6.48 and 6.42 (ddd, J = 7.8, 6.2, 1.4 Hz, 1H), 6.37 – 
6.28 (m, 1H), 4.56 and 4.41 (d, J = 6.1 Hz, 1H), 3.69 and 3.67 (s, 3H), 3.21 (td, J = 10.0, 2.2 Hz, 
1H), 2.99 and 2.95 (dt, J = 10.3, 2.7 Hz, 1H), 2.71 – 2.61 (m, 1H), 1.68 – 1.50 (m, 2H), 1.48 – 
1.24 (m, 4H), 1.00 (dd, J = 11.2, 2.8 Hz, 1H), 0.89 (t, J = 6.7 Hz, 3H); 
13
C NMR (101 MHz, 
CDCl3) (spectrum complicated by conformers) δ 156.2 and 155.8, 133.4 and 133.3, 132.9 and 
132.8, 51.7, 49.2 and 48.8, 48.1 and 47.8, 38.1, 36.6 and 36.5, 30.5 and 30.3, 29.7 and 29.6, 20.3 




 210.15, found 210.07. 
 endo-Methyl 7-propyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2d). Sodium 
cyanoborohydride (264 mg, 4.20 mmol) and ZnCl2 (286 mg, 2.10 mmol) were dissolved in 
anhydrous MeOH (9 mL) and this solution was added to a solution of endo-tosylhydrazone 14b  
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(1.15 g, 2.94 mmol, contains impurities) in anhydrous MeOH (13 mL). After refluxing for 3.5 h, 
the reaction was quenched with 1.0% aqueous NaOH (70 mL) and extracted with cyclohexane (3 
x 50 mL). The combined organics were washed with water (50 mL) and brine (50 mL), dried 
over Na2SO4, and concentrated to yield a pale-yellow, cloudy oil. This was purified by column 
chromatography (6:1 hexanes:EtOAc) to yield endo-isoquinuclidine 2d as a thin yellow oil (372 
mg, ~60% yield, 10% over 2 steps fom 13).
 1
H NMR (400 MHz, CDCl3) (spectrum complicated 
by conformers) δ 6.42 – 6.22 (m, 2H), 4.66 – 4.61 and 4.48 – 4.43 (m, 1H), 3.69 and 3.66 (s, 
3H), 3.24 – 3.16 (m, 1H), 2.97 and 2.92 (dt, J = 10.4, 2.6 Hz, 1H), 2.69 (br s, 1H), 2.12 – 1.99 
(m, 1H), 1.85 – 1.75 (m, 1H), 1.35 – 1.23 (m, 2H), 1.23 – 1.09 (m, 1H), 0.99 – 0.82 (m, 5H); 
13
C 
NMR (101 MHz, CDCl3) (spectrum complicated by conformers) δ 155.5 and 155.1, 134.4 and 
134.0, 130.6 and 130.0, 52.0 and 51.9, 49.5 and 49.0, 46.9 and 46.5, 38.6 and 38.3, 37.7, 31.1 




 210.15, found 
210.02. 
 exo-Methyl 7-benzyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2e). Mixed 
exo/endo-iodides 17 (474 mg, 1.24 mmol) and an excess of NaBH4 (938 mg, 24.8 mmol) were 
dissolved in anhydrous DMPU (12 mL, freshly distilled from CaH2) and stirred for 15 h at room 
temp. The reaction was quenched with water (100 mL) and extracted with Et2O (3 x 40 mL). The 
combined organics were washed with water (3 x 25 mL) and brine (25 mL), dried over Na2SO4, 
and concentrated to yield a clear colorless oil (319 mg, mixture of exo/endo-epimers, 9.5:1 
reduction:elimination). The exo-epimer was separated from this mixture by column 
chromatography (32 g silica gel, 8% to 14% EtOAc in hexanes in 1% steps, 32 mL for each step, 
16 mL fractions) to yield exo-isoquinuclidine 2e as a nearly colorless oil (87 mg, 88:12 exo:endo, 




H NMR (400 MHz, CDCl3) (spectrum complicated by conformers, peaks 
for endo-epimer impurity not listed) δ 7.32 – 7.10 (m, 5H), 6.48 – 6.27 (m, 2H), 4.58 and 4.35 
(d, J = 6.1 Hz and J = 5.8 Hz, 1H), 3.73 and 3.70 (s, 3H), 3.30 (ddd, J = 9.7, 7.7, 2.1 Hz, 1H), 
3.05 and 3.00 (dt, J = 9.9, 2.6 Hz, 1H), 2.79 – 2.55 (m, 3H), 1.97 – 1.83 (m, 1H), 1.67 – 1.57 (m, 
1H), 1.17 – 1.07 (m, 1H); 
13
C NMR (126 MHz, CDCl3) (spectrum complicated by conformers,  
peaks for endo-epimer impurity not listed) δ 157.0 and 156.6, 140.8 and 140.7, 133.90 and 
133.86, 133.34 and 133.29, 129.3 and 129.2 (2C), 128.4 and 128.3 (2C), 126.1 and 126.0, 52.5 
and 52.3, 49.3 and 49.1, 48.72 and 48.68, 41.1 and 40.8, 40.5, 31.0 and 30.8, 29.8 and 29.7; LR-




 258.15, found 258.24. 
 endo-Methyl 7-benzyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2f). SmI2 solution 
(16.6 mL of 0.1 M in THF, 1.66 mmol) was brought to reflux. HMPA (1.15 mL, 1.19 g, 6.62 
mmol) was then added, followed by a solution of ester 18 (108 mg, 0.276 mmol) in anhydrous 
THF (2.4 mL, freshly distilled from Na/benzophenone ketyl), and the dark purple mixture was 
refluxed for 5 min. After removing from heat, the reaction was immediately quenched with 
saturated aqueous NH4Cl (20 mL), and the resulting mixture was extracted with CH2Cl2 (3 x 20 
mL). The combined organics were washed with brine (2 x 20 mL), dried over Na2SO4, and 
concentrated to yield a cloudy white oil. This was purified by column chromatography (8:2 
hexanes:EtOAc) to yield endo-isoquinuclidine 2f as a colorless oil (29 mg, 41%, pure endo-
epimer). The correspronding exo-epimer is unstable under the reaction conditions and was not 
recovered from the reaction mixture. 
1
H NMR (400 MHz, CDCl3) (spectrum complicated by 
conformers) δ 7.32 – 7.09 (m, 5H), 6.51 – 6.29 (m, 2H), 4.63 and 4.41 (d, J = 5.4, 1H), 3.65 and 
3.64 (s, 3H), 3.20 (dd, J = 15.7, 5.6 Hz, 1H), 3.03 – 2.90 (m, 1H), 2.72 (br s, 1H), 2.57 – 2.41 (m, 




(101 MHz, CDCl3) (spectrum complicated by conformers) δ 155.9 and 155.6, 139.8 and 139.7, 
135.0 and 134.6, 130.9 and 130.3 and 130.2, 129.0 and 128.9 (2C), 128.5 (2C), 126.2, 52.4 and 





 258.15, found 258.28. 
 Ethyl 2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2g). Unsubstituted isoquinuclidine 
2g was prepared according to literature procedure
20
 and obtained as an oil with spectral and 
physical properties in agreement with those previously reported (3.77 g, 40%). 
 exo/endo-Methyl 7-phenyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (2h). 
Isoquinuclidine 2h was prepared according to literature procedure
21
 and obtained as a mixture of 
endo- and exo-isomers with spectral and physical properties in agreement with those previously 
reported (colorless oil, 2.86 g, 50%). 
 exo/endo-7-Ethyl 2-methyl 2-azabicyclo[2.2.2]oct-5-ene-2,7-dicarboxylate (10). N-
(methoxycarbonyl)-1,2-dihydropyridine (22.9 g, 165 mmol, freshly prepared according to 
literature procedure
28
) was combined with ethyl acrylate (82.6 g, 825 mmol) and the mixture was 
heated at 105 °C for 4 days. After removing the volatiles in vacuo, the resulting yellow oil was 
purified by column chromatography (3:1 hexanes:EtOAc) to yield mixed exo/endo-esters 10 as a 




H NMR (400 MHz, 
CDCl3) (some partial integrals due to conformers and exo/endo mixture) δ 6.54 – 6.24 (m, 2H), 
5.22 – 4.88 (m, 1H), 4.22 – 4.02 (m, 2H), 3.74 – 3.62 (m, 3H), 3.41 – 3.19 (m, 1H), 3.11 – 2.88 
(m, 1.6H), 2.88 – 2.74 (m, 1H), 2.53 (tdd, J = 10.9, 4.3, 2.1 Hz, 0.4H), 2.10 (tdd, J = 6.8, 4.3, 2.5 
Hz, 0.4H), 1.92 – 1.76 (m, 1.2H), 1.58 – 1.50 (m, 0.4H), 1.26 (m, 3H). 
 exo/endo-2-(Methoxycarbonyl)-2-azabicyclo[2.2.2]oct-5-ene-7-carboxylic acid (11). 
Mixed exo/endo-esters 10 (28.0 g, 117 mmol) were dissolved in THF (440 mL) and water (147 
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mL) and the solution was cooled to 0 °C. H2O2 (34.3 mL of 30% aq. soln., 336 mmol) and LiOH 
 H2O (9.82 g, 234 mmol) were then added and the mixture was warmed to 40 °C and left to stir 
for 12 h. After this time, the reaction was cooled to room temperature and the THF was removed 
in vacuo. The mixture was then diluted with water (100 mL) and washed with CH2Cl2 (3 x 50 
mL). The aqueous phase was acidified with 10% aqueous HCl and extracted with CH2Cl2 (4 x 50 
mL). The combined organic extracts were washed with water (2 x 50 mL), dried over Na2SO4, 
filtered, and concentrated to yield the mixed exo/endo-acids 11 as a colorless oil that slowly 
crystallized into a white, waxy solid (21.5 g, 87%). 
1
H NMR (300 MHz, CDCl3) (some partial 
integrals due to conformers and exo/endo mixture, OH not observed) δ 6.53 – 6.30 (m, 2H), 5.24 
– 4.93 (br m, 1H), 3.78 – 3.62 (m, 3H), 3.37 (dd, J = 10.1, 1.9 Hz, 0.4H), 3.31 – 3.22 (br m, 
0.6H), 3.18 – 3.06 (br m, 0.6H), 2.95 (br t, J = 11.5 Hz, 1H), 2.88 – 2.75 (br m, 1H), 2.64 – 2.53 
(br m, 0.4H), 2.07 (ddd, J = 12.9, 4.0, 2.4 Hz, 0.4H), 1.94 – 1.78 (m, 1.2H), 1.66 – 1.52 (m, 




 212.09, found 212.23. 
 exo/endo-Methyl 7-(methoxy(methyl)carbamoyl)-2-azabicyclo[2.2.2]oct-5-ene-2-
carboxylate (12). Mixed exo/endo-acids 11 (15.0 g, 71.0 mmol) were dissolved in anhydrous 
CH2Cl2 (1.0 L) and cooled to 0 °C. DIPEA (14.8 mL, 11.0 g, 85.2 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (14.3 g, 74.6 mmol), N,O-
dimethylhydroxylamine hydrochloride (8.31 g, 85.2 mmol), and 4-(dimethylamino)pyridine (867 
mg, 7.10 mmol) were then added and the mixture was stirred for 2 h at 0 °C and 2 h at room 
temperature before quenching with water (700 mL). The organic layer was separated and washed 
with 1% aqueous NaOH (2 x 150 mL), 2% aqueous HCl (3 x 100 mL), and water (150 mL), 
dried over Na2SO4, filtered through celite, and concentrated to yield mixed exo/endo-amides 12 
as a yellow oil (16.5 g, 91%). 
1
H NMR (300 MHz, CDCl3) (some partial integrals due to 
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conformers and exo/endo mixture) δ 6.52 – 6.32 (m, 2H), 5.10 – 4.77 (m, 1H), 3.77 – 3.58 (m, 
6H), 3.44 – 3.23 (m, 1.6H), 3.20 – 3.10 (m, 3H), 3.05 – 2.86 (m, 1.4H), 2.86 – 2.71 (m, 1H), 2.25 





 255.13, found 255.23. 
 exo/endo-Methyl 7-propionyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (13, 
synthesis and epimerization). Mixed exo/endo-amides 12 (5.00 g, 19.7 mmol) were dissolved 
in anhydrous THF (200 mL) and the solution was cooled to 0 °C. EtMgBr (13.1 mL of 3.0 M 
soln. in Et2O, 39.4 mmol) was then added, and the reaction was left to stir at 0 °C for 1 h. After 
quenching with ice-cold 5% HCl in 6:1 EtOH:H2O (200 mL), the mixture was diluted with water 
(400 mL) and extracted with CH2Cl2 (3 x 100 mL). The combined organics were washed with 
water (2 x 150 mL), dried over Na2SO4, and concentrated to yield mixed mixed exo/endo-
ketones 13 as a pale-yellow oil (4.06 g, 92%, 38:62 exo:endo determined by 
1
H NMR). To enrich 
the exo-epimer, this material was dissolved in MeOH (140 mL), sodium methoxide (5.90 g, 
109.2 mmol) was added, and the mixture was stirred at room temperature for 4 h. The reaction 
was then diluted with water (50 mL) and acidified to pH 4 with aqueous HCl. After removing the 
MeOH in vacuo, the remaining aqueous was extracted with CH2Cl2 (3 x 50 mL). The combined 
organics were washed with water (50 mL) and brine (50 mL), dried over Na2SO4, and 





H NMR (400 MHz, CDCl3) (some partial integrals due to conformers 
and exo/endo mixture) δ 6.53 – 6.36 (m, 1.6H), 6.31 – 6.25 (m, 0.4H), 5.16 – 4.83 (m, 1H), 3.74 
– 3.58 (m, 3H), 3.34 – 3.23 (m, 1H), 3.16 – 3.06 (m, 0.4H), 3.02 – 2.88 (m, 1H), 2.87 – 2.61 (m, 
2.4H), 2.51 – 2.37 (m, 1.2H), 2.24 – 2.12 (m, 0.6H), 1.91 – 1.67 (m, 0.8H), 1.44 – 1.28 (m, 




 224.13, found 224.00. 
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 exo-Methyl 7-(1-(2-tosylhydrazono)propyl)-2-azabicyclo[2.2.2]oct-5-ene-2-
carboxylate (14a) and endo-methyl 7-(1-(2-tosylhydrazono)propyl)-2-azabicyclo[2.2.2]oct-5-
ene-2-carboxylate (14b) (synthesis and separation). Exo-enriched ketones 13 (4.00 g, 17.9 
mmol) and tosylhydrazine (3.33 g, 17.9 mmol) were combined in anhydrous THF (15 mL) and 
the mixture was stirred at 50 °C for 14 h. After removing the volatiles in vacuo, the resulting off-
white solid was purified by repeated column chromatography (gradients of Et2O in CH2Cl2) to 
yield the pure exo-tosylhydrazone (14a, 1.69 g, 24%), and the endo-tosylhydrazone containing 
an impurity of starting material (14b, 1.17 g, <17%), along with several mixed exo/endo 
fractions (2.65 g, 38%). 
14a. The exo-tosylhydrazone was prepared by separation of the exo/endo mixture as described 
above and obtained as a white solid. 
1
H NMR (400 MHz, CDCl3) (spectrum complicated by 
conformers) δ 7.84 and 7.78 (d, J = 8.3 Hz, 2H), 7.37 (br s, 1H), 7.32 (t, J = 7.3 Hz, 2H), 6.47 – 
6.36 (m, 2H), 4.67 and 4.55 (m, 1H), 3.49 and 3.36 (s, 3H), 3.09 and 2.99 (dd, J = 9.8, 2.1 Hz 
and J = 9.9, 1.9 Hz, 1H), 2.88 and 2.80 (dt, J = 10.1, 2.4 Hz and J = 9.8, 2.6 Hz, 1H), 2.70 (dd, J 
= 5.1, 2.6 Hz, 1H), 2.51 and 2.08 (ddd, J = 10.6, 4.4, 1.7 Hz, 1H), 2.44 (s, 3H), 2.39 – 2.04 (m, 






14b. The endo-tosylhydrazone was prepared by separation of the exo/endo mixture as described 
above and obtained as a white solid containing an impurity of starting material. 
1
H NMR (400 
MHz, CDCl3) (peak list excludes impurity peaks; spectrum complicated by conformers) δ 7.79 
(t, J = 7.2 Hz, 2H), 7.52 (br s, 1H), 7.30 (d, J = 8.1 Hz, 2H), 6.22 – 6.12 (m, 1H), 6.01 – 5.94 (m, 
1H), 4.83 and 4.72 (d, J = 4.1 Hz and 4.3 Hz, 1H), 3.68 and 3.65 (s, 3H), 3.32 – 3.18 (m, 1H), 
3.01 – 2.86 (m, 2H), 2.73 (br s, 1H), 2.44 and 2.43 (s, 3H), 2.23 – 1.96 (m, 2H), 1.83 – 1.62 and 
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 392.16, found 
391.90. 
 exo/endo-Methyl 7-benzoyl-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (15). Mixed 
exo/endo-amides 12 (2.00 g, 7.87 mmol) were dissolved in anhydrous THF (80 mL) and 
PhMgBr (15.7 mL of 3.0 M soln. in Et2O, 47.2 mmol) was added at room temperature. After 
stirring for 15 min. the reaction was quenched with ice-cold 5% HCl in 6:1 EtOH:H2O (160 mL), 
diluted with water (250 mL), and extracted with CH2Cl2 (3 x 80 mL). The combined organics 
were washed with water (100 mL) and brine (100 mL), dried over Na2SO4, and concentrated to 
yield a yellow oil. This was purified by column chromatography (7:3 hexanes:EtOAc) to yield 





H NMR (400 MHz, CDCl3) (spectrum complicated due to conformers and 
exo/endo mixture) δ 8.02 – 7.85 (m, 2H), 7.61 – 7.51 (m, 1H), 7.51 – 7.41 (m, 2H), 6.60 – 6.24 
(m, 2H), 5.20 and 5.03 (br s, 0.6H), 4.97 and 4.82 (d, J = 6.0 Hz, 0.4H), 4.04 – 3.90 (m, 0.6H), 
3.74, 3.73, 3.60, and 3.37 (s, 3H), 3.65 – 3.54 (m, 0.4H), 3.49 – 3.34 (m, 1H), 3.09 – 2.93 (m, 
1H), 2.88 (br s, 1H), 2.31 and 2.25 (ddd, J = 12.9, 4.4, 2.4 Hz, 0.4H), 2.10 – 1.75 (m, 1.2H), 1.61 




 272.13, found 272.26. 
 exo/endo-Methyl 7-(hydroxy(phenyl)methyl)-2-azabicyclo[2.2.2]oct-5-ene-2-
carboxylate (16). Mixed exo/endo-ketones 15 (1.67 g, 6.16 mmol) were dissolved in MeOH (50 
mL) and the solution was chilled to 0 °C. NaBH4 (233 mg, 6.16 mmol) was then added and the 
solution was warmed to room temperature and stirred for 30 min. The volatiles were removed in 
vacuo to yield a white solid, which was partitioned between CH2Cl2 (25 mL) and water (25 mL). 
After separating the organics, the aqueous layer was extracted with additional CH2Cl2 (25 mL). 
The combined organics were washed with water (25 mL) and saturated aqueous NH4Cl (2 x 25 
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mL), dried over Na2SO4, and concentrated to yield mixed exo/endo-alcohols 16 as a white solid 
(1.63 g, 97%). 
1
H NMR (400 MHz, CDCl3) (Due to the presence of conformers and 4 
diastereomers, the 
1
H NMR spectrum is significantly complicated.) δ 7.42 – 7.23 (m, 5H), 6.56 – 
6.20 (m, 2H), 5.25 – 4.92 (m, 0.74H), 4.34 – 4.01 (m, 0.76H), 3.95 (dd, J = 10.4, 3.9 Hz, 0.41H), 
3.86 (d, J = 3.2 Hz, 0.23H), 3.77, 3.73, 3.68, 3.61, and 3.55 (s, 3H), 3.35 – 3.15 (m, 1H), 3.08 – 
2.88 (m, 1H), 2.83 (br s, 0.24H), 2.65 (br s, 0.74H), 2.61 – 2.45 (m, 0.64H), 2.43 (br s, 0.09H), 
2.06 –1.96 (m, 0.38H), 1.96 – 1.66 (m, 1H), 1.56 (br s, 0.25H), 1.45 – 1.34 (m, 0.45H), 1.22 (t, J 





 274.14, found 274.06 
 exo/endo-Methyl 7-(iodo(phenyl)methyl)-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate 
(17). Mixed exo/endo-alcohols 16 (137 mg, 0.500 mmol) were dissolved in anhydrous toluene 
(2.3 mL) and CH3CN (1.1 mL), and the solution was cooled to 0 °C. Triphenylphosphine (386 
mg, 1.47 mmol), imidazole (202 mg, 2.96 mmol), and iodine (386 mg, 1.52 mmol) were then 
added, and the mixture was allowed to warm to room temperature and stirred for 1 h. At this time 
the reaction was quenched with water (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The 
combined organics were washed with saturated aqueous Na2S2O3 (5 mL) and brine (5 mL), dried 
over Na2SO4, and concentrated to yield an off-white solid. This was purified by column 
chromatography (6:4 hexanes:Et2O) to yield mixed exo/endo-iodides 17 as a pale-yellow oil (151 
mg, 79% yield). 
1
H NMR (400 MHz, CDCl3) (Due to the presence of conformers and 4 
diastereomers, the 
1
H NMR spectrum is significantly complicated.) δ 7.48 – 7.12 (m, 5H), 6.65 – 
5.97 (m, 2H), 5.42 – 5.07 (m, 0.19H), 5.03 – 4.85 (m, 0.40H), 4.52 – 4.34 (m, 0.69H), 4.29 – 
4.10 (m, 0.44H), 3.78, 3.74, 3.72, 3.68, 3.63, 3.59, and 3.41 (s, 3H), 3.36 – 3.05 (m, 1.41H), 3.04 
– 2.67 (m, 2H), 2.64 – 2.41 (m, 0.61H), 2.04 (br s, 0.36H), 1.93 (br s, 0.36H), 1.77 – 1.57 (m, 
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0.27H), 1.50 (br d, J = 11.5 Hz, 0.36H), 1.45 – 1.34 (m, 0.11H), 1.33 – 1.21 (m, 0.66H), 1.15 (br 
s, 0.04H), 0.97 (br d, J = 6.6 Hz, 0.04H), 0.89 (br s, 0.13H), 0.80 (br d, J = 9.3 Hz, 0.20H); LR-




 384.04, found = 384.17. 
 exo/endo-Methyl 7-(((4-methylbenzoyl)oxy)(phenyl)methyl)-2-azabicyclo[2.2.2]oct-5-
ene-2-carboxylate (18). Mixed exo/endo-alcohols 16 (480 mg, 1.76 mmol) were dissolved in 
anhydorus CH2Cl2 (22 mL), and the solution was cooled to 0 °C. Tetramethylethylenediamine 
(0.58 mL, 450 mg, 3.87 mmol) and p-toluoyl chloride (0.51 mL, 598 mg, 3.87 mmol) were then 
added, and the mixture was warmed to room temperature and stirred for 30 min. After quenching 
with saturated aqueous NaHCO3 (20 mL), the organic layer was separated and the remaining 
aqueous layer was extracted with additional CH2Cl2 (2 x 20 mL). The combined organics were 
washed with saturated aqueous NaHCO3 (20 mL) and brine (20 mL), dried over Na2SO4, and 
concentrated to yield an off-white oil. This was purified by column chromatography (3:1 
hexanes:EtOAc) to yield mixed exo/endo-esters 18 as a white solid (567 mg, 82%). 
1
H NMR 
(400 MHz, CDCl3) (Due to the presence of conformers and 4 diastereomers, the 
1
H NMR 
spectrum is significantly complicated.) δ 8.03 – 7.87 (m, 2H), 7.51 – 7.18 (m, 7H), 6.60 – 6.22 
(m, 2H), 5.83 (t, J = 11.3 Hz, 0.02H), 5.70 – 5.58 (m 0.30H), 5.44 (d, J = 10.0 Hz, 0.20H), 5.36 – 
5.29 (m, 0.40H), 5.14 – 5.03 (m, 0.32H), 4.94 – 4.86 (m, 0.37H), 4.34 (br s, 0.09H), 4.15 (br s, 
0.11H), 3.73, 3.71, 3.66, 3.63, 3.61, 3.58 and 3.34 (s, 3H), 3.40 – 3.33 (m, 0.43H), 3.33 – 3.19 
(m, 0.68H), 3.08 – 2.78 (m, 1.87H), 2.72 (s, 0.78H), 2.42 and 2.40 (s, 3H), 2.34 (dd, J = 11.0, 5.0 
Hz, 0.30H), 1.94 (t, J = 11.1 Hz, 0.20H), 1.79 (br s, 0.05H), 1.70 (br s, 0.21H), 1.58 – 1.37 (m, 





 392.19, found 392.20. 
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Preparation of Heteroarene Building Blocks 
 5-Methoxybenzofuran-3(2H)-one (3a).  Benzofuranone 3a was prepared from 4-
methoxyphenol according to literature procedure
29
 and obtained as orange-tan crystals (6.68 g, 
40%). 
1
H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 9.0, 2.8 Hz, 1H), 7.06 (d, J = 5.8 Hz, 1H), 
7.05 (s, 1H), 4.64 (s, 2H), 3.80 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 200.3, 169.5, 155.2, 




 165.06, found 
164.99. 
 4-Methoxybenzofuran-3(2H)-one (3d). A mixture of dicarboxylic acid 20 (3.30 g, 14.59 
mmol) and sodium acetate (2.92 g, 35.57 mmol) in acetic anhydride (29 mL) was refluxed for 4 
h. The reaction was then cooled to room temperature, poured into ice water (150 mL), and the 
resulting mixture was stirred for 20 min. It was then extracted with CH2Cl2 (100 mL) and the 
organic layer was dried over Na2SO4 and concentrated, to give a dark-brown oil (3.06 g, difficult 
to remove residual Ac2O). To this material was added 1M aqueous HCl (30 mL) and the mixture 
was refluxed for 2 h, cooled to room temperature, and extracted with CH2Cl2 (3 x 30 mL). The 
combined organics were washed with water (30 mL), dried over Na2SO4, and concentrated to 
provide a dark-red solid (2.31 g). This material was triturated with boiling Et2O and then cooled 
to 0 °C and the solids collected by filtration, washing 3x with ice-cold Et2O. The product 3d was 
thus obtained as a pale, reddish-brown solid containing minor impurities (1.01 g, 42% over 2 
steps). 
1
H NMR (500 MHz, CDCl3) δ 7.52 (t, J = 8.3 Hz, 1H), 6.68 (d, J = 8.3 Hz, 1H), 6.47 (d, 
J = 8.2 Hz, 1H), 4.60 (s, 2H), 3.96 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 197.4, 175.4, 158.4, 




 165.06, found 
164.97. 
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 6-Fluoro-5-methoxybenzofuran-3(2H)-one (3e). To a solution of BCl3 (1M in CH2Cl2, 
41.6 mL, 41.6 mmol) at 0 °C was added a solution of 3-fluoro-4-methoxyphenol (4.93 g, 34.69 
mmol) in anhydrous 1,2-dichloroethane (17 mL) slowly over 20 min. Chloroacetonitrile (2.63 
mL, 41.6 mmol) was then added over 2 min., followed by AlCl3 (2.31 g, 17.4 mmol) in three 
equal portions, and the resulting yellow-orange mixture was allowed to warm to room 
temperature and stirred for 14 h. The reaction was then quenched with ice (35 mL) and 10% 
aqueous HCl (35 mL), and the resulting mixture was stirred for 20 min. At this time, the organic 
layer was separated and the aqueous phase extracted with additional CH2Cl2 (2 x 50 mL, 25 mL). 
The combined organics were washed with brine (50 mL), dried over Na2SO4, filtered, and 
concentrated to provide the crude intermediate α-chloroacetophenone as a yellow solid (6.54 g, 
1
H NMR indicated 74 mass% product, 26 mass% starting material).  
 This material (6.51 g) was combined with sodium acetate (8.53 g, 104 mmol) in 
anhydrous MeOH (35 mL), and the mixture was refluxed for 45 min. The reaction was then 
cooled to room temperature and filtered, washing the filter cake with MeOH (2 x 15 mL). The 
combined filtrate and washings were concentrated to ~1/2 the volume and diluted with 5% 
aqueous NaCl (85 mL). An attempt was made to collect the resulting solids by filtration, but they 
were very clumpy and clogging of the filter occurred. Therefore, the combined liquids (filtrate 
and supernatant) were extracted with Et2O (2 x 40 mL), and these extracts were combined with 
the residual solids and concentrated. The resulting residue was taken up in CH2Cl2 (75 mL) and 
the solution was washed with brine (20 mL), dried over Na2SO4, and concentrated to give a dark-
brown oil (2.83 g). This material was dissolved in a minimal amount of Et2O and cooled to -78 
°C, causing powdery crystals to form, which were collected by filtration and washed once at the 
filter with -78 °C Et2O. These solids were dried to provide the pure benzofuranone 3e as a 
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yellowish-brown powder (555 mg, 9% over 2 steps). 
1
H NMR (400 MHz, CDCl3) (spectrum 
complicated by F-H coupling) δ 7.16 (d, J = 8.5 Hz, 1H), 6.89 (d, J = 10.5 Hz, 1H), 4.63 (s, 2H), 
3.88 (s, 3H); 
13
C NMR (101 MHz, CDCl3) (spectrum complicated by F-C coupling) δ 198.6, 





 183.04, found 183.21. 
 5-Methoxy-6-methylbenzofuran-3(2H)-one (3f). To a solution of BCl3 (1M in CH2Cl2, 
8.69 mL, 8.69 mmol) at 0 °C was added a solution of 4-methoxy-3-methylphenol (1.00 g, 7.24 
mmol) in anhydrous 1,2-dichloroethane (3.6 mL) slowly over 20 min. Chloroacetonitrile (549 
µL, 8.69 mmol) was then added over 2 min., followed by AlCl3 (483 mg, 3.62 mmol) in three 
equal portions, and the resulting orange mixture was allowed to warm to room temperature and 
stirred for 15 h. The reaction was then quenched with ice (7 mL) and 10% aqueous HCl (7 mL), 
diluted with CH2Cl2 (10 mL), stirred for 20 min., and then extracted with CH2Cl2 (4 x 10 mL,  3 
x 20 mL, emulsion = difficult extraction). The combined organics were washed with brine (20 
mL), dried over Na2SO4, and concentrated to provide a yellow solid (1.20 g). This material was 
purified by column chromatography (9:1 hexanes:EtOAc) to provide the pure intermediate α-
chloroacetophenone as very pale-yellow plates (999 mg, 64%).  
 This material (974 mg, 4.54 mmol) was combined with sodium acetate (1.12 g, 13.62 
mmol) in anhydrous MeOH (4.5 mL), and the mixture was refluxed for 50 min. The reaction was 
then cooled to room temperature and filtered, washing the filter cake with MeOH (2 x 5 mL). 
The collected solids (0.80 g, mixture of product and NaOAc) were partitioned between CH2Cl2 
(20 mL) and water (20 mL) and the organic layer was separated, dried over Na2SO4, and 
concentrated to provide pure product 3f as powdery, off-white crystals (649 mg). The combined 
filtrate and washings were concentrated and the residue was partitioned between CH2Cl2 (25 mL) 
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and water (25 mL). The organic layer was separated, dried over Na2SO4 and concentrated to give 
an orange residue, which was recrystallized from methanol to provide additional pure product 3f 
as yellow-orange needles (58.5 mg). Total yield of benzofuranone 3f was 708 mg (88%, 56% 
over 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 6.96 (s, 1H), 6.94 (s, 1H), 4.60 (s, 2H), 3.82 (s, 
3H), 2.30 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 199.91, 169.64, 153.78, 140.71, 118.89, 




 179.07, found 179.17. 
 General Procedure for Preparation of Ethyl Benzofuranylacetates (4). A solution of 
the appropriate benzofuranone (3 or commercially obtained) (1 equivalent) and 
(carbethoxymethylene)triphenylphosphorane (1.1 equivalent) in anhydrous toluene (0.30 M, 
based on benzofuranone) was refluxed until TLC indicated the consumption of starting material 
(typically 2-3 days) and then concentrated in vacuo. The resulting material was triturated with 
9:1 hexanes:EtOAc (~7 mL per mmol substrate) and filtered, and the remaining solids were 
washed with additional portions of 9:1 hexanes:EtOAc (3 x ~3 mL per mmol substrate). The 
combined filtrates were concentrated to give the crude product, which was purified by column 
chromatography with an appropriate solvent mixture (as described individually for each 
compound).  
 Ethyl 2-(5-methoxybenzofuran-3-yl)acetate (4a). The product 4a was prepared 
according to the general procedure and purified by column chromatography (1:1 
hexanes:CH2Cl2, 5 column volumes → CH2Cl2, 3 column volumes → 1:1 CH2Cl2:Et2O, 1 
column volumes) to provide a thin, yellow-orange oil (5.68 g, 81%). 
1
H NMR (400 MHz, 
CDCl3) δ 7.60 (s, 1H), 7.36 (d, J = 9.0 Hz, 1H), 7.02 (d, J = 2.6 Hz, 1H), 6.91 (dd, J = 8.9, 2.6 
Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 3.66 (d, J = 1.0 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H); 
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13
C NMR (101 MHz, CDCl3) δ 170.8, 156.1, 150.4, 143.8, 128.3, 113.42, 113.39, 112.1, 102.3, 




 235.10, found 235.37. 
 Ethyl 2-(5-fluorobenzofuran-3-yl)acetate (4b). The product 4b was prepared according 
to the general procedure and purified by column chromatography (8:2 hexanes:CH2Cl2, 4 column 
volumes → 7:3 hexanes:CH2Cl2, 3 column volumes) to provide a thin red-orange oil (1.12 g, 
78%). 
1
H NMR (500 MHz, CDCl3) (spectrum complicated by F-H coupling) δ 7.66 (s, 1H), 
7.40 (dd, J = 8.9, 4.1 Hz, 1H), 7.23 (dd, J = 8.5, 2.6 Hz, 1H), 7.02 (td, J = 9.0, 2.6 Hz, 1H), 4.20 
(q, J = 7.1 Hz, 2H), 3.65 (s, 2H), 1.28 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) 
(spectrum complicated by F-C coupling) δ 170.5, 160.3 and 158.4, 151.6, 144.7, 128.7 and 





 223.08, found 223.13. 
 Ethyl 2-(7-methoxybenzofuran-3-yl)acetate (4c). The product 4c was prepared 
according to the general procedure and purified by column chromatography (9:1 
hexanes:EtOAc) to provide a pale-yellow oil still containing impurities (423 mg, <30%). 
1
H 
NMR (500 MHz, CDCl3) (Peak list excludes impurity peaks) δ 7.64 (s, 1H), 7.20 – 7.14 (m, 
2H), 6.82 (dd, J = 7.0, 1.8 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 4.01 (s, 3H), 3.68 (d, J = 1.0 Hz, 




 235.10, found 235.25. 
 Ethyl 2-(4-methoxybenzofuran-3-yl)acetate (4d). The product 4d was prepared 
according to the general procedure and purified by column chromatography (9:1 
hexanes:EtOAc) to provide a pale-yellow oil still containing minor impurities (409 mg, <58%).  
1
H NMR (500 MHz, CDCl3) δ 7.49 (s, 1H), 7.19 (t, J = 8.1 Hz, 1H), 7.08 (d, J = 8.3 Hz, 1H), 




C NMR (126 MHz, CDCl3) δ 171.5, 156.7, 154.8, 141.6, 125.3, 117.5, 113.3, 104.9, 




 235.10, found 234.98. 
 Ethyl 2-(6-fluoro-5-methoxybenzofuran-3-yl)acetate (4e). The product 4e was 
prepared according to the general procedure and purified by column chromatography (1:1 
hexanes:CH2Cl2, 3 column volumes → 4:6 hexanes:CH2Cl2, 2 column volumes → 3:7 
hexanes:CH2Cl2, 3 column volumes → CH2Cl2, 2 column volumes)  to provide a yellow oil (423 
mg, 56%). 
1
H NMR (500 MHz, CDCl3) (spectrum complicated by F-H coupling) δ 7.59 (s, 1H), 
7.24 (d, J = 10.6 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.93 (s, 3H), 3.66 
(d, J = 0.9 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) (spectrum 
complicated by F-C coupling) δ 170.7, 152.5 and 150.5, 148.8 and 148.7, 145.3 and 145.2, 143.7 





 253.09, found 253.01. 
 Ethyl 2-(5-methoxy-6-methylbenzofuran-3-yl)acetate (4f). The product 4f was 
prepared according to the general procedure and purified by column chromatography (1:1 
hexanes:CH2Cl2, 2 column volumes → 4:6 hexanes:CH2Cl2, 2 column volumes → 3:7 
hexanes:CH2Cl2, 2 column volumes → CH2Cl2, 2 column volumes)  to provide a yellow oil (542 
mg, 61%). 
1
H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.25 (s, 1H), 6.93 (s, 1H), 4.19 (q, J = 
7.1 Hz, 2H), 3.88 (s, 3H), 3.66 (d, J = 0.9 Hz, 2H), 2.31 (s, 3H), 1.27 (t, J = 7.1 Hz, 30H); 
13
C 
NMR (126 MHz, CDCl3) δ 171.0, 154.5, 150.0, 142.6, 125.7, 124.9, 113.3, 113.0, 99.8, 61.2, 




 249.11, found 248.84. 
 General Procedure for Preparation of Benzofuranylethanols (5). To a suspension of 
LiAlH4 (2.6 equivalents) in anhydrous THF (1.03 M, based on LiAlH4) at room temperature was 
carefully added a solution of the appropriate ester 4 (1 equivalent) in anhydrous THF (1.2 M, 
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based on 4), and the mixture was refluxed until TLC indicated the complete consumption of 
starting material (typically <1 h). After cooling to room temperature, the reaction was quenched 
by the successive addition of H2O (1 mL per gram LiAlH4), 15% aqueous NaOH (1 mL per gram 
LiAlH4), and H2O again (3 mL per gram LiAlH4). The resulting mixture was stirred vigorously 
until the aluminum salts were white and loose and then filtered, washing the filter cake with Et2O 
(3x). The combined filtrate and washings were concentrated to yield the product directly. 
 2-(5-Methoxybenzofuran-3-yl)ethanol (5a). The product 5a was prepared according to 
the general procedure and obtained as a yellow oil (4.50 g, 98%). 
1
H NMR (500 MHz, CDCl3) δ 
7.48 (s, 1H), 7.36 (d, J = 8.9 Hz, 1H), 7.00 (d, J = 2.6 Hz, 1H), 6.90 (dd, J = 8.9, 2.6 Hz, 1H), 
3.91 (t, J = 6.4 Hz, 2H), 3.85 (s, 3H), 2.91 (t, J = 6.4 Hz, 2H), 1.74 (s, 1H); 
13
C NMR (126 





 193.09, found 193.35. 
 2-(5-Fluorobenzofuran-3-yl)ethanol (5b). The product 5b was prepared according to 
the general procedure and obtained as a pale-yellow oil (848 mg, 96%). 
1
H NMR (400 MHz, 
CDCl3) (spectrum complicated by F-H coupling) δ 7.55 (s, 1H), 7.39 (dd, J = 8.9, 4.1 Hz, 1H), 
7.22 (dd, J = 8.5, 2.6 Hz, 1H), 7.01 (td, J = 9.0, 2.6 Hz, 1H), 3.91 (t, J = 6.2 Hz, 2H), 2.90 (td, J 
= 6.3, 0.9 Hz, 2H), 1.63 (br s, 1H); 
13
C NMR (101 MHz, CDCl3) (spectrum complicated by F-C 
coupling) δ 160.4 and 158.1, 151.7, 144.1, 129.0 and 128.9, 117.4 and 117.3, 112.4, 112.3 and 




 181.07, found 
181.13. 
 2-(7-Methoxybenzofuran-3-yl)ethanol (5c). The product 5c was prepared from impure 
ester 4c according to the general procedure and obtained as a pale-yellow oil (304 mg, 27% over 
2 steps from benzofuranone). 
1
H NMR (500 MHz, CDCl3) δ 7.52 (s, 1H), 7.20 – 7.14 (m, 2H), 
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6.82 (dd, J = 6.3, 2.6 Hz, 1H), 4.01 (s, 3H), 3.92 (t, J = 6.2 Hz, 2H), 2.94 (td, J = 6.4, 0.8 Hz, 
2H), 1.54 (br s, 1H); 
13
C NMR (126 MHz, CDCl3) δ 145.8, 144.9, 142.4, 129.9, 123.4, 117.3, 




 193.09, found 193.20 
 2-(4-Methoxybenzofuran-3-yl)ethanol (5d). The product 5d was prepared from impure 
ester 4d according to the general procedure and obtained as a pale-yellow oil containing minor 
impurities (286 mg, <87%). 
1
H NMR (400 MHz, CDCl3) δ 7.38 (s, 1H), 7.20 (t, J = 8.1 Hz, 
1H), 7.10 (dd, J = 8.3, 0.6 Hz, 1H), 6.65 (d, J = 7.9 Hz, 1H), 3.95 - 3.89 (br m, 2H), 3.92 (s, 3H), 
3.05 (td, J = 6.2, 0.8 Hz, 2H), 1.77 (br s, 1H); 
13
C NMR (101 MHz, CDCl3) δ 157.2, 154.7, 





193.09, found 192.97. 
 2-(6-Fluoro-5-methoxybenzofuran-3-yl)ethanol (5e). The product 5e was prepared 
according to the general procedure and obtained as a yellow-orange oil (343 mg, 99%). 
1
H NMR 
(500 MHz, CDCl3) (spectrum complicated by F-H coupling) δ 7.49 (s, 1H), 7.24 (d, J = 10.7 Hz, 
1H), 7.06 (d, J = 8.2 Hz, 1H), 3.93 (s, 3H), 3.92 (t, J = 6.4 Hz, 2H), 2.91 (td, J = 6.4, 0.8 Hz, 
2H), 1.61 (br s, 1H); 
13
C NMR (126 MHz, CDCl3) (spectrum complicated by F-C coupling) δ 
152.4 and 150.5, 148.9 and 148.8, 145.2 and 145.1, 143.0 and 142.9, 123.44 and 123.42, 117.08 





 211.08, found 211.07. 
 2-(5-Methoxy-6-methylbenzofuran-3-yl)ethanol (5f). The product 5f was prepared 
according to the general procedure and obtained as a pale-yellow oil (416 mg, 94%). 
1
H NMR 
(500 MHz, CDCl3) δ 7.42 (s, 1H), 7.25 (s, 1H), 6.92 (s, 1H), 3.95 – 3.89 (br m, 2H), 3.88 (s, 
3H), 2.92 (td, J = 6.4, 0.8 Hz, 2H), 2.32 (s, 3H), 1.54 (br s, 1H); 
13
C NMR (126 MHz, CDCl3) δ 
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 207.10, found 207.23. 
 General Procedure for Preparation of Bromoethylbenzofurans (6). To a solution of 
the appropriate alcohol 5 (1 equivalent) and carbon tetrabromide (1.5 equivalents) in anhydrous 
CH2Cl2 (0.5 M, based on 5) at room temperature was carefully added triphenylphosphine (1.5 
equivalents) and the resulting dark orange-brown mixture was left to stir until TLC indicated the 
complete consumption of starting material (typically <1 h). At smaller scales, the reaction 
mixture was then purified directly by column chromatography with an appropriate solvent 
mixture (as described individually for each compound). For larger scales, the reaction was first 
filtered through a silica plug to remove baseline impurities, washing the plug with additional 
CH2Cl2 until TLC indicated that all product had passed through. The filtrate was the 
concentrated and purified by column chromatography with an appropriate solvent mixture (as 
described individually for each compound). 
 3-(2-Bromoethyl)-5-methoxybenzofuran (6a). The product 6a was prepared according 
to the general procedure and purified by column chromatography (hexanes, 2 column volumes 
→ 20:1 hexanes:Et2O, 2 column volumes → 10:1 hexanes:Et2O, 2 column volumes) to provide a 
pale-yellow oil that slowly crystallized to a white solid (2.81 g, 97%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.51 (s, 1H), 7.37 (d, J = 8.9 Hz, 1H), 6.97 (d, J = 2.5 Hz, 1H), 6.91 (dd, J = 8.9, 2.6 
Hz, 1H), 3.86 (s, 3H), 3.64 (t, J = 7.4 Hz, 2H), 3.23 (td, J = 7.4, 0.7 Hz, 2H); 
13
C NMR (126 





 255.00 and 257.00, found 255.29 and 257.29. 
 3-(2-Bromoethyl)-5-fluorobenzofuran (6b). The product 6b was prepared according to 
the general procedure and purified by column chromatography (hexanes, 2 column volumes → 
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20:1 hexanes:Et2O, 2 column volumes → 10:1 hexanes:Et2O, 1 column volume) to provide a 
thin, pale-yellow oil (1.05 g, 94%). 
1
H NMR (500 MHz, CDCl3) (spectrum complicated by F-H 
coupling) δ 7.58 (s, 1H), 7.41 (dd, J = 8.9, 4.1 Hz, 1H), 7.19 (dd, J = 8.4, 2.6 Hz, 1H), 7.03 (td, J 
= 9.0, 2.6 Hz, 1H), 3.63 (t, J = 7.2 Hz, 2H), 3.23 (t, J = 7.2 Hz, 2H); 
13
C NMR (126 MHz, 
CDCl3) (spectrum complicated by F-C coupling) δ 160.3 and 158.4, 151.6, 144.1, 128.5 and 
128.4, 117.98 and 117.95, 112.53 and 112.50, 112.5 and 112.3, 105.1 and 104.9, 31.1, 27.6; LR-




 241.97 and 243.97, found 242.01 and 244.00. 
 3-(2-Bromoethyl)-7-methoxybenzofuran (6c). The product 6c was prepared according 
to the general procedure and purified directly by column chromatography (hexanes, 2 column 
volumes → 20:1 hexanes:Et2O, 2 column volumes → 10:1 hexanes:Et2O, 2 column volumes) to 
provide a pale-yellow oil (347 mg, 90%). 
1
H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H), 7.19 (t, J 
= 7.8 Hz, 1H), 7.13 (dd, J = 7.8, 1.0 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 4.01 (s, 3H), 3.64 (t, J = 
7.4 Hz, 2H), 3.25 (td, J = 7.4, 0.8 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 145.8, 144.8, 142.3, 





255.00 and 257.00, found 255.49 and 257.49. 
 3-(2-Bromoethyl)-4-methoxybenzofuran (6d). The product 6d was prepared according 
to the general procedure and purified directly by column chromatography (hexanes, 2 column 
volumes → 20:1 hexanes:Et2O, 2 column volumes → 10:1 hexanes:Et2O, 2 column volumes) to 
provide a pale-yellow oil that slowly solidified to large, vitreous pale-yellow crystals (313 mg, 
<85%, 41% over 3 steps from 3d). Note: The product was found to be unstable at room 
temperature. 
1
H NMR (500 MHz, CDCl3) δ 7.39 (s, 1H), 7.21 (t, J = 8.1 Hz, 1H), 7.10 (d, J = 




C NMR (126 MHz, CDCl3) δ 157.0, 154.6, 141.2, 125.3, 117.7, 117.1, 105.0, 103.1, 
55.6, 32.9, 29.0. 
 3-(2-Bromoethyl)-6-fluoro-5-methoxybenzofuran (6e). The product 6e was prepared 
according to the general procedure and purified directly by column chromatography (hexanes, 2 
column volumes → 20:1 hexanes:Et2O, 2 column volumes → 10:1 hexanes:Et2O, 3 column 
volumes) to provide an off-white crystalline solid (389 mg, 90%). 
1
H NMR (500 MHz, CDCl3) 
(spectrum complicated by F-H coupling) δ 7.51 (s, 1H), 7.25 (d, J = 10.5 Hz, 1H), 7.02 (d, J = 
8.1 Hz, 1H), 3.94 (s, 3H), 3.63 (t, J = 7.3 Hz, 2H), 3.23 (td, J = 7.3, 0.8 Hz, 2H); 
13
C NMR (126 
MHz, CDCl3) (spectrum complicated by F-C coupling) δ 152.50 and 150.6, 148.8 and 148.7, 
145.3 and 145.2, 142.92 and 142.89, 122.9, 117.8, 102.52 and 102.50, 100.5 and 100.3, 57.2, 




 272.99 and 274.99, found 272.83 and 
274.83. 
 3-(2-Bromoethyl)-5-methoxy-6-methylbenzofuran (6f). The product 6f was prepared 
according to the general procedure and purified directly by column chromatography (hexanes, 2 
column volumes → 20:1 hexanes:Et2O, 2 column volumes → 10:1 hexanes:Et2O, 2 column 
volumes) to provide a pale-yellow oil that slowly crystallized to a pale-yellow solid (517 mg, 
98%). 
1
H NMR (500 MHz, CDCl3) δ 7.44 (s, 1H), 7.26 (s, 1H), 6.87 (s, 1H), 3.89 (s, 3H), 3.64 
(t, J = 7.5 Hz, 2H), 3.23 (t, J = 7.5 Hz, 2H), 2.32 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 154.6, 
150.0, 141.9, 125.4, 124.9, 117.7, 113.2, 99.2, 56.0, 31.5, 27.9, 17.2. 
 Methyl 2-(2-ethoxy-2-oxoethoxy)-6-methoxybenzoate (19). To a suspension of 6-
methoxysalicylic acid (5.03 g, 29.90 mmol) in anhydrous MeOH (37 mL) was added H2SO4 
(0.75 mL), and the mixture was refluxed for 66 h, adding additional H2SO4 at 38 h (incomplete 
conversion). The reaction was then concentrated to provide a mixture of an off-white solid and a 
 188 
pale-orange oil. This material was dissolved in CH2Cl2 (75 mL) and washed with water (50 mL), 
saturated aqueous NaHCO3 (2 x 50 mL), and water again (50 mL), dried over Na2SO4, and 
concentrated to provide the intermediate ester as a pale-orange oil, which slowly crystallized to 
give a waxy, pale-tan solid containing impurities (4.27 g, <78%, ~11 mol% impurity by NMR). 
 This impure methyl ester (4.19 g) was mixed with K2CO3 (11.44 g, 82.80 mmol), 
anhydrous acetone (115 mL) and ethyl bromoacetate (2.55 mL, 3.84 g, 23.00 mmol) were added, 
and the mixture was refluxed for 20 h. The reaction was then cooled to room temperature and 
filtered, washing the filter cake with additional acetone, and the filtrate was concentrated to give 
an orange oil. This material was dissolved in CH2Cl2 (75 mL), washed with water (2 x 50 mL), 
saturated aqueous Na2SO4 (50 mL), and brine (50 mL), dried over Na2SO4, and concentrated to 
provide an orange oil (5.23 g). This crude product was purified by column chromatography (8:2 
hexanes:EtOAc, 2 column volumes → 7:3 hexanes:EtOAc, 4 column volumes) to provide the 
pure diester 19 as a nearly colorless oil (4.17 g, 53% over 2 steps). 
1
H NMR (400 MHz, CDCl3) 
δ 7.26 (t, J = 8.4 Hz, 1H), 6.60 (d, J = 8.3 Hz, 1H), 6.44 (d, J = 8.2 Hz, 1H), 4.62 (s, 2H), 4.24 
(q, J = 7.1 Hz, 2H), 3.92 (s, 3H), 3.82 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, 
CDCl3) δ 168.5, 166.7, 157.7, 155.9, 131.2, 114.1, 105.3, 105.1, 66.4, 61.5, 56.2, 52.6, 14.3; 




 269.10, found 268.96. 
 2-(Carboxymethoxy)-6-methoxybenzoic acid (20). To a solution of diester 19 (4.15 g, 
15.47 mmol) in THF (46 mL) and MeOH (46 mL) was added 5M aqueous NaOH (31 mL) and 
the mixture was refluxed for 24 h. It was then cooled to room temperature and concentrated in 
vacuo until most of the THF and MeOH had been removed. The thick, pinkish-white slurry was 
diluted with water (200 mL) (solids dissolve), filtered, and acidified with saturated aqueous HCl. 
The mixture was then extracted with CH2Cl2 (50 mL) and EtOAc (5 x 50 mL) (difficult to extract 
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due to high aqueous solubility) and the combined organics were dried over Na2SO4 and 
concentrated to yield dicarboxylic acid 20 as a tan crystalline solid. (3.30 g, 94%). 
1
H NMR (400 
MHz, DMSO-d6) δ 12.84 (br s, 2H), 7.27 (t, J = 8.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 6.54 (d, J 
= 8.4 Hz, 1H), 4.67 (s, 2H), 3.76 (s, 3H); 
13
C NMR (101 MHz, DMSO-d6) δ 169.9, 166.4, 





227.06, found 226.89. 
 2-(5-Methoxybenzo[b]thiophen-3-yl)ethanol (21). To a solution of 4-
methoxythiophenol (3.94 mL, 32.0 mmol) and anhydrous pyridine (10.44 mL, 128.0 mmol) in 
anhydrous Et2O (65 mL) was added ethyl 4-chloroacetoacetate (4.36 mL, 32.0 mmol) at 0 °C, 
and the resulting mixture was allowed to warm to room temperature and stirred for 6.5 h. The 
reaction was then quenched with water (100 mL) and diluted with additional Et2O (50 mL). The 
organic layer was separated, and the residual aqueous extracted with additional Et2O (100 mL). 
The combined organics were washed with 5% aqueous HCl (100 mL) and water (100 mL), dried 
over Na2SO4, and concentrated to give an orange oil. This material was purified by column 
chromatography (9:1 hexanes:EtOAc, 2 column volumes → 7:3 hexanes:EtOAc, 1.5 column 
volumes) to provide the thioether product as an impure yellow oil (6.13 g) that was used in the 
next step without further purification. 
 A mixture of polyphosphoric acid (60 g), P2O5 (1.4 g), and celite (40 g) in toluene (200 
mL) was refluxed for 45 min. A solution of the crude thioether from the previous step (6.03 g) in 
toluene (20 mL) was then added, and reflux was continued for 6 h. At this time, the reaction was 
cooled to room temperature and filtered, washing the filter cake and undissolved solids first with 
toluene and then with Et2O. The combined filtrate and washings were washed with concentrated 
aqueous K2CO3 (100 mL) and water (100 mL), dried over Na2SO4, and concentrated to yield an 
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orange oil. This material was purified by column chromatography (9:1 hexanes:CH2Cl2, 4 
column volumes → 7:3 hexanes: CH2Cl2, 3 column volumes → 4:6 hexanes:CH2Cl2, 4 column 
volumes) to provide the impure benzothiophenyl ester as a yellow-brown oil (1.09 g) that was 
used in the next step without further purification.  
 To a suspension of LiAlH4 (421 mg, 11.10 mmol) in anhydrous THF (10.5 mL) at room 
temperature was added a solution of the crude benzothiophenyl ester (1.07 g) in anhydrous THF 
(3.5 mL) over 10 min., and the mixture was refluxed for 45 min. After cooling to room 
temperature the reaction was quenched by the successive addition of water (0.42 mL), 15% 
aqueous NaOH (0.42 mL), and water again (1.26 mL). The resulting mixture was stirred 
vigorously until the aluminum salts were white and loose and then filtered, washing the filter 
cake with Et2O (3 x 15 mL). The combined filtrate and washings were concentrated to yield a 
yellow-orange oil. This material was purified by repeated column chromatography (Column 1 
and 2 same: 8:2 hexanes:EtOAc, 2 column volumes → 7:3 hexanes:EtOAc, 2 column volumes 
→ 6:4 hexanes:EtOAc, 2 column volumes) to provide the pure alcohol 21 as a yellow oil (359 
mg, 6% over 3 steps). 
1
H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.8 Hz, 1H), 7.22 (d, J = 0.4 
Hz, 1H), 7.20 (d, J = 2.4 Hz, 1H), 7.02 (dd, J = 8.8, 2.5 Hz, 1H), 3.97 (d, J = 3.4 Hz, 2H), 3.89 
(s, 3H), 3.09 (td, J = 6.5, 0.8 Hz, 2H), 1.56 (br s, 1H); 
13
C NMR (101 MHz, CDCl3) δ 157.6, 





 209.06, found 209.39. 
 3-(2-Bromoethyl)-5-methoxybenzo[b]thiophene (22). The product 22 was prepared 
according to the general procedure used to prepare the bromoethylbenzofurans (6) and purified 
directly by column chromatography (hexanes, 2 column volumes → 20:1 hexanes:Et2O, 2 
column volumes → 10:1 hexanes:Et2O, 1 column volume) to provide a nearly colorless oil that 
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slowly crystallized to a white solid (430 mg, 96%). 
1
H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 
8.8 Hz, 1H), 7.25 (s, 1H), 7.15 (d, J = 2.4 Hz, 1H), 7.03 (dd, J = 8.8, 2.4 Hz, 1H), 3.90 (s, 3H), 
3.68 (t, J = 7.6 Hz, 2H), 3.38 (dd, J = 7.9, 7.2 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 157.7, 





 270.98 and 272.98, found 271.30 and 273.30. 
 2-((5-Methoxy-2-nitrophenyl)amino)ethanol (23). Aminoalcohol 23 was prepared 
according to literature procedure
22
 and obtained as a yellow crystalline solid (3.06 g, 76%). 
1
H 
NMR (400 MHz, CDCl3) δ 8.48 (br s, 1H), 8.13 (d, J = 9.5 Hz, 1H), 6.24 (dd, J = 9.5, 2.6 Hz, 
1H), 6.20 (d, J = 2.5 Hz, 1H), 3.95 (t, J = 5.4 Hz, 2H), 3.86 (s, 3H), 3.48 (q, J = 5.4 Hz, 2H), 
1.98 (br s, 1H); 
13
C NMR (101 MHz, CDCl3) δ 166.1, 148.0, 129.5, 126.9, 104.9, 95.6, 61.0, 




 213.09, found 213.12. 
 2-((2-Amino-5-methoxyphenyl)amino)ethanol (24).  Aniline 24 was prepared from 
aminoalcohol 23 according to literature procedure
22
 and obtained as a purple-brown solid (2.47 
g, 95%). 
1
H NMR (400 MHz, CDCl3) δ 6.67 (d, J = 8.3 Hz, 1H), 6.29 (d, J = 2.7 Hz, 1H), 6.22 
(dd, J = 8.3, 2.7 Hz, 1H), 3.98 (br s, 1H), 3.91 – 3.84 (m, 2H), 3.75 (s, 3H), 3.30 (br s, 2H), 3.05 
(br s, 2H), 1.82 (br s, 1H); 
13
C NMR (101 MHz, CDCl3) δ 155.4, 140.0, 127.3, 118.3, 101.9, 




 183.11, found 183.16. 
 2-(6-Methoxy-1H-benzo[d]imidazol-1-yl)ethanol (25). A mixture of aniline 24 (2.45 g, 
13.44 mmol), formic acid (1.03 mL, 26.88 mmol), and 4M aqueous HCl (90 mL) was refluxed 
for 1 h. The reaction was then cooled in ice, basified with saturated NH4OH, and extracted with 
CH2Cl2 (4 x 100 mL). The combined organics were washed with brine (100 mL), dried over 
Na2SO4, and concentrated to provide benzimidazole alcohol 25 as a brownish-purple solid (2.19 
g, 85%). 
1
H NMR (500 MHz, CDCl3) δ 7.56 (s, 1H), 7.27 (d, J = 8.8 Hz, 1H), 6.75 (d, J = 2.3 
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Hz, 1H), 6.71 (dd, J = 8.8, 2.4 Hz, 1H), 5.11 (br s, 1H), 4.17 (t, J = 5.1 Hz, 2H), 4.00 (d, J = 5.1 
Hz, 2H), 3.83 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 156.8, 142.7, 137.5, 134.1, 120.1, 111.5, 




 193.10, found 193.24. 
 1-(2-Chloroethyl)-6-methoxy-1H-benzo[d]imidazole (26). To a mixture of 
benzimidazole alcohol 25 (346 mg, 1.80 mmol) in anhydrous CH2Cl2 (2.5 mL) was added SOCl2 
(131 µL, 1.80 mmol) dropwise over 2 min. at room temperature. After stirring for 2 h, the 
reaction was quenched with saturated aqueous NaHCO3 (20 mL) and extracted with CH2Cl2 (3 x 
10 mL). The combined organics were washed with water (10 mL), dried over Na2SO4, and 
concentrated to provide benzimidazole chloride 26 as a tan solid (355 mg, 94%). 
1
H NMR (400 
MHz, CDCl3) δ 7.87 (s, 1H), 7.70 (d, J = 8.8 Hz, 1H), 6.94 (dd, J = 8.8, 2.4 Hz, 1H), 6.82 (d, J = 
2.3 Hz, 1H), 4.46 (t, J = 6.2 Hz, 2H), 3.88 (s, 3H), 3.84 (t, J = 6.2 Hz, 2H); 
13
C NMR (101 MHz, 





 211.06, found 211.06. 
 2-(5-(Benzyloxy)-1H-indol-3-yl)ethanol (27). To a solution of 2-(5-(benzyloxy)-1H-
indol-3-yl)acetic acid (985 mg, 3.50 mmol) in anhydrous THF (13 mL) at 0 °C was carefully 
added LiAlH4 (146 mg, 3.85 mmol) and the mixture was allowed to warm to room temperature 
and stirred for 1.5 h. The reaction was then quenched by the careful addition of water (0.15 mL), 
15% aqueous NaOH (0.15 mL), and water again (0.45 mL), and diluted with Et2O (50 mL) and 
additional water (50 mL). Potassium sodium tartrate (5 g) was added and the mixture was stirred 
vigorously until the emulsion had dissipated (~1 h). The organic layer was separated and the 
remaining aqueous was extracted with additional Et2O (3 x 50 mL). The combined organics were 
washed with brine (50 mL), dried over Na2SO4, and concentrated to provide alcohol 27 as a pale, 
orange-brown oil (423 mg, 45%). 
1
H NMR (400 MHz, CDCl3) δ 7.95 (br s, 1H), 7.49 (d, J = 7.1 
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Hz, 2H), 7.42 – 7.37 (m, 2H), 7.35 – 7.30 (m, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.16 (d, J = 2.4 Hz, 
1H), 7.06 (d, J = 2.3 Hz, 1H), 6.96 (dd, J = 8.8, 2.4 Hz, 1H), 5.12 (s, 2H), 3.89 (t, J = 6.3 Hz, 
2H), 3.00 (t, J = 6.3 Hz, 2H), 1.52 (br s, 1H); 
13
C NMR (101 MHz, CDCl3) δ 153.4, 137.8, 





 268.13, found 268.00. 
 5-(Benzyloxy)-3-(2-bromoethyl)-1H-indole (28). The product 28 was prepared 
according to the general procedure used to prepare the bromoethylbenzofurans (6) and purified 
directly by column chromatography (hexanes, 2 column volumes → 7:3 hexanes:Et2O, 6 column 
volumes) to provide a pale-pink oil that slowly crystallized to an off-white solid, still containing 
slight baseline impurities (0.26 g). This material was further purified by washing through a silica 
plug with CH2Cl2 (100 mL) to provide the pure bromide as a pale, yellowish-pink oil that slowly 
crystallized to a pale-pink solid (260 mg, 51%). 
1
H NMR (500 MHz, CDCl3) δ 7.93 (br s, 1H), 
7.49 (d, J = 7.4 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.3 Hz, 1H), 7.27 (d, J = 8.8 Hz, 
1H), 7.11 (d, J = 2.3 Hz, 1H), 7.07 (d, J = 2.3 Hz, 1H), 6.96 (dd, J = 8.8, 2.4 Hz, 1H), 5.12 (s, 
2H), 3.61 (t, J = 7.7 Hz, 2H), 3.29 (t, J = 7.7 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 153.6, 
137.8, 131.7, 128.8, 128.1, 127.9, 127.6, 123.3, 113.6, 113.3, 112.2, 102.4, 71.3, 33.0, 29.6; LR-




 330.05 and 332.05, found 329.96 and 331.95. 
 1-(5-Methoxybenzofuran-3-yl)propan-2-one (30). A dark-red mixture of 
benzofuranone 3a (246 mg, 1.50 mmol) and 1-(triphenylphosphoranylidene)-2-propanone (860 
mg, 2.70 mmol) in anhydrous xylene (12 mL) was refluxed for 38 h and then concentrated to 
provide a reddish-brown, sticky solid (1.23 g). This material was triturated with 8:2 
hexanes:EtOAc (10 mL) and the mixture was filtered. The trituration/filtration procedure was 
repeated with two additional portions of solvent, and the combined filtrates were concentrated to 
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provide a dark-orange oil (505 mg). This crude product was purified by column chromatography 
(10% EtOAc in hexanes, 4 column volumes → 15% EtOAc in hexanes, 4 column volumes → 
20% EtOAc in hexanes, 2 column volumes) to provide ketone 30 as a dark-orange oil that slowly 
crystallized to a waxy orange solid (150 mg, 49%). 
1
H NMR (500 MHz, CDCl3) δ 7.59 (s, 1H), 
7.39 – 7.35 (m, 1H), 6.93 – 6.89 (m, 2H), 3.84 (s, 3H), 3.73 (s, 2H), 2.22 (s, 3H); 
13
C NMR (126 
MHz, CDCl3) δ 205.4, 156.2, 150.3, 143.9, 128.3, 113.5, 113.5, 112.2, 102.0, 56.1, 39.1, 29.2; 




 205.09, found 205.33. 
 
Preparation of N-heteroarylethylisoquinuclidines 
 General Procedure for Preparation of N-benzofuranylethylisoquinuclidines (7). To a 
solution of a carbamate protected isoquinuclidine 2a-h (1 equivalent) in anhydrous CH2Cl2 
(0.125 M, based on 2) at 0 °C was added iodotrimethylsilane (4 equivalents), and the resulting 
mixture was stirred for 10 min. at 0 °C and then at room temperature until TLC indicated that no 
2 remained (typically ~1 h). The reaction mixture was then quenched with MeOH (3.0 mL per 
mmol of 2) and concentrated to yield the deprotected isoquinuclidine hydroiodide salt in 
quantitative yield. To this material was added the appropriate bromoethylbenzofuran 6a-f (1 
equivalent) and NaHCO3 (4 equivalents), followed by anhydrous CH3CN (0.208 M, based on 2), 
and the resulting mixture was refluxed until TLC indicated the disappearance of the bromide 
(typically >24 h). The reaction was then diluted with water, made strongly basic with aqueous 
NaOH, and extracted with CHCl3 (3x). The combined organics were washed with water, dried 
over Na2SO4, and concentrated to provide the crude product, which was purified by column 
chromatography with an appropriate solvent mixture (as described below for each compound). 
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 exo-7-Ethyl-2-(2-(5-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene 
(7a). The product 7a was prepared according to the general procedure and purified by column 
chromatography (20:1 hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 5 
column volumes) to provide a pale-yellow oil (288 mg, 74%). 
1
H NMR (400 MHz, CDCl3) δ 
7.46 (s, 1H), 7.33 (d, J = 8.9 Hz, 1H), 6.98 (d, J = 2.5 Hz, 1H), 6.87 (dd, J = 8.9, 2.6 Hz, 1H), 
6.38 – 6.27 (m, 2H), 3.86 (s, 3H), 3.23 (dd, J = 3.4, 1.8 Hz, 1H), 3.09 (dd, J = 9.1, 2.2 Hz, 1H), 
2.85 – 2.63 (m, 3H), 2.57 – 2.47 (m, 1H), 2.44 (dd, J = 4.0, 2.1 Hz, 1H), 1.94 (dt, J = 9.1, 2.5 Hz, 
1H), 1.64 – 1.42 (m, 3H), 1.35 – 1.25 (m, 1H), 0.95 – 0.90 (m, 1H), 0.88 (t, J = 7.4 Hz, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 155.8, 150.3, 142.6, 133.1, 132.8, 129.2, 119.2, 112.6, 111.9, 102.5, 





312.20, found 312.59. 
 endo-7-Ethyl-2-(2-(5-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene 
(7b). The product 7b was prepared according to the general procedure and purified by repeated 
column chromatography (Column 1: 9:1 hexanes:EtOAc, 2 column volumes → 9:1 
hexanes:EtOAc + 2% Et3N, 6 column volumes; Column 2: 9:1 hexanes:EtOAc + 2% Et3N) to 
provide a pale-yellow oil (103 mg, 44%). 
1
H NMR (500 MHz, CDCl3) δ 7.42 (s, 1H), 7.33 (d, J 
= 8.9 Hz, 1H), 7.00 (d, J = 2.5 Hz, 1H), 6.88 (dd, J = 8.9, 2.6 Hz, 1H), 6.38 (t, J = 7.2 Hz, 1H), 
6.17 – 6.11 (m, 1H), 3.85 (s, 3H), 3.40 – 3.35 (m, 1H), 3.02 (dd, J = 9.6, 1.7 Hz, 1H), 2.88 – 2.70 
(m, 3H), 2.57 – 2.48 (m, 2H), 2.07 (dt, J = 9.6, 2.7 Hz, 1H), 2.04 – 1.98 (m, 1H), 1.78 (ddd, J = 
12.1, 9.2, 2.8 Hz, 1H), 1.23 – 1.13 (m, 1H), 1.00 (tt, J = 14.8, 7.4 Hz, 1H), 0.85 (t, J = 7.4 Hz, 
3H), 0.82 – 0.75 (m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 155.8, 150.3, 142.4, 133.7, 130.2, 
129.0, 118.9, 112.7, 111.9, 102.4, 57.8, 57.4, 56.1, 54.5, 40.9, 31.6, 30.7, 28.8, 23.2, 11.8; LR-




 312.20, found 312.63. 
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 exo-2-(2-(5-Methoxybenzofuran-3-yl)ethyl)-7-propyl-2-azabicyclo[2.2.2]oct-5-ene 
(7c). The product 7c was prepared according to the general procedure and purified by column 
chromatography (20:1 hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 5 
column volumes) to provide a pale-yellow oil (178 mg, 73%). 
1
H NMR (500 MHz, CDCl3) δ 
7.46 (s, 1H), 7.33 (d, J = 8.9 Hz, 1H), 6.98 (d, J = 2.5 Hz, 1H), 6.87 (dd, J = 8.9, 2.6 Hz, 1H), 
6.36 – 6.27 (m, 2H), 3.86 (s, 3H), 3.19 (d, J = 5.2 Hz, 1H), 3.09 (dd, J = 9.1, 2.2 Hz, 1H), 2.84 – 
2.63 (m, 3H), 2.55 – 2.47 (m, 1H), 2.44 (dd, J = 3.8, 2.0 Hz, 1H), 1.93 (dt, J = 9.1, 2.4 Hz, 1H), 
1.57 – 1.36 (m, 4H), 1.33 – 1.24 (m, 2H), 0.92 (ddd, J = 11.8, 4.3, 2.1 Hz, 1H), 0.88 (t, J = 7.3 
Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 155.7, 150.2, 142.6, 133.0, 132.8, 129.2, 119.2, 112.5, 





 326.21, found 326.62. 
 endo-2-(2-(5-Methoxybenzofuran-3-yl)ethyl)-7-propyl-2-azabicyclo[2.2.2]oct-5-ene 
(7d). The product 7d was prepared according to the general procedure and purified by column 
chromatography (12.5:1 hexanes:EtOAc + 2% Et3N) to provide a yellow oil (151 mg, 62%). 
1
H 
NMR (500 MHz, CDCl3) δ 7.41 (s, 1H), 7.33 (d, J = 8.9 Hz, 1H), 6.99 (d, J = 2.6 Hz, 1H), 6.87 
(dd, J = 8.9, 2.6 Hz, 1H), 6.38 (t, J = 7.3 Hz, 1H), 6.14 (dd, J = 7.5, 5.9 Hz, 1H), 3.85 (s, 3H), 
3.34 (ddd, J = 5.0, 2.5, 1.3 Hz, 1H), 3.02 (dd, J = 9.6, 1.9 Hz, 1H), 2.88 – 2.70 (m, 3H), 2.57 – 
2.48 (m, 2H), 2.16 – 2.08 (m, 1H), 2.06 (dt, J = 9.6, 2.7 Hz, 1H), 1.77 (ddd, J = 12.1, 9.2, 2.8 Hz, 
1H), 1.36 – 1.21 (m, 2H), 1.15 (ddt, J = 13.0, 9.5, 6.4 Hz, 1H), 1.00 – 0.91 (m, 1H), 0.87 (t, J = 
7.3 Hz, 3H), 0.83 – 0.75 (m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 155.8, 150.3, 142.4, 133.7, 
130.3, 129.0, 118.9, 112.7, 111.9, 102.4, 57.8, 57.6, 56.1, 54.4, 38.6, 38.4, 31.6, 30.8, 23.2, 20.2, 




 326.21, found 326.60. 
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 exo-2-(2-(5-Methoxybenzofuran-3-yl)ethyl)-7-phenyl-2-azabicyclo[2.2.2]oct-5-ene 
(7e). The product 7e was prepared according to the general procedure from isoquinuclidine 2h, 
and obtained as a mixture with the endo-epimer 7f. It was separated by column chromatography 
(20:1 hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 3 column volumes → 
8:2 hexanes:Et2O + 2% Et3N, 5 column volumes → 1:1 hexanes:Et2O + 2% Et3N, 1 column 
volume) and obtained as a nearly colorless oil (30.7 mg, 14%). 
1
H NMR (500 MHz, CDCl3) δ 
7.43 – 7.39 (m, 2H), 7.34 (d, J = 8.8 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.24 – 7.17 (m, 2H), 6.91 (d, 
J = 2.5 Hz, 1H), 6.88 (dd, J = 8.8, 2.6 Hz, 1H), 6.48 – 6.43 (m, 2H), 3.84 (s, 3H), 3.34 (dt, J = 
4.4, 2.0 Hz, 1H), 3.32 (dd, J = 9.0, 2.4 Hz, 1H), 2.82 – 2.57 (m, 5H), 2.53 (ddd, J = 11.4, 8.1, 5.0 
Hz, 1H), 2.09 (dt, J = 9.0, 2.5 Hz, 1H), 1.81 – 1.73 (m, 1H), 1.55 (ddd, J = 12.7, 5.9, 2.0 Hz, 
1H); 
13
C NMR (126 MHz, CDCl3) δ 155.7, 150.2, 145.0, 142.8, 132.9, 132.9, 129.1, 128.7, 





 360.20, found 359.92. 
 endo-2-(2-(5-Methoxybenzofuran-3-yl)ethyl)-7-phenyl-2-azabicyclo[2.2.2]oct-5-ene 
(7f). The product 7f was prepared according to the general procedure from isoquinuclidine 2h, 
and obtained as a mixture with the exo-epimer 7e. It was separated by column chromatography 
(20:1 hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 3 column volumes → 
8:2 hexanes:Et2O + 2% Et3N, 5 column volumes → 1:1 hexanes:Et2O + 2% Et3N, 1 column 
volume) and obtained as a yellow oil (103 mg, 48%). 
1
H NMR (500 MHz, CDCl3) δ 7.44 (s, 
1H), 7.34 (d, J = 8.9 Hz, 1H), 7.28 – 7.22 (m, 2H), 7.21 – 7.15 (m, 3H), 7.00 (d, J = 2.6 Hz, 1H), 
6.89 (dd, J = 8.9, 2.6 Hz, 1H), 6.59 (t, J = 7.4 Hz, 1H), 6.19 (ddd, J = 8.0, 5.3, 1.0 Hz, 1H), 3.86 
(s, 3H), 3.54 – 3.51 (m, 1H), 3.50 – 3.46 (m, 1H), 3.13 (dd, J = 9.7, 1.7 Hz, 1H), 2.91 – 2.75 (m, 
3H), 2.71 (dd, J = 3.6, 1.5 Hz, 1H), 2.63 – 2.56 (m, 1H), 2.18 (dt, J = 9.7, 2.7 Hz, 1H), 2.13 (ddd, 
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J = 12.7, 9.7, 2.8 Hz, 1H), 1.56 (ddt, J = 12.7, 5.4, 2.7 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 
155.9, 150.3, 145.4, 142.4, 134.3, 130.7, 129.0, 128.4, 128.2, 126.2, 118.8, 112.8, 112.0, 102.4, 







(7g). The product 7g was prepared according to the general procedure and purified by column 
chromatography (20:1 hexanes:Et2O, 4 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 4 
column volumes) to provide a pale-yellow oil (41.9 mg, 60%). 
1
H NMR (500 MHz, CDCl3) δ 
7.47 (s, 1H), 7.36 (d, J = 8.9 Hz, 1H), 7.19 – 7.10 (m, 3H), 7.01 (dd, J = 6.5, 2.0 Hz, 3H), 6.91 
(dd, J = 8.9, 2.6 Hz, 1H), 6.34 (t, J = 7.2 Hz, 1H), 6.22 – 6.17 (m, 1H), 3.88 (s, 3H), 3.20 (dd, J = 
9.0, 2.3 Hz, 1H), 3.00 (d, J = 5.5 Hz, 1H), 2.84 (dd, J = 13.1, 9.5 Hz, 1H), 2.81 – 2.68 (m, 4H), 
2.54 – 2.47 (m, 2H), 1.99 (dt, J = 9.0, 2.5 Hz, 1H), 1.74 – 1.66 (m, 1H), 1.51 (ddd, J = 10.8, 6.2, 
3.1 Hz, 1H), 1.03 (ddd, J = 12.3, 4.9, 2.1 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 155.8, 150.3, 
142.6, 142.1, 133.2, 132.6, 129.2, 129.1, 128.2, 125.6, 119.2, 112.7, 112.0, 102.4, 57.9, 56.18, 
56.15, 55.5, 41.2, 40.0, 31.7, 29.9, 23.0; HRMS (FAB+) m/z: [M+H]
+
 Calcd for C25H28NO2
+
 
374.2115, found 374.2111. 
 2-(2-(5-Methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene (7h). The 
product 7h was prepared according to the general procedure and purified by column 
chromatography (9:1 hexanes:EtOAc + 2% Et3N, 2 column volumes → 8:2 hexanes:EtOAc + 
2% Et3N, 4 column volumes) to provide a yellow oil (185 mg, 65%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.41 (s, 1H), 7.33 (d, J = 8.9 Hz, 1H), 6.99 (d, J = 2.5 Hz, 1H), 6.88 (dd, J = 8.9, 2.6 
Hz, 1H), 6.40 (t, J = 7.0 Hz, 1H), 6.27 (ddd, J = 8.0, 5.5, 1.0 Hz, 1H), 3.85 (s, 3H), 3.46 (d, J = 
1.7 Hz, 1H), 3.09 (dd, J = 9.6, 2.0 Hz, 1H), 2.85 – 2.70 (m, 3H), 2.57 – 2.46 (m, 2H), 2.09 (dt, J 
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= 9.6, 2.7 Hz, 1H), 2.01 (ddt, J = 12.6, 9.4, 3.4 Hz, 1H), 1.62 – 1.54 (m, 1H), 1.33 (tdd, J = 12.0, 
3.7, 2.7 Hz, 1H), 1.29 – 1.20 (m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 155.8, 150.3, 142.4, 
133.4, 131.9, 129.0, 118.9, 112.7, 111.9, 102.4, 58.1, 56.1, 55.7, 52.9, 30.9, 26.9, 23.1, 22.2; LR-




 284.16, found 284.54. 
 exo-7-Ethyl-2-(2-(5-fluorobenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene (7i). 
The product 7i was prepared according to the general procedure and purified by column 
chromatography (20:1 hexanes:Et2O, 2 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 4 
column volumes) to provide a pale-yellow oil (38.8 mg, 43%). 
1
H NMR (400 MHz, CDCl3) 
(spectrum complicated by F-H coupling) δ 7.52 (s, 1H), 7.36 (dd, J = 8.9, 4.1 Hz, 1H), 7.18 (dd, 
J = 8.6, 2.6 Hz, 1H), 6.98 (td, J = 9.0, 2.6 Hz, 1H), 6.38 – 6.27 (m, 2H), 3.20 (dt, J = 5.2, 1.7 Hz, 
1H), 3.07 (dd, J = 9.1, 2.3 Hz, 1H), 2.83 – 2.61 (m, 3H), 2.54 – 2.47 (m, 1H), 2.47 – 2.42 (m, 
1H), 1.93 (dt, J = 9.1, 2.6 Hz, 1H), 1.58 – 1.43 (m, 3H), 1.34 – 1.26 (m, 1H), 0.91 (ddd, J = 12.2, 
4.9, 2.2 Hz, 1H), 0.86 (t, J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) (spectrum complicated 
by F-C coupling) δ 160.3 and 158.0, 151.5, 143.6, 133.1, 132.8, 129.6, 119.5, 112.1 and 112.0, 





 300.18, found 300.26. 
 exo-7-Ethyl-2-(2-(6-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene (7j). 
To a solution of amide 29 (144 mg, 0.442 mmol) in anhydrous THF (4.5 mL) at room 
temperature was carefully added LiAlH4 (36.9 mg, 0.972 mmol), and the resulting mixture was 
refluxed for 1.25 h. After cooling to room temperature, the reaction was quenched by the 
successive addition of water (37 µL), 15% aqueous NaOH (37 µL), and water again (111 µL). 
The resulting mixture was diluted with Et2O (10 mL) and stirred vigorously until the aluminum 
salts were white and loose and then filtered, washing the filter cake with Et2O. The combined 
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filtrate and washings were concentrated to yield the crude product (134 mg). This material was 
purified by column chromatography (20:1 hexanes:EtOAc + 2% Et3N) to provide the pure 
product 7j as a pale, yellow-green oil (104 mg, 76%). 
1
H NMR (400 MHz, CDCl3) δ 7.40 – 
7.37 (m, 2H), 6.99 (d, J = 2.2 Hz, 1H), 6.86 (dd, J = 8.5, 2.2 Hz, 1H), 6.37 – 6.26 (m, 2H), 3.85 
(s, 3H), 3.22 (dt, J = 5.2, 1.8 Hz, 1H), 3.08 (dd, J = 9.1, 2.3 Hz, 1H), 2.83 – 2.62 (m, 3H), 2.55 – 
2.47 (m, 1H), 2.44 (ddd, J = 7.8, 4.9, 3.0 Hz, 1H), 1.93 (dt, J = 9.1, 2.6 Hz, 1H), 1.61 – 1.43 (m, 
3H), 1.34 – 1.27 (m, 1H), 0.95 – 0.90 (m, 1H), 0.88 (t, J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, 
CDCl3) δ 158.0, 156.2, 140.8, 133.1, 132.8, 122.1, 119.8, 119.0, 111.3, 96.2, 58.0, 56.3, 56.2, 




 312.20, found 
312.56. 
 exo-7-Ethyl-2-(2-(7-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene 
(7k). The product 7k was prepared according to the general procedure and purified by column 
chromatography (20:1 hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 3 
column volumes → 10:1 hexanes:Et2O + 2% Et3N, 3 column volumes) to provide a pale-yellow 
oil (59.1 mg, 63%). 
1
H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 7.17 – 7.11 (m, 2H), 6.82 – 
6.76 (m, 1H), 6.37 – 6.27 (m, 2H), 4.00 (s, 3H), 3.22 (dt, J = 5.1, 1.8 Hz, 1H), 3.07 (dd, J = 9.1, 
2.3 Hz, 1H), 2.85 – 2.63 (m, 3H), 2.52 (ddd, J = 12.5, 8.9, 5.0 Hz, 1H), 2.46 – 2.40 (m, 1H), 1.93 
(dt, J = 9.1, 2.6 Hz, 1H), 1.63 – 1.42 (m, 3H), 1.34 – 1.24 (m, 1H), 0.94 – 0.89 (m, 1H), 0.87 (t, J 
= 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 145.7, 144.5, 141.8, 133.0, 132.8, 130.4, 123.0, 





 312.20, found 312.26. 
 exo-7-Ethyl-2-(2-(4-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene (7l). 
The product 7l was prepared according to the general procedure and purified by column 
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chromatography (20:1 hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 3 
column volumes → 10:1 hexanes:Et2O + 2% Et3N, 3 column volumes) to provide a pale-yellow 
oil (53.9 mg, 58%). 
1
H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 7.16 (t, J = 8.1 Hz, 1H), 7.06 
(dd, J = 8.3, 0.6 Hz, 1H), 6.61 (d, J = 7.9 Hz, 1H), 6.37 – 6.27 (m, 2H), 3.91 (s, 3H), 3.24 (dt, J = 
4.9, 1.8 Hz, 1H), 3.07 (dd, J = 9.1, 2.3 Hz, 1H), 2.95 – 2.75 (m, 3H), 2.53 – 2.40 (m, 2H), 1.97 
(dt, J = 9.0, 2.6 Hz, 1H), 1.65 – 1.43 (m, 3H), 1.34 – 1.25 (m, 1H), 0.95 – 0.89 (m, 1H), 0.88 (t, J 
= 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 156.8, 155.0, 140.4, 133.0, 132.9, 124.7, 119.3, 





 312.20, found 312.35. 
 exo-7-Ethyl-2-(2-(6-fluoro-5-methoxybenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-
5-ene (7m). The product 7m was prepared according to the general procedure and purified by 
column chromatography (20:1 hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% 
Et3N, 3 column volumes → 10:1 hexanes:Et2O + 2% Et3N, 2 column volumes) to provide a pale-
yellow oil (64.5 mg, 65%). 
1
H NMR (500 MHz, CDCl3) (spectrum complicated by F-H 
coupling) δ 7.46 (s, 1H), 7.21 (d, J = 10.7 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.37 – 6.32 (m, 1H), 
6.32 – 6.27 (m, 1H), 3.94 (s, 3H), 3.22 (dt, J = 5.2, 1.6 Hz, 1H), 3.08 (dd, J = 9.1, 2.3 Hz, 1H), 
2.83 – 2.62 (m, 3H), 2.54 – 2.48 (m, 1H), 2.45 (dd, J = 3.9, 2.2 Hz, 1H), 1.93 (dt, J = 9.1, 2.6 Hz, 
1H), 1.59 – 1.44 (m, 3H), 1.34 – 1.26 (m, 1H), 0.91 (ddd, J = 12.2, 4.8, 2.1 Hz, 1H), 0.87 (t, J = 
7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) (spectrum complicated by F-C coupling) δ 152.2 and 
150.3, 148.6 and 148.5, 144.9 and 144.8, 142.5 and 142.4, 133.1, 132.7, 123.9, 119.2, 103.04 
and 103.02, 100.1 and 100.0, 57.79, 57.19, 56.37, 56.24, 41.30, 31.75, 29.88, 27.41, 22.98, 




 330.19, found 329.99. 
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 exo-7-Ethyl-2-(2-(5-methoxy-6-methylbenzofuran-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-
5-ene (7n). The product 7n was prepared according to the general procedure and purified by 
column chromatography (20:1 hexanes:Et2O, 2 column volumes → 20:1 hexanes:Et2O + 2% 
Et3N, 6 column volumes) to provide a pale-yellow oil (29.4 mg, 30%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.40 (s, 1H), 7.22 (s, 1H), 6.89 (s, 1H), 6.38 – 6.28 (m, 2H), 3.89 (s, 3H), 3.24 (dd, J = 
3.6, 1.7 Hz, 1H), 3.09 (dd, J = 9.1, 2.2 Hz, 1H), 2.84 – 2.64 (m, 3H), 2.52 (ddd, J = 10.7, 8.3, 5.2 
Hz, 1H), 2.47 – 2.42 (m, 1H), 2.32 (s, 3H), 1.94 (dt, J = 9.1, 2.5 Hz, 1H), 1.63 – 1.45 (m, 3H), 
1.35 – 1.27 (m, 1H), 0.95 – 0.91 (m, 1H), 0.89 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) 
δ 154.2, 149.9, 141.4, 133.1, 132.8, 126.5, 124.2, 119.1, 112.9, 99.8, 57.9, 56.27, 56.25, 56.0, 
41.3, 31.8, 29.9, 27.4, 23.1, 17.1, 12.6. 
 exo-7-Ethyl-2-(α-endo-1-(5-methoxybenzofuran-3-yl)propan-2-yl)-2-
azabicyclo[2.2.2]oct-5-ene and exo-7-ethyl-2-(α-exo-1-(5-methoxybenzofuran-3-yl)propan-
2-yl)-2-azabicyclo[2.2.2]oct-5-ene (α-endo-7o and α-exo-7o). To a solution of isoquinuclidine 
2a (97.6 mg, 0.500 mmol) in anhydrous CH2Cl2 (4.0 mL) at 0 °C was added iodotrimethylsilane 
(285 µL, 2.00 mmol), and the orange solution was allowed to warm to room temperature and 
stirred for 1.5 h. The reaction was then quenched with MeOH (1.5 mL) and concentrated to 
provide the isoquinuclidine HI salt as an orange-brown solid. This material was dissolved in 
anhydrous 1,2-dichloroethane (3.0 mL), Et3N (139 µL, 1.00 mmol), ketone 30 (102 mg, 0.500 
mmol), and NaBH(OAc)3 (212 mg, 1.00 mmol) were added, and the pale-orange mixture was 
stirred at room temperature for 66 h. At this time, the reaction was diluted with water (25 mL), 
basified with concentrated aqueous NaOH, and extracted with CH2Cl2 (3 x 10 mL). The 
combined organics were washed with water (10 mL), dried over Na2SO4, and concentrated to 
provide a red-brown oil (163 mg). This material was purified by column chromatography (20:1 
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hexanes:Et2O + 2% Et3N) to provide a mixture of the two diastereomers α-endo-7o and α-exo-7o 
as a yellow-orange oil (132 mg, 81%, 84:16 α-endo:α-exo). 
1
H NMR (500 MHz, CDCl3) 
(Partial integrals due to 84:16 mixture of two diastereomers) δ 7.44 (s, 1H), 7.34 (d, J = 8.9 Hz, 
1H), 6.98 (d, J = 2.6 Hz, 0.84H), 6.96 (d, J = 2.6 Hz, 0.16H), 6.88 (dd, J = 8.9, 2.6 Hz, 1H), 6.37 
– 6.24 (m, 2H), 3.863 (s, 2.52H), 3.858 (s, 0.48H) 3.33 (dt, J = 4.0, 2.2 Hz, 0.84H), 3.18 (d, J = 
5.5 Hz, 0.16H), 3.09 (dd, J = 8.5, 2.5 Hz, 0.84H), 3.00 – 2.95 (m, 0.16H), 2.92 (dd, J = 8.3, 2.6 
Hz, 0.16H), 2.85 (dd, J = 14.6, 5.7 Hz, 0.16H), 2.77 (dd, J = 14.4, 4.2 Hz, 0.84H), 2.75 – 2.66 
(m, 0.84H), 2.50 (dd, J = 14.6, 8.5 Hz, 0.84H), 2.46 (br d, J = 1.9 Hz, 1H), 2.35 (dt, J = 8.4, 2.3 
Hz, 0.16H), 2.31 (dd, J = 14.5, 8.3 Hz, 0.16H), 2.23 (dt, J = 8.5, 2.4 Hz, 0.84H), 1.62 – 1.41 (m, 
3H), 1.33 – 1.26 (m, 1H), 0.98 – 0.86 (m, 6.52H), 0.82 (t, J = 7.4 Hz, 0.48H); 
13
C NMR (126 
MHz, CDCl3) (Additional peaks due to 84:16 mixture of two diastereomers) δ 155.7, 150.3, 
143.1, 142.9, 134.4, 133.6, 132.2, 131.8, 129.5, 129.3, 119.0, 118.7, 112.5, 112.4, 111.9, 111.8, 
102.8, 102.5, 58.6, 57.9, 56.2, 56.1, 54.6, 53.3, 51.3, 50.8, 42.6, 42.0, 31.93, 31.86, 30.2, 30.1, 








2-yl)-2-azabicyclo[2.2.2]oct-5-ene (α-endo-7p and α-exo-7p). To a solution of isoquinuclidine 
2b (195 mg, 1.00 mmol) in anhydrous CH2Cl2 (8.0 mL) at 0 °C was added iodotrimethylsilane 
(569 µL, 4.00 mmol), and the orange solution was allowed to warm to room temperature and 
stirred for 1.5 h. The reaction was then quenched with MeOH (3.0 mL) and concentrated to 
provide the isoquinuclidine HI salt as an orange-brown solid. To this material (insoluble) was 
added anhydrous 1,2-dichloroethane (6.0 mL), Et3N (279 µL, 2.00 mmol), ketone 30 (204 mg, 
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1.00 mmol), and NaBH(OAc)3 (424 mg, 2.00 mmol), and the resulting pale-orange mixture was 
stirred at room temperature for 34 h. At this time, additional NaBH(OAc)3 (212 mg, 1.00 mmol) 
was added and the reaction was stirred for an additional 51 h. the reaction was then diluted with 
water (25 mL), basified with concentrated aqueous NaOH, and extracted with CH2Cl2 (3 x 10 
mL). The combined organics were washed with water (10 mL), dried over Na2SO4, and 
concentrated to provide a dark-brown oil (323 mg). This material was purified by repeated 
column chromatography (Column 1: 7:3 hexanes:EtOAc, 4 column volumes → 7:3 
hexanes:EtOAc + 2% Et3N, 4 column volumes; Column 2: 9:1 hexanes:EtOAc + 2% Et3N) to 
provide a mixture of the two diastereomers α-endo-7p and α-exo-7p as a yellow oil (139 mg, 
43%, 54:46 α-endo:α-exo). 
1
H NMR (500 MHz, CDCl3) (Partial integrals due to 54:46 mixture 
of two diastereomers) δ 7.50 (s, 0.46H), 7.43 (s, 0.54H), 7.35 – 7.32 (m, 1H), 6.98 (d, J = 2.6 Hz, 
0.54H), 6.97 (d, J = 2.6 Hz, 0.46H), 6.90 – 6.86 (m, 1H), 6.39 – 6.33 (m, 1H), 6.22 – 6.18 (m, 
0.46H), 6.11 (ddd, J = 7.9, 5.4, 1.0 Hz, 0.54H), 3.86 (s, 1.38H), 3.85 (s, 1.62H), 3.55 – 3.50 (m, 
0.54H), 3.49 (ddd, J = 5.4, 2.8, 1.4 Hz, 0.46H), 3.10 (dd, J = 9.4, 2.0 Hz, 0.54H), 2.97 – 2.83 (m, 
2H), 2.68 – 2.59 (m, 0.54H), 2.55 – 2.46 (m, 1.46H), 2.45 – 2.36 (m, 0.92H), 2.24 (dt, J = 9.4, 
2.6 Hz, 0.54H), 2.04 – 1.93 (m, 1H), 1.84 – 1.78 (m, 1H), 1.24 – 1.10 (m, 1H), 1.06 – 0.94 (m, 
1H), 1.01 (d, J = 6.3 Hz, 1.62H), 0.96 (d, J = 6.4 Hz, 1.38H), 0.87 – 0.78 (m, 4H); 
13
C NMR 
(126 MHz, CDCl3) (Additional peaks due to 54:46 mixture of two diastereomers) δ 155.8, 
150.3, 143.1, 133.2, 131.2, 130.3, 129.4, 118.6, 112.50, 112.46, 111.9, 102.9, 102.6, 59.3, 58.3, 
56.1, 53.7, 53.5, 52.7, 51.0, 42.0, 41.6, 31.8, 31.0, 31.0, 29.7, 29.5, 28.84, 28.75, 18.5, 18.1, 
11.78, 11.76. 
 exo-1-(7-Ethyl-2-azabicyclo[2.2.2]oct-5-en-2-yl)-2-(6-methoxybenzofuran-3-
yl)ethanone (29). To a solution of isoquinuclidine 2a (146 mg, 0.750 mmol) in anhydrous 
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CH2Cl2 (6.0 mL) at 0 °C was added iodotrimethylsilane (427 µL, 3.00 mmol), and the orange 
solution was allowed to warm to room temperature and stirred for 1 h. The reaction was then 
quenched with MeOH (2.3 mL) and concentrated to provide the isoquinuclidine HI salt as an 
orange-brown solid. To this material was added 2-(6-methoxy-1-benzofuran-3-yl)acetic acid 
(155 mg, 0.750 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (151 
mg, 0.787 mmol), 4-(dimethylamino)pyridine (9.2 mg, 0.075 mmol), and iPr2NEt (157 µL, 0.900 
mmol) followed by anhydrous CH2Cl2 (10.5 mL), and the resulting solution was stirred for 20 
min. at room temperature. The reaction was then quenched with water (20 mL) and diluted with 
CH2Cl2 (10 mL). The organic layer was separated and washed with 1% aqueous NaOH (2 x 10 
mL), 2% aqueous HCl (2 x 10 mL), and water (10 mL), dried over Na2SO4, and concentrated to 
give a yellow oil. This material was washed through a short silica column with 1:1 
hexanes:EtOAc to remove baseline impurities, and the eluate was concentrated to provide pure 
amide 29 as a nearly colorless oil (155 mg, 64%). 
1
H NMR (500 MHz, CDCl3) (some partial 
integrals due to conformers) δ 7.48 – 7.41 (m, 2H), 7.00 – 6.98 (m, 1H), 6.89 – 6.84 (m, 1H), 
6.47 (ddd, J = 7.8, 6.3, 1.4 Hz, 0.6H), 6.34 (td, J = 6.6, 1.1 Hz, 1H), 6.26 (ddd, J = 7.8, 6.1, 1.4 
Hz, 0.4H), 5.15 (d, J = 6.2 Hz, 0.6H), 4.25 (d, J = 6.1 Hz, 0.4H), 3.84 (d from conformers, 3H), 
3.78 – 3.51 (m, 2H), 3.37 (dd, J = 9.2, 2.2 Hz, 0.6H), 3.29 (dd, J = 11.7, 2.0 Hz, 0.4H), 3.17 – 
3.10 (m, 1H), 2.77 – 2.68 (m, 1H), 1.69 – 1.63 (m, 1H), 1.53 – 1.44 (m, 1H), 1.44 – 1.22 (m, 
2H), 1.06 (ddd, J = 12.6, 4.5, 2.2 Hz, 0.4H), 0.97 (ddd, J = 12.8, 4.5, 2.3 Hz, 0.6H), 0.93 (t, J = 
7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) (spectrum complicated by conformers) δ 167.0, 
158.3, 156.4, 141.7, 141.6, 134.6, 134.0, 133.5, 132.5, 121.4, 121.3, 120.2, 120.0, 114.5, 113.9, 
111.8, 111.7, 96.14, 96.10, 55.9, 52.7, 49.5, 48.3, 46.9, 41.0, 40.5, 31.3, 30.6, 30.4, 30.2, 29.77, 




 326.18, found 326.61. 
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 exo-7-Ethyl-2-(2-(5-methoxybenzo[b]thiophen-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-
ene (31). The product 31 was prepared according to the general procedure used to prepare the N-
benzofuranylethylisoquinuclidines (7) and purified by column chromatography (20:1 
hexanes:Et2O, 3 column volumes → 20:1 hexanes:Et2O + 2% Et3N, 3 column volumes → 10:1 
hexanes:Et2O + 2% Et3N, 3 column volumes) to provide a pale-yellow oil (108 mg, 66%). 
1
H 
NMR (400 MHz, CDCl3) δ 7.72 – 7.67 (m, 1H), 7.18 (s, 2H), 7.02 – 6.96 (m, 1H), 6.38 – 6.27 
(m, 2H), 3.90 (s, 3H), 3.24 (d, J = 3.9 Hz, 1H), 3.11 (d, J = 8.7 Hz, 1H), 2.96 – 2.78 (m, 3H), 
2.62 – 2.51 (m, 1H), 2.45 (br s, 1H), 1.96 (d, J = 9.0 Hz, 1H), 1.63 – 1.42 (m, 3H), 1.36 – 1.27 
(m, 1H), 0.96 – 0.91 (m, 1H), 0.88 (t, J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 157.5, 
140.5, 135.1, 133.1, 132.8, 123.5, 122.9, 114.1, 104.5, 58.0, 56.4, 56.3, 55.8, 41.3, 31.8, 29.9, 




 328.17, found 328.45. 
 exo-7-Ethyl-2-(2-(6-methoxy-1H-benzo[d]imidazol-1-yl)ethyl)-2-azabicyclo[2.2.2]oct-
5-ene (34). To a solution of isoquinuclidine 2a (97.6 mg, 0.500 mmol) in anhydrous CH2Cl2 (4.0 
mL) at 0 °C was added iodotrimethylsilane (285 µL, 2.00 mmol), and the orange solution was 
allowed to warm to room temperature and stirred for 1 h. The reaction was then quenched with 
MeOH (1.5 mL) and concentrated to provide the isoquinuclidine HI salt as an orange-brown 
solid. This material was dissolved in anhydrous DMF (1.9 mL), chloride 26 (105 mg, 0.500 
mmol) and triethylamine (209 µL, 1.50 mmol) were added, and the reaction was heated to 70 °C 
for 12 h. At this time, additional triethylamine (209 µL, 1.50 mmol) was added and the 
temperature was raised to 90 °C for an additional 33 h (still incomplete conversion). The reaction 
was then diluted with water (10 mL), made strongly basic with NaOH, and extracted with Et2O 
(3 x 10 mL). The combined organics were washed with water (10 mL) and brine (10 mL), dried 
over Na2SO4, and concentrated to give an orange-brown oil (115 mg). This material was purified 
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by column chromatography (1:1 hexanes:EtOAc + 2% Et3N) followed by preparative TLC (9:1 
CH2Cl2:Et2O) to provide the pure product 34 as a yellow oil (19.6 mg, 13%). 
1
H NMR (400 
MHz, CDCl3) δ 7.88 (s, 1H), 7.66 (d, J = 8.8 Hz, 1H), 6.89 (dd, J = 8.8, 2.4 Hz, 1H), 6.80 (d, J = 
2.4 Hz, 1H), 6.36 – 6.29 (m, 1H), 6.29 – 6.23 (m, 1H), 4.06 (dd, J = 6.8, 5.4 Hz, 2H), 3.87 (s, 
3H), 3.07 – 3.00 (m, 2H), 3.00 – 2.91 (m, 1H), 2.56 (dt, J = 12.8, 5.3 Hz, 1H), 2.44 (dd, J = 3.9, 
2.3 Hz, 1H), 1.87 (dt, J = 9.0, 2.6 Hz, 1H), 1.48 – 1.32 (m, 3H), 1.29 – 1.19 (m, 1H), 0.86 (ddd, J 
= 12.2, 4.6, 2.2 Hz, 1H), 0.74 (t, J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 156.7, 143.1, 
138.4, 134.6, 133.3, 132.5, 120.8, 111.0, 93.4, 58.2, 57.4, 56.5, 56.0, 44.1, 41.0, 31.6, 29.7, 27.4, 




 312.21, found 312.01. 
 exo-2-(2-(5-(Benzyloxy)-1H-indol-3-yl)ethyl)-7-ethyl-2-azabicyclo[2.2.2]oct-5-ene 
(37). The product 37 was prepared according to the general procedure used to prepare the N-
benzofuranylethylisoquinuclidines (7) and purified by column chromatography (7:3 
hexanes:EtOAc, 3 column volumes → 7:3 hexanes:EtOAc + 2% Et3N, 5 column volumes) to 
provide a yellow oil (141 mg, 73%). 
1
H NMR (500 MHz, CDCl3) δ 7.85 (br s, 1H), 7.51 (d, J = 
7.4 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.34 (t, J = 7.3 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H), 7.14 (d, J 
= 2.3 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 6.94 (dd, J = 8.7, 2.4 Hz, 1H), 6.40 – 6.29 (m, 2H), 5.13 
(s, 2H), 3.29 (dd, J = 3.6, 1.6 Hz, 1H), 3.13 (dd, J = 9.1, 2.2 Hz, 1H), 2.91 – 2.74 (m, 3H), 2.58 – 
2.50 (m, 1H), 2.50 – 2.42 (m, 1H), 1.98 (dt, J = 9.1, 2.5 Hz, 1H), 1.69 – 1.47 (m, 3H), 1.38 – 
1.29 (m, 1H), 0.99 – 0.94 (m, 1H), 0.94 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 
153.1, 137.9, 132.91, 132.90, 131.7, 128.6, 128.2, 127.9, 127.8, 122.5, 115.0, 112.7, 111.8, 









Preparation of Oxaibogamine Analogs 
 General Procedure for Preparation of Oxaibogamine Analogs by Ni(0)-catalyzed 
Cyclization (8). In a glovebox, a vial was charged with Ni(COD)2 (0.20 equivalents) and 1,3-
bis(2,4,6-trimethylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene (IMes, 0.24 equivalents) followed 
by anhydrous heptane (0.100 M, based on Ni(COD)2), and the resulting black solution was 
stirred at room temperature for 15 min. To this mixture was then added a solution of the N-
benzofuranylethylisoquinuclidine substrate 7a-p (1 equivalent) in anhydrous heptane (0.333 M, 
based on 7), and the reaction vessel was sealed, removed from the glovebox, and heated at 130 
°C for 3 h. After cooling to room temperature, the reaction mixture was purified directly by a 
combination of column chromatography and/or preparative TLC (as described below for each 
compound). Note: For substrates that are insoluble in heptane, the catalyst solution is instead 
added into the heterogeneous mixture of the substrate and heptane. 
 rac-16-Oxaibogamine (1a). For preparation of 1a see Chapter 2. 
 rac-16-Oxa-4-epi-ibogamine (1b). For preparation of 1b see Chapter 2. 
 rac-12-Methoxy-16-oxaibogamine (8a). Prepared according to the general procedure. 
The crude reaction mixture was purified directly by column chromatography (30:1 
hexanes:EtOAc + 1% Et3N) to yield the crude product as a pale-yellow oil. This material was 
further purified by preparative TLC (30:1 hexanes:EtOAc + 1% Et3N) to provide the pure 
product 8a as a pale-brown oil (118 mg, 76%). 
1
H NMR (500 MHz, CDCl3) δ 7.24 (d, J = 8.8 
Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.81 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 (s, 3H), 3.46 – 3.36 (m, 
1H), 3.25 – 3.11 (m, 3H), 3.02 – 2.91 (m, 2H), 2.80 (s, 1H), 2.52 – 2.42 (m, 1H), 2.08 – 1.99 (m, 
1H), 1.88 – 1.76 (m, 2H), 1.64 (ddd, J = 13.1, 6.4, 3.2 Hz, 1H), 1.59 – 1.42 (m, 3H), 1.24 – 1.16 
(m, 1H), 0.91 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.1, 155.8, 148.6, 131.4, 
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111.8, 111.4, 111.0, 101.9, 57.2, 56.2, 53.3, 49.8, 41.5, 41.2, 33.1, 32.3, 27.5, 26.5, 19.5, 11.9; 




 312.20, found 312.52. 
 rac-12-Methoxy-16-oxa-4-epi-ibogamine (8b). Prepared according to the general 
procedure. The crude reaction mixture was purified directly by column chromatography (9:1 
hexanes:EtOAc + 2% Et3N, 4 column volumes → 8:2 hexanes:EtOAc + 2% Et3N, 3 column 
volumes) to yield the crude product as a yellow-orange oil. This material was further purified by 
preparative TLC (Et2O + 1% Et3N) to provide the pure product 8b as a nearly colorless oil that 
slowly crystallized to a white solid (27.0 mg, 28%). 
1
H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 
8.8 Hz, 1H), 6.87 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 (s, 3H), 3.43 (ddd, J = 
13.6, 4.6, 2.2 Hz, 1H), 3.36 – 3.17 (m, 3H), 3.11 – 3.02 (m, 2H), 2.86 (s, 1H), 2.46 (dt, J = 16.4, 
2.9 Hz, 1H), 2.08 – 1.91 (m, 3H), 1.91 – 1.85 (m, 1H), 1.65 – 1.57 (m, 1H), 1.45 – 1.33 (m, 2H), 
1.17 – 1.07 (m, 1H), 0.93 (t, J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 161.7, 155.9, 
148.4, 131.3, 112.3, 111.5, 111.1, 101.8, 56.5, 56.2, 53.5, 49.1, 42.0, 34.5, 34.2, 31.7, 28.5, 26.4, 




 312.20, found 312.63. 
 exo-2-Methoxy-7-propyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-
d]pyrido[1,2-a]azepine (8c). Prepared according to the general procedure. The crude reaction 
mixture was purified directly by column chromatography (30:1 hexanes:EtOAc + 1% Et3N) to 
yield the crude product as a pale-yellow oil. This material was further purified by preparative 
TLC (20:1 hexanes:EtOAc + 2% Et3N) to provide the pure product 8c as a nearly colorless oil 
that slowly crystallized to a white solid (82.6 mg, 67%). 
1
H NMR (500 MHz, CDCl3) δ 7.24 (d, 
J = 8.8 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 (s, 3H), 3.47 – 3.37 
(m, 1H), 3.24 – 3.11 (m, 3H), 3.00 – 2.91 (m, 2H), 2.76 (s, 1H), 2.52 – 2.43 (m, 1H), 2.08 – 1.99 
(m, 1H), 1.87 – 1.82 (m, 1H), 1.82 – 1.75 (m, 1H), 1.69 – 1.59 (m, 2H), 1.55 – 1.38 (m, 2H), 
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1.37 – 1.28 (m, 2H), 1.23 – 1.17 (m, 1H), 0.92 (t, J = 7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) 
δ 161.0, 155.8, 148.6, 131.4, 111.8, 111.4, 111.0, 101.8, 57.8, 56.2, 53.3, 49.7, 41.2, 39.3, 37.1, 




 326.21, found 326.59. 
 endo-2-Methoxy-7-propyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-
d]pyrido[1,2-a]azepine (8d). Prepared according to the general procedure. The crude reaction 
mixture was purified directly by column chromatography (9:1 hexanes:EtOAc + 2% Et3N, 3 
column volumes → 8:2 hexanes:EtOAc + 2% Et3N, 3 column volumes) to yield the crude 
product as a yellow-brown oil. This material was further purified by preparative TLC (Et2O + 
1% Et3N) to provide the pure product 8d as a nearly colorless oil that slowly crystallized to a 
white solid (46.3 mg, 36%). 
1
H NMR (500 MHz, CDCl3) δ 7.24 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 
2.5 Hz, 1H), 6.80 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 (s, 3H), 3.42 (ddd, J = 13.9, 4.6, 2.2 Hz, 1H), 
3.36 – 3.26 (m, 2H), 3.22 (ddd, J = 17.0, 12.3, 4.7 Hz, 1H), 3.10 – 3.01 (m, 2H), 2.83 (dd, J = 
2.9, 2.0 Hz, 1H), 2.49 – 2.42 (m, 1H), 2.11 – 2.00 (m, 2H), 2.00 – 1.93 (m, 1H), 1.90 – 1.85 (m, 
1H), 1.61 (ddd, J = 13.3, 6.7, 3.5 Hz, 1H), 1.42 – 1.27 (m, 4H), 1.16 – 1.08 (m, 1H), 0.93 (t, J = 
5.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.7, 155.8, 148.3, 131.3, 112.3, 111.5, 111.1, 





 326.21, found 326.66. 
 exo-2-Methoxy-7-phenyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-
d]pyrido[1,2-a]azepine (8e). Prepared according to the general procedure. The crude reaction 
mixture was purified directly by column chromatography (30:1 hexanes:EtOAc + 1% Et3N) to 
yield the crude product as a nearly colorless oil. This material was further purified by repeated 
preparative TLC (Plate 1: 30:1 hexanes:EtOAc + 1% Et3N; Plate 2: 20:1 hexanes:EtOAc + 2% 
Et3N) to provide the pure product 8e as a nearly colorless glass (14.5 mg, 54%). 
1
H NMR (500 
 211 
MHz, CDCl3) δ 7.46 (d, J = 7.3 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.26 (d, J = 8.8 Hz, 1H), 7.22 
(t, J = 7.3 Hz, 1H), 6.87 (d, J = 2.5 Hz, 1H), 6.82 (dd, J = 8.8, 2.5 Hz, 1H), 3.85 (s, 3H), 3.44 – 
3.36 (m, 2H), 3.26 – 3.16 (m, 1H), 3.15 – 3.07 (m, 4H), 2.92 (dd, J = 10.2, 8.1 Hz, 1H), 2.55 – 
2.48 (m, 1H), 2.21 – 2.08 (m, 2H), 2.02 (d, J = 1.7 Hz, 1H), 1.84 – 1.74 (m, 2H); 
13
C NMR (126 
MHz, CDCl3) δ 160.2, 155.8, 148.7, 146.8, 131.4, 128.2, 128.0, 126.1, 111.8, 111.6, 111.0, 





 360.20, found 359.58. 
 endo-2-Methoxy-7-phenyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-
d]pyrido[1,2-a]azepine (8f). Prepared according to the general procedure. The crude reaction 
mixture was purified directly by column chromatography (7:3 hexanes:EtOAc + 2% Et3N, 4 
column volumes → 1:1 hexanes:EtOAc + 2% Et3N, 5 column volumes) to yield the impure 
product 8f as a yellow oil (11.9 mg, <10%) that was used in the next step without further 




 360.20, found 359.87. 
 exo-7-Benzyl-2-methoxy-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-
d]pyrido[1,2-a]azepine (8g). Prepared according to the general procedure. The crude reaction 
mixture was purified directly by column chromatography (30:1 hexanes:EtOAc + 1% Et3N) to 
yield the crude product as a yellow-orange oil. This material was further purified by preparative 
TLC (30:1 hexanes:EtOAc + 2% Et3N) to provide the pure product 8g as a nearly colorless glass 
(26.0 mg, 62%). 
1
H NMR (500 MHz, CDCl3) δ 7.26 (t, J = 7.4 Hz, 2H), 7.22 – 7.18 (m, 3H), 
7.16 (t, J = 7.2 Hz, 1H), 6.85 (d, J = 2.5 Hz, 1H), 6.79 (dd, J = 8.8, 2.6 Hz, 1H), 3.84 (s, 3H), 
3.52 – 3.42 (m, 1H), 3.26 – 3.12 (m, 2H), 3.08 – 3.00 (m, 3H), 2.86 (dd, J = 13.3, 9.2 Hz, 1H), 
2.75 (dd, J = 13.3, 6.0 Hz, 1H), 2.70 (s, 1H), 2.52 – 2.42 (m, 1H), 2.07 – 1.93 (m, 2H), 1.88 (s, 




C NMR (126 MHz, CDCl3) δ 160.9, 155.8, 148.5, 141.64, 131.4, 129.3, 128.3, 125.8, 





 374.21, found 374.70. 
 2-Methoxy-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-d]pyrido[1,2-
a]azepine (8h). Prepared according to the general procedure. The crude reaction mixture was 
purified directly by column chromatography (8:2 hexanes:EtOAc + 2% Et3N, 3 column volumes 
→ 7:3 hexanes:EtOAc + 2% Et3N, 3 column volumes) to yield the pure product 8h as a brown 
oil that slowly crystallized to a pale-brown solid (101 mg, 71%). 
1
H NMR (500 MHz, CDCl3) δ 
7.24 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.8, 2.6 Hz, 1H), 3.84 (s, 3H), 
3.43 – 3.38 (m, 1H), 3.31 – 3.16 (m, 3H), 3.11 – 3.04 (m, 2H), 3.04 – 3.00 (m, 1H), 2.51 – 2.44 
(m, 1H), 2.15 – 2.07 (m, 1H), 2.06 – 1.99 (m, 1H), 1.88 (s, 1H), 1.81 – 1.73 (m, 1H), 1.73 – 1.60 
(m, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.1, 155.8, 148.5, 131.3, 111.9, 111.5, 111.0, 101.8, 





284.16, found 284.51. 
 rac-12-Fluoro-16-oxaibogamine (8i). Prepared according to the general procedure. The 
crude reaction mixture was purified directly by column chromatography (80:1 hexanes:EtOAc + 
2% Et3N) to yield the crude product as a pale-yellow oil. This material was further purified by 
preparative TLC (80:1 hexanes:EtOAc + 2% Et3N) to provide the pure product 8i as a very pale-
pink oil that slowly crystallized to a white solid (22.7 mg, 73%). 
1
H NMR (400 MHz, CDCl3) 
(spectrum complicated by F-H coupling) δ 7.26 (dd, J = 8.7, 4.2 Hz, 1H), 7.04 (dd, J = 8.7, 2.6 
Hz, 1H), 6.90 (td, J = 9.1, 2.6 Hz, 1H), 3.46 – 3.35 (m, 1H), 3.25 – 3.10 (m, 3H), 2.99 – 2.91 (m, 
2H), 2.80 (d, J = 1.6 Hz, 1H), 2.49 – 2.38 (m, 1H), 2.09 – 1.99 (m, 1H), 1.89 – 1.75 (m, 2H), 




NMR (101 MHz, CDCl3) (spectrum complicated by F-C coupling) δ 162.0, 160.4 and 158.0, 
149.8, 131.8 and 131.7, 112.04 and 112.01, 111.1 and 111.0, 110.7 and 110.5, 104.6 and 104.3, 





 300.18, found 300.37. 
 rac-13-Methoxy-16-oxaibogamine (8j). Prepared according to the general procedure. 
The crude reaction mixture was purified directly by column chromatography (30:1 
hexanes:EtOAc + 1% Et3N) to yield the crude product as a yellow oil. This material was further 
purified by preparative TLC (30:1 hexanes:EtOAc + 1% Et3N) to provide the pure product 8j as 
a nearly colorless oil (54.7 mg, 59%). 
1
H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 1H), 
6.93 (d, J = 2.2 Hz, 1H), 6.83 (dd, J = 8.5, 2.2 Hz, 1H), 3.84 (s, 3H), 3.44 – 3.36 (m, 1H), 3.23 – 
3.11 (m, 3H), 2.97 (d, J = 8.9 Hz, 1H), 2.93 (dt, J = 8.9, 3.2 Hz, 1H), 2.79 (d, J = 1.8 Hz, 1H), 
2.53 – 2.44 (m, 1H), 2.02 (tt, J = 11.6, 2.3 Hz, 1H), 1.87 – 1.75 (m, 2H), 1.66 – 1.61 (m, 1H), 
1.59 – 1.42 (m, 3H), 1.19 (ddt, J = 12.7, 6.6, 2.3 Hz, 1H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(126 MHz, CDCl3) δ 159.1, 157.5, 154.6, 124.3, 118.8, 111.3, 110.6, 95.8, 57.4, 55.9, 53.3, 





312.20, found 312.57 
 rac-14-Methoxy-16-oxaibogamine (8k). Prepared according to the general procedure. 
The crude reaction mixture was purified directly by column chromatography (30:1 
hexanes:EtOAc + 1% Et3N) to yield the crude product as a pale-green oil. This material was 
further purified by preparative TLC (20:1 hexanes:EtOAc + 2% Et3N) to provide the pure 
product 8k as a nearly colorless oil (33.7 mg, 68%). 
1
H NMR (500 MHz, CDCl3) δ 7.12 (t, J = 
7.8 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 6.75 (d, J = 7.9 Hz, 1H), 4.00 (s, 3H), 3.41 (dd, J = 14.7, 
4.3 Hz, 1H), 3.27 – 3.11 (m, 3H), 2.98 (d, J = 9.0 Hz, 1H), 2.93 (dt, J = 8.9, 3.0 Hz, 1H), 2.79 (s, 
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1H), 2.50 (dd, J = 17.3, 3.0 Hz, 1H), 2.08 – 1.99 (m, 1H), 1.87 – 1.75 (m, 2H), 1.65 (dd, J = 
13.3, 3.1 Hz, 1H), 1.58 – 1.41 (m, 3H), 1.22 – 1.14 (m, 1H), 0.90 (t, J = 7.1 Hz, 3H); 
13
C NMR 
(126 MHz, CDCl3) δ 160.2, 144.9, 142.6, 132.5, 122.8, 112.1, 111.2, 105.5, 57.4, 56.1, 53.3, 





312.20, found 312.03. 
 rac-11-Methoxy-16-oxaibogamine (8l). Prepared according to the general procedure. 
The crude reaction mixture was purified directly by column chromatography (30:1 
hexanes:EtOAc + 1% Et3N) to yield the crude product as a pale-yellow oil. This material was 
further purified by preparative TLC (20:1 hexanes:EtOAc + 2% Et3N) to provide the pure 
product 8l as a cloudy, very pale-green oil (29.4 mg, 63%).  
1
H NMR (500 MHz, CDCl3) δ 7.10 
(t, J = 8.1 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 3.88 (s, 3H), 3.39 – 3.29 
(m, 2H), 3.19 – 3.03 (m, 3H), 2.98 (d, J = 9.1 Hz, 1H), 2.93 (dt, J = 9.1, 3.0 Hz, 1H), 2.79 (s, 
1H), 2.08 – 1.99 (m, 1H), 1.87 – 1.75 (m, 2H), 1.64 (ddd, J = 13.3, 6.3, 3.2 Hz, 1H), 1.58 – 1.50 
(m, 2H), 1.50 – 1.42 (m, 1H), 1.22 – 1.16 (m, 1H), 0.91 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 
MHz, CDCl3) δ 158.6, 155.1, 154.9, 123.9, 119.7, 112.2, 104.2, 103.1, 57.0, 55.5, 53.9, 49.8, 






 rac-13-Fluoro-12-methoxy-16-oxaibogamine (8m). Prepared according to the general 
procedure. The crude reaction mixture was purified directly by column chromatography (20:1 
hexanes:EtOAc + 2% Et3N) to yield the pure product 8m as a yellow oil that slowly crystallized 
to a pale-yellow solid (42.0 mg, 75%). 
1
H NMR (500 MHz, CDCl3) (spectrum complicated by 
F-H coupling) δ 7.12 (d, J = 10.7 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 3.92 (s, 3H), 3.45 – 3.36 (m, 
1H), 3.24 – 3.11 (m, 3H), 2.99 – 2.91 (m, 2H), 2.78 (d, J = 1.4 Hz, 1H), 2.49 – 2.40 (m, 1H), 
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2.06 – 1.98 (m, 1H), 1.88 – 1.75 (m, 2H), 1.62 (ddd, J = 13.2, 6.4, 3.1 Hz, 1H), 1.59 – 1.42 (m, 
3H), 1.19 (ddt, J = 12.7, 6.4, 2.3 Hz, 1H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) 
(spectrum complicated by F-C coupling) δ 160.93 and 160.90, 151.7 and 149.7, 147.0 and 146.9, 
144.6 and 144.5, 126.1 and 126.0, 111.57 and 111.56, 102.46 and 102.45, 99.5 and 99.3, 57.24, 





 330.19, found 329.98. 
 rac-12-Methoxy-13-methyl-16-oxaibogamine (8n). Prepared according to the general 
procedure. The crude reaction mixture was purified directly by column chromatography (20:1 
hexanes:EtOAc + 2% Et3N) to yield the crude product as a pale-yellow oil. This material was 
further purified by preparative TLC (20:1 hexanes:EtOAc + 2% Et3N) to provide the pure 
product 8n as a very pale-brown oil (20.1 mg, 70%). 
1
H NMR (500 MHz, CDCl3) δ 7.13 (s, 
1H), 6.78 (s, 1H), 3.86 (s, 3H), 3.46 – 3.34 (m, 1H), 3.25 – 3.09 (m, 3H), 2.98 (d, J = 9.0 Hz, 
1H), 2.93 (dt, J = 8.9, 3.1 Hz, 1H), 2.79 (s, 1H), 2.55 – 2.41 (m, 1H), 2.30 (s, 3H), 2.06 – 1.97 
(m, 1H), 1.86 – 1.75 (m, 2H), 1.62 (ddd, J = 13.2, 6.3, 3.1 Hz, 1H), 1.56 – 1.42 (m, 3H), 1.22 – 
1.15 (m, 1H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 159.7, 154.2, 148.2, 
128.8, 123.0, 112.2, 111.7, 99.4, 57.3, 56.1, 53.4, 49.7, 41.5, 41.1, 33.1, 32.3, 27.5, 26.5, 19.6, 




 326.21, found 326.52. 
 rac-12-Methoxy-7-α-endo-methyl-16-oxaibogamine (α-endo-8o). The product α-endo-
8o was prepared according to the general procedure, starting from the mixed diastereomers 7o, 
and obtained as a mixture with the α-exo-epimer, α-exo-8o. It was separated by column 
chromatography (40:1 hexanes:EtOAc + 1% Et3N, 3 column volumes → 20:1 hexanes:EtOAc + 
2% Et3N, 2 column volumes) to provide a very pale-brown oil (72.4 mg, 64%, 76% based on 
quantity of α-endo in starting material). 
1
H NMR (500 MHz, CDCl3) δ 7.23 (d, J = 8.8 Hz, 1H), 
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6.86 (d, J = 2.6 Hz, 1H), 6.80 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 (s, 3H), 3.30 – 3.22 (m, 1H), 3.12 
(dt, J = 11.5, 2.5 Hz, 1H), 2.98 – 2.88 (m, 2H), 2.83 (d, J = 8.7 Hz, 1H), 2.77 (d, J = 1.8 Hz, 1H), 
2.54 (dd, J = 16.7, 4.1 Hz, 1H), 2.02 (tt, J = 7.5, 2.2 Hz, 1H), 1.86 – 1.81 (br m, 1H), 1.81 – 1.74 
(m, 1H), 1.62 (ddd, J = 13.3, 6.5, 3.0 Hz, 1H), 1.59 – 1.44 (m, 3H), 1.23 (d, J = 6.7 Hz, 3H), 1.20 
– 1.13 (m, 1H), 0.90 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.0, 155.8, 148.4, 
131.5, 111.5, 110.92, 110.86, 101.8, 58.7, 58.3, 56.15, 46.2, 41.4, 40.8, 33.8, 32.7, 27.5, 26.5, 




 326.21, found 326.64. 
 rac-12-Methoxy-7-α-exo-methyl-16-oxaibogamine (α-exo-8o). The product α-exo-8o 
was prepared according to the general procedure, starting from the mixed diastereomers 7o, and 
obtained as a mixture with the α-endo-epimer, α-endo-8o. It was separated by column 
chromatography (40:1 hexanes:EtOAc + 1% Et3N, 3 column volumes → 20:1 hexanes:EtOAc + 
2% Et3N, 2 column volumes) followed by preparative TLC (20:1 hexanes:EtOAc + 2% Et3N) to 
provide a very pale-yellow oil containing minor impurities (6.7 mg, 6%, 38% based on quantity 
of α-exo in starting material). 
1
H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 1H), 6.86 (d, J 
= 2.5 Hz, 1H), 6.79 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 (s, 3H), 3.21 – 3.15 (m, 2H), 3.15 – 3.11 (m, 
1H), 3.09 (dt, J = 8.7, 3.1 Hz, 1H), 3.03 (dd, J = 16.0, 5.5 Hz, 1H), 2.87 (dt, J = 8.6, 1.7 Hz, 1H), 
2.53 (ddd, J = 16.0, 7.2, 0.9 Hz, 1H), 2.03 – 1.96 (m, 1H), 1.85 – 1.74 (m, 3H), 1.60 – 1.50 (m, 
2H), 1.49 – 1.41 (m, 1H), 1.21 – 1.14 (m, 1H), 1.17 (d, J = 6.7 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 160.1, 155.8, 149.0, 131.2, 111.2, 111.0, 110.6, 101.7, 56.7, 





 326.21, found 326.67. 
 rac-12-Methoxy-7-α-endo-methyl-16-oxa-4-epi-ibogamine (α-endo-8p). The product 
α-endo-8p was prepared according to the general procedure, starting from the mixed 
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diastereomers 7p, and obtained as a mixture with the α-exo-epimer, α-exo-8p. It was separated 
by column chromatography (30:1 hexanes:EtOAc + 2% Et3N, 4 column volumes → 9:1 
hexanes:EtOAc + 2% Et3N, 4 column volumes → 7:3 hexanes:EtOAc + 2% Et3N, 1 column 
volume) followed by preparative TLC (9:1 hexanes:EtOAc + 2% Et3N) to provide a yellow oil 
(58.9 mg, 44%, 81% based on quantity of α-endo in starting material). 
1
H NMR (500 MHz, 
CDCl3) δ 7.23 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.8, 2.6 Hz, 1H), 3.85 
(s, 3H), 3.46 – 3.37 (m, 1H), 3.26 (ddd, J = 11.7, 3.6, 1.9 Hz, 1H), 3.04 – 2.96 (m, 2H), 2.93 (d, J 
= 9.2 Hz, 1H), 2.83 (s, 1H), 2.49 (dd, J = 16.6, 3.6 Hz, 1H), 2.06 – 1.92 (m, 3H), 1.86 (s, 1H), 
1.62 – 1.55 (m, 1H), 1.44 – 1.30 (m, 2H), 1.27 (d, J = 6.7 Hz, 3H), 1.15 – 1.07 (m, 1H), 0.93 (t, J 
= 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.8, 155.8, 148.2, 131.4, 111.5, 111.3, 111.0, 





 326.21, found 326.06. 
 rac-12-Methoxy-7-α-exo-methyl-16-oxa-4-epi-ibogamine (α-exo-8p). The product α-
exo-8p was prepared according to the general procedure, starting from the mixed diastereomers 
7p, and obtained as a mixture with the α-endo-epimer, α-endo-8p. It was separated by column 
chromatography (30:1 hexanes:EtOAc + 2% Et3N, 4 column volumes → 9:1 hexanes:EtOAc + 
2% Et3N, 4 column volumes → 7:3 hexanes:EtOAc + 2% Et3N, 1 column volume) followed by 
preparative TLC (9:1 hexanes:EtOAc + 2% Et3N) to provide a yellow oil containing significant 
impurities, which was used in the next step without further purification (25.7 mg, <19%, <41% 
based on quantity of α-exo in starting material). 
1
H NMR (500 MHz, CDCl3) (peak list excludes 
impurity peaks) δ 7.25 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.8, 2.5 Hz, 
1H), 3.85 (s, 3H), 3.27 (dt, J = 10.2, 2.2 Hz, 1H), 3.25 – 3.15 (m, 3H), 3.00 (dd, J = 16.2, 3.8 Hz, 
1H), 2.87 – 2.82 (m, 1H), 2.56 (dd, J = 16.2, 7.2 Hz, 1H), 2.07 (ddd, J = 14.3, 5.8, 2.9 Hz, 1H), 
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2.00 – 1.87 (m, 2H), 1.86 – 1.80 (m, 1H), 1.67 – 1.59 (m, 1H), 1.46 – 1.31 (m, 2H), 1.24 (d, J = 





 326.21, found 326.30. 
 General Procedure for Preparation of Phenolic Oxaibogamine Analogs by 
Demethylation (9). To a solution of the methoxyoxaibogamine 8a-p (1 equivalent) in dry 
dichloromethane (0.125 M, based on 8) at 0 °C was added aluminum chloride (6 equivalents) 
followed by ethanethiol (18 equivalents), and the resulting mixture was allowed to warm to room 
temperature and stirred until TLC indicated the complete consumption of starting material 
(typically <1.5 h). The reaction was then quenched with saturated aqueous NaHCO3 (100 mL per 
mmol of 8) and extracted with CH2Cl2 (4x-6x, until no further extraction by TLC). The 
combined organic layers were dried over Na2SO4 and concentrated to provide the crude product. 
This material was purified by column chromatography with an appropriate solvent mixture (as 
described below for each compound). 
 rac-12-Hydroxy-16-oxaibogamine (9a). The product 9a was prepared according to the 
general procedure and purified by column chromatography (1:1 hexanes:EtOAc) to provide a 
white, foamy solid (24.3 mg, 82%).  
1
H NMR (500 MHz, CDCl3) δ 7.19 (d, J = 8.6 Hz, 1H), 
6.80 (d, J = 2.5 Hz, 1H), 6.70 (dd, J = 8.6, 2.5 Hz, 1H), 4.71 (br s, 1H), 3.44 – 3.34 (m, 1H), 3.20 
– 3.10 (m, 3H), 2.99 – 2.91 (m, 2H), 2.81 (s, 1H), 2.48 – 2.37 (m, 1H), 2.08 – 2.00 (m, 1H), 1.88 
– 1.77 (m, 2H), 1.64 (ddd, J = 13.2, 6.3, 3.1 Hz, 1H), 1.59 – 1.43 (m, 3H), 1.21 (ddd, J = 10.5, 
4.8, 2.2 Hz, 1H), 0.91 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.1, 151.4, 148.6, 
131.8, 111.64, 111.55, 110.9, 104.2, 57.3, 53.3, 49.6, 41.6, 41.1, 33.0, 32.2, 27.5, 26.4, 19.4, 




 298.18, found 298.51.  
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 rac-12-Hydroxy-16-oxa-4-epi-ibogamine (9b). The product 9b was prepared according 
to the general procedure and purified by column chromatography (20:1 CH2Cl2:MeOH, 4 
column volumes → 20:1 acetone:MeOH, 4 column volumes) to provide a white, foamy solid 
(13.7 mg, 92%). 
1
H NMR (500 MHz, CDCl3) δ 7.19 (d, J = 8.7 Hz, 1H), 6.79 (d, J = 2.4 Hz, 
1H), 6.71 (dd, J = 8.7, 2.5 Hz, 1H), 5.62 (br s, 1H), 3.40 (ddd, J = 14.2, 4.6, 2.4 Hz, 1H), 3.34 – 
3.26 (m, 2H), 3.20 – 3.08 (m, 2H), 3.02 (d, J = 9.8 Hz, 1H), 2.91 (s, 1H), 2.43 (dt, J = 16.6, 2.9 
Hz, 1H), 2.08 – 1.95 (m, 3H), 1.90 (s, 1H), 1.65 – 1.58 (m, 1H), 1.44 – 1.33 (m, 2H), 1.15 – 1.09 
(m, 1H), 0.92 (t, J = 7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.5, 152.1, 148.2, 131.4, 
112.11, 112.07, 111.0, 104.2, 56.5, 53.6, 49.0, 41.2, 34.0, 33.9, 31.4, 28.4, 26.1, 18.8, 12.3; LR-




 298.18, found 298.56. 
 exo-7-Propyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-d]pyrido[1,2-
a]azepin-2-ol (9c). The product 9c was prepared according to the general procedure and purified 
by column chromatography (7:3 hexanes:EtOAc) to provide a very pale-pink, foamy solid (27.8 
mg, 89%). 
1
H NMR (500 MHz, CDCl3) δ 7.19 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 2.5 Hz, 1H), 
6.70 (dd, J = 8.6, 2.6 Hz, 1H), 4.63 (br s, 1H), 3.45 – 3.34 (m, 1H), 3.20 – 3.10 (m, 3H), 2.99 – 
2.91 (m, 2H), 2.77 (s, 1H), 2.48 – 2.37 (m, 1H), 2.03 (dd, J = 13.3, 11.9 Hz, 1H), 1.85 (s, 1H), 
1.83 – 1.75 (m, 1H), 1.69 – 1.60 (m, 2H), 1.55 – 1.38 (m, 2H), 1.37 – 1.28 (m, 2H), 1.24 – 1.17 
(m, 1H), 0.91 (t, J = 7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.1, 151.4, 148.6, 131.8, 
111.58, 111.53, 110.9, 104.2, 57.8, 53.3, 49.6, 41.1, 39.3, 37.1, 32.9, 32.3, 26.4, 20.4, 19.4, 14.5; 




 312.20, found 312.56. 
 endo-7-Propyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-
d]pyrido[1,2-a]azepin-2-ol (9d). The product 9d was prepared according to the general 
procedure and purified by column chromatography (20:1 CH2Cl2:MeOH, 4 column volumes → 
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20:1 acetone:MeOH, 4 column volumes) to provide a white foamy solid (24.3 mg, 78%). 
1
H 
NMR (500 MHz, CDCl3) δ 7.19 (d, J = 8.7 Hz, 1H), 6.79 (d, J = 2.5 Hz, 1H), 6.71 (dd, J = 8.7, 
2.5 Hz, 1H), 5.44 (br s, 1H), 3.39 (ddd, J = 14.1, 4.6, 2.5 Hz, 1H), 3.34 – 3.26 (m, 2H), 3.20 – 
3.07 (m, 2H), 3.02 (d, J = 9.8 Hz, 1H), 2.88 (dd, J = 2.7, 1.9 Hz, 1H), 2.43 (dt, J = 16.6, 3.0 Hz, 
1H), 2.18 – 2.11 (m, 1H), 2.09 – 2.02 (m, 1H), 1.99 (ddd, J = 13.6, 5.7, 2.9 Hz, 1H), 1.92 – 1.87 
(m, 1H), 1.62 (ddd, J = 13.2, 6.7, 3.3 Hz, 1H), 1.40 – 1.25 (m, 4H), 1.16 – 1.08 (m, 1H), 0.94 – 
0.87 (m, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.5, 152.2, 148.2, 131.4, 112.2, 112.1, 111.0, 





 312.20, found 312.59. 
 exo-7-Phenyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-d]pyrido[1,2-
a]azepin-2-ol (9e). The product 9e was prepared according to the general procedure and purified 
by column chromatography (8:2 hexanes:EtOAc, 2 column volumes → 7:3 hexanes:EtOAc, 4 
column volumes) to provide a white, foamy solid (7.8 mg, 68%). 
1
H NMR (400 MHz, CDCl3) δ 
7.45 (d, J = 7.3 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.24 – 7.19 (m, 2H), 6.80 (d, J = 2.5 Hz, 1H), 
6.71 (dd, J = 8.6, 2.6 Hz, 1H), 4.61 (br s, 1H), 3.43 – 3.34 (m, 2H), 3.23 – 3.04 (m, 5H), 2.95 – 
2.88 (m, 1H), 2.49 – 2.41 (m, 1H), 2.20 – 2.07 (m, 2H), 2.04 – 1.99 (m, 1H), 1.84 – 1.73 (m, 
2H); 
13
C NMR (101 MHz, CDCl3) δ 160.4, 151.3, 148.8, 146.7, 131.8, 128.2, 127.9, 126.1, 





 346.18, found 345.81. 
 endo-7-Phenyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-
d]pyrido[1,2-a]azepin-2-ol (9f). The product 9f was prepared according to the general 
procedure and purified by column chromatography (20:1 acetone:MeOH) to provide an off-




NMR (500 MHz, CDCl3) δ 7.38 – 7.33 (m, 4H), 7.25 – 7.20 (m, 1H), 7.11 (d, J = 8.7 Hz, 1H), 
6.79 (d, J = 2.5 Hz, 1H), 6.67 (dd, J = 8.7, 2.5 Hz, 1H), 3.59 (br s, 1H), 3.48 (ddd, J = 14.3, 4.8, 
2.5 Hz, 1H), 3.44 – 3.35 (m, 1H), 3.27 – 3.06 (m, 5H), 2.45 (d, J = 16.6 Hz, 1H), 2.28 – 2.14 (m, 





 346.18, found 345.60. 
 exo-7-Benzyl-6,6a,7,8,9,10,12,13-octahydro-6,9-methanobenzofuro[2,3-d]pyrido[1,2-
a]azepin-2-ol (9g). The product 9g was prepared according to the general procedure and purified 
by column chromatography (7:3 hexanes:EtOAc) to provide a white, foamy solid (14.2 mg, 
79%). 
1
H NMR (400 MHz, CDCl3) δ 7.29 – 7.24 (m, 2H), 7.22 – 7.14 (m, 4H), 6.78 (d, J = 2.5 
Hz, 1H), 6.68 (dd, J = 8.6, 2.6 Hz, 1H), 4.83 (br s, 1H), 3.52 – 3.38 (m, 1H), 3.23 – 3.10 (m, 2H), 
3.07 – 2.98 (m, 3H), 2.86 (dd, J = 13.3, 9.1 Hz, 1H), 2.78 – 2.67 (m, 2H), 2.48 – 2.35 (m, 1H), 
2.06 – 1.92 (m, 2H), 1.88 (s, 1H), 1.86 – 1.77 (m, 1H), 1.63 (ddd, J = 13.2, 6.4, 3.2 Hz, 1H), 1.36 
– 1.28 (m, 1H); 
13
C NMR (101 MHz, CDCl3) δ 161.0, 151.3, 148.5, 141.6, 131.7, 129.3, 128.3, 
125.8, 111.6, 111.5, 110.9, 104.1, 55.7, 53.0, 49.7, 41.5, 40.8, 40.6, 33.0, 32.4, 26.5, 19.4; LR-




 360.20, found 360.69. 
 6,6a,7,8,9,10,12,13-Octahydro-6,9-methanobenzofuro[2,3-d]pyrido[1,2-a]azepin-2-ol 
(9h). Prepared according to the general procedure. The poorly soluble crude product was 
triturated with a small quantity of MeOH and the supernatant carefully removed by pipet. This 
washing procedure was repeated once more and the resulting solids were dried in vacuo to 
provide the pure product 9h as a white solid (16.7 mg, 62%). 
1
H NMR (500 MHz, CDCl3 + 
several drops methanol-d4) δ 7.05 (d, J = 8.7 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 6.61 (dd, J = 
8.7, 2.4 Hz, 1H), 3.82 (br s, 1H), 3.28 – 3.19 (m, 1H), 3.14 – 2.98 (m, 3H), 2.96 – 2.86 (m, 3H), 
2.38 (d, J = 16.6 Hz, 1H), 2.07 – 1.88 (m, 2H), 1.78 (s, 1H), 1.69 – 1.51 (m, 4H); 
13
C NMR (126 
 222 
MHz, CDCl3 + several drops methanol-d4) δ 160.2, 152.3, 147.9, 131.1, 111.7, 111.3, 110.6, 





270.15, found 270.51. 
 rac-13-Hydroxy-16-oxaibogamine (9j). The product 9j was prepared according to the 
general procedure and purified by column chromatography (1:1 hexanes:EtOAc) to provide a 
pale-gray solid (25.7 mg, 86%). 
1
H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.3 Hz, 1H), 6.86 (d, 
J = 2.1 Hz, 1H), 6.73 (dd, J = 8.3, 2.2 Hz, 1H), 4.84 (br s, 1H), 3.46 – 3.34 (m, 1H), 3.22 – 3.10 
(m, 3H), 2.99 – 2.90 (m, 2H), 2.81 (d, J = 2.0 Hz, 1H), 2.55 – 2.41 (m, 1H), 2.02 (t, J = 12.3 Hz, 
1H), 1.90 – 1.76 (m, 2H), 1.63 (ddd, J = 13.2, 6.3, 2.9 Hz, 1H), 1.59 – 1.43 (m, 3H), 1.25 – 1.17 
(m, 1H), 0.90 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 158.8, 154.5, 153.3, 124.3, 





 298.18, found 298.59. 
 rac-14-Hydroxy-16-oxaibogamine (9k). The product 9k was prepared according to the 
general procedure and purified by column chromatography (7:3 hexanes:EtOAc, 2 column 
volumes → 1:1 hexanes:EtOAc, 3 column volumes) to provide an off-white, foamy solid (14.2 
mg, 64%). 
1
H NMR (500 MHz, CDCl3) δ 7.06 (t, J = 7.8 Hz, 1H), 6.96 (dd, J = 7.7, 1.0 Hz, 
1H), 6.75 (dd, J = 7.8, 1.0 Hz, 1H), 5.53 (br s, 1H), 3.46 – 3.37 (m, 1H), 3.25 – 3.13 (m, 3H), 
3.00 – 2.94 (m, 2H), 2.82 (d, J = 1.6 Hz, 1H), 2.55 – 2.46 (m, 1H), 2.07 – 1.99 (m, 1H), 1.86 (s, 
1H), 1.84 – 1.77 (m, 1H), 1.65 (ddd, J = 13.2, 6.5, 3.1 Hz, 1H), 1.59 – 1.45 (m, 3H), 1.25 – 1.19 
(m, 1H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 160.1, 141.8, 140.6, 132.6, 





 298.18, found 298.15. 
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 rac-11-Hydroxy-16-oxaibogamine (9l). The product 9l was prepared according to the 
general procedure and purified by column chromatography (1:1 hexanes:EtOAc, 4 column 
volumes → EtOAc, 2 column volumes) to provide a white, foamy solid (9.1 mg, 61%). 
1
H NMR 
(400 MHz, CDCl3) δ 7.00 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 7.6 Hz, 1H), 6.47 (d, J = 7.5 Hz, 1H), 
5.12 (br s, 1H), 3.45 – 3.32 (m, 2H), 3.23 – 3.12 (m, 2H), 3.07 – 2.91 (m, 3H), 2.81 (s, 1H), 2.09 
– 1.98 (m, 1H), 1.88 – 1.75 (m, 2H), 1.64 (ddd, J = 13.2, 6.3, 3.2 Hz, 1H), 1.60 – 1.42 (m, 3H), 
1.24 – 1.15 (m, 1H), 0.91 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 155.7, 150.5, 
123.9, 118.9, 111.6, 108.0, 104.0, 57.2, 53.8, 49.7, 41.5, 41.2, 33.2, 32.3, 27.5, 26.4, 20.8, 12.0; 




 298.18, found 298.32. 
 rac-13-Fluoro-12-hydroxy-16-oxaibogamine (9m). The product 9m was prepared 
according to the general procedure and purified by column chromatography (7:3 hexanes:EtOAc, 
2 column volumes → 1:1 hexanes:EtOAc, 4 column volumes) to provide a white, foamy solid 
(19.6 mg, 62%). 
1
H NMR (500 MHz, CDCl3) (spectrum complicated by F-H coupling) δ 7.11 
(d, J = 10.2 Hz, 1H), 6.94 (d, J = 8.6 Hz, 1H), 4.24 (br s, 1H), 3.44 – 3.33 (m, 1H), 3.21 – 3.09 
(m, 3H), 2.98 – 2.91 (m, 2H), 2.79 (d, J = 1.5 Hz, 1H), 2.46 – 2.37 (m, 1H), 2.02 (t, J = 12.4 Hz, 
1H), 1.85 (s, 1H), 1.79 (ddd, J = 8.1, 6.8, 3.5 Hz, 1H), 1.62 (ddd, J = 13.2, 6.4, 3.1 Hz, 1H), 1.58 
– 1.41 (m, 3H), 1.19 (ddt, J = 12.7, 6.4, 2.2 Hz, 1H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 
MHz, CDCl3) (spectrum complicated by F-C coupling) δ 161.13 and 161.09, 150.1 and 148.2, 
146.8 and 146.7, 140.10 and 140.0, 126.9, 111.4, 105.20 and 105.19, 98.5 and 98.3, 57.3, 53.2, 





316.17, found 315.99. 
 rac-12-Hydroxy-13-methyl-16-oxaibogamine (9n). The product 9n was prepared 
according to the general procedure and purified by column chromatography (1:1 hexanes:EtOAc, 
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2 column volumes → EtOAc, 3 column volumes) to provide a white, foamy solid (9.7 mg, 68%). 
1
H NMR (400 MHz, CDCl3) δ 7.10 (s, 1H), 6.75 (s, 1H), 4.61 (br s, 1H), 3.45 – 3.32 (m, 1H), 
3.21 – 3.07 (m, 3H), 3.00 – 2.89 (m, 2H), 2.79 (d, J = 1.6 Hz, 1H), 2.50 – 2.35 (m, 1H), 2.33 (s, 
3H), 2.07 – 1.96 (m, 1H), 1.87 – 1.75 (m, 2H), 1.62 (ddd, J = 13.3, 6.4, 3.1 Hz, 1H), 1.58 – 1.41 
(m, 3H), 1.23 – 1.14 (m, 1H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 160.2, 
149.7, 148.7, 129.5, 120.2, 112.0, 111.3, 103.7, 57.3, 53.3, 49.7, 41.5, 41.1, 33.1, 32.3, 27.5, 




 312.20, found 312.48. 
 rac-12-Hydroxy-7-α-endo-methyl-16-oxaibogamine (α-endo-9o). The product α-endo-
9o was prepared according to the general procedure and purified by column chromatography (8:2 
hexanes:EtOAc) to provide a white, foamy solid (22.6 mg, 73%). 
1
H NMR (400 MHz, CDCl3) δ 
7.19 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 2.5 Hz, 1H), 6.70 (dd, J = 8.6, 2.6 Hz, 1H), 4.64 (br s, 1H), 
3.30 – 3.18 (m, 1H), 3.11 (dt, J = 11.5, 2.6 Hz, 1H), 2.96 – 2.86 (m, 2H), 2.82 (d, J = 8.7 Hz, 
1H), 2.77 (d, J = 2.1 Hz, 1H), 2.48 (dd, J = 16.8, 4.1 Hz, 1H), 2.02 (ddd, J = 13.6, 4.5, 2.3 Hz, 
1H), 1.87 – 1.71 (m, 2H), 1.62 (ddd, J = 13.2, 6.6, 2.9 Hz, 1H), 1.58 – 1.43 (m, 3H), 1.22 (d, J = 
6.7 Hz, 3H), 1.20 – 1.13 (m, 1H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
161.3, 151.2, 148.5, 131.9, 111.4, 110.9, 110.7, 104.2, 58.7, 58.3, 46.2, 41.4, 40.8, 33.7, 32.7, 




 312.20, found 312.49. 
 rac-12-Hydroxy-7-α-exo-methyl-16-oxaibogamine (α-exo-9o). The product α-exo-9o 
was prepared according to the general procedure and purified by column chromatography (6:4 
hexanes:EtOAc, 4 column volumes → 1:1 hexanes:EtOAc, 2 column volumes) to provide a 
yellow glass (3.9 mg, 62%). 
1
H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 
2.5 Hz, 1H), 6.69 (dd, J = 8.6, 2.6 Hz, 1H), 4.52 (br s, 1H), 3.20 – 3.06 (m, 4H), 2.99 (dd, J = 
16.0, 5.5 Hz, 1H), 2.86 (d, J = 8.8 Hz, 1H), 2.49 (ddd, J = 16.0, 7.2, 1.0 Hz, 1H), 2.04 – 1.95 (m, 
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1H), 1.85 – 1.73 (m, 3H), 1.61 – 1.40 (m, 3H), 1.20 – 1.12 (m, 1H), 1.15 (d, J = 6.7 Hz, 3H), 
0.92 (t, J = 7.2 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 160.4, 151.2, 149.1, 131.7, 111.2, 





 312.20, found 312.47. 
 rac-12-Hydroxy-7-α-endo-methyl-16-oxa-4-epi-ibogamine (α-endo-9p). The product 
α-endo-9p was prepared according to the general procedure and purified by column 
chromatography (20:1 CH2Cl2:MeOH, 2 column volumes → 20:1 acetone:MeOH, 3 column 
volumes) to provide a white, foamy solid (24.4 mg, 78%). 
1
H NMR (500 MHz, CDCl3) δ 7.18 
(d, J = 8.6 Hz, 1H), 6.81 (d, J = 2.5 Hz, 1H), 6.71 (dd, J = 8.6, 2.4 Hz, 1H), 5.63 (br s, 1H), 3.44 
(br s, 1H), 3.26 (dd, J = 11.8, 2.0 Hz, 1H), 3.04 (br s, 1H), 2.99 – 2.86 (m, 3H), 2.45 (dd, J = 
16.7, 2.5 Hz, 1H), 2.15 – 1.96 (m, 3H), 1.89 (br s, 1H), 1.58 (ddd, J = 13.3, 6.4, 3.5 Hz, 1H), 
1.43 – 1.31 (m, 2H), 1.28 (d, J = 7.8 Hz, 3H), 1.11 (d, J = 13.2 Hz, 1H), 0.91 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 161.5, 151.7, 148.2, 131.6, 111.8, 111.0, 110.9, 104.1, 59.0, 





 312.20, found 312.16. 
 rac-12-Hydroxy-7-α-exo-methyl-16-oxa-4-epi-ibogamine (α-exo-9p). The product α-
exo-9p was prepared according to the general procedure and purified by column chromatography 
(20:1 acetone: MeOH) to provide a white, foamy solid (12.4 mg, 10% over 2 steps from 7p). 
1
H 
NMR (500 MHz, CDCl3) δ 7.20 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 2.5 Hz, 1H), 6.71 (dd, J = 8.7, 
2.5 Hz, 1H), 5.36 (br s, 1H), 3.32 (d, J = 8.5 Hz, 1H), 3.28 – 3.17 (m, 3H), 2.95 (dd, J = 16.4, 3.6 
Hz, 1H), 2.86 (d, J = 10.5 Hz, 1H), 2.56 (dd, J = 16.3, 6.9 Hz, 1H), 2.09 (t, J = 12.3 Hz, 1H), 
2.03 – 1.90 (m, 2H), 1.86 (br s, 1H), 1.67 – 1.59 (m, 1H), 1.44 – 1.30 (m, 2H), 1.26 (d, J = 5.7 
Hz, 3H), 1.12 – 1.03 (m, 1H), 0.92 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 160.8, 
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151.8, 148.7, 131.3, 111.9, 111.8, 111.1, 104.1, 60.6, 54.6, 50.2, 41.0, 33.5, 32.8, 31.6, 27.9, 




 312.20, found 312.18. 
 
Preparation of Other Heteroaryl Ibogamine Analogs 
 exo-1-Ethyl-10-methoxy-1,2,3,4,6,7,14,14a-octahydro-3,14-methanobenzo[4,5] 
imidazo[1,2-d]pyrido[2,1-g][1,4]diazepine (35). The product 35 was prepared according to the 
general Ni(0) cyclization procedure used to prepare the oxaibogamine analogs (8), and purified 
directly by column chromatography (1:1 CH2Cl2:Et2O, 4 column volumes → 1:1 CH2Cl2:Et2O + 
2% Et3N, 3 column volumes) to yield the crude product as a pale, reddish-brown glass (9.3 mg, 
48%). 
1
H NMR (500 MHz, CDCl3) δ 7.53 (d, J = 8.7 Hz, 1H), 6.84 (dd, J = 8.7, 2.3 Hz, 1H), 
6.74 (d, J = 2.1 Hz, 1H), 4.59 – 4.50 (m, 1H), 3.93 (d, J = 14.8 Hz, 1H), 3.86 (s, 3H), 3.41 – 3.33 
(m, 1H), 3.33 – 3.18 (m, 2H), 3.13 (d, J = 10.9 Hz, 1H), 3.04 (dt, J = 10.7, 2.7 Hz, 1H), 2.89 (d, 
J = 2.4 Hz, 1H), 2.23 – 2.14 (m, 1H), 1.94 (s, 1H), 1.91 – 1.82 (m, 1H), 1.80 – 1.69 (m, 2H), 
1.60 – 1.50 (m, 1H), 1.47 – 1.36 (m, 1H), 1.27 – 1.20 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 158.8, 156.4, 137.2, 136.8, 119.7, 110.5, 93.2, 56.1, 55.1, 54.7, 51.0, 
42.2, 41.9, 40.6, 31.5, 30.8, 28.9, 26.5, 12.1. HRMS (FAB+) m/z: [M+H]
+
 Calcd for C19H26N3O
+
 
312.2070; found 312.2048. 
 exo-1-Ethyl-1,2,3,4,6,7,14,14a-octahydro-3,14-methanobenzo[4,5]imidazo[1,2-
d]pyrido[2,1-g][1,4]diazepin-10-ol (36). The product 36 was prepared according to the general 
procedure used to prepare the phenolic oxaibogamine analogs (9), and purified by column 
chromatography (EtOAc, 2 column volumes → 9:1 EtOAc:acetone, 2 column volumes → 8:2 
EtOAc:acetone, 2 column volumes) to provide a white, foamy solid (4.8 mg, 64%). 
1
H NMR 
(400 MHz, CDCl3) δ 7.41 (dd, J = 8.0, 1.1 Hz, 1H), 6.81 – 6.76 (m, 2H), 4.50 (ddd, J = 14.0, 
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11.1, 2.5 Hz, 1H), 3.85 (dd, J = 12.7, 2.1 Hz, 1H), 3.38 (dd, J = 11.9, 7.5 Hz, 1H), 3.30 – 3.15 
(m, 2H), 3.11 (d, J = 11.0 Hz, 1H), 3.01 (d, J = 10.7 Hz, 1H), 2.86 (d, J = 2.5 Hz, 1H), 2.21 – 
2.11 (m, 1H), 1.92 (s, 1H), 1.87 – 1.65 (m, 3H), 1.60 – 1.46 (m, 1H), 1.45 – 1.33 (m, 1H), 1.24 – 
1.17 (m, 1H), 0.85 (t, J = 7.3 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 158.4, 153.7, 137.3, 





 298.19, found 298.01.  
 General Procedure for Preparation of Ibogamine Analogs by Pd(II)-mediated 
Cyclization (32 and 38). In a glovebox, a Schlenk flask was charged with Pd(CH3CN)4(BF4)2 
(1.3 equivalents). It was then sealed and removed from the glovebox and anhydrous CH3CN 
(0.093 M, based on Pd(CH3CN)4(BF4)2) was added to form a yellow solution. To this solution 
was added a solution of the substrate 31 or 37 (1 equivalent) in anhydrous CH3CN (0.028 M 
based on 31 or 37) resulting in a color change (yellow to orange/orange-red). The reaction 
mixture was stirred for 2 h at room temperature and then warmed to 70 °C and stirred for a 
further 16 h. At this time, the reaction was cooled to 0 °C, and anhydrous MeOH (9 mL per 
mmol of 31 or 37) was added followed by NaBH4 (3.2 equivalents), causing the immediate 
precipitation of palladium black. The resulting black mixture was stirred for 20 min. at 0 °C, then 
diluted with Et2O, filtered through celite, and the filter cake washed with additional Et2O (4x). 
The combined filtrate and washings were concentrated to afford the crude product. This material 
was purified by preparative TLC with an appropriate solvent mixture (as described below for 
each compound). 
 rac-12-Methoxy-16-thiaibogamine (32). The product 32 was prepared according to the 
general Pd(II)-mediated cyclization procedure and purified by preparative TLC (20:1 
hexanes:EtOAc + 2% Et3N) to provide a colorless oil that slowly crystallized to a white solid 
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(41.7 mg, 42%). 
1
H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 8.7 Hz, 1H), 7.07 (d, J = 2.4 Hz, 
1H), 6.91 (dd, J = 8.7, 2.4 Hz, 1H), 3.87 (s, 3H), 3.41 (ddd, J = 16.3, 12.6, 3.8 Hz, 1H), 3.32 (dt, 
J = 14.5, 3.3 Hz, 1H), 3.22 – 3.13 (m, 1H), 3.10 (dt, J = 9.8, 2.4 Hz, 1H), 3.04 (dt, J = 9.9, 2.5 
Hz, 1H), 2.97 – 2.92 (m, 1H), 2.91 (s, 1H), 2.71 (dt, J = 16.3, 2.8 Hz, 1H), 2.14 (tt, J = 11.9, 3.0 
Hz, 1H), 1.89 (dt, J = 5.4, 2.7 Hz, 1H), 1.80 (ddt, J = 13.1, 10.5, 2.6 Hz, 1H), 1.73 (ddt, J = 13.3, 
5.6, 2.7 Hz, 1H), 1.65 – 1.50 (m, 3H), 1.48 – 1.38 (m, 1H), 1.20 (ddd, J = 13.1, 7.1, 3.0 Hz, 1H), 
0.90 (t, J = 7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 157.6, 147.3, 143.0, 130.6, 129.8, 





 328.17, found 328.50. 
 rac-12-Hydroxy-16-thiaibogamine (33). The product 33 was prepared according to the 
general procedure used to prepare the phenolic oxaibogamine analogs (9), and purified by 
column chromatography (7:3 hexanes:EtOAc, 2 column volumes → 1:1 hexanes:EtOAc, 4 
column volumes → EtOAc, 4 column volumes) to provide a white, foamy solid (18.3 mg, 58%). 
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 8.5 Hz, 1H), 7.02 (d, J = 2.3 Hz, 1H), 6.82 (dd, J = 
8.5, 2.4 Hz, 1H), 4.81 (br s, 1H), 3.38 – 3.25 (m, 2H), 3.15 (dd, J = 19.1, 7.8 Hz, 1H), 3.10 – 
3.03 (m, 2H), 2.98 – 2.92 (m, 2H), 2.67 – 2.59 (m, 1H), 2.18 – 2.10 (m, 1H), 1.93 – 1.88 (m, 
1H), 1.81 (dd, J = 12.8, 10.6 Hz, 1H), 1.72 (ddt, J = 11.2, 5.5, 2.6 Hz, 1H), 1.65 – 1.52 (m, 2H), 
1.51 – 1.40 (m, 1H), 1.24 – 1.18 (m, 1H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) 
δ 153.5, 147.3, 143.2, 130.4, 129.4, 122.9, 113.3, 106.7, 57.6, 54.2, 50.8, 42.5, 42.3, 35.1, 31.7, 




 314.16, found 314.43. 
 12-(Benzyloxy)ibogamine (38). The product 38 was prepared according to the general 
Pd(II)-mediated cyclization procedure and purified by preparative TLC (8:2 hexanes:EtOAc + 
2% Et3N) to provide a pale-yellow glass (25.1 mg, 18%). 
1
H NMR (500 MHz, CDCl3) δ 7.53 
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(br s, 1H), 7.49 (d, J = 7.3 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.3 Hz, 1H), 7.14 (d, J = 
8.6 Hz, 1H), 7.03 (d, J = 2.3 Hz, 1H), 6.85 (dd, J = 8.7, 2.4 Hz, 1H), 5.12 (s, 2H), 3.40 – 3.29 (m, 
2H), 3.18 – 3.10 (m, 1H), 3.08 (d, J = 9.3 Hz, 1H), 2.98 (dt, J = 9.3, 2.9 Hz, 1H), 2.89 (ddd, J = 
11.6, 4.1, 1.7 Hz, 1H), 2.85 (s, 1H), 2.59 (dt, J = 5.9, 3.9 Hz, 1H), 2.08 – 1.99 (m, 1H), 1.87 – 
1.77 (m, 2H), 1.68 – 1.62 (m, 1H), 1.61 – 1.51 (m, 2H), 1.51 – 1.42 (m, 1H), 1.21 (ddt, J = 12.7, 
5.2, 2.4 Hz, 1H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 153.3, 143.1, 138.0, 
130.3, 130.1, 128.6, 127.8, 127.7, 111.6, 110.9, 109.3, 102.3, 71.3, 57.6, 54.3, 50.1, 42.1, 41.7, 




 387.24, found 387.04. 
 Noribogaine (39). A mixture of benzyloxy substrate 38 (24.5 mg, 0.0634 mmol) and 5% 
Pd/C (20 mg) in anhydrous EtOH (0.30 mL) was stirred under 50 psi H2 for 2 h at room 
temperature. The mixture was then diluted with CH2Cl2 (10 mL) and filtered through celite, 
washing the filter cake with additional CH2Cl2 (3 x 5 mL). The filtrate was then concentrated to 
provide the product 39 as a foamy, white solid (11.0 mg, 59%) (Note: Yield is likely 
quantitative, but significant product was lost due to bumping during concentration.). 
1
H NMR 
(500 MHz, CDCl3) δ 7.49 (br s, 1H), 7.10 (d, J = 8.5 Hz, 1H), 6.87 (d, J = 2.3 Hz, 1H), 6.67 (dd, 
J = 8.5, 2.4 Hz, 1H), 4.56 (br s, 1H), 3.40 – 3.26 (m, 2H), 3.17 – 3.09 (m, 1H), 3.07 (d, J = 9.3 
Hz, 1H), 2.97 (dt, J = 9.2, 2.7 Hz, 1H), 2.89 (ddd, J = 11.6, 4.0, 1.6 Hz, 1H), 2.85 (s, 1H), 2.58 – 
2.51 (m, 1H), 2.08 – 2.00 (m, 1H), 1.87 – 1.77 (m, 2H), 1.65 (ddd, J = 13.2, 6.7, 3.4 Hz, 1H), 
1.61 – 1.50 (m, 2H), 1.50 – 1.41 (m, 1H), 1.24 – 1.18 (m, 1H), 0.89 (t, J = 7.2 Hz, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 149.5, 143.4, 130.7, 130.1, 110.8, 110.5, 109.0, 103.0, 57.6, 54.3, 









 Materials: BRET Assays. All biological assays were performed by Madalee Gassaway 
(graduate student, Sames Lab), with the aid of our collaborators in the laboratory of professor 
Jonathan Javitch at Columbia University Medical Center. HEK-293T cells were obtained from 
the American Type Culture Collection (Rockville, MD) and were cultured in a 5% CO2 
atmosphere at 37
o
C in Dulbecco’s Modified Eagle Medium (high glucose #11965; Life 
Technologies Corp.; Grand Island, NY) supplemented with 10% FBS (Premium Select, Atlanta 
Biologicals; Atlanta, GA) and 100 U/mL penicillin and 100 µg/mL streptomycin (#15140, Life 
Technologies).  
 DNA Constructs. The human MOR (hMOR), human DOR (hDOR), human KOR 
(hKOR), GRK2, and GRK3 cDNA were obtained from the Missouri S&T Resource Center. The 
human G protein constructs used here have been previously described and were provided by C. 
Galés, or were obtained from the Missouri S&T Resource Center unless otherwise noted.
24,30
 The 
G proteins used included untagged GαoB (GαoB); GαoB with Renilla luciferase 8 (RLuc8) inserted 
at position 91 (GαoB-RLuc8); Gβ1 (β1); untagged Gγ2 (γ2); Gγ2 which we fused to the full-length 
mVenus at its N-terminus via the amino acid linker GSAGT (mVenus-γ2). The plasmids 
employed in the arrestin recruitment assays, hKOR-Rluc8, arrestin3-mVenus, RLuc8-arrestin3-
Sp1, and mem-linker-citrine-SH3, were synthesized in-house as previously described.
23,24
 All 
constructs were sequence-confirmed prior to use in experiments. 
 Transfection. The following cDNA amounts were transfected into HEK-293T cells (5 x 
10
6
 cells/plate) in 10-cm dishes using polyethylenimine (PEI) in a 1:1 ratio (diluted in Opti-
MEM, Life Technologies): G protein activation: 2.5 µg hMOR/hDOR/hKOR, 0.125 µg GαoB-
RLuc8, 6.25 µg β1, 6.25 µg mVenus-γ2; Arrestin recruitment with unlabelled receptor: 2 µg 
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hMOR/hDOR, 0.25 µg Rluc8-arrestin3-Sp1, 5 µg mem-linker-citrine-SH3, 5 µg GRK2; Arrestin 
recruitment with labelled receptor: 0.2 µg hKOR-Rluc8, 21 µg arrestin3-mVenus, 5 µg GRK3. 
Cells were maintained in the HEK-293T media described above. After 24 hours the media was 
changed, and the experiment was performed 24 hours later (48 hours after transfection). 
 BRET. Transfected cells were dissociated and resuspended in phosphate-buffered saline 
(PBS). Approximately 200,000 cells/well were added to a black-framed, white well 96-well plate 
(#60050; Perkin Elmer; Waltham, MA). The microplate was centrifuged and the cells were 
resuspended in phosphate-bufferd saline (PBS). For agonist experiments, 5 µM of the luciferase 
substrate coelenterazine H was added to each well. After 5 minutes, ligands were added, and the 
BRET signal was measured at 5 minutes on a PHERAstar FS plate reader. For antagonist 
competition experiments, cells were preincubated with the antagonist at varying concentration 
for 30 minutes. Coelenterazine H (5 µM) was then added to each well for 5 minutes. Following 
coelenterazine H incubation, a fixed concentration of the reference agonist (5x EC50) was added, 
and the BRET signal was measured at 30 minutes on a PHERAstar FS plate reader. The BRET 
signal was quantified by calculating the ratio of the light emitted by the energy acceptor, mVenus 
(510-540 nm), over the light emitted by the energy donor, RLuc8 (485 nm). This drug-induced 
BRET signal was normalized using the Emax of [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin 
(DAMGO), [D-Pen(2,5)]enkephalin (DPDPE), or U-50,488 as the maximal response at hMOR, 
hDOR, and hKOR respectively. Dose response curves were fit using a three-parameter logistic 
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 The leaves of the psychoactive plant Mitragyna speciosa (Figure 1A), known as 
“kratom” in Thailand, or "biak biak" in Malaysia, have been used by humans in South East Asia 
for centuries to treat a variety of ailments. The plant material is typically consumed as a tea or 
chewed directly. At low doses, kratom is primarily used for it's stimulating effects, often by 
laborers. At higher doses, opioid-like effects are present, and the plant has been used as a general 
analgesic, and as a substitute for opium or to treat opium withdrawal symptoms. Other medicinal 
applications are also known, including use as a treatment for fever, cough, diarrhea, and 
depression. Unsurprisingly, the pleasurable opium-like effects of the plant can often lead to 
abuse and dependence, a fact the has contributed to legal control of Mitragyna speciosa  in both 
Thailand and Malaysia. However, outside its endemic regions, the plant remains completely 
uncontrolled and little is known about the extent of recreational use.
1-5 
 In light of its well documented medicinal properties, the molecular constituents of 
Mitragyna speciosa responsible for its psychoactive effects have been well studied, with more 
than 20 unique indole alkaloids 
having been identified in the 
plant.
1,2,6
 The indole alkaloid 
mitragynine (Figure 1B) has 
been universally cited as the 
primary alkaloid constituent of 
Mitragyna speciosa, 
accounting for up to 66% by 
mass of crude alkaloid 
Figure 1. (A) Leaves of Mitragyna speciosa; (B) Structure of 




 The other major alkaloids in the plant have been found to include paynantheine, 
speciogynine, and speciociliatine (Figure 1C).
1
 These major alkaloids are complimented by a 
wide variety of minor alkaloids, the nature and quantity of which, is considerably varied amongst 
different regional varieties of the plant, and is also dependent on plant age. Indeed, even the 
quantities of the major alkaloids are subject to variation, due to similar regional and cultivation 
considerations, a fact that considerably complicates the interpretation of reported psychoactive 
effects from the raw plant material.
1,2,6
 Amongst the minor alkaloids, the oxidized derivative 7-
hydroxymitragynine
7
 (Figure 1C) is of particular interest, as it has been reported to have 
analgesic effects mediated through agonist activity at the mu-opioid receptor (MOR) exceeding 
those of the prototypical opioid agonist morphine.
5,8 
 The mechanism of action of Mitragyna alkaloids has also been studied both in vitro and 
in vivo. In particular, Takayama and coworkers in Japan have accumulated a large body of 
evidence implicating the opioid receptor system as the primary mediator of the psychoactive 
effects of these alkaloids. Specifically, both mitragynine and 7-hydroxymitragynine show 
nanomolar binding affinities for the MOR.
5,8
 Further, both alkaloids inhibit electrically 
stimulated contractions in isolated guinea pig ileum, a tissue rich in opioid receptors, and this 
effect is blocked by the opioid receptor antagonist naloxone.
 5,8
 Lastly, the antinociceptive effects 




 Despite this seemingly strong evidence for the involvement of opioid receptor systems, 
and specifically MOR, in mediating the analgesic effects of mitragynine and its related alkaloids, 
there are conflicting reports in the literature. Most notably, an early study that reported on the 
effects of mitragynine in several animal species, indicated that behavioral effects in cats, and 
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analgesic effects in rats, were not reversed by treatment with nalorphine, an opioid antagonist.
10
 
Further, this report also described several qualitative differences between the behavioral and 
physiological effects produced by mitragynine and the classical opioid agonist codeine. For 
example, mitragynine was found to produce markedly less respiratory depression than codeine. 
However, in interpreting these results, it is important to note that more recent work has found 
nalorphine to have mixed agonist/antagonist activity at the opioid receptors, and to produce an 
analgesic effect of its own at sufficiently high doses.
11
  
 Nevertheless, studies implicating non-opioid activity in the physiological effects of 
mitragynine are not limited to this single report. Mitragynine has been shown to bind in some 
degree to several non-opioid CNS receptors, including alpha-2 adrenergic receptor (α2R), 
adenosine A2a, dopamine D2, and the serotonin receptors 5-HT2C and 5-HT7, but the strength of 
these affinities has not been reported.
12
 Mitragynine analgesia has also been shown to be 
inhibited by α2R antagonist idazoxan, and by the non-specific serotonin antagonist 
cyproheptadine.
13
 However, another study showed that in a cell line expressing α2R, mitragynine 
does not act directly as an agonist of this receptor.
14
 Further, idazoxan has also been reported to 
inhibit morphine analgesia
15
, so the relevance of such information in establishing the direct 
molecular mechanism of action for mitragynine is unclear. In contrast, naloxone has been shown 
to inhibit the analgesic effects of the α2R agonist clonidine,
16
 similarly questioning the validity 
of using naloxone inhibition studies in vivo for establishing a direct, receptor-level target for 
mitragynine.  
 Considering the many possible confounding factors present at the tissue or system level, 
such in vivo and ex vivo functional assays are not ideal for positive confirmation of a functional 
effect at a particular receptor. Ideally, functional assays should be conducted in vitro using cell 
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lines overexpressing the cloned receptor of interest. Although receptor-level functional activity 
studies ([
35
S]GTPγS binding) using cloned opioid receptors have recently been reported for 
several synthetic oxidized analogs
17
, no similar rigorous functional studies have been reported 
for mitragynine itself, or for other naturally occurring alkaloids in Mitragyna speciosa. Agonist 
activity by mitragynine at human opioid receptors has been recently described in a conference 
abstract, but the details of this work have not been published as of this writing.
18
 Given the 
interesting and still unclear molecular pharmacology surrounding Mitragyna alkaloids, and the 
ongoing interest of our lab in the opioid receptor system, we initiated studies to further explore 
the bioactivity of this unique molecular scaffold. 
 
Results and Discussion 
 Isolation of Mitragyna Alkaloids. Ground and dried leaves of the Thai strain of 
Mitragyna speciosa were purchased on the internet. Extraction with methanol followed by acid-
base extraction provided multi-gram quantities of a crude alkaloid extract containing four 
alkaloids, which were clearly resolved on TLC. From this mixture were easily isolated pure 
mitragynine and speciociliatine by flash column chromatography on silica gel. Pure samples of 
paynantheine and speciogynine were also obtained but the small RF difference between these 
two alkaloids resulted in the bulk of this material being isolated as a mixture. Two independent 
extractions on separate 
batches of plant 
material produced 
similar quantities of raw 
Table 1.  Isolated alkaloids from two separate extractions of dry Mitragyna 








186 g 3.62 g (1.9%) 1.57 g (0.84%) 1.01 g (0.54%) 
454 g 8.03 g (1.8%) 3.33 g (0.73%) ~3 g (~0.7%) 
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alkaloid and mitragynine, but by qualitative observations, the ratios between the three minor 
alkaloids were somewhat varied (Table 1). 
 Interestingly, only trace quantities of 7-hydroxymitragynine were observed (by mass 
spectrometry) and it was not possible to isolate any measurable quantity of this derivative. 
Therefore, it seems unlikely that this alkaloid is a universal constituent of all Mitragyna speciosa 
preparations, and is unlikely to generally account for the psychoactive properties of this plant. 
However, considering that this derivative has been previously reported as a natural product 
having highly potent opioid activity, we felt it was important to study its pharmacology 
alongside the primary natural alkaloids. Therefore, mitragynine was oxidized with 
[bis(trifluoroacetoxy)iodo]benzene (PIFA), as previously reported, to provide 7-
hydroxymitragynine for characterization (see below, Scheme 1A).
1
 
 The MOR Activity of Mitragynine is Species Dependent. Having isolated mitragynine 
and the other primary alkaloids of Mitragyna speciosa, and prepared 7-hydroxymitragynine by 
semi-synthesis, we set out to evaluate the activity of these compounds using bioluminescence 
resonance energy transfer (BRET) functional assays at both rodent and human MOR, delta-
opioid receptor (DOR), and kappa-opioid receptor (KOR). Throughout this work, two different 
BRET assays are used. In the G protein assay, the Gα subunit is fused with a luciferase donor, 
and the Gγ subunit is fused with a yellow fluorescent protein acceptor. Thus, on receptor 
activation, the G protein subunits dissociate and the observed BRET signal decreases. In the 
cAMP assay, the cAMP binding BRET sensor CAMYEL (see Chapter 1) is used to monitor the 
decline in forskolin-stimulated cAMP concentration resulting from opioid receptor activation. As 
cAMP declines, it dissociates from CAMYEL, resulting in an increased BRET signal as the 
sensor changes conformation.  All functional assays were performed by Madalee Gassaway 
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(graduate student, Sames Lab) with the aid of our collaborators in the Jonathan Javitch 
laboratory at Columbia University Medical Center. 
 Surprisingly, in initial investigations with rodent opioid receptors, it was found that none 
of the natural alkaloids showed any agonist activity at concentrations up to 100 µM. In contrast, 
mitragynine was found to be a competitive antagonist at mouse MOR (mMOR) (Table 2, IC50 = 
1.1 µM; estimated Kd = 807 ± 573 nM). Similarly, mitragynine was also a competitive antagonist 
at rat KOR (rKOR), but showed no activity at mouse DOR (mDOR). The other isolated natural 
products, paynantheine, speciogynine, and speciociliatine, showed no agonist activity at any of 
the rodent opioid receptors. Accordingly, the natural Mitragyna alkaloids appear to have no 
opioid agonist activity at rodent receptors. 
 However, when the natural alkaloids were tested at the human opioid receptors (hMOR, 
hKOR, and hDOR), results in better agreement with previous reports were obtained (Table 2 and 
Figure 2). Mitragynine was a partial agonist at hMOR (Table 2, EC50 = 339 ± 178 nM; Emax = 
34%) but remained a competitive antagonist at hKOR (Table 2, IC50 = 8.5 ± 7.6 µM; estimated 
Kd = 1.4 ± 0.40 µM)   and   showed   only   very   weak   antagonism   at   hDOR.   Once  again,  
 
Compound hMOR mMOR hDOR mDOR hKOR rKOR 
Mitragynine 
EC50 = 339 ± 
178 nM 
(34%) 
IC50 = 1.1 µM 
(Schild Kd 





IC50 = 8.5 ± 
7.6 µM 
(Schild Kd 1.4 
± 0.4 µM) 
Antagonist 
7-Hydroxymitragynine 
EC50 = 34.5 ± 
4.5 nM 
(47%) 
EC50 = 38.3 ± 
24.7 nM 
(23%) 
IC50 = 15.6 
± 9.1 µM 
EC50 = 664 
± 435 nM 
(16%) 
IC50 = 7.9 ± 
3.7 µM 
(Schild Kd 
490 ± 131 
nM) 
Antagonist 
Table 2. Functional activity of mitragynine and 7-hydroxymitragynine at rodent and human opioid receptors 
as determined in G protein BRET assays. Agonist activity is indicated by EC50 values with Emax in 
parentheses; antagonist activity is indicated by IC50 values. In some cases, antagonist activity was further 
characterized by estimating a Kd value using Schild analysis experiments. All data represents mean ± SEM of 
at least 2 independent experiments; "X" indicates inactive at 100 µM in both agonist and antagonist mode. 

































Figure 2. Activity of mitragynine and 7-hydroxymitragyine at the human opioid receptors; hMOR, hKOR, and 
hDOR were co-expressed with GαoB-RLuc8, β1, and mVenus-γ2 to assay G-protein activation. Curves represent 
the average of two or more independent experiments. (A) Agonist activity at hMOR, positive control = [D-Ala2, 
N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO); (B) Agonist activity at hKOR, positive control = U-50,488; (C) 
Agonist activity at hDOR, positive control = [D-Pen(2,5)]enkephalin (DPDPE); (D) Competitive inhibition of 
DAMGO, positive control = naloxone; (E) Competitive inhibition of U-50,488, positive control = nor-
binaltorphimine (nor-BNI); (F) Competitive inhibition of DPDPE, positive control = TIPP-psi. In antagonist 
experiments, the agonist was used at 5x its EC50 concentration. Data collected by Madalee Gassaway. 
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paynantheine, speciogynine, and speciociliatine, showed no agonist activity at any of the human 
opioid receptors at concentrations up to 100 µM. 
 The oxidized analog 7-hydroxymitragynine, a derivative which is reported to be a 
significantly more potent opioid than mitragynine itself, was also characterized at the opioid 
receptors (Table 2 and Figure 2). It was found that 7-hydroxymitragynine is a potent, partial 
agonist of both the mMOR (Table 2, EC50 = 38.3 ± 24.7 nM; Emax = 23%) and the hMOR (Table 
2, EC50 = 34.5 ± 4.5 nM; Emax = 47%). Further, it is a competitive antagonist at both hKOR 
(Table 2, IC50 = 7.9 ± 3.7 µM; estimated Kd = 490 ± 131 nM) and hDOR (Table 2, IC50 = 15.6 ± 
9.1 µM). Interestingly, when 7-hydroxymitragynine was tested at mDOR, low efficacy partial 
agonist activity was observed (Table 2, EC50 = 664 ± 435 nM, Emax = 16%). This result, in 
addition to the observed switch of mitragynine from antagonist to agonist on moving from 
mMOR to hMOR, emphasizes the fact that subtle changes in receptor structure (e.g. interspecies) 
may have significant effects on the observed functional activity of low efficacy partial agonists. 
The partial agonist activity of mitragynine and 7-hydroxymitragynine was further confirmed in 
antagonist experiments, as both compounds were able to partially inhibit the response elicited by 
the full agonist [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO). 
 Considering the widely accepted view that mitragynine acts as an MOR agonist, the 
variable results obtained here according to species, leads to some uncertainty in interpreting the 
literature that has been directed towards understanding the analgesic properties of Mitragyna 
speciosa extracts using animal models. Although the partial hMOR agonist activity of 
mitragynine is likely to explain its analgesic effects in humans, the relevance of studies reporting 
analgesic effects in rodent models are no longer clear, given the antagonistic effect of 
mitragynine at rodent opioid receptors. Further, although it was confirmed that 7-
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hydroxymitragynine is a significantly higher potency MOR partial agonist than mitragynine 
itself, the failure to isolate any measurable quantity in two extractions of the raw plant material 
calls into question the ability of this derivative to mediate the gross effects of Mitragyna 
speciosa extracts (unless if forms in vivo as a metabolite). This is especially true when the very 
high concentrations of the primary alkaloid mitragynine (~1 mass%) are taken into account, as it 
is likely to dominate the psychoactive profile. In light of these considerations, we undertook 
further explorations of our own, in order to better understand the overall pharmacological profile 
of Mitragyna alkaloids and the molecular mediators of their psychoactive and therapeutic effects. 
 Mitragyna Alkaloids Have a Complex Pharmacology. In order to assess the broad 
spectrum CNS pharmacology of Mitragyna alkaloids, the four isolated natural products, along 
with 7-hydroxymitragynine, were screened for binding at >50 CNS receptors by the 
Psychoactive Drug Screening Program (PDSP), operated by the National Institute of Mental 
Health (NIMH).
19
 The PDSP screens test compounds for inhibition of binding of a radiolabeled 
reference compound at a single 10 µM test concentration. Ligands showing >50% inhibition in 
this primary screen are then evaluated in full concentration range binding experiments to 
determine Ki. Significant binding (<10 µM) of Mitragyna alkaloids was found at a variety of 
receptors across several different classes, with some activities in the submicromolar range 
(Table 3). 
 As expected from their activity in our functional assays, both mitragynine and 7-
hydroxymitragynine displayed significant binding affinities at hMOR. Similarly, the other 
natural alkaloids also displayed binding to hMOR, although with lower potency. Binding was 
also observed for mitragynine and 7-hydroxymitragynine at hKOR and hDOR, again in 
agreement  with  the  results  of  the  functional  assays.  Further,  the Ki values determined in the  
 245 
binding experiments were in accord with the estimated Kd values determined by Schild analysis 
in the antagonist experiments, and with the EC50 values determined in the agonist experiments. 
Taken together, the functional and binding results thus provide a rigorous and internally 
consistent assessment of the activity of the Mitragyna alkaloids at all three opioid receptors. 
 Amongst the other binding activities observed in the screen, those at α2R were of 
particular note, as agonists of this receptor class are known to have analgesic properties.
20
 That 
the Mitragyna alkaloids possess adrenergic activity is unsurprising, given their close structural 
relationship to yohimbine, a well known α2R antagonist. Therefore, the functional activity of the 
Mitragyna alkaloids at these receptors was also determined by the PDSP. In Tango assays of 
Table 3. Binding affinities determined by PDSP for the indicated alkaloids at human receptors. Data represents 
mean Ki ± SEM (nM) for three or more independent trials. Where no error is indicated, data represents n = 1. 
 
    Ki ± SEM (nM) 
Class Receptor mitragynine paynantheine speciogynine speciociliatine 7-OH-mitragynine 
MOR 233 ± 48 410 ± 152 728 ± 61 560 ± 168 47 ± 18 
DOR > 10,000 > 10,000 > 10,000 > 10,000 219 ± 41 opioid 
KOR 772 ± 207 2555 ± 372 3201 ± 358 329 ± 112 188 ± 38 
5-HT1A > 10,000 154 ± 14 121 ± 19 > 10,000 > 10,000 
5-HT1D 1,244 1,265 1,123 > 10,000 > 10,000 
5-HT2A > 10,000 1799 ± 433 2562 ± 594 > 10,000 > 10,000 
5-HT2B 620 62 37 > 10,000 > 10,000 
5-HT2C > 10,000 774 3,184 > 10,000 > 10,000 
serotonin 
5-HT7 > 10,000 1565 ± 761 415 ± 81 > 10,000 > 10,000 
nicotinic α3β2 7,199 > 10,000 > 10,000 > 10,000 > 10,000 
alpha-2A 839 ± 193 131 ± 22 119 ± 31 1535 ± 146 > 10,000 
alpha-2B 2257 ±  486 947 ± 90 1207 ± 111 2735 ± 657 > 10,000 adrenergic 
alpha-2C 1469 ± 417 191 ±  40 288 ± 107 1680 ± 418 > 10,000 
dopamine D3 > 10,000 1,218 205 > 10,000 > 10,000 
muscarinic M5 > 10,000 > 10,000 > 10,000 1874 > 10,000 
sigma sigma-2 577 782 948 566 > 10,000 
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alpha-2A, alpha-2B, and alpha-2C adrenergic receptors, the natural alkaloids and 7-
hydroxymitragynine showed no agonist activity, in agreement with prior reports.
14
 The ability to 
displace a radioligand ([
3
H]rauwolscine) in binding assays, while also displaying no activity as 
agonists, would appear to indicate that these compounds must necessarily act as competitive or 
allosteric antagonists to some degree. Surprisingly, it was found that they were not able to inhibit 
EC80 concentrations of the agonist norepinephrine in the same assay. Accordingly, the functional 
activity of the Mitragyna alkaloids at the α2R receptors remains unclear, and these contradictory 
preliminary results should be repeated. 
 The screened compounds were also found to have significant affinity for several 
serotonin receptor subtypes (Table 3). Most notably, the closely related compounds 
paynantheine and speciogynine displayed submicromolar binding at both 5-HT1A and 5-HT7. 
However, the functional activity at these receptors has not been determined at this time, and their 
relevance to the therapeutic and psychoactive effects of Mitragyna speciosa extracts remains 
uncertain. 
 SAR Exploration: Strategy. Having confirmed the MOR agonist activity of both 
mitragynine and 7-hydroxymitragynine, we chose to explore the structure-activity relationships 
(SAR) of these scaffolds. In particular, we were interested in the effects of modifications at three 
key positions: the methoxy group at position 9, the ethyl group on 
ring D, and the β-methoxyacrylate moiety (Figure 3). The aryl 
methoxy group was of particular interest, as in the classical 
morphinan and benzomorphan opioid scaffolds, the change from 
aryl methoxy to phenol at key position 3 (e.g. codeine to 
morphine), produces a dramatic increase in potency. Likewise, 
Figure 3. Key SAR locants of 
Mitragyna alkaloids, highlighted 
in green. 
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unsubstituted phenyl analogs in these scaffolds also show weak activity. The importance of a 
phenolic moiety in many known MOR ligands is proposed to be due to formation of a water-
mediated hydrogen bonding network with histidine-297, as shown in the recent x-ray structure of 
MOR.
21
 Accordingly, it was hypothesized that if mitragynine and 7-hydroxymitragynine bind in 
similar poses, then the corresponding phenolic, desmethyl analogs would be expected to show 
significant increases in potency. 
 The pendant groups on ring D were also of interest from the perspective of synthetic 
simplicity. It was envisioned that controlling the stereochemistry of the ethyl group, which is in 
the thermodynamically unfavorable axial configuration, would be challenging in a potential total 
synthesis. Similarly, the β-methoxyacrylate was also expected to be troublesome to install in the 
late stages of a synthesis. Therefore, we sought to understand the SAR of these two 
functionalities, both from a fundamental perspective, and with a view towards designing analogs 
of more rapid synthetic accessibility. 
 Synthesis of Semi-Synthetic Analogs. We were conveniently able to explore some key 
SAR through preparation of several semi-synthetic analogs from the naturally derived alkaloids 
(Scheme 1). As discussed above, mitragynine was easily oxidized to 7-hydroxymitragynine with 
the hypervalent iodine species PIFA, but this reaction produced numerous byproducts and was 
low yielding. It was also found that the same transformation could be carried out cleanly using 
singlet oxygen generated by visible light irradiation in the presence of rose bengal, but yields 
were still modest (Scheme 1A). This reaction produces an intermediate 7-hydroperoxide as the 
direct product, which is then reduced with sodium sulfite to the final 7-hydroxy derivative. 
Although higher yielding and cleaner than the PIFA reaction, we found this transformation 
cumbersome in practice due to the lack of a dedicated photochemistry apparatus in our 
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laboratory. The halogen 
lamp used emitted 
significant radiant heat, 
thus necessitating 
frequent manual 
changes of the cooling 
ice. Further, the 
reaction required use of 
an oxygen atmosphere 
in order to obtain 
maximum yields and 
provide reasonable 
reaction rates (<4 h). 
Accordingly, the PIFA 
reaction was used more 
frequently in the 
preparation of the other oxidized analogs, as discussed below. Interestingly, it was also found 
that the photooxidation reaction could take place at room temperature under sunlight 
illumination, with no need for the addition of an external reducing agent, albeit in low yield (8% 
by NMR). Therefore, it is conceivable that a similar process occurs in the plant itself, or more 
likely, in dry leaf material that has been exposed to air for considerable periods of time, with 
highly colored phytochemicals serving as a substitute for rose bengal. This behavior may account 
Scheme 1. Synthesis of semi-synthetic mitragynine analogs. 
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for the observation of 7-hydroxymitragynine in some samples of Mitragyna speciosa, but not in 
those analyzed in the present report. 
 Since speciogynine is epimeric with mitragynine at the position 19 ethyl group, its 
oxidized derivative was synthesized to probe the significance of this stereochemistry. A mixture 
of speciogynine and paynantheine isolated from Mitragyna speciosa was hydrogenated to 
provide pure speciogynine, which was then oxidized with PIFA to yield oxidized derivative 1 
(Scheme 1B). The demethylated, phenolic analog of 7-hydroxymitragynine was also prepared. 
The position 9 methoxy group of mitragynine was demethylated under nucleophilic conditions 
and the resulting phenol 2 was protected as the acetate ester 3. This material was then oxidized 
and deprotected to provide phenolic analog 4 (Scheme 1C). 
 The spirocyclic, base-catalyzed rearrangement product of 7-hydroxymitragynine 5 
(Scheme 2) has also been reported to be a high potency opioid agonist.
5
 Therefore, we attempted 
to prepare this compound according to the literature procedure. Unfortunately, it was found that 
rearrangement in refluxing methanolic sodium methoxide (as reported) resulted in concomitant 
addition of methanol across the acrylate moiety to give an inseparable diastereomeric mixture of 
acetals 6 as a competing product (Scheme 2). In fact, when the reaction was driven to 
completion or with extended reaction times, this acetal 6 was found to be the major product. If 
the reaction was refluxed for shorter times, conversion of starting material was incomplete, but 
the desired product 5 was 
obtained as the major 
product. Therefore, both 5 
and 6 were successfully 
obtained by this procedure, 
Scheme 2. Synthesis of spirocyclic analogs. 
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but this is not an ideal 
preparation for either 
compound, as purification 
of both products was 
tedious and yields were low. Furthermore, we found the diastereomeric ratio of 6 was variable 
between runs, introducing an additional complicating factor in evaluating its biological activity. 
 Synthetic Analogs and Total Synthesis of Mitragynine. We also wanted to develop a 
total synthesis of mitragynine that would allow us to prepare more extensively modified analogs, 
as well as the natural product itself. We envisioned a synthesis starting from 4-methoxyindole, 
where ring C could be installed via Bischler-Napieralski reaction to give a 3,4-dihydro-β-
carboline. This intermediate would then be subjected to an enantioselective, proline-catalyzed 
Michael-Mannich type cyclization with the appropriate enone to install ring D and set the 
stereocenter at position 3. This transformation was discovered by Itoh and coworkers, and has 
been successfully employed in the total synthesis of several indole alkaloids closely related to 
mitragynine.
22-24
 The resulting tetracyclic ketone would serve as a versatile intermediate for the 
synthesis of a variety of analogs, including mitragynine itself (Figure 4). 
 Synthesis of Starting Materials. The required 3,4-dihydro-β-carboline was successfully 
prepared in a six step sequence starting from commercially available 4-methoxyindole (Scheme 
3A). The indole was formylated and the resulting aldehyde condensed with nitromethane and 
reduced to provide tryptamine 9. Reaction with neat ethyl formate then provided 
formyltryptamine 10. Initially, we cyclized 10 directly and then attempted to install the N-tosyl 
group. However, tosylation of the 3,4-dihydro-β-carboline proved to be very low yielding. 
Therefore,  the  reaction  order  was  reversed,  first  tosylating  the  formyltryptamine  and  then 
Figure 4. Retrosynthesis of mitragynine. 
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cyclizing. Unfortunately, tosylated tryptamine 11 provided only modest yields in the Bischler-
Napieralski reaction under standard conditions employing POCl3. After some optimization 
however, POBr3 was identified as a more active dehydrating agent, and good yields of the 
desired carboline 12 were obtained. The required enone was synthesized according to previously 
described procedures (Scheme 3B).
25
 Briefly, methyl 2-ethyl-3-oxobutanoate was protected and 
reduced, and the resulting alcohol 14 was deprotected and eliminated with iodine to provide the 
desired enone 15. 
 Proline-Catalyzed Cyclization. With the necessary building blocks in hand, we 
attempted the key proline-catalyzed step for formation of ring D. When carboline 12 was treated 
with an excess of enone 15 in the presence of proline, the desired ketones 16 and 17 were 
obtained in moderate yield, as an approximately 2:1 mixture of diastereomers, epimeric at the 
ethyl group (Scheme 4A). The stereocenter proximal to the indole was reversed depending on 
Scheme 3. Synthesis of key carboline and enone starting materials 
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the proline isomer 
employed, with both 
providing a similar 
ratio of diastereomers. 
Interestingly, we 
found that the major 
diastereomer 16 was 
obtained in high 
enantiomeric excess 
(ee), while the minor 
diastereomer 17 was 
obtained in much lower ee. Therefore, the minor diastereomer was unacceptable for further 
elaboration, resulting in a significant loss of valuable intermediate. In initial explorations with 
the carboline lacking the 9-methoxy group, we had observed both higher diastereoselectivity, and 
overall yield, in this reaction. Therefore, it was felt that the above results could be improved. We 
noted that in the reactions providing low diastereoselectivity, carboline 12 had not been purified 
beyond standard extractive workup (appeared pure by NMR). Therefore, carboline 12 was 
purified by column chromatography, but this did not result in a noticeable improvement in purity 
as judged by NMR. Surprisingly, when this purified material was used in the cyclization, 
significantly better results were obtained (Scheme 4B). The reasons for this variability are not 
clear at this time, but may involve a decrease in water or other protic impurities in the carboline 
following purification on silica. Itoh has previously noted
22
 a significant effect of minor amounts 
of  water  in  this  reaction,  so  such  behavior  would not be unexpected.  It is also reasonable on 
Scheme 4. Proline-catalyzed cyclization for formation of ring D. 
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theoretical grounds, as this reaction likely proceeds via both imine and enamine intermediates, 
the equilibrium of which, would be expected to strongly depend on proton sources. Indeed, a two 
step mechanism (Figure 5, D-proline shown) can be imagined, in which a Mannich-like reaction 
bewteen the enamine formed from enone 15 and proline, and the carboline 12, first sets the 
stereocenter at position 3. This is then followed by intramolecular Michael addition to close the 
ring. In the last step, proline controls the face of protonation during hydrolysis, thereby also 
influencing the stereocenter at position 19. Proline is believed to be involved in control of the 
stereochemistry at the 19-position, as the diastereomeric ratio obtained in the reaction varies, and 
is different from 
that observed when 
either ketone (16 or 
17) is epimerized 
under basic 
conditions. Thus, it 
Figure 5. Mechanistic rationale for the control of stereochemistry by proline during the key cyclization reaction. 
Proline is involved in controling the configuration at both stereocenters. 
Table 4. Yields, diastereoselectivities, and enantioselectivities for several trials of the 
proline-catalyzed cyclization reaction. 
 
* Run with purified carboline. 
Trial Scale (12) Catalyst 
Total 
Yield 
16:17 Isolated Yield 16 % ee 16 % ee 17 
1 4.00 mmol D-proline 74% 2.3:1 40% 91 74 
2* 0.500 mmol D-proline 82% 6.2:1 44% 92 65 
3* 5.00 mmol D-proline 86% 4.8:1 59% (2 columns) 95 - 
4 4.00 mmol L-proline 62% 2.4:1 39% 93 74 
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would appear that the orientation of this stereocenter is not due simply to thermodynamic 
equilibration of the ketone product. To provide a general sense of typical yields and selectivities 
obtained from this reaction, the results obtained from four individual runs are collected in Table 
4. 
 Epimerization of the Ethyl Group. With key intermediate ketone 16S in hand, the next 
important challenge of the synthesis was to effect epimerization of the pendant ethyl group into 
the appropriate β stereochemical configuration (as in mitragynine). This could not be 
accomplished by thermodynamic equilibration of the ketone with base or acid, as the desired 
stereochemistry positions the ethyl group in the less favorable axial configuration. In fact, it was 
confirmed experimentally that only traces of the desired diastereomer (17S) were obtained when 
ketone 16S was treated with base.  As an alternative strategy, we envisioned that pseudo-allylic 
strain (either in the ketone itself or a transition state) might be used to perturb the equilibrium 
away from the equatorial alignment, which would experience greater strain, and towards the 
desired axial configuration.  
 With very similar substrates, it has previously been reported that such epimerization 
occurs during Horner-Wadsworth-Emmons (HWE) reactions.
26
 Therefore, ketone 16S was 
treated with the carbanion formed from methyl diethylphosphonoacetate, and partial 
epimerization was indeed observed (Scheme 5A and Table 5). The ene-ester with the desired 
axial ethyl group was obtained as a mixture of E and Z isomers 18E and 18Z (55 mol% of total 
product by NMR), while the ene-ester with retention of configuration at the ethyl group, 19, was 
obtained exclusively as the E isomer (45 mol% of total product by NMR). Considering that a 
significant amount of the product retained the undesired stereochemical configuration, efforts 
were made to optimize this process (Table 5). During this work, several general observations 
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were made that are of use in understanding this reaction, although the details remain unclear. 
Firstly, ketone 16 is fairly unreactive towards the stabilized carbanions used in HWE reactions, 
as both extended heating and large excesses of carbanion were required to drive the reaction to 
completion. In contrast, when excess NaH was used in forming the carbanion, the reaction with 
16 proceeded rapidly at room temperature. This appears to imply a kinetically controlled process, 
whereby the excess base would act to maintain a slight equilibrium quantity of the epimeric 
ketone 17, which in turn would react more rapidly with the carbanion (as the rate-limiting step) 
to selectively produce the produce 18 over 19.  However, when a mixture of 16 and 17 was used  
Scheme 5. Elaboration of ring D substituents and total synthesis of mitragynine. 
 256 
as the starting material, a nearly identical ratio of products was observed, despite a more rapid 
disappearance of 17 (as monitored by TLC). If the production of 18 is kinetically controlled by 
reaction of the carbanion with 17 as the rate-limiting step, pre-enrichment of 17 in the starting 
material would be expected to further enrich the product mixture in 18, a behavior that was not 
observed. Instead, this result argues for kinetic control at a later step, perhaps collapse of the 
oxaphosphetane intermediate to the ene-ester product (which would be more rapid to the product 
experiencing less allylic strain, 18). Overall, this reaction appears to be governed by a complex 
interplay of both kinetic effects, and equilibration between the two starting materials and various 
intermediates.  
 In any case, a clear steric dependence was observed, as the bulk of the phosphonoacetate 
employed affected the ratio of products observed. For example, when the smaller trimethyl 
phosphonoacetate was employed, retention of configuration to produce 19 was favored (Table 5, 
Entry 2). In 




improving (Table 5, 
Entries 3,4), and 
sometimes 
degrading (Table 5, 
Entry 5) the 
selectivity for the 
Table 5. Optimization of the HWE reaction. 
a
In some cases partial transesterification occured, in which case, the reported yields and 
ratios are for the mixed esters, 
b
equimolar quantity of base used, 24 equiv. added in 3 




5 equiv. of 18-crown-6 added 
relative to KHMDS, "-" = not determined 
 





1 Et NaH 1,2-DME 0 to R.T. 3.5 83 53:47 
2 Me NaH 1,2-DME 0 to R.T. to 60 8 92 25:75 
3 iPr NaH 1,2-DME 0 to R.T. to 60 4.5 29 64:36 
4
b 
iPr NaH 1,2-DME 0 to R.T. to 60 44 82 61:39 
5 Ph NaH 1,2-DME 0 to R.T. 30 57 29:71 
6
c
 CF3CH2 NaH 1,2-DME 0 to R.T. to 60 18 0 - 
7
d
 CF3CH2 KHMDS THF 0 to R.T. 27 0 - 
8 Et KH 1,2-DME 0 to R.T. 21 11 - 
9 Et NaH THF 0 to R.T. 48 81 57:43 
10
c




desired product 18. The use of alternative ethereal solvents resulted in similar product ratios but 
substantially reduced reactivity (Table 5, Entries 9,10). Similarly, switching base to KH gave 
poor yield (Table 5, Entry 8). Unfortunately, the only set of conditions giving both good yield 
and an improved product ratio (Table 5, Entry 4), suffered from low reactivity, requiring 
extended heating and the repeated addition of fresh carbanion to drive the reaction to completion, 
while providing only a modest increase in selectivity for 18. Accordingly, the original conditions 
were deemed to be the most convenient. 
 The requirement of large excesses of phosphonoaceate and the use of excess base 
introduced a further complication at this stage, partial transesterification of the methyl ester 
(Scheme 5A). In several trials, the ene-ester obtained from the HWE reaction was found to 
contain ~25 mol% of the ethyl ester product. This presumably results from partial hydrolysis of 
the methyl diethylphosphonoacetate by trace water, yielding small quantities of ethoxide in the 
reaction mixture that may effect transesterification. This behavior could be suppressed by 
avoiding the use of excess base, however, as discussed above, this resulted in much lower 
reactivity. Although inconvenient, this transesterification did not represent a major failing of this 
synthetic route, as the mixture was easily converted back to the pure methyl ester at a later stage 
(see Scheme 5 and below, Total Synthesis of Mitragynine). 
 We also explored an alternative strategy employing a Knoevenagel condensation between 
ketone 16 and malononitrile as the key step.
27
 Although this resulted in complete epimerization 
of the ethyl group intro the desired position, elaboration of the resulting dinitrile into the required 
β-methoxyacrylate proved low yielding and cumbersome in our hands, so this route was 
abandoned in favor of the HWE strategy. 
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 Total Synthesis of Mitragynine. With the ethyl group successfully epimerized to the 
appropriate position, we set out to convert ene-ester 18 into mitragynine (Scheme 5). 
Conveniently, treatment of the mixed E and Z isomers of 18 with magnesium afforded reduction 
of the ester and simultaneous removal of the tosyl group to afford the single ester product 20, 
still contaminated with the ethyl ester analog. This reduction was modestly selective (~6:4) for 
the production of the syn-product, with both the resulting ester and the ethyl group on the same 
face (as desired), although the anti-product was also observed. This material was then 
transesterified by brief treatment with sodium methoxide to provide the pure methyl ester 
product 20. Formylation to give aldehyde 21, followed by methylation, provided both (-)-
mitragynine and the isomeric analog (Z)-mitragynine (22) in modest yields. Starting from 
ketone 16R and employing the same transformations, the unnatural enantiomer, (+)-mitragynine, 
was also obtained (Scheme 5B). Comparison of this material to the natural product by chiral 
HPLC confirmed their opposite stereochemistry, and thus, the absolute stereochemistry of the 
ketone products 16 and 17 obtained in the proline catalyzed cyclization. Ester intermediate 20 
was also used to prepare an oxidized analog (23) lacking the β-methoxyacrylate moiety, thus 
allowing us to probe the importance of this group in mediating opioid activity (Scheme 5A). 
 Opioid Activity of Synthetic Analogs. With a variety of semi-synthetic and fully 
synthetic mitragynine derivatives in hand, the SAR of this molecular scaffold at the opioid 
receptors could be further explored. In particular, the synthesized analogs allowed investigation 
of the key moieties highlighted above, namely the methoxy group at position 9, the ethyl group 
on ring D, and the β-methoxyacrylate moiety (see above SAR Exploration: Strategy). As 
expected, the unnatural enantiomer (+)-mitragynine was found to be a much lower potency 
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Table 6. Agonist activity of synthetic analogs at mouse and human opioid receptors as determined in G 
protein and/or cAMP (indicated in parentheses) BRET assays. All data represents mean EC50 ± SEM of at 
least 2 independent experiments, or EC50 from a single experiment if no error is indicated; Emax in parentheses; 




low potency partial agonist at hKOR (Table 6). Apparently, inversion of the stereochemistry in 
this scaffold is sufficient to switch from antagonist to agonist activity at hKOR. The very close 
analog (Z)-mitragynine (22), was found to have very similar activity to the natural product, 
indicating that stereochemical inversion of the β-methoxyacrylate moiety is tolerated (Table 6). 
 The oxidized analog 1 (7-hydroxyspeciogynine), epimeric at the ethyl group, allowed us 
to probe the importance of this stereochemistry. Similar to speciogynine itself, compound 1 was 
found to be completely inactive as an agonist at all tested opioid receptors (Table 6), 
demonstrating the critical importance of the ethyl group stereochemistry in maintaining opioid 
activity. However, it should be noted that these results do not rigorously demonstrate the 
necessary presence of the ethyl group. An alternative possibility is that inverting the 
stereochemical alignment of this moiety creates a repulsive steric interaction with the receptor 
surface, or acts as a conformational lock that positions the neighboring β-methoxyacrylate in an 
unfavorable orientation for binding. In other words, the observed results may be due to negative 
interactions created by the stereochemical inversion, not necessarily by the loss of positive 
interactions. To fully map the importance of the ethyl group, the desethyl derivatives lacking this 
group entirely would be required. Although synthesis of these analogs is currently in progress, 
they have not been completed as of this writing (see below, Designing Additional Analogs: 
Future Directions). 
 Through the desmethyl analogs of mitragynine (2) and 7-hydroxymitragynine (4), we 
were able to test our hypothesis regarding the potential enhancement afforded by a free phenol in 
place of the aryl methoxy group (see above, SAR Exploration: Strategy). Remarkably, 
phenolic analog 2 was found to be completely inactive as an opioid agonist at both mouse and 
human receptors (Table 6). The change to a phenol also failed to enhance the activity of 7-
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hydroxymitragynine at mMOR and hMOR, as both the potency and efficacy of analog 4 were 
roughly comparable to the parent compound. Although 4 did show enhanced  agonist activity at 
both mDOR and hDOR, the changes were likewise not dramatic (Table 6). Taken together, these 
results suggest that both the mitragynine and oxidized mitragynine scaffolds are likely to adopt 
unique binding poses compared to classical morphinan- and benzomorphan-derived opioids, 
which display a dramatic relationship between their MOR activity and an exposed phenol group. 
 We also evaluated the two spirocyclic analogs 5 and 6 representing yet another unique 
mitragynine-derived molecular scaffold. In agreement with prior reports
5
, analog 5 proved to be 
the most potent compound at hMOR, showing an approximately 2-fold increase compared to 7-
hydroxymitragynine, as well as increased efficacy (Table 6). In contrast, compound 6, although 
still active, was significantly less potent at both mMOR and hMOR (Table 6). Thus, although a 
switch to Z stereochemistry appears to be tolerated (see results for (Z)-mitragynine), conversion 
to the more bulky sp
3
 hybridized acetal is detrimental to activity, indicating that the planar 
arrangement of the β-methoxyacrylate is important. 
 The simplified ester analog 23 allowed for further definition of the tolerance for 
modification at the β-methoxyacrylate. Indeed, this analog proved to be entirely inactive as an 
agonist (Table 6), demonstrating that although some variation of this group is permissible, its 
complete removal is not. Further, 23 was also found to be inactive as an antagonist at MOR, thus 
it appears that the β-methoxyacrylate is not only critical for agonist activity, but for receptor 
binding in general. 
 Designing Additional Analogs: Future Directions. Overall, both the mitragynine and 7-
hydroxymitragynine scaffolds are fairly intolerant to modification at the key functionalities 
studied here (see SAR summary, Figure 6). Of particular importance appears to be the β-
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methoxyacrylate, an unfortunate 
outcome given the synthetic difficulty 
involved in the installation of this 
functionality. This group is also 
expected to be potentially problematic 
from a drug development standpoint, 
as it may act as a Michael acceptor to biological nucleophiles or be susceptible to metabolic 
hydrolysis at the ester (metabolism of mitragynine is unknown as of this writing). Accordingly, 
in designing mitragynine or 7-hydroxymitragynine analogs with improved synthetic accessibility 
and drug-like properties, a key goal might be the replacement of the acrylate with an appropriate 
isostere. 
 Complete removal of the ethyl group might also be envisioned to be a particularly 
advantageous design strategy, as analogs lacking this group would be expected to be much 
simpler to synthesize. However, it is not clear if such desethyl analogs would retain opioid 
agonist activity. In order to answer this question, progress has been made towards the 
desethylmitragynine analog, but the synthesis remains incomplete at this time (Scheme 6). 
Briefly, carboline 12 was treated with methyl vinyl ketone in the presence of D-proline to 
provide ketone 24S in moderate yield and good ee. Since there was no need to control the 
stereochemistry of the ethyl group, the HWE reaction was conducted with trimethyl 
phosphonoacetate, to provide ene-ester 25 without the complication of transesterification. 
Unfortunately, on reduction with magnesium, this material provided the undesired isomer 27 as 
the major product. Presumably, with no axial ethyl group to hinder the upper face, the reductant 
preferentially approaches from above, yielding the undesired stereochemistry obtained in 27. 
Figure 6. Summary of SAR in the Mitragyna scaffold. 
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Nonetheless, a significant quantity of the desired ester 26 was also obtained, which should be 
convertible to desethylmitragynine by formylation and methylation in a manner analogous to the 
procedures described in the total synthesis of mitragynine itself. 
 Mitragyna Alkaloids are Functionally Biased Agonists. Having evaluated the 
functional activity of the major naturally occuring Mitragyna alkaloids, and accomplished a 
preliminary mapping of the SAR of this scaffold through analog synthesis, we wanted to check 
for possible biased agonism at the opioid receptors. Functionally selective agonists of the opioid 
receptors, which preferentially activate only certain downstream signaling pathways, hold 
promise as potential analgesics or antidepressants with reduced side effects. In particular, some 
evidence indicates that MOR agonists biased towards G protein signaling over β-arrestin 
signaling display less respiratory depression and constipation, while remaining potent analgesics 
(for detailed discussion, see Chapter 1). To assess the level of β-arrestin recruitment induced by 
Mitragyna alkaloids, we employed a recently described BRET assay in transfected HEK cells, 
which was adapted for use with the opioid receptors.
28
 In this assay, the unlabeled receptor (in 
this case MOR) is transfected alongside β-arrestin-2 (arrestin-3), fused with luciferase and an 
SH3 binding domain (Sp1), and the membrane protein GAP43, fused with a yellow fluorescent 
Scheme 6. Synthetic progress towards desethylmitragynine. 
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protein (YFP) and an SH3 
domain. Accordingly, when an 
agonist induces β-arrestin 
recruitment to MOR, the Sp1 on 
arrestin is brought into proximity 
with the membrane-localized 
SH3 domain, and binding occurs. 
This results in concomitant 
association of the luciferase 
donor and YFP acceptor, and a 
BRET signal is observed. 
 To assess the potential of 
Mitragyna alkaloids to act as biased agonists at MOR, mitragynine and 7-hydroxymitragynine 
were tested in the arrestin recruitment BRET assay. Interestingly, both compounds were found to 
induce very little β-arrestin binding as compared to the reference agonist DAMGO (<10% Emax), 
even in the presence of G protein-coupled receptor kinase 2 (GRK2), which typically enhances 
coupling to β-arrestin (Figure 7). Since these compounds show significantly higher efficacy in 
the G protein dissociation assay, this result qualitatively indicates a bias in favor of G protein 
signaling, at least in terms of efficacy.  
 To quantify the observed bias, the EC50 and Emax values found in the arrestin assay were 
used in conjunction with those obtained in the G protein assay, to calculate the bias factors for 
mitragynine and 7-hydroxymitragynine relative to DAMGO, using the relative activity (RA) 
method (see Chapter 1). This confirmed the strong G protein selectivity of 7-
Compound G protein Assay β-Arrestin Assay Log Bias Factor 
DAMGO 2.07 ± 1.21 nM (100%) 90.3 nM (100 %) 0 
mitragynine 339 ± 178 nM (34%) 1.06 µM (8.7%) -0.553 
7-hydroxymitragynine 34.5 ± 4.5 nM (47%) 6.60 µM (8.4%) 1.39 
 
Figure 7. To measure β-arrestin recruitment induced by MOR 
activation, HEK cells were transfected with hMOR, RLuc8-arrestin3-
Sp1, mem-linker-citrine-SH3, and GRK2. Under these conditions an 
increase in BRET signal indicates β-arrestin recruitment. Curves 
represent the average of two independent experiments. EC50 ± SEM, 
Emax (%), and calculated log bias factor (RA method) are also provided 
for each compound. Data collected by Madalee Gassaway. 
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hydroxymitragynine, with the calculated  log bias factor of 1.39 indicating a greater than 20-fold 
bias in terms of RA (Figure 7). Surprisingly however, a negative bias factor of -0.553 was 
obtained for mitragynine, indicating a bias in favor of β-arrestin signaling, in spite of the very 
low efficacy for activation of this pathway (Figure 7). This unexpected result stems from the 
lower interassay potency shift observed for mitragynine as compared to DAMGO. However, 
calculated bias factors based on such extremely low efficacy agonism (<10%) are not reliable, as 
it is difficult to accurately determine Emax and EC50 with such low dynamic range. Therefore, it is 
very likely that the apparent β-arrestin bias of mitragynine is simply an artifact of inaccurate 
EC50 determination, and that instead, this agonist is indeed G protein biased as suggested by 
qualitative observation. Such selectivity for G protein signaling may explain the reduced 
respiratory depression previously reported for mitragynine compared to codeine
10
, although any 
such connection between molecular-level events and physiological properties must be considered 
as highly speculative without further evidence. In any case, both mitragynine and 7-
hydroxymitragynine elicit downstream signaling significantly different from that induced by 
DAMGO, as both recruit β-arrestin with only very low efficacy. Additional experiments will be 
necessary to better quantify the magnitude of this signaling bias and further explore its 
implications for downstream signaling and behavior. 
 Potential Therapeutic Applications. The potent opioid activity of the Mitragyna 
alkaloids immediately suggests their applicability as leads for the development of novel 
analgesic and/or antidepressant drugs. As shown by this work and others, the scaffold displays 
some activity at all three opioid receptor subtypes, and indeed, agonists of each of these 
receptors are well precedented to show analgesic effects in both animals and humans (for 
detailed discussion, see Chapter 1). Further, crude extracts of Mitragyna speciosa are well 
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known to relieve pain in man. There is also some suggestion that mitragynine and analogs may 
be able to exert their analgesic effects with reduced side effects compared to classical opioid 
agonists (e.g. morphine). For example, at equianalgesic doses, mitragynine reportedly causes less 
respiratory depression than the classical opiate codeine.
10
 Similarly, 7-hydroxymitragynine has 
been reported to produce less constipation than morphine in rodents at equianalgesic doses.
29
 
Such improved side effect profiles may result from the biased signaling of these compounds, as 
demonstrated here. The ability of some Mitragyna alkaloid analogs to interact with two or more 
opioid receptor subtypes simultaneously may also provide benefits over classical MOR selective 
opioids. For example, the oxidized mitragynine analog MGM-9 is a dual action MOR/KOR 
agonist that acts as a potent analgesic with limited rewarding properties in mice.
30
 In this case, 
the aversive effects of KOR agonism presumably act to counter the rewarding effects of MOR 
activation, producing an analgesic with reduced abuse potential. 
 Given the growing precedent for the involvement of the opioid receptor system in 
depression and related mood disorders, the Mitragyna alkaloids or their synthetic derivatives 
may also serve as leads for novel antidepressants. In this regard, mitragynine itself is of 
particular interest, as it acts as both a low efficacy MOR partial agonist, and a KOR antagonist. 
Both of  these mechansms have been shown to elicit antidepressant effects in animals, and in the 
case of MOR, humans as well (see Chapter 1). Indeed, mitragynine shows antidepressant 
activity in the forced swim test (a rodent model of depression).
31
 Therefore, Mitragyna alkaloids 






 In this work, we have presented a thorough characterization of the opioid and other CNS 
pharmacology of the natural Mitragyna alkaloids. To our knowledge, this is the most careful in 
vitro pharmacological study of these compounds to date, and the only work demonstrating the 
MOR agonist activity of mitragynine in receptor-level functional assays. Although the partial 
agonist activity of mitragynine at hMOR is likely to account for many of the effects of 
Mitragyna speciosa extracts in humans, it is important to remember that mitragynine and the 
other major natural products (paynantheine, speciogynine, and speciociliatine) also showed 
submicromolar binding at both serotonin and adrenergic receptors. However, the contribution of 
these activities to the gross physiological effects of Mitragyna speciosa extracts remains 
uncertain. 
 In the course of these studies, several surprising observations were also made. Notably, 
mitragynine acts as a competitive antagonist at the mouse MOR, a result which confounds our 
understanding of prior animal studies with this compound. It was also found that the potent 
oxidized analog 7-hydroxymitragynine is not necessarily present in all exctracts of plant material 
(as previously claimed), so the potential contribution of this alkaloid to the effects of Mitragyna 
speciosa is not general (unless 7-hydroxymitragynine is formed as a metabolite). Excitingly, it 
was also shown that mitragynine and 7-hydroxymitragynine display biased signaling at MOR. 
These properties may derive from a unique binding pose at the opioid receptors, as through 
studies with novel semi- and fully-synthetic analogs, we found that the Mitragyna alkaloid 
scaffold displays SAR unique from classical opioids. Future molecular docking studies may help 
to further inform these observations. 
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 In sum, the work presented here represents an initial foray into a class of natural products 
with potential application in the treatment of pain and mood disorders. We hope that the 
synthetic methods described here will provide a means and starting point for future exploration 
of this exciting molecular scaffold, and that the in vitro pharmacological data and discussion 
have convinced the reader of the worth of such efforts. 
 
Experimental  
 General Considerations: Chemistry. Reagents and solvents were obtained from 
commercial sources and were used without further purification unless otherwise stated (including 
anhydrous solvents). All reactions were performed in flame-dried glassware under an argon 
atmosphere unless otherwise stated, and monitored by TLC using solvent mixtures appropriate to 
each reaction. All column chromatography was performed on silica gel (40-63µm). For 
compounds containing a basic nitrogen, Et3N was often used in the mobile phase in order to 
provide better resolution. In these cases, TLC plates should be pre-soaked in the Et3N containing 
solvent and then allowed to dry briefly before use in analysis, such that an accurate 
representation of Rf is obtained. Nuclear magnetic resonance spectra were recorded on Bruker 
400 or 500 MHz instruments as indicated. Chemical shifts are reported as δ values in ppm 
referenced to CDCl3 (
1
H NMR = 7.26 and 
13
C NMR = 77.16) or DMSO-d6 (
1
H NMR = 2.50 and 
13
C NMR = 39.52). Multiplicity is indicated as follows: s (singlet); d (doublet); t (triplet); q 
(quartet); p (pentet); dd (doublet of doublets); ddd (doublet of doublet of doublets); dddd 
(doublet of doublet of doublet of doublets); dt (doublet of triplets); td (triplet of doublets); qd 
(quartet of doublets); ddt (doublet of doublet of triplets); m (multiplet); br (broad). In some 
cases, spectra are complicated by the presence of multiple conformers, resulting in peak 
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broadening or additional splitting. As a result of these effects, multiple peaks may correspond to 
the same proton group or carbon atom. When possible, this is indicated by an "and" joining two 
peaks or spectral regions. All carbon peaks are rounded to one decimal place unless such 
rounding would cause two close peaks to become identical. In these cases, two decimal places 
are retained. Low-resolution mass spectra were recorded on a JEOL LCmate (ionization mode: 
APCI+). 
 Isolation of Mitragyna speciosa Alkaloids. Dry, finely powdered Mitragyna speciosa 
leaves (186 g) (Thai strain, Arena Ethnobotanicals, Del Mar, CA) were extracted repeatedly with 
boiling MeOH (4 x 500 mL), vacuum filtering the solids thoroughly between each extraction. 
The combined extracts were concentrated to provide a dark green-black solid (56.19 g). This 
material was crushed and extracted twice with room temperature 10% aqueous AcOH (2 x 300 
mL), filtering each extract through celite (slow). The combined, coffee colored acidic extracts, 
were washed with hexanes (2 x 150 mL) and carefully basified (with ice cooling) to pH 8-9 
using concentrated aqueous NaOH (thick tan precipitate forms). The basic mixture was then 
extracted thoroughly with CHCl3 (6 x 200 mL, emulsions), shaking vigorously with each 
extraction (not all solids dissolve). The combined organics were washed with water (2 x 400 
mL), dried over Na2SO4, and concentrated to yield the crude alkaloid fraction as a foamy brown 
solid (3.62 g, 1.9 mass%). TLC analysis of this material revealed four distinct spots 
(mitragynine, paynantheine, speciogynine, and speciociliatine in order of increasing polarity), in 
addition to baseline. The crude alkaloid mixture was separated by column chromatography (8:2 
→ 7:3 → 6:4 → 1:1 hexanes:EtOAc + 2% Et3N, 2 column volumes each) to provide fractions 
containing pure mitragynine (1.38 g), mitragynine + minor paynantheine and speciogynine (0.25 
g), paynantheine and speciogynine + minor mitragynine and speciociliatine (0.61 g), 
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speciociliatine + minor paynantheine and speciogynine (0.20 g), and speciociliatine + minor 
impurities (0.20 g). These mixed fractions were further separated by repeated column 
chromatography (gradients of hexanes:EtOAc mixtures, with or without 2% Et3N) to provide 
additional mitragynine (190 mg), along with pure samples of paynantheine (46 mg), 
speciogynine (12 mg), and speciociliatine (148 mg). The total yield of isolated mitragynine was 
1.57 g (0.84 mass%), and of total mixed paynantheine, speciogynine, and speciocoliatine was 
1.01 g (0.54 mass%). However, the yields for the pure samples of the minor alkaloids should not 
be considered indicative of the quantities contained in the plant material, due to purification 
losses. 
 This isolation procedure was repeated a second time on a larger, separate batch of 
powdered Mitragyna speciosa leaves (454 g), scaling quantities appropriately. It should be noted 
that in this second extraction, it was found that basification of the aqueous extracts to pH 12 
(instead of 8-9) was beneficial, as it prevented the formation of emulsions in the subsequent 
CHCl3 extractions. This extraction provided the crude alkaloid fraction as a foamy greenish-
brown solid (8.03 g, 1.8 mass%). The mixed alkaloids were separated by column 
chromatography as before, to provide pure mitragynine (3.33 g, 0.73 mass%) and fractions 
containing mixtures of the minor alkaloids (total >3 g). No effort was made to further purify 
paynantheine, speciogynine, and speciociliatine from the mixed fractions, but the ratios between 
these alkaloids clearly differed from the first extraction, with speciociliatine being significantly 
more prevalent. 
Mitragynine. Isolated as an amorphous, pale-yellow solid. tR (Chiralcel OD column, 8:2 
hexanes:iPrOH + 0.20% Et2NH, 1 mL/min) = 8.29 min.; 
1
H NMR (500 MHz, CDCl3) δ 7.71 (br 
s, 1H), 7.43 (s, 1H), 6.99 (t, J = 7.9 Hz, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.46 (d, J = 7.7 Hz, 1H), 
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3.88 (s, 3H), 3.73 (s, 3H), 3.71 (s, 3H), 3.18 – 3.07 (m, 2H), 3.07 – 2.99 (m, 2H), 2.97 (dd, J = 
15.5, 4.0 Hz, 1H), 2.92 (dd, J = 11.3, 5.8 Hz, 1H), 2.57 – 2.48 (m, 2H), 2.45 (dd, J = 11.7, 2.8 
Hz, 1H), 1.84 – 1.73 (m, 2H), 1.65 – 1.61 (m, 1H), 1.24 – 1.15 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 169.4, 160.7, 154.6, 137.4, 133.9, 121.9, 117.8, 111.6, 108.0, 





 399.23, found 399.06. 
Paynantheine. Isolated as an amorphous, pale-pink solid. 
1
H NMR (400 MHz, CDCl3) δ 7.81 
(br s, 1H), 7.33 (s, 1H), 7.00 (t, J = 7.9 Hz, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.46 (d, J = 7.6 Hz, 
1H), 5.58 (ddd, J = 18.2, 10.3, 8.2 Hz, 1H), 5.00 (dd, J = 17.2, 1.4 Hz, 1H), 4.95 (dd, J = 10.3, 
2.0 Hz, 1H), 3.87 (s, 3H), 3.76 (s, 3H), 3.70 (s, 3H), 3.26 (d, J = 11.1 Hz, 1H), 3.23 – 3.12 (m, 
1H), 3.11 – 2.96 (m, 4H), 2.76 (td, J = 11.8, 3.7 Hz, 1H), 2.59 (td, J = 11.2, 4.3 Hz, 1H), 2.29 (t, 





 397.21, found 397.06. 
Speciogynine. Isolated as an amorphous, yellow-tan solid. 
1
H NMR (400 MHz, CDCl3) δ 7.74 
(br s, 1H), 7.39 (br s, 1H), 7.02 (t, J = 7.9 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 6.48 (d, J = 7.5 Hz, 
1H), 3.90 (s, 3H), 3.75 (br s, 6H), 3.30 – 3.14 (m, 3H), 3.10 (dd, J = 11.3, 5.5 Hz, 1H), 3.06 – 
2.98 (m, 1H), 2.70 – 2.53 (m, 2H), 2.37 – 2.23 (m, 1H), 2.08 (t, J = 11.0 Hz, 2H), 1.98 (br s, 1H), 





399.23, found 399.07. 
Speciociliatine. Isolated as an amorphous, orange solid. 
1
H NMR (400 MHz, CDCl3) δ 7.70 (br 
s, 1H), 7.45 (s, 1H), 7.04 (t, J = 7.9 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H), 6.50 (d, J = 7.6 Hz, 1H), 
4.14 (br s, 1H), 3.92 (s, 3H), 3.81 (s, 3H), 3.70 (s, 3H), 3.28 – 3.10 (m, 2H), 3.10 – 2.96 (m, 2H), 
2.96 – 2.88 (m, 2H), 2.79 (dd, J = 10.9, 5.7 Hz, 1H), 2.65 (br s, 1H), 1.97 – 1.88 (m, 1H), 1.77 
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 399.23, found 399.04. 
 7-Hydroxymitragynine: PIFA oxidation. To a solution of mitragynine (399 mg, 1.00 
mmol) in CH3CN (14 mL) and water (5 mL) at 0 °C, was added a solution of 
[bis(trifluoroacetoxy)iodo]benzene (PIFA, 473 mg, 1.10 mmol) in CH3CN (4 mL) dropwise over 
4 min., and the resulting orange solution was left to stir. Additional solid PIFA was added in 
portions over the next several hours (43.0 mg, 86.0 mg, and 43.0 mg at 1.25 h, 1.75 h, and 2.5 h 
respectively). After 3 h, the reaction was poured into saturated aqueous NaHCO3 (40 mL) at 0 °C 
and extracted with CH2Cl2 (3 x 30 mL). The combined organics were washed with water (30 
mL) and brine (30 mL), dried over Na2SO4, and concentrated to provide a dark-brown solid (507 
mg). The material was purified by repeated column chromatography (Column 1: 6:4 
hexanes:EtOAc + 2% Et3N; Column 2: 8:2 CH2Cl2:Et2O; Column 3: 6:4 hexanes:EtOAc + 2% 
Et3N) to provide the pure product as a pale-yellow, amorphous solid (121 mg, 29%). 
1
H NMR 
(400 MHz, CDCl3) δ 7.44 (s, 1H), 7.30 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 7.5 Hz, 1H), 6.74 (d, J = 
8.2 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.70 (s, 3H), 3.12 (dd, J = 11.1, 2.3 Hz, 1H), 3.08 – 2.97 
(m, 2H), 2.88 – 2.75 (m, 2H), 2.68 – 2.59 (m, 2H), 2.48 (dd, J = 11.5, 2.5 Hz, 1H), 2.18 (s, 1H), 
1.89 (d, J = 13.6 Hz, 1H), 1.76 – 1.63 (m, 2H), 1.62 – 1.56 (m, 1H), 1.30 – 1.18 (m, 1H), 0.82 (t, 




 415.22, found 415.30. 
 7-Hydroxymitragynine: Photooxidation Under Air. A solution of mitragynine (319 
mg, 0.800 mmol) and rose bengal Na salt (8.0 mg) in MeOH (1.6 mL) was irradiated with a 500 
W halogen work lamp at 0 °C under air for 32 h. Additional MeOH (5.0 mL) and a solution of 
Na2SO3 (504 mg, 4.00 mmol) in water (4.5 mL) were both added and the pink mixture was 
stirred vigorously at room temperature until mass spectrometry indicated the disappearance of 
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the hydroperoxide intermediate (23 h). The reaction was then diluted with water (20 mL) and 
extracted with Et2O (3 x 20 mL). The combined organics were washed with water (2 x 20 mL) 
and brine (20 mL), dried over Na2SO4, and concentrated to provide a foamy orange solid (215 
mg). This material was purified by column chromatography (6:4 hexanes:EtOAc + 2% Et3N) to 
provide the pure product as a yellow amorphous solid (114 mg, 34%) with spectral properties 
identical to the material obtained from the PIFA oxidation (above). 
 7-Hydroxymitragynine: Photooxidation Under O2. A solution of mitragynine (20.0 
mg, 0.0500 mmol) and rose bengal Na salt (0.5 mg) in MeOH (0.30 mL) was irradiated with a 
500 W halogen work lamp at 0 °C under O2 atmosphere for 1.5 h. Additional MeOH (0.30 mL) 
and a solution of Na2SO3 (30.0 mg, 0.240 mmol) in water (0.27 mL) were both added and the 
pink mixture was stirred vigorously at room temperature until mass spectrometry indicated the 
disappearance of the hydroperoxide intermediate (5 h). The reaction was then diluted with water 
(2 mL) and extracted with Et2O (3 x 2 mL). The combined organics were washed with water (2 x 
2 mL) and brine (2 mL), dried over Na2SO4, and concentrated to provide a foamy orange-brown 
solid (17.9 mg). The yield of product contained in this material was determined by NMR using 
mesitylene as an internal standard (58% yield). 
 Speciogynine (by Hydrogenation). To a mixture of paynantheine and speciogynine 
(48:52 molar ratio paynantheine:speciogynine, 153 mg, 0.385 mmol) and 10 wt% Pd/C (26.8 
mg) was added EtOAc (18 mL) and the mixture was stirred under 1 atmosphere H2 for 24 h. The 
mixture was then filtered through celite, washing the filter cake thorougly with EtOAc, and the 
filtrate was concentrated to provide pure speciogynine as a pale, yellow-orange solid (129 mg, 
84%) with spectral properties identical to the material obtained from the natural source (above). 
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 Methyl (E)-2-((2S,3R,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12b-
octahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (7-hydroxyspeciogynine, 1). To a 
solution of speciogynine (94.4 mg, 0.237 mmol) in CH3CN (3.4 mL) and water (1.2 mL) at 0 °C, 
was added a solution of [bis(trifluoroacetoxy)iodo]benzene (PIFA, 111 mg, 0.257 mmol) in 
CH3CN (1.0 mL) dropwise over 4 min., and the resulting orange solution was left to stir. 
Additional solid PIFA was added in portions over the next several hours (10.2 mg portions at 
1.25 h and 2.5 h). After 3.5 h, the reaction was poured into saturated aqueous NaHCO3 (20 mL) 
at 0 °C and extracted with CH2Cl2 (3 x 15 mL). The combined organics were washed with water 
(15 mL) and brine (15 mL), dried over Na2SO4, and concentrated to provide a dark-brown solid 
(118 mg). The material was purified by column chromatography (7:3 Et2O:hexanes  + 2% Et3N) 
to provide the pure product 1 as a very pale-yellow, foamy solid (10.2 mg, 10%) as well as 
additional impure product (36.0 mg, ~37 %). No effort was made to further purify the impure 
fractions. 
1
H NMR (500 MHz, CDCl3) δ 7.33 (br s, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 
7.6 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 3.86 (s, 3H), 3.77 (br s, 3H), 3.68 (s, 3H), 3.20 (d, J = 10.6 
Hz, 1H), 3.14 (dd, J = 11.0, 3.6 Hz, 1H), 2.84 (t, J = 11.4 Hz, 1H), 2.76 (ddd, J = 11.6, 4.2, 2.1 
Hz, 1H), 2.66 (d, J = 14.3 Hz, 1H), 2.63 – 2.52 (m, 1H), 2.47 – 2.16 (m, 3H), 2.08 (t, J = 11.1 
Hz, 1H), 1.76 – 1.67 (m, 2H), 1.43 (br s, 1H), 1.04 (br s, 1H), 0.84 (t, J = 7.1 Hz, 3H); 
13
C NMR 
(126 MHz, CDCl3) (additional peaks due to conformers) δ 183.8, 169.5, 160.0, 156.1, 155.2, 
131.1, 126.6, 114.4, 111.5, 109.2, 81.2, 61.9, 61.5, 61.4, 60.7, 60.5, 55.6, 51.6, 51.1, 50.2, 46.2, 





415.22, found 415.62. 
 Methyl (E)-2-((2S,3S,12bS)-3-ethyl-8-hydroxy-1,2,3,4,6,7,12,12b-
octahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (9-hydroxycorynantheidine, 2). 
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To a solution of mitragynine (299 mg, 0.750 mmol) in anhydrous CH2Cl2 (6.0 mL) at 0 °C was 
added aluminum chloride (300 mg, 2.25 mmol) followed by ethanethiol (1.00 mL, 839 mg, 13.5 
mmol) and the resulting cloudy brownish-orange mixture was allowed to warm to room 
temperature and stirred for 3 h. Additional aluminum chloride (300 mg, 2.25 mmol) was then 
added and stirring was continued for a further 2 h. The reaction was then concentrated and the 
resulting sticky brown material was partitioned between a solution of potassium sodium tartrate 
(10 g in 20 mL water) and CH2Cl2 (20 mL). The organic layer was separated and the aqueous 
layer was extracted with additional CH2Cl2 (2 x 20 mL). The combined organics were washed 
with water (20 mL) and brine (20 mL), dried over Na2SO4, and concentrated to yield a pale-
brown solid (266 mg). This crude product was purified by column chromatography (CH2Cl2 + 
2% Et3N) to provide a pale-tan amorphous solid (126 mg) containing trapped Et3N (presumably 
due to acidity of phenol). This material was dissolved in Et2O (20 mL), washed with water (2 x 
10 mL), dried over Na2SO4, and concentrated again to provide the pure product 2 as an 
amorphous, pale-brown solid (103 mg, 36%). 
1
H NMR (500 MHz, CDCl3) δ 7.81 (br s, 1H), 
7.44 (s, 1H), 6.93 – 6.87 (m, 1H), 6.85 (d, J = 7.4 Hz, 1H), 6.38 (dd, J = 7.4, 0.6 Hz, 1H), 5.49 
(br s, 1H), 3.720 (s, 3H), 3.716 (s, 3H), 3.24 – 3.16 (m, 1H), 3.14 (d, J = 11.3 Hz, 1H), 3.07 – 
2.99 (m, 2H), 2.99 – 2.91 (m, 2H), 2.59 – 2.52 (m, 1H), 2.50 (d, J = 11.7 Hz, 1H), 2.45 (dd, J = 
11.4, 2.6 Hz, 1H), 1.83 – 1.72 (m, 2H), 1.64 (d, J = 11.1 Hz, 1H), 1.25 – 1.16 (m, 1H), 0.87 (t, J 
= 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 169.5, 160.8, 150.2, 138.0, 134.1, 122.0, 116.81, 





 385.21, found 385.56. 
 Methyl (E)-2-((2S,3S,12bS)-8-acetoxy-3-ethyl-1,2,3,4,6,7,12,12b-
octahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (3). To a solution of phenol 2 (100 
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mg, 0.260 mmol) in anhydrous pyridine (4.6 mL) was added acetic anhydride (2.3 mL) and the 
resulting solution was stirred at room temperature for 1 h. The reaction was then poured into 
chipped ice (~25 mL) to which excess NaHCO3 had been added. When effervescence subsided, 
the mixture was extracted with Et2O (3 x 15 mL) and the combined organics were washed with 
water (20 mL) and brine (20 mL), dried over Na2SO4, and concentrated to provide an orange-
yellow oil contaminated with residual pyridine. This was dissolved in a small amount of Et2O, 
crashed out with hexanes, and concentrated again to provide the pure product 3 as a tan solid 
(104 mg, 94%). 
1
H NMR (500 MHz, CDCl3) δ 8.00 (br s, 1H), 7.43 (s, 1H), 7.14 (d, J = 8.1 Hz, 
1H), 7.04 (t, J = 7.9 Hz, 1H), 6.75 (d, J = 7.6 Hz, 1H), 3.72 (s, 3H), 3.71 (s, 3H), 3.15 (d, J = 
10.9 Hz, 1H), 3.08 – 2.97 (m, 3H), 2.92 (dd, J = 11.1, 5.8 Hz, 1H), 2.71 (d, J = 14.7 Hz, 1H), 
2.59 – 2.43 (m, 3H), 2.35 (s, 3H), 1.79 (d, J = 12.8 Hz, 1H), 1.77 – 1.70 (m, 1H), 1.63 (d, J = 
10.7 Hz, 1H), 1.25 – 1.15 (m, 1H), 0.86 (t, J = 7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 
170.1, 169.4, 160.7, 143.8, 138.0, 136.3, 121.3, 120.5, 112.0, 111.5, 109.0, 106.4, 61.7, 61.2, 





427.22, found 427.55. 
 Methyl (E)-2-((2S,3S,7aS,12bS)-3-ethyl-7a,8-dihydroxy-1,2,3,4,6,7,7a,12b-
octahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (4). To a solution of acetate 3 (101 
mg, 0.237 mmol) in CH3CN (3.4 mL) and water (1.2 mL) at 0 °C, was added a solution of 
[bis(trifluoroacetoxy)iodo]benzene (PIFA, 111 mg, 0.257 mmol) in CH3CN (1.0 mL) dropwise 
over 4 min., and the resulting orange solution was left to stir. Additional solid PIFA was added in 
portions over the next several hours (20.4 mg, 30.6 mg, and 30.6 mg at 2 h, 3 h, and 4 h 
respectively). After 5 h, the reaction was poured into saturated aqueous NaHCO3 (20 mL) at 0 °C 
and extracted with CH2Cl2 (3 x 15 mL). The combined organics were washed with water (15 
 277 
mL) and brine (15 mL), dried over Na2SO4, and concentrated to provide a dark-brown solid (105 
mg). The material was purified by repeated column chromatography (Column 1: 6:4 
hexanes:EtOAc + 2% Et3N; Column 2: 6:4 Et2O:hexanes + 2% Et3N) to provide the acetate-
protected, oxidized product as a tan solid still containing ~10 mol% of a close eluting impurity 




 443.22, found 443.50). A quantity 
(15.3 mg) of this intermediate was dissolved in MeOH (0.43 mL) and cooled to 0 °C. Aqueous 
15% m/m NaOH (65 µL) was then added and the mixture was stirred for 15 min. at 0 °C. At this 
time, the reaction was quenched with saturated aqueous NH4Cl (1 mL) and extracted with Et2O 
(3 x 1 mL). The combined organics were dried over Na2SO4 and concentrated to give a greenish-
white solid (14.3 mg). This was purified by column chromatography (2:1 EtOAc:hexanes, 3 
column volumes → EtOAc, 2 column volumes) to provide the product 4 as an amorphous yellow 
solid (9.6 mg, 11% over 2 steps). 
1
H NMR (400 MHz, CDCl3) δ 7.40 (s, 1H), 7.12 (t, J = 7.8 
Hz, 1H), 7.07 (d, J = 7.1 Hz, 1H), 6.65 (d, J = 7.8 Hz, 1H), 3.73 (s, 3H), 3.64 (s, 3H), 3.14 (d, J = 
9.3 Hz, 1H), 3.04 (d, J = 10.1 Hz, 1H), 2.98 (dt, J = 13.6, 3.3 Hz, 1H), 2.89 – 2.74 (m, 2H), 2.69 
– 2.61 (m, 2H), 2.52 – 2.44 (m, 1H), 1.85 (d, J = 13.5 Hz, 1H), 1.75 – 1.63 (m, 2H), 1.62 – 1.55 
(m, 1H), 1.27 – 1.16 (m, 1H), 0.81 (t, J = 7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 183.9, 
169.5, 161.0, 154.8, 152.9, 130.9, 125.1, 114.7, 113.9, 111.3, 81.2, 61.9, 61.6, 58.3, 51.5, 50.2, 




 401.21, found 401.54. 
 Methyl (E)-2-((2S,6'S,7'S,8a'S)-6'-ethyl-4-methoxy-3-oxo-2',3',6',7',8',8a'-
hexahydro-5'H-spiro[indoline-2,1'-indolizin]-7'-yl)-3-methoxyacrylate (5). A fresh solution 
of sodium methoxide was prepared by dissolving Na metal (7.6 mg, 0.330 mmol) in anhydrous 
MeOH (5.6 mL) at room temperature. To this solution was then added 7-hydroxymitragynine 
(62.2 mg, 0.150 mmol) and the yellow solution was refluxed for 4.5 h (incomplete conversion). 
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After cooling to room temperature, the reaction was diluted with water (20 mL) and extracted 
with Et2O (3 x 20 mL). The combined organics were washed with water (10 mL) and brine (10 
mL), dried over Na2SO4, and concentrated to provide a brown foam (60 mg). This material was 
purified by repeated preparative TLC (1 mm silica layer, 20 x 20 cm plates; Plate 1: Et2O + 2% 
Et3N; Plate 2: 7:3 CH2Cl2:Et2O; Plate 3: Et2O + 2% Et3N) to provide spirocyclic product 5 as a 
foamy yellow solid (9.9 mg, 16%). 
1
H NMR (500 MHz, CDCl3) δ 7.31 (t, J = 8.1 Hz, 1H), 7.28 
(s, 1H), 6.40 (d, J = 8.1 Hz, 1H), 6.13 (d, J = 8.1 Hz, 1H), 5.11 (br s, 1H), 3.89 (s, 3H), 3.66 (s, 
3H), 3.62 (s, 3H), 3.12 (br s, 2H), 2.77 (d, J = 12.1 Hz, 1H), 2.41 – 2.28 (m, 2H), 2.28 – 2.08 (m, 
3H), 1.90 (br s, 1H), 1.64 (br s, 1H), 1.51 (br s, 1H), 1.23 – 1.16 (m, 1H), 1.16 – 1.08 (m, 1H), 
0.85 (t, J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 199.6, 169.0, 162.2, 160.4, 158.7, 
138.8, 125.7, 111.8, 103.9, 99.2, 75.3, 73.4, 61.6, 55.8, 54.9, 53.3, 51.3, 40.2, 38.5, 35.2, 23.9, 




 415.22, found 416.36. 
 Methyl 2-((2S,6'S,7'S,8a'S)-6'-ethyl-4-methoxy-3-oxo-2',3',6',7',8',8a'-hexahydro-
5'H-spiro[indoline-2,1'-indolizin]-7'-yl)-3,3-dimethoxypropanoate (6). A fresh solution of 
sodium methoxide was prepared by dissolving Na metal (8.6 mg, 0.374 mmol) in anhydrous 
MeOH (6.4 mL) at room temperature. To this solution was then added 7-hydroxymitragynine 
(71.0 mg, 0.171 mmol) and the yellow solution was refluxed for 64 h. After cooling to room 
temperature, the reaction was diluted with water (20 mL) and extracted with Et2O (3 x 20 mL). 
The combined organics were washed with water (20 mL) and brine (20 mL), dried over Na2SO4, 
and concentrated to provide an orange-brown solid (62 mg). This material was purified by 
repeated column chromatography (Column 1: 7:3 CH2Cl2:Et2O; Column 2: 10% → 15% → 
20% → 25% Et2O in CH2Cl2, 2 column volumes each; Column 3: 6:4 hexanes:EtOAc + 2% 




H NMR (400 MHz, CDCl3) (partial integrals due to mixture of diastereomers) 
δ 7.33 (t, J = 8.1 Hz, 0.6H), 7.31 (t, J = 8.1 Hz, 0.4H), 6.38 (d, J = 8.1 Hz, 0.6H), 6.36 (d, J = 8.1 
Hz, 0.4H), 6.15 (d, J = 8.1 Hz, 0.6H), 6.14 (d, J = 8.1 Hz, 0.4H), 5.04 (br s, 0.6H), 5.02 (br s, 
0.4H), 4.39 (d, J = 7.4 Hz, 0.4H), 4.30 (d, J = 6.9 Hz, 0.6H), 3.901 (s, 1.8H), 3.898 (s, 1.2H), 
3.66 (s, 1.8H), 3.52 (s, 1.2H), 3.33 (s, 1.2H), 3.32 (s, 1.2H), 3.28 (s, 1.8H), 3.15 – 3.02 (m, 2H), 
3.09 (s, 1.8H), 2.75 – 2.67 (m, 1H), 2.38 – 2.19 (m, 3H), 2.04 (t, J = 9.5 Hz, 1H), 1.98 – 1.80 (m, 
2H), 1.65 – 1.50 (m, 1H), 1.46 – 1.38 (m, 0.6H), 1.37 – 1.11 (m, 3H), 1.02 – 0.94 (m, 0.4H), 0.94 




 447.25, found 446.88. 
 4-Methoxy-1H-indole-3-carbaldehyde (7). Phosphoryl chloride (9.61 mL, 105 mmol) 
was added slowly over 3 min. to anhydrous DMF (60 mL) at 0 °C. A solution of 4-
methoxyindole (10.30 g, 70.00 mmol) in anhydorus DMF (40 mL) was then added slowly over 5 
min. The resulting bright yellow suspension was heated to 45 °C and stirred for 1 h. The reaction 
was then quenched with ice water (800 mL) and the resulting purplish-brown solution was 
washed with Et2O (2 x 100 mL) (Note: If insufficient water is used, a voluminous precipitate 
may form during the Et2O washes.). The washed aqueous was basified with concentrated 
aqueous NaOH (effervescence), resulting in a color change to pale-yellow and slow formation of 
a crystalline precipitate (Note: This precipitate is an adduct of the product and should not be 
collected.). The basic mixture was then extracted with Et2O (3 x 600 mL) (Note: Lesser 
quantities of Et2O can be used if the aqueous/organic mixture is left to stir overnight.) and the 
combined organics were washed with brine (200 mL), dried over Na2SO4, and concentrated to 
provide the product 7 as a tan crystalline solid (11.69 g, 95%). 
1
H NMR (400 MHz, CDCl3) δ 
10.51 (s, 1H), 8.96 (br s, 1H), 7.93 (d, J = 3.1 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 8.2 
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Hz, 1H), 6.73 (d, J = 7.9 Hz, 1H), 4.01 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 188.6, 154.7, 
137.9, 128.8, 124.5, 119.6, 116.3, 105.4, 102.8, 55.5. 
 (E)-4-Methoxy-3-(2-nitrovinyl)-1H-indole (8).  A mixture of aldehyde 7 (11.68 g, 66.67 
mmol) and ammonium acetate (12.85 g, 166.7 mmol) in nitromethane (200 mL) was refluxed for 
30 min. and then concentrated to provide a bright orange-red solid (17.27 g). This material was 
triturated with water (100 mL) and the wash water was removed by filtration. All solids were 
recombined, the water washing procedure was repeated twice more, and the resulting solids were 
dried in vacuo. This crude material was then recrystallized from MeOH to provide several crops 
of pure product 8 as dark-red needles (or orange-red powder, dependent on crystal size) (10.29 g, 
71%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.23 (br s, 1H), 8.56 (d, J = 13.3 Hz, 1H), 8.26 (s, 
1H), 8.10 (d, J = 13.3 Hz, 1H), 7.17 (t, J = 7.9 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 6.74 (d, J = 7.7 
Hz, 1H), 3.95 (s, 3H); 
13
C NMR (101 MHz, DMSO-d6) δ 153.6, 138.8, 135.5, 132.2, 124.3, 
115.1, 107.9, 106.0, 102.5, 55.4. 
 2-(4-Methoxy-1H-indol-3-yl)ethan-1-amine (9). To a suspension of LiAlH4 (7.00 g, 
185 mmol) in anhydrous THF (70 mL) was slowly added a solution of nitrovinylindole 8 (6.28 g, 
28.8 mmol) in anhydrous THF (165 mL) with ice cooling over 15 min. The resulting orange-gray 
suspension was refluxed for 1 h and then cooled in ice and carefully quenched by the addition of 
water (7 mL), 15% aqueous NaOH (7 mL), and water again (21 mL). The mixture was stirred 
until the solids were white and loose and then filtered, washing the filter cake with several 
portions of THF (4x). The combined filtrate and washings were concentrated to provide a pale-
brown solid (5.26 g). This material was redissolved in CH2Cl2 (300 mL), washed with water (100 
mL), and then extracted with 5% aqueous HCl (100 mL) followed by water (2 x 100 mL). The 
combined acidic extracts were washed with CH2Cl2 (100 mL), basified with concentrated 
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aqueous NaOH, and extracted with CH2Cl2 (2 x 100 mL, 50 mL). The combined organics were 
washed with brine (100 mL), dried over Na2SO4, and concentrated to yield the pure product 9 as 
a pale, grayish-brown solid (4.61 g, 84%). 
1
H NMR (400 MHz, CDCl3) δ 8.18 (br s, 1H), 7.08 
(t, J = 8.0 Hz, 1H), 6.96 (d, J = 8.1 Hz, 1H), 6.88 (s, 1H), 6.49 (d, J = 7.7 Hz, 1H), 3.92 (s, 3H), 
3.01 (s, 4H), 1.36 (br s, 2H); 
13
C NMR (101 MHz, CDCl3) δ 155.02, 138.39, 122.89, 121.09, 
117.52, 114.35, 104.61, 99.50, 55.23, 43.43, 31.29. 
 N-(2-(4-Methoxy-1H-indol-3-yl)ethyl)formamide (10). A suspension of tryptamine 9 
(6.76 g, 35.5 mmol) in ethyl formate (60 mL) was refluxed for 21 h (solids dissolve) and then 
concentrated to provide a viscous brown oil. This was dissolved in CH2Cl2 (100 mL), washed 
with 3% aqueous HCl (100 mL), saturated aqueous K2CO3 (100 mL), and brine, dried over 
Na2SO4, and concentrated to give the product 10 as a viscous brown oil (7.32 g, 94%). 
1
H NMR 
(400 MHz, CDCl3) (spectrum complicated by conformers) δ 8.15 (br s, 1H), 8.09 and 7.94 and 
7.91 (s, 1H), 7.10 (t, J = 8.0 Hz, 1H), 6.98 and 6.97 (d, J = 8.2, 1H), 6.90 and 6.85 (d, J = 2.1 Hz, 
1H), 6.512 and 6.505 (d, J = 7.7, 1H), 5.87 and 5.67 (br s, 1H), 3.94 and 3.93 (s, 3H), 3.64 and 
3.54 (q, J = 6.1 Hz, 2H), 3.10 and 3.05 (t, J = 6.5 Hz, 2H). 
 N-(2-(4-Methoxy-1-tosyl-1H-indol-3-yl)ethyl)formamide (11). To a solution of 
formyltryptamine 10 (7.26 g, 33.3 mmol), p-toluenesulfonyl chloride (11.10 g, 58.21 mmol), and 
tetrabutylammonium hydrogensulfate (1.13 g, 3.33 mmol) in CH2Cl2 (170 mL) was added 50% 
m/m aqueous NaOH (16.6 mL) and the resulting mixture was stirred vigorously at room 
temperature for 1 h. The reaction was then diluted with water (200 mL), the organic layer was 
separated, and the remaining aqueous layer was extracted with additional CH2Cl2 (2 x 50 mL). 
The combined organics were washed with water (2 x 150 mL) and brine (150 mL), dried over 
Na2SO4, and concentrated to give a foamy, pale-brown solid (15.1 g). This material was purified 
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by column chromatography (EtOAc) to provide the product 11 as an off-white solid (6.60 g, 
53%). 
1
H NMR (400 MHz, CDCl3) (spectrum complicated by conformers) δ 8.11 and 7.93 and 
7.90 (s, 1H), 7.76 – 7.69 (m, 2H), 7.60 and 7.58 (d, J = 8.0 Hz, 1H), 7.26 – 7.19 (m, 4H), 6.64 (d, 
J = 8.0 Hz, 1H), 5.59 (br s, 1H), 3.88 (s, 3H), 3.60 and 3.49 (q, J = 6.3 Hz, 2H), 3.01 and 2.99 (t, 
J = 6.6 Hz, 2H), 2.34 (s, 3H); 
13
C NMR (101 MHz, CDCl3) (spectrum complicated by 
conformers) δ 164.5, 161.2, 154.4, 145.1, 137.2, 135.3, 130.1 and 130.00, 127.0, 126.0, 123.1 





 373.12, found 373.30. 
 5-Methoxy-9-tosyl-4,9-dihydro-3H-pyrido[3,4-b]indole (12). To a solution of protected 
tryptamine 11 (6.39 g, 17.16 mmol) in anhydrous CH3CN (86 mL) and anhydrous CH2Cl2 (86 
mL) at room temperature was added a solution of phosphoryl bromide (14.76 g, 51.48 mmol) in 
anhydrous CH3CN (43 mL) slowly over 5 min. The resulting yellow solution was stirred for 1.75 
h and then quenched with water (350 mL). After basification with saturated NH4OH, the mixture 
was extracted with Et2O (175 mL, 2 x 100 mL). The combined organics were washed with water 
(100 mL) and brine (100 mL), dried over Na2SO4, and concentrated to provide an orange brown 
foamy solid (5.65 g) (Note: The purity of this crude material is the same as after chromatography 
as judged by NMR). This was purified by column chromatography (Et2O) to give the pure 
product 12 as a crystalline tan solid (4.57 g, 75%). 
1
H NMR (500 MHz, CDCl3) δ 8.93 (t, J = 
2.2 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.67 – 7.62 (m, 2H), 7.32 (t, J = 8.3 Hz, 1H), 7.17 (d, J = 
8.0 Hz, 2H), 6.64 (d, J = 8.0 Hz, 1H), 3.85 (s, 3H), 3.81 – 3.74 (m, 2H), 2.99 – 2.92 (m, 2H), 
2.32 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 155.4, 151.1, 145.2, 138.2, 134.9, 129.9, 128.4, 





 355.11, found 354.80. 
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 Methyl 2-(2-methyl-1,3-dioxolan-2-yl)butanoate (13). A mixture of methyl 2-ethyl-3-
oxobutanoate (86.5 g, 600 mmol), ethylene glycol (44.5 mL, 49.5 g, 798 mmol), and p-
toluenesulfonic acid monohydrate (50 mg) in toluene (190 mL) was refluxed for 17 h, removing 
water with a Dean-Stark trap. The reaction mixture was then washed with 5% aqueous NaHCO3 
(100 mL), water (100 mL), and brine (100 mL), dried over Na2SO4, and concentrated to provide 
ketal ester 13 as a pale-yellow oil (108 g) containing residual starting material and toluene (93.0 
g, 82%, corrected for impurities). 
1
H NMR (400 MHz, CDCl3) δ 4.05 – 3.88 (m, 4H), 3.71 (s, 
3H), 2.58 (dd, J = 11.4, 3.7 Hz, 1H), 1.82 – 1.70 (m, 1H), 1.70 – 1.61 (m, 1H), 1.39 (s, 3H), 0.89 




 189.11, found 189.06. 
 2-(2-Methyl-1,3-dioxolan-2-yl)butan-1-ol (14). To a suspension of LiAlH4 (14.69 g, 
387 mmol) in anhydrous Et2O (46 mL) at 0 °C was slowly added a solution of ketal ester 13 (387 
mmol, 72.9 g = 84.4 g of crude corrected for toluene and starting material impurities) in 
anhydrous Et2O (182 mL) over 1.25 h. The resulting mixture was refluxed for 1 h and then 
quenched by the careful addition of water (14.7 mL), 15% aqueous NaOH (29.4 mL), and water 
again (14.7 mL). The mixture was stirred until the solids were white and loose and then filtered, 
washing the filter cake with several portions of Et2O. The filtrate was washed with water (100 
mL) and brine (100 mL), dried over Na2SO4, and concentrated to give ketal alcohol 14 as a pale-
yellow oil (60.93 g, 98%). 
1
H NMR (400 MHz, CDCl3) δ 3.99 – 3.92 (m, 4H), 3.70 – 3.57 (m, 
2H), 2.71 (br s, 1H), 1.68 (ddt, J = 11.2, 7.8, 3.3 Hz, 1H), 1.60 – 1.48 (m, 1H), 1.28 (s, 3H), 1.23 
– 1.08 (m, 1H), 0.95 (t, J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 113.2, 64.6, 64.4, 62.3, 




 161.12, found 161.58. 
 3-Methylenepentan-2-one (15). A mixture of the ketal alcohol 14 (59.9 g, 374 mmol), 
water (136 mL), EtOH (13.6 mL), and 37% aqueous HCl (0.39 mL) was refluxed for 50 min. 
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The mixture was then cooled to room temperature, neutralized with 2M aqueous NaOH, and 
saturated with (NH4)2SO4 to salt out the product. The resulting heterogeneous mixture (yellow 
oil on top) was extracted with Et2O (2 x 200 mL) and the combined organics were dried over 
Na2SO4 and concentrated to provide the intermediate keto alcohol as a yellow oil (42.8 g) 
containing ~10 mass% ethylene glycol impurity, which was used directly in the next step. 
 Iodine (2.88 g) was placed in a distillation apparatus and the boiling flask was preheated 
to 175 °C. The crude keto alcohol was then added slowly over ~30 min. by syringe while the 
product distilled over continuously at 84 - 110 °C. The collected distillate (32.73 g) contained a 
cloudy yellow upper layer (product) and a colorless lower layer (water). After careful removal of 
the water layer, the crude product was obtained (25.49 g). A generous quantity of Na2SO4 was 
added to this material and it was redistilled through a 19 cm Vigreux column. The fraction 
distilling at 110 - 120 °C contained pure product 15 as a very pale-yellow liquid (17.40 g, 47% 
over 2 steps). Bp 118 °C; 
1
H NMR (400 MHz, CDCl3) δ 5.98 (s, 1H), 5.74 (t, J = 1.4 Hz, 1H), 
2.32 (s, 3H), 2.31 – 2.22 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
200.0, 150.8, 124.0, 26.1, 23.6, 12.7. 
 General Procedure for Preparation of 3-ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-
hexahydroindolo[2,3-a]quinolizin-2(1H)-ones (16 and 17).  Carboline 12 (1 equivalent), enone 
15 (3 equivalents), and proline (1 equivalent, D-proline for 16/17S, L-proline for 16/17R) were 
dissolved in anhydrous DMSO (0.0200 M, based on 12) and the mixture was stirred until TLC 
indicated the disappearance of 12 (3-6 days). The reaction was then diluted with 4x its volume of 
water, made slightly basic with saturated aqueous NaHCO3, and extracted with CH2Cl2 (3x). The 
combined organics were washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, 
and concentrated to provide the crude product as a sticky brown solid or yellow foam (depending 
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on quantity of residual DMSO). The ratio of diastereomers 16 and 17 in the crude product was 
determined by NMR (key peaks 4.54 ppm = 16 and 4.14 ppm = 17) and these were then 
separated by column chromatography (6:4 hexanes:EtOAc, 4 column volumes → 1:1 
hexanes:EtOAc, 2 column volumes). The enantiomeric excess of each product was determined 
by chiral HPLC (Daicel Chiralcel OD column, 20% iPrOH in hexanes + 0.20% Et2NH, 1 
mL/min).  
 Note 1: Some of the fractions contained a mixture of diastereomers and thus, running a 
second chromatography column allowed for higher isolated yields of product 16 if desired.  
 Note 2: Early fractions containing only compound 17 were invariably contaminated with 
an inseparable impurity. Due to the low ee of 17, this diastereomer was not used in the following 
steps and no further efforts were made to isolate pure samples.  
 Note 3: Yield and diastereoselectivity were found to vary significantly in several trials, 
mostly dependent on the prior purification of carboline 12 (see discussion in text and Table 4). 
(3S,12bS)-3-Ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-
2(1H)-one (16S). The product was prepared according to the above procedure using D-proline 
and obtained as an amorphous, pale-yellow solid (40, 44, and 59% isolated in three individual 
trials). tR (Chiralcel OD column, 8:2 hexanes:iPrOH + 0.20% Et2NH, 1 mL/min) = 6.86 min.; 
1
H 
NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.3 Hz, 1H), 7.49 (d, J = 8.3 Hz, 2H), 7.15 (t, J = 8.2 
Hz, 1H), 7.09 (d, J = 8.1 Hz, 2H), 6.61 (d, J = 8.0 Hz, 1H), 4.54 (d, J = 10.7 Hz, 1H), 3.81 (s, 
3H), 3.43 (dd, J = 13.0, 6.2 Hz, 1H), 3.32 – 3.21 (m, 2H), 3.13 (dt, J = 16.4, 3.9 Hz, 1H), 3.02 – 
2.81 (m, 3H), 2.61 – 2.49 (m, 2H), 2.27 (s, 3H), 1.99 – 1.86 (m, 1H), 1.31 – 1.17 (m, 1H), 0.97 
(t, J = 7.5 Hz, 3H). 
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(3R,12bR)-3-Ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-
2(1H)-one (16R). The product was prepared according to the above procedure using L-proline 
and obtained as an amorphous, pale-yellow solid (39% isolated) having spectral properties 
identical to the opposite enantiomer 16S. tR (Chiralcel OD column, 8:2 hexanes:iPrOH + 0.20% 
Et2NH, 1 mL/min) = 8.93 min. 
(3R,12bS)-3-Ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-
2(1H)-one (17S). The product was prepared according to the above procedure using D-proline 
and obtained as an amorphous, pale-yellow solid containing significant impurities. tR (Chiralcel 
OD column, 8:2 hexanes:iPrOH + 0.20% Et2NH, 1 mL/min) = 6.43 min.; 
1
H NMR (500 MHz, 
CDCl3) (Peak list excludes impurity peaks) δ 7.66 (d, J = 8.3 Hz, 1H), 7.46 (d, J = 8.2 Hz, 2H), 
7.16 (t, J = 8.2 Hz, 1H), 7.08 (d, J = 8.1 Hz, 2H), 6.61 (d, J = 8.1 Hz, 1H), 4.14 (d, J = 8.5 Hz, 
1H), 3.80 (s, 3H), 3.42 (dd, J = 15.0, 2.4 Hz, 1H), 3.11 (dd, J = 11.5, 5.6 Hz, 1H), 3.06 – 2.97 
(m, 3H), 2.82 (d, J = 17.1 Hz, 1H), 2.65 – 2.57 (m, 1H), 2.52 – 2.45 (m, 1H), 2.41 (br s, 1H), 
2.29 (s, 3H), 1.89 – 1.79 (m, 1H), 1.69 – 1.61 (m, 1H), 0.94 (t, J = 7.4 Hz, 3H). 
(3S,12bR)-3-Ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-
2(1H)-one (17R). The product was prepared according to the above procedure using L-proline 
and obtained as an amorphous, pale-yellow solid containing significant impurities and having 
spectral properties identical to the opposite enantiomer 17S. tR (Chiralcel OD column, 8:2 
hexanes:iPrOH + 0.20% Et2NH, 1 mL/min) = 10.52 min. 
 Methyl 2-((12bS)-3-ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-
a]quinolizin-2(1H)-ylidene)acetates (18Z, 18E, 19). To a suspension of NaH (596 mg of 60% 
in oil, 14.90 mmol) in anhydrous 1,2-dimethoxyethane (8.0 mL) was added methyl 
diethylphosphonoacetate (1.95 mL, 2.24 g, 10.64 mmol) dropwise over 5 min. at 0 °C and the 
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mixture was stirred for 5 min. Ketone 16S (602 mg, 1.33 mmol) was then added all at once and 
the resulting yellow mixture was allowed to warm to room temperature and stirred for 3 h. The 
reaction was quenched with water (50 mL) and extracted with Et2O (3 x 50 mL).  The combined 
organics were washed with water (25 mL) and brine (25 mL), dried over Na2SO4, and 
concentrated to give a viscous yellow oil. This was purified by repeated column chromatography 
(Column 1: 20:1 CH2Cl2:Et2O, 5 column volumes → 9:1 CH2Cl2:Et2O, 4 column volumes; 
Column 2: 8:2 → 7:3 → 6:4 hexanes:EtOAc, 2 column volumes each → 1:1 hexanes:EtOAc, 4 
column volumes) to provide a mixture of Z and E ene-esters with (3S, 12bS) stereochemistry, 
18Z and 18E (254 mg, 1.6:1 E:Z, 27 mol% ethyl esters, 37% yield), and the E ene-ester with 
(3R, 12bS) stereochemistry, 19 (183 mg, 26 mol% ethyl ester, 36% yield), both as amorphous, 
pale-yellow solids.  
 Note 1: If desired 18Z and 18E may also be separated by column chromatography, but 
this is unnecessary as both are converted to the same product following reduction (see 
preparation of 20 below). 
 Note 2: The NMR peaks for the ethyl ester impurities of each product overlap except for 
those peaks corresponding to the ethyl group itself. 
Methyl (Z)-2-((3S,12bS)-3-ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-
a]quinolizin-2(1H)-ylidene)acetate (18Z). This product may be obtained as an amorphous, 
pale-yellow solid from the mixture of 18Z and 18E by additional chromatography, but is 
invariably contaminated with a quantity of the ethyl ester analog. 
1
H NMR (500 MHz, CDCl3) δ 
7.68 (d, J = 8.3 Hz, 1H), 7.44 (d, J = 8.0 Hz, 2H), 7.15 (t, J = 8.2 Hz, 1H), 7.05 (d, J = 8.0 Hz, 
2H), 6.60 (d, J = 8.1 Hz, 1H), 5.91 (s, 1H), 3.85 – 3.79 (m, 1H), 3.78 (s, 3H), 3.75 – 3.70 (m, 
1H), 3.70 (s, 3H), 3.17 (d, J = 12.7 Hz, 1H), 3.04 – 2.91 (m, 3H), 2.85 – 2.79 (m, 1H), 2.73 (d, J 
 288 
= 16.5 Hz, 1H), 2.60 – 2.52 (m, 1H), 2.44 (t, J = 11.6 Hz, 1H), 2.27 (s, 3H), 1.78 – 1.66 (m, 2H), 
0.92 (t, J = 7.4 Hz, 3H); ethyl ester peaks: 4.19-4.11 (m, 2H), 1.28 (t, J = 7.1 Hz). 
Methyl (E)-2-((3S,12bS)-3-ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-
a]quinolizin-2(1H)-ylidene)acetate (18E). This product may be obtained as an amorphous, 
pale-yellow solid from the mixture of 18Z and 18E by additional chromatography, but is 
invariably contaminated with a quantity of the ethyl ester analog. 
1
H NMR (500 MHz, CDCl3) δ 
7.67 (d, J = 8.3 Hz, 1H), 7.45 (d, J = 7.7 Hz, 2H), 7.13 (t, J = 8.2 Hz, 1H), 7.04 (d, J = 7.6 Hz, 
2H), 6.59 (d, J = 8.0 Hz, 1H), 5.73 (s, 1H), 4.56 (d, J = 13.3 Hz, 1H), 3.83 – 3.71 (m, 1H), 3.78 
(s, 6H), 3.05 – 2.89 (m, 4H), 2.73 (d, J = 16.0 Hz, 1H), 2.64 – 2.55 (m, 1H), 2.26 (s, 3H), 2.24 – 
2.11 (m, 2H), 1.80 – 1.69 (m, 1H), 1.69 – 1.62 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H); ethyl ester 
peaks: 4.25 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz). 
Methyl (E)-2-((3R,12bS)-3-ethyl-8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-
a]quinolizin-2(1H)-ylidene)acetate (19). Obtained as an amorphous, pale-yellow solid 
invariably contaminated with a quantity of the ethyl ester analog. 
1
H NMR (500 MHz, CDCl3) δ 
7.68 (d, J = 8.3 Hz, 1H), 7.50 (d, J = 8.1 Hz, 2H), 7.14 (t, J = 8.2 Hz, 1H), 7.08 (d, J = 8.2 Hz, 
2H), 6.60 (d, J = 8.0 Hz, 1H), 5.67 (s, 1H), 4.45 (d, J = 13.1 Hz, 1H), 4.34 (br d, J = 7.3 Hz, 1H), 
3.81 (s, 3H), 3.80 (s, 3H), 3.33 (dd, J = 12.8, 4.4 Hz, 1H), 3.30 – 3.20 (br m, 1H), 3.10 (d, J = 
16.3 Hz, 1H), 2.96 – 2.85 (br m, 1H), 2.85 – 2.73 (br m, 2H), 2.41 – 2.32 (br m, 1H), 2.26 (s, 
3H), 2.25 – 2.19 (m, 1H), 1.75 – 1.64 (m, 1H), 1.35 – 1.23 (m, 1H), 1.01 (t, J = 7.4 Hz, 3H); 
ethyl ester peaks: 4.27 (q, J = 7.2 Hz, 2H), 1.35 (t, J = 7.1 Hz). 
 Methyl 2-((2R,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-
a]quinolizin-2-yl)acetate (20). To a solution of mixed ene-esters 18E and 18Z (248 mg, 1.6:1 
E:Z, 27 mol% ethyl esters, 0.484 mmol) in anhydrous MeOH (11.6 mL) were added Mg turnings 
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(235 mg, 9.68 mmol) and NH4Cl (118 mg, 2.20 mmol) and the mixture was stirred vigorously 
for 1.33 h at room temperature (effervescence). The reaction was then quenched with saturated 
aqueous NH4Cl (20 mL) and water (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organics were washed with saturated aqueous NaHCO3 (20 mL) and brine (20 mL), 
dried over Na2SO4, and concentrated to give a pale, yellow-olive foam (167 mg). This material 
was purified by column chromatography (7:3 CH2Cl2:Et2O) to provide compound 20 as a pale, 
yellow-green amorphous solid contaminated with the ethyl ester analog (88.5 mg, 23 mol% ethyl 
ester, 51% yield). A quantity of this mixed ester material (87.4 mg, 0.243 mmol) was dissolved 
in freshly prepared 1M sodium methoxide in MeOH (5.0 mL) and the solution was stirred for 1 h 
at room temperature. The reaction was then diluted with CH2Cl2 (50 mL), washed with water (2 
x 25 mL) and brine (10 mL), dried over Na2SO4 and concentrated to provide pure methyl ester 
20 as a pale, yellow-green amorphous solid (90.9 mg, quantitative for transesterification, 51% 
over 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.80 (br s, 1H), 7.00 (t, J = 7.9 Hz, 1H), 6.89 (d, J 
= 8.0 Hz, 1H), 6.46 (d, J = 7.7 Hz, 1H), 3.88 (s, 3H), 3.73 (s, 3H), 3.24 (d, J = 9.5 Hz, 1H), 3.11 
(dddd, J = 14.4, 11.7, 5.9, 2.6 Hz, 1H), 3.03 – 2.89 (m, 3H), 2.57 (td, J = 11.6, 4.2 Hz, 1H), 2.43 
– 2.33 (m, 2H), 2.33 – 2.21 (m, 2H), 1.89 (d, J = 12.6 Hz, 1H), 1.72 – 1.58 (m, 1H), 1.58 – 1.42 
(m, 2H), 1.30 – 1.19 (m, 1H), 0.92 (t, J = 7.3 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 173.8, 
154.6, 137.5, 133.4, 122.0, 117.7, 108.1, 104.4, 99.9, 60.0, 57.6, 55.4, 53.8, 51.7, 40.1, 38.1, 




 357.22, found 356.64. 
 Methyl 2-((2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-
a]quinolizin-2-yl)-3-hydroxyacrylate (21). To a solution of diisopropylamine (115 µL, 82.3 
mg, 0.813 mmol, 99.95% redistilled grade) in anhydrous THF (1.7 mL, freshly distilled from 
Na/benzophenone) at -78 °C was added n-BuLi (2.5 M in hexanes, 325 µL, 0.813 mmol). The 
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resulting solution was stirred at -78 °C for 5 min. and then warmed to 0 °C and stirred for 30 
min. The reaction was then cooled back to -78 °C and a solution of ester 20 (85.6 mg, 0.240 
mmol) in anhydrous THF (1.7 mL, freshly distilled from Na/benzophenone) was added dropwise 
over 5 min. After stirring the orange solution for 1 h at -78 °C, anhydrous methyl formate (1.69 
mL, 1.65 g, 27.4 mmol, freshly distilled from P2O5) was added and the mixture was warmed to 0 
°C and stirred for 45 min. The reaction was then quenched with water (35 mL), made strongly 
basic with 10% aqueous NaOH (15 mL), and extracted with Et2O (3 x 10 mL). The aqueous 
layer was then neutralized to pH 7 with 10% aqueous HCl and extracted with CH2Cl2 (4 x 25 
mL). The Et2O and CH2Cl2 extracts were combined, dried over Na2SO4, and concentrated to 
provide a viscous, yellow-orange oil (180 mg). This crude product was purified by column 
chromatography (9:1 CH2Cl2:Et2O + 2% Et3N) to give a pale-yellow glass. This material was 
then dissolved in CH2Cl2 (30 mL), washed with saturated aqueous NaHCO3 (5 mL) and brine (5 
mL), dried over Na2SO4, and concentrated to yield pure aldehyde 21 as an amorphous, pale-
yellow solid (52.7 mg, 57%). 
1
H NMR (500 MHz, CDCl3) (spectrum extremely complex due to 
mixture of tautomers and E/Z enol) δ 11.76 (br s, 0.35H), 9.77 – 9.64 (m, 0.40H), 8.00 – 7.68 (m, 
1.2H), 7.09 – 6.97 (m, 1H), 6.94 – 6.85 (m, 1.35H), 6.51 – 6.42 (m, 1H), 4.02 – 3.93 (m, 0.25H), 
3.93 – 3.61 (m, 6H), 3.61 – 3.53 (m, 0.20H), 3.37 (ddd, J = 39.8, 11.1, 3.9 Hz, 0.50H), 3.27 – 
2.82 (m, 5H), 2.77 – 2.34 (m, 3H), 2.10 – 1.93 (m, 0.50H), 1.83 – 1.66 (m, 2H), 1.62 – 1.40 (m, 
1.7H), 1.33 – 1.21 (m, 1H), 1.21 – 1.09 (m, 1H), 0.97 – 0.81 (m, 3H); 
13
C NMR (126 MHz, 
CDCl3) (spectrum extremely complex due to mixture of tautomers and E/Z enol) δ 196.9, 172.7, 
171.6, 169.5, 169.0, 162.8, 161.4, 154.62, 154.57, 138.0, 137.4, 133.1, 132.7, 131.2, 122.9, 
122.23, 122.17, 117.7, 117.6, 117.5, 116.8, 108.42, 108.35, 107.6, 106.8, 105.6, 104.44, 104.38, 
100.1, 100.0, 62.4, 61.8, 60.9, 60.3, 60.1, 58.0, 57.6, 57.4, 56.0, 55.43, 55.39, 55.35, 53.6, 52.7, 
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52.6, 51.8, 51.23, 51.15, 46.2, 40.0, 39.6, 39.2, 38.4, 38.0, 37.8, 37.6, 33.9, 30.1, 29.8, 29.7, 25.2, 





385.21, found 384.50. 
 (-)-Mitragynine and (Z)-mitragynine (22) (synthetic). To aldehyde 21 (50.4 mg, 0.131 
mmol) was added anhydrous Et2O (2.5 mL) followed by freshly prepared 1M sodium methoxide 
in MeOH (131 µL, 0.131 mmol) and the resulting solution was concentrated to give a foamy, 
yellow-beige solid. This material (presumed Na enolate) was dissolved in anhydrous benzene 
(6.6 mL), a solution of 1M dimethyl sulfate in benzene (131 µL, 0.131 mmol) was added, and the 
resulting yellow solution was stirred at room temperature for 16 h. Additional dimethyl sulfate 
(19.7 µL, 0.0197 mmol) was then added and stirring was continued for a further 4 h. At this time, 
the reaction was diluted with Et2O (50 mL) and washed with 5% aqueous NaOH (30 mL) and 
brine (30 mL), dried over Na2SO4, and concentrated to provide a foamy, yellow-tan solid (43 
mg). This material was purified by preparative TLC (1 mm silica layer, 20 x 20 cm plate, 1:1 
hexanes:EtOAc + 2% Et3N) to provide pure fully synthetic (-)-mitragynine (14.2 mg, 27%) and 
(Z)-mitragynine (22, 16.0 mg, 31%), both as amorphous, pale-yellow solids. 
(-)-Mitragynine. Fully synthetic mitragynine was obtained as an amorphous, pale-yellow solid 
(14.2 mg, 27%) having spectral properties identical to the natural product. 
(Z)-Mitragynine = methyl (Z)-2-((2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-
octahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (22). The Z-isomer of mitragynine 
was obtained as an amorphous, pale-yellow solid (16.0 mg, 31%). 
1
H NMR (500 MHz, CDCl3) 
δ 7.84 (br s, 1H), 7.01 (t, J = 7.9 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.47 (d, J = 7.8 Hz, 1H), 6.15 
(s, 1H), 3.88 (s, 3H), 3.79 (s, 3H), 3.77 (s, 3H), 3.24 (dd, J = 10.7, 1.5 Hz, 1H), 3.14 – 3.04 (m, 
1H), 3.01 (dd, J = 11.6, 2.1 Hz, 1H), 2.99 – 2.90 (m, 3H), 2.55 (td, J = 11.4, 4.2 Hz, 1H), 2.47 
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(dd, J = 11.5, 2.2 Hz, 1H), 1.75 – 1.59 (m, 3H), 1.59 – 1.48 (m, 1H), 1.28 – 1.17 (m, 1H), 0.86 (t, 
J = 7.4 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 167.4, 156.0, 154.7, 137.5, 133.3, 122.2, 117.7, 
111.2, 108.5, 104.3, 100.0, 62.1, 60.7, 57.9, 55.4, 53.6, 51.6, 39.9, 39.1, 30.4, 24.1, 18.3, 12.8; 




 399.23, found 398.41. 
 (+)-Mitragynine. The unnatural enantiomer of mitragynine was prepared from ketone 
16R according to the same procedures described above for the natural product and obtained as an 
amorphous, pale-yellow solid (1.2 mg) having spectral properties identical to the opposite 
enantiomer. Chiral HPLC with this material both alone, and mixed with natural (-)-mitragynine, 
confirmed the opposite stereochemistry. tR (Chiralcel OD column, 8:2 hexanes:iPrOH + 0.20% 
Et2NH, 1 mL/min) = 7.62 min. 
 Methyl 2-((2R,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12b-
octahydroindolo[2,3-a]quinolizin-2-yl)acetate (23). A solution of ester 20 (35.1 mg, 0.0985 
mmol) and rose bengal Na salt (1.0 mg) in MeOH (0.20 mL) was irradiated with a 500 W 
halogen work lamp at 0 °C under O2 atmosphere for 7 h. Additional MeOH (0.60 mL) and a 
solution of Na2SO3 (62.1 mg, 0.493 mmol) in water (0.54 mL) were both added and the pink 
mixture was stirred vigorously at room temperature for 42 h, adding additional portions of 
Na2SO3 (12.4 mg, 0.0985 mmol) at 22 h and 30 h (reaction much slower than with mitragynine). 
The reaction was then diluted with water (10 mL) and extracted with Et2O (3 x 10 mL). The 
combined organics were washed with water (2 x 10 mL) and brine (10 mL), dried over Na2SO4, 
and concentrated to provide an orange glass (21 mg). This material was purified by repeated 
column chromatography (6:4 hexanes:EtOAc + 2% Et3N) to provide oxidized analog 23 as a 
nearly colorless, amorphous solid (9.5 mg, 26%). 
1
H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 8.0 
Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 6.74 (d, J = 8.3 Hz, 1H), 3.87 (s, 3H), 3.67 (s, 3H), 3.16 (dd, J 
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= 9.8, 3.7 Hz, 1H), 3.03 (d, J = 11.2 Hz, 1H), 2.79 (t, J = 11.2 Hz, 1H), 2.66 – 2.59 (m, 2H), 2.43 
– 2.34 (m, 3H), 2.32 – 2.22 (m, 2H), 1.92 – 1.81 (m, 2H), 1.70 – 1.50 (m, 3H), 1.32 – 1.23 (m, 
1H), 0.86 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 184.00, 173.44, 156.07, 155.01, 
131.11, 126.54, 114.33, 109.19, 81.21, 60.37, 58.18, 55.64, 51.63, 50.02, 39.27, 38.24, 36.33, 




 373.21, found 373.53. 
 (S)-8-Methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-2(1H)-one 
(24S). To a solution of carboline 12 (2.34 g, 6.60 mmol) and D-proline (760 mg, 6.60 mmol) in 
anhydrous DMSO (330 mL) was added methyl vinyl ketone (3.21 mL, 2.78 g, 39.6 mmol, 
freshly distilled) and the resulting yellow solution was stirred at room temperature for 4 days 
(turns orange-brown). The reaction was then diluted with water (900 mL), saturated aqueous 
NaHCO3 (100 mL) was added, and the mixture was extracted with Et2O (400 mL, 2 x 200 mL). 
The combined organics were washed with saturated aqueous NaHCO3 (150 mL) and brine (150 
mL), dried over Na2SO4, and concentrated to give an orange foam (2.75 g). This material was 
purified by column chromatography (7:3 EtOAc:hexanes, 5 column volumes → 9:1 
EtOAc:hexanes, 2 column volumes → EtOAc, 3 column volumes) to provide pure ketone 24S as 
a pale-yellow, amorphous solid (1.57 g, 56%). The enantiomeric excess (91%) was determined 
by chiral HPLC (Daicel Chiralcel OD column, 20% iPrOH in hexanes + 0.20% Et2NH, 1 
mL/min).  
 Note (purification of MVK): Methyl vinyl ketone was allowed to stand over pre-dried 
K2CO3 (heated under vacuum) for 45 min. and then decanted and distilled at atmospheric 
pressure under argon. The fraction distilling at 78-87 °C was collected as a colorless liquid in a 
receiving flask containing ~0.05 mass% hydroquinone as stabilizer. 
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tR(S) (Chiralcel OD column, 8:2 hexanes:iPrOH + 0.20% Et2NH, 1 mL/min) = 11.16 min.; tR(R) 
(same method) = 14.81 min. 
1
H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.4 Hz, 1H), 7.49 (d, J 
= 8.4 Hz, 2H), 7.16 (t, J = 8.2 Hz, 1H), 7.10 (d, J = 8.2 Hz, 2H), 6.62 (d, J = 8.1 Hz, 1H), 4.47 
(dd, J = 10.1, 1.2 Hz, 1H), 3.82 (s, 3H), 3.42 (ddd, J = 12.9, 7.0, 1.4 Hz, 1H), 3.35 – 3.29 (m, 
1H), 3.29 – 3.19 (m, 2H), 3.15 – 3.08 (m, 1H), 2.94 (dddd, J = 14.8, 7.3, 5.4, 1.7 Hz, 1H), 2.80 
(dt, J = 10.8, 5.2 Hz, 1H), 2.69 (ddd, J = 14.7, 12.9, 7.2 Hz, 1H), 2.52 (dd, J = 14.6, 11.4 Hz, 
1H), 2.39 – 2.33 (m, 1H), 2.28 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 207.7, 154.2, 144.8, 
139.0, 134.5, 134.3, 129.7, 126.6, 125.7, 120.1, 119.9, 108.9, 105.0, 58.3, 55.5, 53.8, 46.1, 46.0, 




 425.15, found 424.66. 
 Methyl (S)-2-(8-methoxy-12-tosyl-3,4,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-
2(1H)-ylidene)acetate (25). To a suspension of NaH (210 mg of 60% in oil, 5.26 mmol) in 
anhydrous 1,2-dimethoxyethane (20 mL) at 0 °C was added trimethyl phosphonoacetate (609 µL, 
685 mg, 3.76 mmol) slowly over 5 min. (effervescence) and the thick white slurry was stirred for 
10 min. Ketone 24S (200 mg, 0.470 mmol) was then added all at once and the resulting beige 
mixture was allowed to warm to room temperature and stirred for 2 h. At this time, the reaction 
was quenched with water (50 mL) and extracted with Et2O (50 mL, 25 mL). The combined 
organics were washed with water (25 mL) and brine (25 mL), dried over Na2SO4, an 
concentrated to provide a pale-yellow, foamy solid (270 mg). This material was purified by 
column chromatography (EtOAc) to yield a mixture of the E and Z ene-esters 25 as a pale-yellow 
amorphous solid (185 mg, 82%, ~1:1 E:Z). 
1
H NMR (400 MHz, CDCl3) (spectrum complicated 
by mixture of E and Z isomers) δ 7.72 – 7.65 (m, 1H), 7.54 – 7.45 (m, 2H), 7.17 – 7.10 (m, 1H), 
7.10 – 7.04 (m, 2H), 6.64 – 6.55 (m, 1H), 5.89 and 5.74 (s, 1H), 4.50 (d, J = 13.9 Hz, 0.5H), 4.26 
(t, J = 11.8 Hz, 1H), 3.83 – 3.75 (m, 0.5H), 3.80 (s, 3H), 3.77 and 3.70 (s, 3H), 3.33 – 2.99 (m, 
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4.5H), 2.94 – 2.83 (m, 1H), 2.79 – 2.69 (m, 1H), 2.62 (td, J = 13.0, 5.2 Hz, 0.5H), 2.43 (t, J = 
11.9 Hz, 0.5H), 2.38 – 2.19 (m, 1H), 2.27 and 2.26 (s, 3H), 2.11 (d, J = 13.1 Hz, 0.5H); 
13
C 
NMR (101 MHz, CDCl3) (spectrum complicated by mixture of E and Z isomers) δ 167.4 and  
166.9, 159.5 and 157.0, 154.2 and 154.1, 144.7 and 144.5, 139.0, 135.3 and 134.8, 134.7 and 
134.5, 129.7 and 129.6, 126.7 and 126.6, 125.5 and 125.4, 120.2, 119.8 and 119.4, 115.2 and 
114.3, 108.91 and 108.85, 105.0 and 104.8, 59.9 and 58.8, 55.7 and 55.6, 55.44 and 55.42, 51.3 





 481.18, found 480.24. 
 Methyl 2-((12bS)-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-
yl)acetates (26 and 27). To a solution of ene-ester 25 (mixed E/Z isomers, 181 mg, 0.377 mmol) 
in anhydrous MeOH (9.0 mL) were added magnesium turnings (183 mg, 7.54 mmol) and NH4Cl 
(91.5 mg, 1.71 mmol) and the resulting mixture was sirred vigorously for 1 h (effervescence). 
The reaction was quenched with saturated aqueous NH4Cl (30 mL) and water (30 mL) and 
extracted with CH2Cl2 (4 x 30 mL). The combined organics were washed with saturated aqueous 
NaHCO3 (50 mL) and brine (50 mL), dried over Na2SO4, and concentrated to provide a yellow-
tan foam (128 mg). This material was purified by column chromatography (1:1 hexanes:EtOAc + 
2% Et3N, 3 column volumes → EtOAc + 2% Et3N, 4 column volumes) to provide the epimeric 
esters 26 and 27. 
Methyl 2-((2R,12bS)-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-
yl)acetate (26). The product was obtained by the above procedure as an off-white, amorphous 
solid (30.1 mg, 24%). 
1
H NMR (500 MHz, CDCl3) δ 7.83 (br s, 1H), 7.01 (t, J = 7.9 Hz, 1H), 
6.89 (d, J = 8.1 Hz, 1H), 6.46 (d, J = 7.8 Hz, 1H), 3.87 (s, 3H), 3.71 (s, 3H), 3.23 (d, J = 11.2 Hz, 
1H), 3.20 – 3.10 (m, 1H), 3.10 – 2.96 (m, 3H), 2.58 (td, J = 11.6, 4.6 Hz, 1H), 2.42 (td, J = 12.0, 
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2.6 Hz, 1H), 2.37 – 2.24 (m, 2H), 2.16 (d, J = 12.6 Hz, 1H), 2.11 – 2.00 (m, 1H), 1.78 (d, J = 
12.9 Hz, 1H), 1.52 (qd, J = 12.5, 4.2 Hz, 1H), 1.39 – 1.27 (m, 1H); 
13
C NMR (126 MHz, 
CDCl3) δ 173.2, 154.6, 137.5, 132.7, 122.2, 117.7, 108.1, 104.4, 99.9, 59.7, 55.5, 55.4, 53.5, 




 329.19, found 328.91. 
Methyl 2-((2S,12bS)-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-
yl)acetate (27). The product was obtained by the above procedure as an off-white, amorphous 
solid (66.9 mg, 54%, more polar). 
1
H NMR (500 MHz, CDCl3) δ 7.94 (br s, 1H), 7.02 (t, J = 7.9 
Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.47 (d, J = 7.7 Hz, 1H), 3.93 (br s, 1H), 3.88 (s, 3H), 3.70 (s, 
3H), 3.23 – 3.08 (m, 2H), 2.97 – 2.86 (m, 2H), 2.82 (ddd, J = 11.5, 7.7, 3.7 Hz, 1H), 2.59 (ddd, J 
= 11.3, 7.6, 3.3 Hz, 1H), 2.39 (d, J = 7.3 Hz, 2H), 2.08 (br s, 2H), 1.87 – 1.73 (br m, 2H), 1.53 – 
1.43 (br m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 173.4, 154.5, 137.3, 131.8, 122.1, 117.8, 108.0, 





 329.19, found 328.91. 
 Materials: BRET Assays. All biological assays were performed by Madalee Gassaway 
(graduate student, Sames Lab), with the aid of our collaborators in the laboratory of professor 
Jonathan Javitch at Columbia University Medical Center. HEK-293T cells were obtained from 
the American Type Culture Collection (Rockville, MD) and were cultured in a 5% CO2 
atmosphere at 37
o
C in Dulbecco’s Modified Eagle Medium (high glucose #11965; Life 
Technologies Corp.; Grand Island, NY) supplemented with 10% FBS (Premium Select, Atlanta 
Biologicals; Atlanta, GA) and 100 U/mL penicillin and 100 µg/mL streptomycin (#15140, Life 
Technologies). 
 DNA Constructs. The mouse MOR (mMOR), the mouse DOR (mDOR), and the rat 
KOR (rKOR) were provided by Dr. Lakshmi Devi at Mount Sinai Hospital. The human MOR 
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(hMOR), human DOR (hDOR), human KOR (hKOR), and GRK2 were obtained from the 
Missouri S&T Resource Center. The human G protein constructs used here have been previously 
described and were provided by C. Galés, or were obtained from the Missouri S&T Resource 
Center unless otherwise noted.
32,33
 The G proteins used included untagged GαoB (GαoB); GαoB 
with Renilla luciferase 8 (RLuc8) inserted at position 91 (GαoB-RLuc8); Gβ1 (β1); untagged Gγ2 
(γ2); Gγ2 which we fused to the full-length mVenus at its N-terminus via the amino acid linker 
GSAGT (mVenus-γ2). YFP-Epac-RLuc (CAMYEL) was obtained from ATCC (no. MBA-
277).
34
 The plasmids employed in the arrestin recruitment assay, RLuc8-arrestin3-Sp1 and mem-
linker-citrine-SH3, were synthesized in-house as previously described.
28
 All constructs were 
sequence-confirmed prior to use in experiments. 
 Transfection. The following cDNA amounts were transfected into HEK-293T cells (5 x 
10
6
 cells/plate) in 10-cm dishes using polyethylenimine (PEI) in a 1:1 ratio (diluted in Opti-
MEM, Life Technologies): G protein activation: 2.5 µg MOR/DOR/KOR, 0.125 µg GαoB-
RLuc8, 6.25 µg β1, 6.25 µg mVenus-γ2; cAMP inhibition: 1.25 µg MOR/DOR/KOR, 10 µg 
CAMYEL, 1.25 µg GαoB, 1.25 µg β1, 1.25 µg γ2; Arrestin recruitment with unlabelled receptor: 
2 µg hMOR, 0.25 µg Rluc8-arrestin3-Sp1, 5 µg mem-linker-citrine-SH3, 5 µg GRK2. Cells were 
maintained in the HEK-293T media described above. After 24 hours the media was changed, and 
the experiment was performed 24 hours later (48 hours after transfection). 
 BRET. Transfected cells were dissociated and resuspended in phosphate-buffered saline 
(PBS). Approximately 200,000 cells/well were added to a black-framed, white well 96-well plate 
(#60050; Perkin Elmer; Waltham, MA). The microplate was centrifuged and the cells were 
resuspended in either phosphate-buffered saline (PBS) for the G protein activation assay, or PBS 
containing 1 µM forskolin for the cAMP accumulation assay. For agonist experiments, after 5 
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minutes, 5 µM of the luciferase substrate coelenterazine H was added to each well. After 5 
minutes, ligands were added and the BRET signal was measured at 5 minutes on a PHERAstar 
FS plate reader. For antagonist competition experiments, cells were preincubated with the 
antagonist at varying concentration for 30 minutes. Coelenterazine H (5 µM) was then added to 
each well for 5 minutes. Following coelenterazine H incubation, a fixed concentration of the 
reference agonist (5x EC50) was added, and the BRET signal was measured at 30 minutes on a 
PHERAstar FS plate reader. The BRET signal was quantified by calculating the ratio of the light 
emitted by the energy acceptor, mVenus (510-540 nm), over the light emitted by the energy 
donor, RLuc8 (485 nm). This drug-induced BRET signal was normalized using the Emax of [D-
Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO), [D-Pen(2,5)]enkephalin (DPDPE), or U-
50,488 as the maximal response at MOR, DOR, and KOR respectively. Dose response curves 
were fit using a three-parameter logistic equation in GraphPad Prism 6. 
 Receptor Screening and Ki Determination. Receptor screening and Ki determination 
were generously provided by the National Institute of Mental Health's Psychoactive Drug 
Screening Program, Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is 
Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and 
Project Officer Jamie Driscol at NIMH, Bethesda, MD, USA. For experimental details please 
refer to the PDSP website http://pdsp.med.unc.edu/. Mitragyna alkaloids were evaluated in a 
primary radioligand binding screen against a panel of 51 CNS receptors and transporters. The 
primary screen is used to select ligands that show >50% inhibition of binding of a radiolabeled 
reference compound at a single 10 µM test concentration. This primary screen was followed by 
Ki determination where appropriate (>50% inhibition). In all cases, the reported Ki values are the 
average of 2 or more independent experiments, each run with triplicate wells for each 
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concentration. The following receptors and transporters were included in the primary screening 
panel: serotonin: 5-HT1A,B,D,E, 5-HT2A,B,C, 5-HT3,5A,6,7; nicotinic: α2β2, α3β2, α3β4, α4β2, α4β4, α7; 
adrenergic: Alpha-1A,B,D, Alpha-2A,B,C; Beta-1,2,3; cannibinoid: CB1,2; dopamine: D1–5; 
monoamine transporters: DAT, NET, SERT; opioid: DOR, KOR, MOR; histamine: H1,3; 
muscarinic: M1–5; GABAA; BZP rat brain site; peripheral benzodiazepine receptor; sigma-1,2. 
Activity at additional receptors (mGluR1A,2,4,5,6,8 and H4) was also determined in primary 
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 Tianpetine: An Unusual Antidepressant. The atypical tricyclic 
antidepressant tianeptine (Figure 1) has been used clinically in Europe, 
Asia, and South America for several decades.
1-3
 Its efficacy in humans is 
well documented, and comparable to, or better, than that of several 
commonly used classes of antidepressants, including selective serotonin 
reuptake inhibitors (SSRIs) and tricyclics (TCAs).
1-9
 Similar to these 
other known agents, tianeptine is also effective in the treatment of 
anxiety disorders associated with depression.
1-3,7-9
 However, tianeptine possesses some notable 
advantages over more traditional therapies. In comparison to both SSRIs and TCAs, tianeptine 
displays improved tolerability and reduced incidence and severity of adverse side effects.
1,3,6,10-13
 
In particular, it lacks the negative cardiovascular effects of TCAs, and does not elicit sexual 
dysfunction, in contrast to SSRIs.
12,13
 There is also some evidence that tianeptine is more rapid 
acting than other antidepressants, with initial therapeutic benefits being observable after one 
week
14
, and substantial anecdotal reports indicating even more rapid effects. In comparison, 
several weeks of therapy are typically required with SSRIs and other monoaminergic 
antidepressants, a serious shortcoming in patients presenting with suicidal ideation. Further, two 
recent studies have demonstrated a positive response in patients refractory to SSRI monotherapy, 
suggesting the potential of this agent in addressing treatment resistant depression (TRD).
15,16 
 The beneficial effects of tianeptine in humans have been recapitulated and extended in a 
large number of rodent studies, where the drug shows antidepressant activity in a variety of 
classic depression models.
1-3,17,18
  At the neurostructural, circuit, and cellular levels, tianeptine 
has been shown to positively modulate neuronal plasticity and remodeling, and these effects have 
Figure 1. Structure 
of tianeptine. 
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been well studied in the hippocampus, amygdala, and prefrontal cortex, all brain regions strongly 
associated with depressive symptoms and the beneficial actions of antidepressants (see Chapter 
1 for general discussion).
1-3
 In these areas, it has been shown that tianeptine generally opposes 
the effects of chronic stress on neuronal structure and plasticity. In the hippocampus, both 
chronic stress and corticosteroid treatment result in dendritic atrophy, an effect that is both 
inhibited and reversed by tianeptine.
19,20
 Likewise, chronic stress produces a decrease in 
hippocampal volume, which is rescued by tianeptine treatment.
21
 Opposite effects are observed 
in the amygdala, where stress induces increased dendritic length and arborization, an effect that 
is not surprising given the importance of this region for fear conditioning. However, tianeptine is 
also able to counteract these differential changes
22,23
, suggesting that the drug is able to generally 
resist neuronal remodeling in response to stress stimuli. Relatedly, tianeptine has also been 
shown to enhance basal hippocampal long term potentiation (LTP), and to reverse the 
suppression of LTP in this region in response to stress.
24,25
 Similar observations have also been 
made in the prefrontal cortex.
26
 
 There is also some suggestive evidence that the neuromodulatory effects of tianeptine in 
the corticolimbic regions may be related to enhanced expression of brain-derived neurotrophic 
factor (BDNF). Two independent reports have shown that tianeptine elevates BDNF mRNA 
and/or protein levels in the hippocampus and amygdala.
27,28
 This represents a potentially 
interesting and relevant finding, as most other known antidepressants elevate BDNF in these 
regions, and direct BDNF injection into the hippocampus produces antidepressant effects, 
perhaps suggesting a common mechanism of antidepressant action through indirect modulation 
of growth factor release (see Chapter 1 for additional discussion). 
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 It is appealing to suggest a connection between the structural and synaptic modulatory 
effects of tianeptine, and its antidepressant or other behavioral effects. Indeed, imaging studies in 
depressed human subjects have revealed hippocampal dysfunction and volume loss compared to 
healthy controls.
29
 Likewise, postmortem analyses in the brains of depressed patients have also 
revealed morphological changes, including dendritic atrophy and glial cell loss in the limbic 
regions (see Chapter 1 for additional discussion).
30
 In rodents, stress-induced impairment of 
spatial memory is prevented or reversed by tianeptine treatment, an observation that is consistent 
with the behavioral importance of the drug's neuroprotective effects in the hippocampus, a brain 
region strongly linked to memory formation.
31,32
 However, at this time there does not appear to 
be any direct evidence that indisputably links the observed effects of tianeptine (or other 
antidepressants) on neuronal plasticity and resilience, to the efficacy of this agent as an 
antidepressant. In fact, in rodents it has been shown that stress-induced changes in fear 
conditioning and open field exploration are not inhibited by tianeptine, despite its successful  
concomitant blockade of hippocampal atrophy.
33
 Accordingly, this suggests that 
neuroplasticity/protection in this brain region is not inherently linked to behavior, and thus, the 
connection between these observations and human antidepressant efficacy remains unclear. 
 An Unknown Molecular Target. Despite this long history of human use, and extensive 
study in animals, the direct molecular-level target of tianeptine has remained enigmatic. It was 
originally suggested that tianeptine functioned through enhancing synaptic reuptake of serotonin, 
a mechanism surprisingly opposed to SSRIs and other known monoaminergic antidepressants, 
which elevate serotonin levels through blockade of the serotonin transporter (SERT).
34,35
 
However, this early work was limited to in vitro or ex vivo studies in isolated synaptosomes, and 
has been contradicted by later reports applying other methods. Using in vivo microdialysis and 
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electrophysiology techniques in rats, it has been shown that tianeptine (acute or chronic) does not 
alter serotonin concentrations, nor does it change the firing activity of serotonergic neurons, 
either at basal levels or in response to several serotonin receptor agonists and antagonists.
36,37
 
Given this newer evidence, a direct serotonergic mechanism for tianeptine is highly unlikely. 
 In the search for its molecular target, tianeptine has also been evaluated in broad CNS 
target binding screens.
38,39
 Cumulatively, these studies have demonstrated that tianeptine has no 
or low (>10 µM) affinity for a large number of CNS targets, including receptors: serotonin (5-
HT1A,B,D,E, 5-HT2A,B,C, 5-HT3, 5-HT4, 5-HT5A, 5-HT6, 5-HT7), dopamine (D1-5), adrenergic 
(Alpha-1A,B, Alpha-2A,B,C, Beta-1,2), adenosine (1,2), histamine (1,2), acetylcholine 
(muscarinic, nicotinic), GABA (A,B), glycine, ionotropic glutamate (NMDA, AMPA, kainate), 
transporters: vesicular monoamine transporters (VMAT1, VMAT2), serotonin transporter 





 channel. Tianeptine also failed to inhibit monoamine oxidases A and B. Thus, 
despite a fairly extensive effort, a direct molecular target for tianeptine was not identified in this 
work. Likewise, these studies have further confirmed the implausibility of a serotonergic  
mechanism, as tianeptine shows no significant affinity for either the serotonin transporter, or for 
any of the known serotonin receptors. 
 A Glutamate Connection? Despite the observed lack of affinity for the ionotropic 
glutamate receptors N-methyl-D-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR), and kainate receptor (KA), there is currently 
growing evidence implicating the modulation of the glutamate system and these receptors 
(indirectly) in the mechanism of action of tianeptine.
1
 There is significant evidence that 
modulation of glutamate signaling is generally associated both with depressive or anxious 
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symptoms, and also with the remediation of those symptoms by known antidepressants.
1,40-44
 
Most frequently, depressive, anxious, and stressed states have been shown to be associated with 
enhanced glutamate signaling or levels in the corticolimbic structures, including the 
hippocampus, while treatment with antidepressants opposes or reverses these changes. For 
example, stress is known to increase glutamate release, while chronic treatment with several 




 Similarly, antidepressants are known to modulate the expression and activity of both 
ionotropic and metabotropic glutamate receptors.
1,40-44
 For example, chronic treatment with both 
SSRIs and TCAs results in reduced expression of mRNA for several NMDAR subunits as well 
as diminished binding affinity and number of binding sites of several radioligands for this 
receptor.
47,48
 Consistent with this general reduction in NMDAR activity, direct antagonists of this 
receptor, most notably ketamine, elicit rapid and profound antidepressant effects in both animals 
and humans (see Chapter 1 for additional discussion).
40
 In contrast, chronic antidepressant 
treatment is associated with increased expression and phosphorylation of AMPAR in the 
hippocampus and other corticolimbic regions, so this receptor appears to play an opposing role to 
NMDAR in regulating mood.
49,50
 In agreement with this observation, AMPAR potentiators show 
antidepressant properties in animals, and can enhance the beneficial effects of standard classes of 
antidepressants.
51-53
 Accordingly, normalization of glutamate signaling through an increase in the 
AMPAR/NMDAR activity ratio may represent a common mechanism of antidepressant action.  
 The activity and expression of metabotropic glutamate receptors (mGluRs) is also known 
to be altered in depressive states and by treatment with classical antidepressants, and the direct 




 Unfortunately, results in this area are quite mixed, and often appear 
to be contradictory. For example, in several rodent models of depression, and in imaging and 
postmortem studies of depressed human patients, expression of group I mGluRs (specifically 
mGluR5) is decreased in the hippocampus.
57-59
 Consistent with this observation, chronic 
imipramine (a TCA) treatment increases the expression of group I mGluRs (mGluR1,5).
60
 
However, changes in the expression of group I mGluRs appear to be highly region and subtype 
specific, as mGluR5 expression is increased in the CA1 region of the hippocampus of rodents 
after chronic mild stress and mGluR1a expression is generally increased in the hippocampus 
following olfactory bulbectomization.
61,62
 Lastly, antagonists of group I mGluRs are known to be 
antidepressant in animal models, a result that does not concur with decreased expression of these 
receptors in depressive states.
63 
 The situation is similarly complex with group II mGluRs (mGluR2,3). Multiple studies 
have demonstrated decreased hippocampal expression of these receptors in animal models of 
depression, and such deficits are opposed or reversed by treatment with TCAs.
58,62,64,65
 In 
contrast, postmortem studies in the brains of depressed human patients have demonstrated 
elevated expression of group II mGluRs in the prefrontal cortex.
66
 These opposing modulations 
are consistent with observed ability of both agonists and antagonists of group II mGluRs to elicit 
beneficial effects on mood, with antagonists being antidepressant, and agonists showing 
anxiolytic activity.
67-69
 In rationalizing the seemingly contradictory evidence relating mGluR 
expression and activity to behavioral states, it is important to consider that some of the observed 
modulations in this receptor class may not necessarily be causative of behavioral deficits, but 
may represent adaptive or compensatory changes in response to variation in glutamate signaling 
elicited through other mechanisms. However, the cellular- and circuit-level variations in mGluR 
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mediated signaling, and the importance of that activity to mood modulation, remain to be fully 
clarified. 
 Like NMDAR antagonists, there is also evidence that the antidepressant activity of 
mGluR antagonists is dependent on AMPAR activation. For example, the antidepressant effects 
of the mGluR2/3 antagonist LY341595 are inhibited by the AMPAR antagonist NBQX.
68
 In sum, 
a large body of work now indicates the importance of glutamate signaling in the mediation of 
depressive and anxious symptoms and suggests modulation of that signaling, either directly or 
indirectly, as a new means of treatment. Further, increased AMPAR signaling appears to be 
shared as a common, critical factor in modulations of the glutamate system that induce 
antidepressant effects. 
 In specific reference to tianeptine, several observations have been made that demonstrate 
this agent's ability to modulate glutamatergic signaling in a manner consistent with 
antidepressant effects.
1
 In the rodent amygdala, tianeptine inhibits the acute, stress-induced 
elevation of glutamate efflux and decreases NMDAR currents in unstressed animals.
70,71
 
Similarly, in the hippocampus, tianeptine treatment prevents chronic stress-induced increases in 
NMDAR currents, and elicits a normalization in the ratio of AMPAR and NMDAR excitatory 
postsynaptic currents (EPSCs), changes that appear to be phosphorylation dependent.
72
 More 
specifically, in rodents, treatment with tianeptine increases phosphorylation of the AMPAR 
subunit GluR1 at both Ser831 and Ser845 in the CA3 region of the hippocampus, and at Ser845 
in the prefrontal cortex, and these phosphorylations depend on both protein kinase A (PKA) and 
Ca
2+
/calmodulin-dependent protein kinase II (CaMKII).
39,73
 In contrast, the prototypical SSRI 
fluoxetine has no effect on Ser831 phosphorylation. As phosphorylation of the GluR1 subunit is 
known to potentiate AMPAR function, such actions represent a potential terminal molecular 
 311 
mechanism for the antidepressant effects of tianeptine. In accord with this possibility, increased 
phosphorylation of Ser831 has also been observed to occur concomitantly with the restoration of 
stress-inhibited LTP in hippocampus-prefrontal cortex circuits.
74
 Further, tianeptine has also 
recently been shown to prevent corticosterone-induced AMPAR surface diffusion by a CaMKII-
dependent mechanism in hippocampal neurons, an effect that may enhance AMPAR localization, 
and thus activity, at synapses.
75
 The importance of AMPAR activation to the antidepressant 
activity of tianeptine has also been demonstrated pharmacologically in mice, where co-
administration of the AMPAR inhibitor NBQX blocks the antidepressant effect of tianeptine in 
the forced-swim test.
18
 Lastly, tianeptine treatment has been found to prevent the stress-induced 
upregulation of the glial glutamate transporter (GLT-1) in the rat hippocampus.
76 
 In total, the currently available data appears to indicate a clear connection between 
modulation and normalization of glutamate signaling in the corticolimbic structures by 
tianeptine, and the antidepressant actions of this agent. However, important questions remain 
unanswered, most importantly, what is the initial molecular target interrogated by tianeptine? 
Given that tianeptine displays no significant binding affinity for NMDAR or AMPAR, a direct 
interaction with these receptors appears unlikely. Thus, the observed ability of tianeptine to 
modulate glutamate signaling is likely to be mediated via an indirect mechanism.  
 Intrigued by this mysterious target, we initiated studies to attempt identification of the 
primary molecular binding partner of tianeptine. Here we report our discovery that tianeptine is 
an agonist of both the mu- (MOR) and delta-opioid receptors (DOR), and suggest that activation 
of one or both of these receptors is the initial molecular-level signaling event responsible for the 
beneficial in vivo effects of this agent. To support this hypothesis, we present initial in vivo data 
in mice, using both pharmacological inhibition and genetic knockout studies to implicate the 
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opioid receptors in the antidepressant effects of tianeptine. Lastly, we discuss the results of 
detailed structure-activity relationship (SAR) studies within the tianeptine scaffold, which 
permitted the identification of functionality critical for opioid activity and the design of novel 
analogs with improved pharmacokinetic properties. 
 
Results and Discussion 
Uncovering an Opioid Mechanism 
 Tianeptine is an Agonist of MOR and DOR. In an attempt to elucidate tianeptine’s 
primary molecular target, we screened the drug for binding and/or functional activity at a broad 
panel of CNS targets (64) utilizing the services of the Psychoactive Drug Screening Program 
(PDSP), operated by the National Institute of Mental Health (NIMH).
77
 In primary binding 
assays, the PDSP screens test compounds for inhibition of binding of a radiolabeled reference 
compound at a single 10 µM test concentration. Ligands showing >50% inhibition in this 
primary screen are then evaluated in full concentration range binding experiments to determine 
Ki. Alternatively, when an appropriate binding assay is not available for a given receptor, 
primary screening is instead conducted in a functional assay (both agonist and antagonist mode). 
 These studies confirmed the previously reported results at the ionotropic glutamate 
receptors, NMDAR, AMPAR, and kainate, as tianeptine showed no binding to these receptors at 
the 10 µM test concentration. Further, in the present screen, tianeptine showed no agonist or 
antagonist activity at a number of metabotropic glutamate receptors (mGluR1A,2,4,5,6,8). Therefore, 
the reported modulation of glutamate signaling by tianeptine is likely to occur by an indirect 
mechanism. Based on in vivo pharmacological experiments, it has also been suggested that 
 313 
tianeptine may act as an adenosine 
A1 receptor (A1R) agonist.
78
 
However, we found that tianeptine 
had no agonist or antagonist activity 
at A1R. 
 At the remainder of the panel 
targets, tianeptine was found to be 
completely without activity, except 
for human MOR (hMOR), where it 
bound with nanomolar potency 
(Table 1, Ki = 383 ± 183 nM). 
Intrigued by this unexpected binding, we (functional assays performed by Madalee Gassaway 
with the aid of collaborators in the laboratory of Jonathan Javitch at Columbia University 
Medical Center) further investigated the functional activity of tianeptine at this receptor, as well 
as at the related DOR and kappa-opioid receptor (KOR), using bioluminescence resonance 
energy transfer (BRET) assays measuring G protein dissociation and inhibition of cAMP 
accumulation (see Chapters 3 and 4 for assay principles). Remarkably, tianeptine was found to 
be a full agonist at mouse MOR (mMOR) in both the G protein (Table 1 and Figure 2A, EC50 
(mMOR, G Protein) = 641 ± 120 nM) and the cAMP assay (Table 1, EC50 (mMOR, cAMP) = 1.03 ± 0.10 
µM). Additionally, the tianeptine-induced activation of mMOR was blocked by the opioid 
antagonist naltrexone in a dose-dependent manner (Figure 2B). Tianeptine was also a full 
agonist at human MOR (hMOR), with higher potency in both the G protein and cAMP assays 
(Table 1, EC50 (hMOR, G Protein) = 194 ± 70 nM; EC50 (hMOR, cAMP) = 151 ± 45 nM). The EC50 values 
Table 1. Binding affinity and functional activity of tianeptine at 
rodent and human opioid receptors as determined in radioligand 
binding experiments and BRET assays measuring G protein 
dissociation or inhibition of cAMP accumulation. In all cases, 
Emax was equivalent to the reference agonist, indicating full 
agonist activity. All data represent mean ± SEM of at least 2 
independent experiments; "X" indicates inactive at 100 µM in 
both agonist and antagonist mode; "-" indicates not tested. 
 
Receptor Ki 
EC50                    
(G protein) 
EC50                          
(cAMP inhibition) 
mMOR - 641 ± 120 nM 1.03 ± 0.10 µM 
hMOR 383 ± 183 nM 194 ± 70 nM 151 ± 45 nM 
mDOR - 14.5 ± 6.6 µM 9.46 ± 1.34 µM 
hDOR >10 µM 37.4 ± 11.2 µM 12.2 ± 5.25 µM 
rKOR X X X 





observed at hMOR were also in good agreement with the Ki, which was determined using the 
human receptor. 
 We also evaluated the activity of tianeptine at the DOR. In binding assays, it was found 
that tianeptine has a very low affinity for human DOR (hDOR, Table 1, Ki > 10 µM). However, 
in our functional assays using the mouse DOR (mDOR), full agonist activity was still observed, 
although with much lower potency compared 
to MOR in both the G protein assay (Table 1 
and Figure 3A, EC50 (mDOR, G Protein) = 14.5 ± 6.6 
µM) and the cAMP assay (Table 1, EC50 (mDOR, 
cAMP) = 9.46 ± 1.34 µM). Furthermore, the 
DOR antagonist TIPP-psi dose-dependently 
blocked the tianeptine-induced activation of 
mDOR (Figure 3B). Similar to MOR, we also 
observed an interspecies potency shift at DOR, 
but in this case, tianeptine was less potent at 
the human receptor (Table 1, EC50 (hDOR, G 
protein) = 37.4 ± 11.2 µM, EC50 (hDOR, cAMP) = 
12.2 ± 5.25 µM). Thus, while the selectivity of 
MOR over DOR is approximately 20-fold in 
mice, it is nearly 200-fold in humans. 
 In order to complete our 
characterization of tianeptine’s activity at the 
opioid receptors, we assessed its activity at the 
A/
B/
Figure 2. Tianeptine is a full agonist at the mouse 
MOR (mMOR). Curves represent the average of two 
or more independent experiments. (A) Agonist 
activity at mMOR in the G protein activation BRET 
assay, control agonist = [D-Ala2, N-Me-Phe4, Gly5-
ol]-enkephalin (DAMGO); (B) The inhibition of 
cAMP accumulation by tianeptine is inhibited by the 
opioid antagonist naltrexone in a dose-dependent 
manner. Data collected by Madalee Gassaway. 
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KOR. In binding assays, it was found that 
tianeptine showed no affinity for human KOR 
at concentrations up to 100 µM (Table 1). 
Likewise, in both the G protein and cAMP 
assays, we found tianeptine to be inactive as an 
agonist of rat KOR (rKOR, Table 1 and 
Figure 4A). Similarly, it also showed no 
agonist activity at human KOR (hKOR, Table 
1). Considering the strong evidence for the 
antidepressant activity of KOR antagonists (see 
Chapter 1 for discussion), it was also desirable 
to exclude the possibility that tianeptine’s 
antidepressant effects might in fact result from 
activity as a KOR antagonist. Accordingly, we 
tested tianeptine’s ability to dose-dependently 
block the activation of KOR by control agonist 
U-50,488. In contrast to the known KOR 
antagonist, nor-binaltorphimine (nor-BNI), 
tianeptine failed to inhibit the activation of rKOR by U-50,488 (Figure 4B). Therefore, the 
combined binding and functional data indicate that tianeptine has no activity at the KOR.  
Mechanistic Theories 
 A New Mechanistic Hypothesis. The data presented above establish the first, and at this 
time, only direct molecular binding partners for tianpetine, namely MOR and DOR. Importantly, 
A/
B/
Figure 3. Tianeptine is a full agonist at the mouse DOR 
(mDOR). Curves represent the average of two or more 
independent experiments. (A) Agonist activity at 
mDOR in the G protein activation BRET assay, control 
agonist = [D-Pen(2,5)]enkephalin (DPDPE); (B) The 
inhibition of cAMP accumulation by tianeptine is 
inhibited by the DOR antagonist TIPP-psi in a dose-
dependent manner. Data collected by Madalee 
Gassaway. 
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the potency of tianeptine in activating these 
receptors appears to be sufficiently high to 
render these targets relevant in vivo. In humans, a 
single clinical dose of tianeptine (12.5 mg) 
results in a maximal plasma concentration of ~1 
µM, while in rodents, standard acute and chronic 
dosing (10 mg/kg/day) leads to plasma 
concentrations of ~10 µM  (in vivo brain 
concentrations have not been determined; an 
estimate in ex vivo tissue is low micromolar).
79,80 
Therefore, the in vivo concentration range 
appears adequate for activation of MOR in both 
humans and rodents (EC50 ~0.2-1 µM, Table 1). 
In contrast, activation of DOR (EC50 ~10-34 µM, 
Table 1) may only become relevant with higher 
dosing. This is especially true at the human 
receptors, where the selectivity for MOR over 
DOR is much higher (~200-fold). 
 These are unexpected results, as previous mechanistic studies have focused almost 
entirely on tianeptine’s modulation of monoaminergic and glutamatergic neurotransmission. 
Given our demonstration that tianeptine is inactive at both ionotropic and metabotropic 
glutamate receptors, combined with the prior results of others also corroborating this 
observation
38,39
, a direct modulatory effect on glutamate signaling is highly unlikely. Instead, 
A/
B/
Figure 4. Tianeptine is inactive at the rat KOR 
(rKOR). Curves represent the average of two or more 
independent experiments. (A) Agonist activity at 
rKOR in the G protein activation BRET assay, 
control agonist = U-50,488; (B) The inhibition of 
cAMP accumulation by U-50,488 is not inhibited by 
tianeptine, but is blocked by the control antagonist 
nor-binaltorphimine (nor-BNI). Data collected by 
Madalee Gassaway. 
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tianeptine may normalize glutamateric transmission via an indirect mechanism acting through 
the opioid receptors.  
 Opioid Modulation of Hippocampal Glutamate Signaling. A number of prior reports 
support the ability of opioid receptor activation to modulate the activity of glutamatergic neurons 
in brain regions known to be of importance in mood disorders. In the hippocampus, multiple 
studies have shown that acute treatment with opioid agonists, and in particular MOR selective 
agonists, increases glutamate excitatory activity in both the CA1 and CA3 regions of the 
hippocampus.
81-85
 Importantly, this activation is elicited via an indirect mechanism, through 
opioid receptor-mediated inhibition of GABAergic inhibitory interneurons, which thus results in 
depressed GABA release onto glutamatergic pyramidal cells, and their concomitant disinhibition. 
Several observations support this disinhibitory mechanism. For one, in the hippocampus, MOR 
and DOR are known to be expressed primarily on interneurons, with little expression on 
glutamatergic pyramidal cells themselves.
86-88
 Further, opioid-induced changes in excitatory 
activity are inhibited in the presence of GABA receptor antagonists and opioids appear to have 
no direct effect on pyramidal cells.
81,82,85
 Thus, the modulation of hippocampal glutamate 
signaling by acute application of multiple MOR agonists is in agreement with the effects of acute 
tianeptine, which also increases both AMPAR and NMDAR currents in pyramidal cells of this 
region (probably through opioid-mediated inhibition of interneurons).
71,72,96
 
 Fascinatingly, it has also been shown that acute morphine treatment activates CaMKII in 
the rat hippocampus.
89
 Thus, as an MOR agonist, tianeptine is also likely to increase the activity 
of this kinase. Such upregulation of CaMKII would be in agreement with several reports 
indicating the importance of GluR1 (an AMPAR subunit) phosphorylation at Ser831 in 




 More generally, increases in CaMKII activity have been linked to 
AMPAR translocation into hippocampal synapses, and the increase in AMPAR and NMDAR 
currents in this region caused by tianeptine treatment has also been shown to be kinase 
dependent.
72,90
 Thus, tianeptine appears to induce increased presence or activity of AMPAR at 
hippocampal glutamatergic synapses via an indirect pathway beginning with activation of MOR. 
Such upregulation of AMPAR activity is consistent with the beneficial effects of acute tianeptine 
treatment on LTP.
24-26 
 In contrast to acute treatment, prolonged exposure to morphine decreases hippocampal 
CaMKII activity
89
 and also induces dephosphorylation-dependent internalization of AMPARs.
91
 
These reports appear to stand in opposition to the observed effects of tianeptine, as with this 
agent, enhanced AMPAR-mediated ESPCs are maintained in vivo even after chronic treatment.
72
 
Likewise, the increased phosphorylation of GluR1 subunits induced by tianeptine is only 
observed after chronic treatment, not acute.
39
 Accordingly, it would appear that the long-term 
modulatory effects of tianeptine and classical opioids (e.g. morphine) in the hippocampus are 
distinct, with reduced tolerance-associated adaptation with tianeptine. Although the reasons for 
these differences are unclear, it can be postulated that such reduced tolerance development at the 




 Tianeptine is also known to have a number of procognitive effects in both animals and 
humans. In rodents, it blocks stress- and ethanol-induced impairment in memory tasks, and also 
produces enhanced performance in normal animals.
31,32,93,94
 Relatedly, tianeptine enhances 
attention and vigilance in both cats and monkeys.
95,96
 These effects may be related to 
hippocampal function, as lesion of the diagonal band of Broca, which supplies excitatory inputs 
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to the hippocampus, impairs memory retention in rodents, and that impairment is reversed by 
tianeptine.
97
 In humans, long-term tianeptine treatment of depressed patients elicits 
improvements in memory and learning.
98
 Further, the procognitive effects of tianeptine are likely 
to be induced by its enhancement of AMPAR signaling and LTP via an indirect MOR-dependent 
mechanism. It has been reported that ablation of MOR in the CA3 hippocampus using the 
irreversible MOR antagonist β-funaltrexamine, impairs both memory acquisition and recall in 
rats.
99
 The potential procognitive effects of MOR agonists are also supported by the observation 
that GABA antagonists, which would mimic the disinhibitory effects of opioid agonists, are both 
procognitive and antidepressant.
100,101
 Thus, MOR appears to play a critical role in hippocampal 
memory formation, likely involving release of endogenous opioids from granule cells along the 
mossy fiber pathway onto interneuron opioid receptors. 
 In sum, the known modulations of glutamate signaling by tianeptine in the hippocampus 
are consistent with activation of MOR as the initial signaling event. Considering the currently 
available data, a potential hippocampal mechanism for tianeptine can be summarized in several 
steps: 1) Activation of MORs on GABAergic interneurons induces hyperpolarization and 
decreases GABA release, 2) This increases the excitatory activity of primary glutamatergic 
neurons by disinhibition, 3) Increased glutamate signaling causes increased calcium influx via 
NMDAR, 4) Elevation of calcium activates CaMKII, thereby increasing phosphorylation and 
synaptic translocation of GluR1, 5) AMPAR activity is increased, eliciting LTP and 
antidepressant effects (Figure 5). Over time, repeated stimulation of these pathways normalizes 
the AMPAR/NMDAR ratio and overall glutamatergic tone in the hippocampus. 
 Opioid Modulation of Amygdalar Glutamate Signaling. The MOR is strongly and 























































































































Figure 5. Potential modulation of glutamatergic pyramidal cells in the hippocampus by tianeptine. (A) In 
the drug naive state, GABAergic interneurons exert a basal inhibitory tone on pyramidal cells via activation 
of GABA receptors. (B) Activation of MOR on interneurons hyperpolarizes them, reducing GABA release, 
and disinhibiting glutamate signaling in pyramidal cells. The resulting increased Ca
2+
 influx through 
NMDARs activates CaMKII, thus increasing phosphorylation of AMPAR GluR1 subunits. This enhances 
their trafficking to the synapse and ultimately results in LTP. 
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glutamatergic transmission in this region.
102
 However, the interpretation of signaling studies in 
this area is complicated by the expression of MOR on both glutamatergic pyramidal cells, as well 
as GABAergic interneurons. Accordingly, activation of inhibitory G protein signaling via this 
receptor can be expected to elicit competing inhibitory and disinhibitory effects on glutamate 
signaling. However, MOR activation has generally been found to decrease amygdalar activity, 
with ~50% of neurons in the lateral amygdala (LA) being hyperpolarized, and thus inhibited, by 









 Specific inhibition of LA pyramidal cells by morphine and DAMGO has also 
been observed, as well as inhibition of EPSCs in the central amygdala (CeA).
104,105
 These results 
are in agreement with studies using tianeptine, which has been shown to reduce NMDAR 
currents and firing rate in LA neurons.
71
 However, another study showed that DAMGO and 
morphine have opposing effects on LA pyramidal cell firing rate, with morphine surprisingly 
increasing activity.
106
 In a PET imaging study in humans, it has also been found that increased 
MOR binding potential is associated with reduced brain activity in this region in response to 
aversive stimuli, suggesting a role for endogenous opioid release in the amygdala in controlling 
anxiety.
107
 Lastly, chronic fluoxetine treatment increases both MOR expression and 
preproenkephalin mRNA in the rat amygdala, suggesting the importance of MOR modulation in 
this area in mediating the effects of other antidepressants.
108,109 
 Alternative Mechanisms: Modulation of the Mesolimbic Pathway. Activation of 
opioid receptors in the ventral tegmental area (VTA) and nucleus accumbens (NAc), and the 
concomitant control of dopamine signaling in this area, is important for mediating the reward 
response to positive stimuli (e.g. food, drugs of abuse, etc.). Accordingly, dysregulation of these 
pathways is likely to play an important role in depressive and anhedonic states, and modulation 
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of this area represents a potential approach for eliciting antidepressant effects.
110-112
 In humans it 
has been shown that depressed individuals show decreased NAc activity.
113-116
 In rodents, several 
models of stress elicit anhedonic states characterized by decreased response to subsequent 
positive stimuli, and associated with depressed dopamine levels in NAc, diminished dopamine 
release in NAc in response to rewarding stimuli, and decreased firing of VTA dopaminergic 
neurons projecting onto the NAc (for detailed discussion see Chapter 1).
117-124 
 As endogenous opioid release represents an important mechanism in modulating the 
activity of the mesolimbic pathway, it is not surprising that opioid signaling is involved in 
regulation of depressive states. For one, the actions of several classes of antidepressants appear 
to depend on opioid receptors, as their beneficial effects in rodents are blocked by the opioid 
antagonist naloxone, and they increase expression of MOR itself, or of enkephalin 
protein/mRNA in several areas, including the reward circuits.
108,109,125-130
 Further, exogenously 
administered opioids have antidepressant effects. The opioid peptide β-endorphin, as well as 
several small molecule MOR agonists have all been reported to rapidly and robustly improve the 
symptoms of MDD and/or anxiety disorders in the clinical setting.
131-138
 These results are 
mirrored in rodent models, where a variety of MOR agonists, including morphine and the 
endogenous endomorphins, show antidepressant effects, which are blocked by naloxone.
139-142
 It 
can be imagined that such compounds exert their therapeutic benefit by compensating for an 
underactive endogenous opioid system, which may be the root cause of reduced basal hedonic 
tone and diminished natural reward response in depressed individuals. There is some evidence 
for populations afflicted with such dysfunctional reward circuits. For example, as monitored by a 
PET study with an MOR tracer, untreated patients with MDD showed decreased endogenous 




 This implies that depressed individuals have a reduced ability to cope with 
stress through compensatory mesolimbic activation, and also a decreased ability to experience 
reward through the same pathway, mediated by endogenous opioids (for detailed discussion see 
Chapter 1). 
 Notably, several investigations with tianeptine have observed modulations of the 
mesolimbic pathway and related circuits consistent with the opioid agonist activity of this agent. 
Both acute and chronic treatment of rats with tianeptine elevates dopamine levels in the NAc and 
the prefrontal cortex.
144,145
 Further, these increases do not appear to be the result of locally-
mediated release or reuptake inhibition, as perfusion of tianeptine into the NAc has no effect and 
it also does not bind to DAT. Such observations would be in agreement with remote disinhibition 
of VTA-NAc dopaminergic projections via MOR-mediated inhibition of GABAergic 
interneurons in the VTA, in line with the action of classical MOR agonists.
146
 Additionally, it 
should be noted that one of these studies
145
 also found that no tolerance for dopamine release in 
the NAc developed after 15 days of treatment with tianeptine, suggesting that this opioid may 
have a reduced potential for tolerance development in comparison to other MOR agonists.
147
 
Relatedly, both acute and chronic tianeptine administration have been found to decrease levels of 
met-enkephalin in the striatum while having no effect on levels of mRNA for this peptide, thus 
indicating decreased release, not synthesis.
148
 These results suggest that tianeptine may substitute 
for this endogenous opioid, but as fluoxetine, which is not an opioid agonist, elicited similar 
effects, the interpretation of this study is unclear. Tianeptine has also been shown to rapidly (2 h) 
increase available D2 and D3 dopamine receptor binding sites in the NAc (as measured by 




Lastly, at the systems level, tianeptine has been shown to be analgesic in acute thermal pain 
models, which is consistent with an MOR agonist action.
150
 
 Alternative Mechanisms: Modulation of Nucleus Accumbens Glutamate. The NAc 
also receives excitatory glutamatergic inputs from other regions strongly associated with the 
actions of antidepressants, namely, the hippocampus, amygdala, and prefrontal cortex. Thus, the 
NAc appears to be a key locus for the integration of mood-related signaling originating from 
multiple pathways. Therefore, modulation of glutamate receptor signaling in this region via 




 Generally, it has been found that reward response (to both drugs of abuse and natural 
positive stimuli) is mediated by decreased activity of NAc GABAergic medium spiny neurons 
(MSNs), and in particular, those expressing inhibitory G protein-coupled D2 dopamine receptors 
(D2 MSNs).
153
 These neurons project onto the ventral pallidum, and thus, their inhibition results 
in disinhibition in this region, which evidence indicates may represent a final common pathway 
for rewarding stimuli.
154
 In contrast, D1 MSNs, which are activated by dopamine via stimulatory 
G protein-coupled D1 receptors, project inhibitory outputs back onto local dopaminergic 
synapses and onto VTA dopaminergic cell bodies, thus acting as a negative feedback mechanism 
in the mesolimbic pathway. 
 It can therefore be envisioned that D2 MSNs act as a common integrator of inhibitory 
dopaminergic afferents from the VTA and excitatory glutamatergic afferents from other 
corticolimbic regions (e.g. hippocampus), and that these competing influences are combined to 
modulate reward response. This hypothesis is supported by several lines of evidence. In 
knockout mice lacking D2 receptors, self-administration of, and conditioned place preference 
 325 
(CPP) for, morphine are inhibited.
155,156
 Notably, several classes of antidepressants increase D2 
receptor mRNA and/or binding in the NAc, indicating that upregulation of D2 may be related to 
normalization of hedonic tone in depressed patients.
149,157
 However, dopamine release onto D2 
receptors is not necessary for reward, as rats self-administer NMDAR antagonists directly into 
the NAc, and these actions are not inhibited by the D2/D3 antagonist sulpiride.
158
 Therefore, in 
agreement with the above hypothesis, antagonism of excitatory glutamatergic inputs to D2 
MSNs also appears sufficient for activating a reward response. 
 The precise modulations of glutamate signaling in the NAc that control reward behavior 
are only just beginning to be unraveled. However, as in the hippocampus, modulation of 
AMPAR and NMDAR signaling appears to be important, and several interesting observations 
have been made in this area. In particular, the GluR1 and GluR2 subunits of AMPARs appear to 
have opposing effects in D2 MSNs. In rats, increased expression of accumbal GluR1 inhibits 
intracranial self-stimulation (ICSS) and cocaine reward, while an increase in GluR2 potentiates 
these stimuli.
159,160
 At the same time, genetic knockout of GluR2 produces mice that show no 
CPP for food reward.
161
 Accordingly, upregulation of GluR1 may be involved in depressive 
states, while increases in GluR2 may elicit antidepressant effects. In turn, these observations 
appear to be related to control of Ca
2+
 influx, as AMPARs containing the GluR2 subunit are 
impermeable to Ca
2+
, while those lacking this subunit allow Ca
2+
 flow. Indeed, accumbal 
injection of the Ca
2+
 channel blocker diltiazem potentiates cocaine CPP.
162
 Thus, other signaling 
mechanisms inhibiting Ca
2+
 influx, for example blockade of NMDAR, or Ca
2+
 channel inhibition 
by opioid receptors, would be expected to increase the magnitude of hedonic response. In fact, 
MORs are known to colocalize with, and modulate, NMDARs in the NAc, and the actions of 
these receptors may therefore be synergistic.
163,164
 Decreased intracellular Ca
2+
 can also be 
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expected to lower the activity of certain kinases including CaMKII and protein kinase C (PKC), 
which are known to phosphorylate GluR1 and GluR2. Interestingly, the synaptic trafficking of 
these two subunits appears to be differentially regulated by phosphorylation, with decreased 
phosphorylation increasing synaptic GluR2 and decreasing GluR1.
39,73,75,90,165-167
 Therefore, 
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Figure 6. Potential modulation of D2 MSNs in the NAc by tianeptine. By activation of MORs on GABAergic 
interneurons in the VTA, tianeptine increases dopamine release onto D2 MSNs via a disinhibitory mechanism. This 
activates inhibitory D2 receptors, which, along with activation of MORs on the MSNs themselves, results in 
inhibitory G protein signaling. This inhibits Ca
2+
 channels and general glutamate signaling and NMDAR activity via 
hyperpolarization. The resulting decreased activity of GABAergic projections to the ventral pallidum elicits a reward 
response. Further, decreased free Ca
2+
 reduces the activity of kinases responsible for phosphorylation of AMPAR 
subunits. This enriches GluR2 and depletes GluR1 in the synapse, inducing LTP of the reward response. NMDAR 
antagonists like ketamine produce similar effects in the NAc. 
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may initiate long-lasting antidepressant effects through normalization of AMPAR signaling and 
increased hedonic tone (Figure 6). This conjecture is further supported by the recent observation 
that chronic fluoxetine downregulates CaMKII in the NAc of mice, and that inhibition of this 
kinase has antidepressant effects similar to fluoxetine in a chronic stress model.
168 
 In summary, although MOR activation at first appears to be a surprising molecular 
mechanism for the beneficial effects of tianeptine on mood, full consideration of available 
evidence reveals that activation of this receptor represents a highly plausible initial molecular 
signaling event for this agent. Activation of MOR would be expected to modulate 
neurotransmission in several brain regions (hippocampus, amygdala, and mesolimbic pathway) 
in a manner consistent with both mood elevation, and with prior observations of tianeptine's 
neuromodulatory effects. However, the full understanding of the relationship between the opioid 
receptor system and mood is complicated by several factors, including: 1) opioid receptors are 
broadly expressed in multiple mood-related areas of the brain, 2) opioid receptor activation may 
elicit complementary or opposing effects in different regions and cell types, and 3) those regions 
are interconnected via multiple direct and indirect pathways that are not fully defined. 
Accordingly, the precise, circuit-level modulations responsible for the gross behavioral effects of 
opioid receptor activation remain to be fully clarified. 
 
Confirming Opioid Involvement 
 In Vivo Studies Confirm the Involvement of Opioid Receptors. To confirm the 
importance of opioid receptor activation to the mechanism of tianeptine, we collaborated with 
the laboratory of Professor René Hen at Columbia University Medical Center, to perform 
behavioral studies in mice. The following in vivo studies were kindly performed by Dr. Benjamin 
 328 
Samuels (a postdoctoral scientist in the Hen laboratory) and Marjorie Levinstein (a research 
technician in the Hen laboratory). Using a combination of genetic and pharmacological 
inhibition experiments, this preliminary work confirmed the important role of MOR and also, 
surprisingly, DOR, in mediation of the acute behavioral effects of tianeptine. 
 The forced swim test (FST) and elevated plus maze (EPM) are two commonly used 
rodent models of depressive or anxious behavior, respectively, which are responsive to the 
actions of classical antidepressants (e.g. SSRIs and TCAs) or anxiolytics (e.g. benzodiazepines). 
In the FST, mice are place in a water tank with vertical walls and their swimming/escape 
behavior is monitored. Mice treated with antidepressants display reduced immobility, which 
appears to be correlated to increased motivation to escape. In the EPM, mice are placed in an 
elevated, plus-shaped maze, where two arms are open and two are surrounded by walls. 
Increased entry into, or time spent in, the open arms is associated with a decreased level of 
anxiety.  
 Tianeptine is Ineffective in MOR Knockout Mice. To test the behavioral effects of 
tianeptine and confirm its mechanism of action, we measured the acute effects of tianeptine in 
these models, using both MOR knockout mice and their wild type (WT) littermates. Tianeptine 
(30 mg/kg, i.p.) induced significant effects in both tests (1 h post drug), which were completely 
eliminated in the MOR knockout mice (Figure 7A and B), indicating the importance of MOR in 
the actions of this drug. In WT mice, we also observed a significant tianeptine-induced increase 
in latency to feed in a novel environment and decrease in total home cage food consumption, 
indicating an anorectic effect (Figure 7C). In MOR knockout mice, the baseline feeding latency 
was increased compared to WT mice, but no effect was observed on tianeptine treatment, 
demonstrating that this effect is also dependent on MOR (Figure 7C). In all groups, no 
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significant changes in overall locomotor activity in an open field were noted, indicating that the 
behavioral effects of tianeptine are not due to general motor stimulation or depression. 
 Pharmacological Inhibition Suggests DOR is Also Involved. To further confirm the 
importance of the opioid receptors, and specifically MOR, to the mechanism of tianeptine, we 
also conducted pharmacological inhibition experiments with opioid receptor agonists. 
Specifically, we examined the effects of tianeptine (30 mg/kg, i.p.) in the same behavioral 
models following pretreatment (15 minutes before) with either the MOR selective antagonist 
cyprodime (10 mg/kg, s.c.) or the DOR selective antagonist naltrindole (3 mg/kg, s.c.). It should 








































































































Figure 7. The behavioral effects of tianeptine are eliminated in MOR knockout mice. Tianeptine (30 mg/kg i.p.) 
was dosed to C57BL/6 wild type (WT) or MOR knockout mice (KO) (n = 10 per group) 1 h before behavioral 
testing. (A) In the EPM, tianeptine significantly increased open arm entries in WT but not KO mice; (B) In the 
FST, tianeptine signifcantly decreased mean immobility time in WT but not KO mice; (C) Tianeptine increased 
latency to feed in WT mice, but had no effect in KO mice; ** = p < 0.01. 
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provide adequate receptor blockade while still affording subtype selectivity. In the case of 
cyprodime, which is a lesser-used antagonist (compared to naltrindole), we also confirmed the 
MOR selectivity using antagonist experiments in our BRET assays. In competition with control 
agonists (5x EC50 concentration), cyprodime was ~45-fold more potent at MOR than at KOR, 
and ~1000-fold more potent over DOR. From this data, selectivity over DOR appeared to be of 
no concern. Further, this same dose of cyprodime has been previously reported to inhibit the 
analgesic effects of morphine, but not those of the KOR agonist U-50,488, indicating selectivity 
over KOR at this dosage level.
169
  
 Surprisingly, these studies indicated that both MOR and DOR are involved in mediating 
the behavioral effects of tianeptine. In the EPM, the effects of tianeptine were completely 
inhibited by naltrindole, whereas mixed results were observed with cyprodime (Figure 8A and 
B). In terms of open arm entries, inhibition by cyprodime was not significant, while in terms of 
open arm duration, post hoc analysis indicated partial inhibition by cyprodime. In contrast, in the 
FST, cyprodime had a more robust inhibitory effect (Figure 8C). No significant change in 
immobility time was observed with tianeptine following pretreatment with either cyprodime or 
naltrindole, suggesting inhibition by both antagonists. However, the tianeptine+naltrindole 
treated group was not significant compared to the tianeptine+saline group, suggesting that the 
inhibition by naltrindole in this test was only partial. Unfortunately, the strength of the treatment 
effect in this FST experiment was quite weak and thus, it is inadvisable to draw strong 
conclusions regarding potential differences between the effect of cyprodime and naltrindole 
based on this data alone. As a general trend over multiple experiments, we observed that the 
effects of tianeptine in the FST were less robust and more variable than those observed in the 
EPM. 
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 In total, these results appear to indicate that the behavioral effects of tianeptine in mood-
related mouse models depend on both MOR and DOR. Additionally, the interaction between 
these receptors is complex, as antagonists for each differentially modulate the observed activity 
of tianeptine in the EPM and FST. Despite the well known antidepressant and anxiolytic actions 
of DOR agonists
170
 (for additional discussion, see Chapter 1), these results were surprising 
given the observed 20-fold selectivity of tianeptine for MOR over DOR using mouse receptors 
(see above). However, considering the high 30 mg/kg dose used in these studies, it is possible 
that sufficient brain concentrations are achieved to activate mDOR (see below, 













































































































































Figure 8. The behavioral effects of tianeptine in C57BL/6 mice are inhibited by cyprodime and naltrindole. 
Cyprodime (10 mg/kg, s.c.), naltrindole (3 mg/kg, s.c.), or saline was dosed 15 min. before tianeptine; tianeptine (30 
mg./kg, i.p.) or saline was given and behavior was measured 1 h later; in the hot plate assay (D) behavior was 
measured 15 min. post tianeptine; n = 10 per group. (A)/(B) In the EPM, the effects of tianeptine were blocked by 
naltrindole and partially blocked by cyprodime; (C) In the FST, the effect of tianeptine was blocked by cyprodime 
and partially blocked by naltrindole; (D) In the hot plate assay, the analgesic effect of tianeptine was blocked by 
cyprodime but not by naltrindole; * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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(EC50 = 10-15 µM). In fact, using the standard allometric conversion, this mouse dose 
corresponds to a single human dose in the range of 150-200 mg, more than 10-fold greater than 
the typically prescribed dose (12.5 mg, 3 times daily). Furthermore, the MOR/DOR selectivity 
was found to be ~200-fold at the human receptors, thus making the direct activation of DOR 
highly unlikely in humans at therapeutic doses. Accordingly, the relevance of this mouse data 
implicating DOR, to the mechanism of action in humans, is unclear. 
 Nonetheless, several scenarios can be imagined in which DOR activation would also be 
relevant to antidepressant effects in humans. For one, the action of tianeptine at DOR might be 
indirect. For example, activation of MOR might induce translocation of DOR sequestered in 
intracellular vesicles to the cell surface, where it could mediate signaling by endogenous opioids 
(e.g. enkephalin). It is known that DOR is largely localized to intracellular compartments and 
that its trafficking depends on MOR, thus such a hypothesis is not entirely implausible (for 
additional discussion, see Chapter 1).
171-173
 The existence of additional pharmacologically 
distinct DOR subtypes with unique CNS expression patterns (potentially corresponding to 
different splice variants) has also been reported.
174
 Thus, it is possible that tianeptine enjoys a 
much higher affinity for one of these putative splice variants, which is not accurately described 
by the affinity observed in vitro. Yet another possibility to consider is that in certain brain 
regions, a large receptor reserve of DOR exists, which would thus left shift its apparent potency 
in vivo in these areas, allowing for relevant downstream signaling at unexpectedly low 
concentrations. In any case, more experiments are necessary to rationalize the apparent 
involvement of DOR in the behavioral effects of tianeptine in animals, and to potentially relate 
these observations to the human mechanism of action. 
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 The Analgesic and Anorectic Activity of Tianeptine is MOR-dependent. Considering 
the MOR agonist activity of tianeptine, we also expected this agent to display analgesic 
properties and in fact, this has been previously reported.
150
 Surprisingly, in an initial experiment 
using the hot plate assay, we failed to observe any analgesic effect at the same time point (1 h 
post dosing) used in the other behavioral assays (data not shown). Reasoning that this might 
indicate surprisingly rapid metabolism of tianeptine in this particular mouse strain (see below, 
Pharmacokinetic Considerations), we instead tested tianeptine at an earlier time point (15 min. 
post dosing). Indeed, with this timing, tianeptine elicited a very robust analgesic effect (Figure 
8D). Further, this effect was completely blocked by pretreatment with cyprodime, while 
naltrindole had no effect. Likewise, the suppression of feeding by tianeptine was also completely 
inhibited by cyprodime, but not by naltrindole (data not shown). Thus, the analgesic and 
anorectic activity of tianeptine appears to be mediated entirely by MOR. This data also shows 
that the analgesic and mood-related effects of tianeptine are temporally dissociated, as effects are 
observed in the EPM and FST at a time point at which no analgesic activity remains. Therefore, 
it appears that some of the behavioral effects of tianeptine are longer lasting and not dependent 
on active receptor occupancy (see below, Pharmacokinetic Considerations). The analgesic test 
also demonstrated the DOR selectivity of the employed naltrindole dose, as no cross-inhibition 
of analgesia via MOR was observed. 
 Conflicting Results are Obtained with Other Opioid Antagonists. We also examined 
the ability of the low selectivity MOR antagonists naloxone and naltrexone to inhibit the effects 
of tianeptine. Surprisingly, we found that naloxone (2 mg/kg, i.p., 15 minutes before tianeptine) 
did not inhibit tianeptine's effects in the EPM or FST (Figure 9A and B). This finding was 
remarkable, given that similar or lower doses of naloxone, delivered by the same route of 
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administration in rodents, have been previously reported to both fully inhibit the analgesic effects 
of moderate doses of morphine (a much more potent opioid) and induce withdrawal in habituated 
animals.
175-177
 However, it is also known that naloxone undergoes extensive first pass 
metabolism (in humans), and that it has a very short half-life in mice (~15 min. or less).
178
 Given 
that a significant percentage of an intraperitoneally administered drug is known to be absorbed 
via the liver through the portal vein
179
, we reasoned that the observed discrepancy might 
represent a pharmacokinetic effect. That is, the naloxone concentration might decrease too 
rapidly to effectively blockade the MOR. Therefore, we tested higher doses of naloxone (5 































































































































Figure 9. The behavioral effects of tianeptine are only inhibited by high doses of naloxone. (A)/(B) Naloxone (2 
mg/kg, i.p.) or saline was dosed 15 min. before tianeptine; tianeptine (30 mg./kg, i.p.) or saline was given and 
behavior was measured 1 h later; no inhibition was observed in the EPM (A) or FST (B). (C)/(D) Naloxone (5 
mg/kg, s.c.), naltrexone (10 mg/kg, s.c.), or saline was dosed 15 min. before tianeptine; tianeptine (30 mg./kg, i.p.) 
or saline was given and behavior was measured 1 h later; both naloxone and naltrexone blocked the effect of 
tianeptine in the EPM (C), but no significant effects were observed in the FST (D). n = 10 per group; ** = p < 0.01, 
*** = p < 0.001. 
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subcutaneous administration to prevent first pass 
metabolism (Figure 9C and D). In the EPM, both 
antagonists fully blocked the effects of tianeptine. 
Unfortunately, in this particular experiment, the 
effect of tianeptine in the FST was not 
significant, however, there was a clear trend 
towards activity and also towards inhibition by 
both antagonists. Thus, it appears that the 
ineffectiveness of naloxone can be overcome with 
higher dosing and a different route of 
administration. 
 Considering these conflicting results, we also examined the ability of the lower, 
intraperitoneal dose of naloxone to inhibit tianeptine analgesia at the 15 minute time point. 
Amazingly, the same dose of naloxone that failed to inhibit tianeptine's effects in the EPM and 
FST, inhibited analgesia in the hot plate assay (Figure 10). Thus, the lower dose of naloxone 
appears to be effective in blockading the MORs involved in the analgesic effects of tianeptine, 
without interfering with its antidepressant effects. This observation is intriguing, as it suggests 
that tianeptine's antidepressant and anxiolytic effects may be mediated by a subpopulation of 
MOR that is less sensitive to naloxone than those receptors involved in analgesia. However, 
further experiments will be necessary to confirm such a possibility. 
 Pharmacokinetic Considerations. To aid interpretation of the behavioral experiments 
described above, we also conducted a pharmacokinetic study to determine the actual 
concentrations of tianeptine reached in both plasma and brain, using the same mouse strain  
*
Figure 10. The analgesic effect of tianeptine is 
inhibited by a low dose of naloxone. Naloxone (2 
mg/kg, i.p.) or saline was dosed 15 min. before 
tianeptine; tianeptine (30 mg./kg, i.p.) or saline was 
given and analgesic activiy was measured  in the hot 
plate assay 15 min. later; n = 10 per group; * = p < 
0.05. 
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(C57BL/6) and dosing (30 mg/kg, i.p.) 
employed in our other experiments 
(Figure 11). This data helped to 
explain and reinforce several of the 
observations and conclusions derived 
from the behavioral experiments. For 
one, the pharmacokinetic data showed 
that absorption and elimination of 
tianeptine by the intraperitoneal route 
in C57 mice is extremely rapid. 
Maximum concentration was reached 
at the earliest recorded time point (5 
min.) in both plasma and brain, and the 
drug was no longer detectable (<10 
nM) at time points beyond one hour 
(t1/2 (plasma) = 0.11 h; t1/2 (brain) = 
0.12 h). At the same time, brain 
penetration was only modest, with a brain-plasma ratio of 0.13 (based on area under the curve). 
For the most part, these results are in agreement with those previously reported in rats, where 
rapid elimination was also observed.
80
  
 Therefore, it seems that the antidepressant and anxiolytic effects observed above do 
indeed represent a long-lasting phenomenon that persists beyond the presence of tianeptine itself. 
Several explanations may account for this observation. One possibility is that the short pulse of 
A/
B/
Figure 11. Plasma (A) and brain (B) concentrations (nM) of 
tianeptine following administration to C57BL/6 mice (30 mg/kg, 
i.p.). Tianeptine was undetectable beyond 1 h. 
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MOR activation may be sufficient to initiate persistent downstream signaling pathways, for 
example AMPAR potentiation or transcriptional events. Alternatively, longer-lasting metabolites 
of tianeptine might also activate MOR, maintaining active signaling for longer periods. Lastly, 
were tianeptine to display slow binding kinetics, a tianeptine-bound, active receptor state might 
endure significantly longer than indicated by the apparent concentration of drug in brain or 
plasma. However, the lack of significant analgesic activity at 1 h (when tianpetine concentrations 
are negligible) appears to argue against the presence of MOR active metabolites or slow off-rate. 
In other words, the lack of analgesia appears to indicate that MOR is no longer being activated at 
1 h, in agreement with the low drug concentration at this time point. During the behavioral 
testing, it was also qualitatively observed that the mice displayed markedly increased locomotor 
activity following drug treatment, but this apparent stimulation subsided by the time (1 h) that 
the behavioral experiments were run. Thus, this increased locomotor activity, which might be 
considered as a surrogate for the "high" or euphoric state induced by opioids, also appears to 
depend on active receptor occupancy and is temporally dissociated from the longer-lasting 
activity of tianpetine in antidepressant and anxiolytic tests. 
 Unfortunately, the pharmacokinetic data does not appear to offer a satisfying explanation 
for the involvement of DOR. The maximum concentration achieved in brain was ~3.5 µM, 
which, when considering the observed potency at mDOR, would only produce ~25% Emax 
activation of DOR, and then only for a very short period of time. Whether such a slight and 
transient activation of DOR is sufficient to contribute to the observed mood-elevating effects of 
tianeptine is uncertain. Thus, direct activation of DOR, even at the high dose used here, may not 
be the mechanism by which this receptor contributes to tianeptine's behavioral effects in mice. 
 338 
 Comparison of Behavioral Effects to Morphine. The prototypical small molecule 
MOR agonist, morphine, has also been evaluated by others in the same rodent behavioral models 
used here. We had hoped that comparison with these prior reports would reveal tianeptine to be a 
unique agent with distinct properties compared to morphine, perhaps indicating that this 
compound would be less likely to suffer the negative side effects and abuse potential of classical 
opioids. Unfortunately, the available data for morphine is largely mixed. In both the EPM and 
FST in rodents, variable effects of morphine have been reported, with some investigations 
reporting antidepressant and anxiolytic activity, and others reporting opposing results.
180-183
 
Similarly, morphine displays a polyphasic effect on feeding, with both anorectic and orexigenic 
effects depending on time.
184
 Locomotor stimulation has also been reported with morphine in 
mice and rats, but this effect is both time and dose dependent, with higher doses instead eliciting 
an initial sedation. Further, large variability is observed between different mouse strains and the 
increased motor activity does not correlate well with dopamine release in the mesolimbic 
circuits.
185-186
 Accordingly, a comparison between the behavioral effects of tianeptine and 
morphine is not particularly useful given the current confused state of the literature in this area. 
Additional experiments with morphine, carried out alongside tianeptine using the same 
experimental conditions, will thus be needed to further clarify this situation. 
 
Exploring the Tianeptine Scaffold 
 SAR Exploration: Goals. As a complement to our mechanistic investigations with 
tianeptine itself, we also wanted to explore structure-activity relationships (SAR) within this 
molecular scaffold, via the synthesis of novel analogs. In addition to understanding the key 
functionalities required for opioid activity in this unusual skeleton, we sought to achieve several 
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key goals in this effort. Perhaps most significant among these was increasing the metabolic 
stability in comparison to tianeptine. Given the extremely rapid metabolism and elimination of 
tianeptine observed in mice, and also considering the known short half-life in humans
79
, we 
reasoned that increasing the total drug exposure might provide a therapeutic with increased 
efficacy. Further, the 3-times-daily dosing of tianeptine may result in compliance issues with 
patients, and a once daily therapeutic would be more ideal.  
 In contrast, we were not particularly concerned with increasing potency, as it is well 
known that high potency MOR agonists may induce potentially lethal respiratory depression in 
overdose and have a high potential for abuse. In contrast, tianeptine has a good safety profile
187
 
and low incidence of abuse, properties that we expect derive from its comparatively low potency 
at MOR. Although there are sporadic reports of both tianeptine abuse and overdose (fatal in 
combination with other drugs) consistent with its activity at MOR
188-192
, these issues appear 
minimal relative to the ubiquitous problems associated with traditional opioid analgesics. 
Likewise, a recent placebo-controlled study showed that a single high dose of tianeptine (75 mg) 
does not elicit a significant change in responses to the Addiction Research Center Inventory, a 
questionnaire designed to assess the subjective psychoactive effects of drugs and sensitive to the 
mood elevating properties of commonly abused substances, including opioids.
193 
 Lastly, we wanted to develop analogs which would allow us to further probe the 
mechanism of tianeptine via pharmacological methods. Given the surprising involvement of 
DOR noted in our in vivo studies, we were particularly interested in close structural derivatives 
that would either eliminate or enhance the DOR component of tianeptine's activity. We would 
then be able to compare such analogs to the parent drug using the in vivo behavioral models, to 
confirm or refute the importance of direct DOR activation in mediating antidepressant effects in 
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this class. Similarly, close structural analogs lacking activity at MOR could be used to further 
confirm this receptor as the primary molecular target for tianpetine, as they would be expected to 
induce no antidepressant or anxiolytic effects. 
 SAR Exploration: Molecular Design and Strategy. In order to fully map the SAR of 
the tianeptine skeleton, it was required to synthesize analogs varied at several key regions: 1) the 
amine side chain, 2) the ring substituents, and 3) the sulfonamide bridge (Figure 12). In 
particular we were interested in the amine side chain, as the heptanoic acid group in the parent 
compound is highly unusual, and thus, we wanted to determine if this functionality was required 
for opioid activity. Further, in the classical morphinan and benzomorphan opioid skeletons, 
varying the alkyl substituent on the basic nitrogen exerts a dramatic effect on both potency and 
efficacy. In fact, the appropriate substituent at this position can switch these scaffolds from 
agonist to antagonist. For example, replacing the N-methyl substituent in the opioid agonist 
oxymorphone, with an allyl substituent, results in the pure opioid antagonist naloxone. 
 In considering the ring substituents, we were particularly interested in several potential 
modifications. For one, we wanted to determine the importance of the chlorine substituent, as a 
review of the early patents on tianeptine and related 
structures seemed to indicate that some optimization had 
been done to select this particular substituent and position. 
We also wanted to determine if additional ring substitution 
would be tolerated, or if the unsubstituted phenyl ring in 
tianeptine might be replaced with a thiophene isostere. 
Lastly, considering the importance of a phenolic hydroxy 
group in mediating the high potency binding of classical 
Figure 12. Key SAR locants of 
tianeptine. 
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morphinan opioids, we imagined we might be able to install a hydroxy group in an analogous 
position on the tianeptine core, so as to take advantage of a similar effect. 
 Based on consideration of a recent x-ray crystal structure
194
 and a 3D model generated in 
silico using the Open Babel software suite
195
, the sulfonamide bridge region in tianeptine appears 
to induce a wing-like bend in the core. Thus, tianeptine is not planar and in fact, exhibits a 
surprising degree of three-dimensionality, which is not obvious from a more cursory examination 
of its 2D structure. We therefore expected the sulfonamide bridge to be of significant importance 
in mediating the binding of tianeptine at the opioid receptors. Furthemore, this region is host to 
three potential hydrogen bond acceptors, further enhancing its potential as a key interacting 
moiety. 
 To further inform our design strategy, we conducted a preliminary molecular docking 
study of tianeptine in the binding pocket of the recently reported mouse MOR crystal structure 
(PDBID=4DKL)
196
 using AutoDock Vina
197
 and the PyRx modeling suite
198
 (Figure 13). 
Although (-)-tianeptine is known to be the more active enantiomer (compared to (+)-
tianeptine)
199
, the absolute configurations of the two enantiomers have not been reported. 
Therefore, we docked both enantiomers at MOR in an attempt to determine which might be more 
active at this receptor. Unfortunately, both enantiomers afforded a similar binding pose and 
calculated binding affinity. Thus, we have selected to display the S enantiomer in this work, but 
as of this time, there is no definitive indication that this is in fact equivalent to the more active (-) 
enantiomer. Nonetheless, given the similar binding poses adopted by the two enantiomers, 
conclusions regarding the key interactions are the same in either case.  
 Most notably, the docking results suggest that tianeptine forms a salt bridge between its 
amino group and aspartate-147, an interaction that is known to be critical for the binding of other 
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opioid alkaloids, including β-
funaltrexamine (β-FNA, 
Figure 13B), the morphinan 
antagonist co-crystallized with 
MOR in structure 4DKL. The 
modeling also suggests a 
potential hydrogen bonding 
interaction between the 
sulfonamide and tyrosine-148, 
an interaction also shared by β-
FNA. Further, the 
unsubstituted phenyl ring 
appears to be oriented towards 
the interior of the binding 
pocket, while the chloro-
substituted phenyl ring faces 
outward. Thus, from this model 
it was expected that variation 
of the chloro group would be tolerated, while steric tolerance on the other aryl ring would be 
limited. Notably, tianeptine lacks a phenolic hydroxy group, and thus is not expected to form the 
hydrogen bonding network with histidine-297 critical to the activity of the morphinans 
(including β-FNA). However, the docking results suggested that a hydroxy group installed ortho 









Figure 13.  Molecular docking of (S)-tianeptine at the mouse MOR 
(mMOR, PDBID = 4DKL) predicts key interactions. (A) Predicted 
binding pose of tianeptine showing potential salt bridge to Asp147 
and hydrogen bonding interaction with Tyr148; (B) Binding pose of 
β-FNA co-crystallized with mMOR (from 4DKL) showing similar 
interactions to tianeptine; β-FNA also forms a hydrogen bonding 
network with His297 via several intervening water molecules (red 
spheres); amide side chain of β-FNA has been removed for clarity. 
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tianeptine scaffold. Lastly, in the calculated binding pose, the heptanoic acid chain extends deep 
into the binding pocket, and thus might be expected to be important for binding. However, there 
was no obvious polar interaction partner for the carboxylate terminus of this substituent, 
suggesting that the majority of the binding energy in this region is provided by hydrophobic 
interactions of the alkyl chain, and not by hydrogen bonding or ionic interactions with the 
carboxylate. As tantalizing as these results may be, it is important to mention that in structure 
4DKL, the receptor was co-crystallized with an antagonist and therefore, is likely to be in a 
conformation not indicative of the activated receptor state. As we did not consider receptor or 
binding site flexibility in these preliminary studies, the results thus represent the docking an 
agonist into the rigid binding pocket of an antagonist-bound state, and should be taken with 
reserve. 
 With this knowledge in hand, we set out to synthesize a library of tianeptine analogs to 
test the hypotheses described here, and to accomplish the goals set out above. It should be noted 
that in practice, the following studies were largely conducted in an iterative fashion, with new 
analogs continuously tested in opioid functional assays as available, and the resulting data used 
to guide further design and synthesis efforts. However, in the interest of clarity, the synthesis of 
the analog library, and the biological evaluation of those analogs, have been divided, such that 
the reader may more easily consider the available data as a whole. Further, although more than 
80 unique analogs have been synthesized as of this writing, only those necessary for illustrating 
key SAR trends will be described here. 
 Synthesis of Diverse Tianeptine Analogs: Approach. In order to explore the tianeptine 
structural space in a rapid and efficient manner, we employed a modular route whereby a diverse 
collection of diarylthiazepine cores were first prepared, and then coupled to an equally diverse  
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set of amine side chains via alkylation (Scheme 1). To prepare the cores themselves, the 
appropriate anilines and sulfonyl chlorides were combined to provide sulfonamide intermediates, 
which were then cyclized under Friedel-Crafts conditions to provide tricyclic 
diarylthiazepinones. These could then be reduced and chlorinated to provide the required 
benzylic chlorides (Scheme 1). 
 Synthesis of Diarylthiazepinones: Sulfonyl 
Chloride Route. To approach several uniquely 
subsituted diarylthiazepine cores, we required the 
corresponding chlorosulfonyl benzoate esters. These 
were prepared via diazotization of the corresponding 
Scheme 1.  General approach for the synthesis of tianeptine analogs. 
Scheme 2. Synthesis of sulfonyl chlorides. 
Scheme 3. Synthesis of diarylthiazepinones from sulfonyl chlorides. 
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aniline, followed by capture with sulfur dioxide (Scheme 2). The sulfonyl chlorides thus 
obtained were converted to sulfonamides of type 2 via treatment with the appropriate aniline 
(Scheme 3), and if necessary, methylation of the resulting N-H sulfonamide (for the thiophene 
derivatives, Scheme 3A). Sulfonamides 2 were then hydrolyzed to the corresponding carboxylic 
acids, converted to the acyl chlorides, and cyclized under intramolecular Friedel-Crafts 
conditions to provide a collection of diarylthiazepinones (3a-g). 
 Synthesis of Diarylthiazepinones: Via Common Intermediate. We were pleased to 
find that ketone 3h was commercially available, and thus, it was possible to use this versatile 
building block as a starting point for further derivatization. It was found the ketone 3h was 
ammenable to several 




(Scheme 4B), and 
nucleophilic aromatic 
substitution at the chloro 
substituent (Scheme 4C). 
Accordingly, we were able 
to rapidly access 
additional, diverse 
diarylthiazepinones, 
including 3i-o. Further, the 
Scheme 4.  Synthesis of diarylthiazepinones from common intermediate. 
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 iodo-substituted derivative 3p 
could be obtained by ipso 
substitution of the 
trimethylsilyl analog 3k on 
treatment with iodine 
monochloride (Scheme 4D). 
 Synthesis of 
Diarylthiazepinyl Chlorides. The ketones of type 3 were easily converted to their 
corresponding benzylic chlorides in effectively quantitative yield via reduction with sodium 
borohydride, followed by nucleophilic chlorination with thionyl chloride (Scheme 5). Thus we 
obtained a diverse collection of highly electrophilic diarylthiazepinyl chlorides 5, which were 
versatile intermediates for the synthesis of tianeptine analogs in one step, via alkylation of 
different primary amines (see below). 
 Synthesis of 7-Substituted Analogs. As described above, our docking studies indicated 
the potential of phenolic analogs bearing a hydroxy group at position 7 (ortho to the sulfonamide 
nitrogen) to participate in hydrogen bonding interations with the receptor in a manner analogous 
to classical opioids (e.g. morphine). Accordingly, we were particularly interested in synthesizing 
analogs with this substitution pattern. Unfortunately, our Friedel-Crafts route proved ineffective 
in this case, as when substrates bearing a methoxy or halogen group ortho to the sulfonamide 
nitrogen were treated in the usual manner, no cyclized product was obtained. Presumably, this 
results from steric strain between the ortho substituent and sulfonamide methyl group in the 
roughly planar transition state leading to the ketone product (Scheme 6A). This difficulty was 
overcome by using a Nozaki-Hiyama-Kishi (NHK) reaction in the key cyclization step, and 
Scheme 5. Synthesis of diarylthiazepinyl chlorides. 
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alcohol 4q was obtained directly 
by cyclization of iodoaldehyde 7 
(Scheme 6B). Presumably, the sp
3
 
hybridization of the resulting 
alcohol product allows for less 
planarity, and thus, less strain in 
the transition state. Even so, a high 
temperature was still required to 
effect cyclization, in contrast to the 
low-temperature conditions 
typically employed in NHK 
reactions. 
 Synthesis of Tianeptine Analogs: Side Chain Variation. To explore the importance of 
the amino side chain, we synthesized a large number of derivatives bearing different substituents 
at this position, including alkyl groups, esters, ethers, and aromatic substituents. At the same 
time, we maintained the same ring substitution pattern as tianeptine, such that we could probe the 
side chain region in isolation of interfering effects from variation in the core region. This was 
accomplished by treatment of the commercially available chloride 5h with diverse primary 
amines in a simple and brief (<1 h) reaction, which provided the desired products of type 8 in 
high yield (Scheme 7). This process is also quite clean, and in many cases, purification of the 
resulting products beyond simple extraction was not necessary.  
 Synthesis of Tianeptine Analogs: Core Variation. In a similar manner, we also 
prepared analogs varied at the diarylthiazepine core (8 and 9) using the previously prepared,  




















diverse, chlorides 5a-p as coupling partners for select amines (Scheme 8 and Scheme 9). In this 
case, we again attempted to study this region in isolation by limiting these analogs to several 
select amine side chains, which we had previously found to be among the most potent (see 
below, Side Chain SAR). 
 Synthesis of Additional Analogs. Lastly, additional derivatization on compounds of type 
8 allowed for the preparation of several other analogs. For example, congeners with an alcohol 
side chain could be converted into additional ether analogs via selective O-methylation (Scheme  





















10). Relatedly, a phenolic analog bearing the desired 7-position hydroxy group (8ae) was 
prepared via nucleophilic demethylation of the corresponding methoxy analog (Scheme 10). 
Analogs bearing an ester side chain were easily hydrolyzed under either basic or acidic 
conditions to provide carboxylic acid derivatives, analogous to tianeptine itself, and including the 
Scheme 8. Synthesis of core analogs. 
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known tianeptine metabolite 10a 
(Scheme 11). The acidic hydrolysis was 
notably superior for this purpose, as the 
reaction mixtures could simply be 
concentrated directly to provide the pure 
hydrochloride salts of the products. 
 SAR of the Tianeptine 
Scaffold. With a diverse collection of 
tianeptine analogs in hand, we were in a position to thorougly map the SAR of this scaffold in 
the key regions identified above (Figure 12), namely, 1) the amino side chain, 2) the aryl ring 
substituents, and 3) the sulfonamide bridge. Thus, the derivatives synthesized above were 
screened for functional activity (by Madalee Gassaway) at the three human opioid receptors 











Scheme 9. Synthesis of thiophene analogs. 
Scheme 10. Synthesis of additional analogs 
by methylation or demethylation. 
Scheme 11. Synthesis of additional analogs by 
hydrolysis. 
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 SAR of the Amino Side Chain. The amino side chain of tianeptine was found to be 
fairly amenable to variation (Table 2). For one, the known tianeptine metabolite 10a (also 
known as MC5) bearing a pentanoic acid side chain we also found to be active at MOR with only 
slightly reduced potency, compared to tianeptine itself. Interestingly, the already weak DOR 
activity was completely lost in this analog, indicating that if the MC5 metabolite plays a role in 
mediating tianeptine's behavioral effects, it is likely to be only through MOR. We also found that  
 
 
Class Compound R hMOR hDOR 
tianeptine heptanoic acid 0.194 ± 0.070 37.4 ± 11.2 
10a pentanoic acid 0.361 ± 0.093 X 
8b ethyl heptanoate 0.657 ± 0.366 12.5 ± 2.00 
Acids and 
Esters 
8a ethyl pentanoate 0.533 ± 0.267 - 
8c n-propyl 0.773 ± 0.211 X 
8d n-pentyl 0.633 ± 0.010 15.9 ± 11.5 Alkyl 
8e n-heptyl 1.04 ± 0.590 X 
8f 3-hydroxypropyl 1.81 X 
Alcohols 
8g 5-hydroxypentyl X - 
8h 3-methoxypropyl 0.264 ± 0.085 X 
8ad 5-methoxypentyl 0.563 ± 0.247 53.8 
8i 3-ethoxypropyl 0.893 ± 0.147 X 
8j 3-methoxybutyl 0.604 ± 0.139 X 
8k 2-methoxyethyl 7.38 ± 1.17 X 
Ethers and 
Thioethers 
8l 3-thiomethoxypropyl 1.48 ± 0.230 X 
Aromatic 8m 2-furanylethyl 13.6 X 
Table 2. Diverse amino side chains are tolerated in the tianeptine scaffold. Agonist activity at hMOR and 
hDOR as determined in the G protein BRET assay. All data represents mean EC50 ± SEM (µM) of at least 2 
independent experiments, or EC50 from a single experiment if no error is indicated; observed Emax was 100% 
for all active compounds; "X" indicates inactive or EC50  >100 µM in agonist mode. All compounds were 
inactive at hKOR. Data collected by Madalee Gassaway. 
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ester analogs (eg. 8a and 8b) were well tolerated, suggesting that potential salt bridge or 
hydrogen bond donor interactions mediated by this group are not important. This observation 
was further supported by the finding that simple linear alkyl chains could effectively substitute 
for the heptanoic acid group, retaining submicromolar potency (8c-e). 
 In suprising contrast to these results, primary alcohol analogs were very poorly tolerated. 
For example, the propyl alcohol derivative 8f was only weakly active, and the pentyl alcohol 8g 
was completely inactive. The reasons for this strong SAR remain unclear at this time, but seem 
to indicate the potential for disruptive hydrogen bonding interactions in this region of the binding 
pocket, potentially mediated through interaction with receptor-associated water molecules. 
 Fascinatingly, the corresponding methyl ether derivatives 8h and 8ad were amongst the 
most potent side chain analogs, with the methoxypropyl compound (8h) nearly matching the 
potency of tianeptine itself. Unfortunately, we were not able to further optimize the activity of 
the ether analogs, as extending the chain to ethoxypropyl (8i) or adding a branch point (8j) 
reduced activity. Similarly, shortening this substituent to a methoxyethyl group (8k) induced a 
dramatic loss in potency, while replacement with a thioether (8l) also reduced activity. Thus, 
these results further demonstrate the ability of a polar atom (oxygen) to enhance activity in this 
region, but only if positioned an appropriate distance from the tricylic core. 
 Another noteworthy observation in this region was the complete intolerance for aromatic 
substitutents. For example, analog 8m, bearing a furanylethyl group, was only very weakly 
active, despite bearing an oxygen atom at the position analogous to compound 8h. Similarly, we 
observed that furanylmethyl, phenylethyl, and benzyl substituted analogs were either very low 
potency or entirely inactive (data not shown). This was surprising, given that our docking results 
had indicated that the nitrogen substituent in tianeptine was likely to protrude into the same 
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region of the binding pocket occupied by the nitrogen substituent in classical morphinan and 
benzomorphan opioids. In the morphinan scaffold, N-phenylethyl substitution yields analogs 
with considerably higher potency than the parent N-methyl compounds.
200
 Similarly, the 
extremely potent opioid fentanyl, and its analogs, bear arylethyl substituents on nitrogen that are 
believed to extend into the same region of the binding pocket.
201
 Accordingly, our results suggest 
that tianeptine may bind in an entirely different pose from other known opioid agonists and that 
the preliminary computer modeling results may be incorrect. Alternatively, the tianeptine 
scaffold may occupy a similar approximate binding pose, but be subtly translocated in a manner 
which has unexpected effects on steric tolerance in this region. Contrastingly, we also found that 
several large, but fully saturated, cyclic ether substituents were tolerated in this region (data not 
shown), seemingly indicating that general steric bulk is permissible, but conformational 
inflexibility is not. 
 In sum, the observed SAR in the side chain region was peculiar, with several clear trends, 
but also unexpected observations. In general, the scaffold was quite tolerant to variation of this 
substituent, and several carboxyl, ester, alkyl, and ether analogs maintained submicromolar 
potency at MOR. However, no side chain substitution exceeded the activity of tianeptine itself, 
and several variations, namely the alcohols, were inexplicably inactive. Another important 
observation is that an acid or ester side chain (ideally 7 carbons in length)  appears to be 
important for retaining the weak activity at DOR, as most other side chain substitutions, 
including the ether analogs, eliminated this activity. Nonetheless, we did identify two side chain 
substititions, namely the ethyl heptanoate ester and 3-methoxypropyl ether, which we expected 
might accomplish our goal of improving metabolic stability while maintaining similar MOR 
potency to tianeptine itself. For example, the ester analog 8b might be expected to act as a 
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prodrug for tianeptine, which would not only activate MOR itself, but would also release 
tianeptine on hydrolysis, thus acting as a slowly releasing reservoir of the drug. Similarly, the 
ether analog 8h was expected to be more metabolically stable than tianeptine, as the β-oxidation 
pathway by which the heptanoic acid side chain is degraded is not available with this derivative.  
 SAR of Core Region: 3-position. Having thorougly explored SAR in the side chain 
region, we moved on to consider the core region, specifically substitution of the 3-position 
chloro  substituent  (Table 3).  To  accomplish  this  goal,  we  employed  only  the  side  chains  
 
 
Class Compound R1 R2 hMOR hDOR 
tianeptine A Cl 0.194 ± 0.070 37.4 ± 11.2 
10b A Br 0.086 ± 0.051 7.65 ± 0.790 Acids 
10c A I 0.027 ± 0.012 3.94 ± 0.370 
8n B F 2.04 ± 0.334 X 
8b B Cl 0.657 ± 0.366 12.5 ± 2.00 
8o B Br 0.311 ± 0.229 7.90 ± 2.30 
Esters 
8p B I 0.137 ± 0.017 10.3 ± 4.90 
8r C H 2.01 ± 0.700 X 
8s C F 5.53 ± 0.250 X 
8h C Cl 0.264 ± 0.085 X 
8t C Br 0.074 ± 0.018 X 
8u C I 0.015 ± 0.007 X 
8z C OMe 0.665 ± 0.163 X 
8aa C SMe 0.159 ± 0.092 X 
8ab C OPh 0.466 ± 0.274 X 
Ethers 
8ac C Ph 1.29 ± 0.140 X 
 
Table 3. Larger, more polarizable atoms at position 3 increase potency in the tianeptine scaffold. Agonist 
activity at hMOR and hDOR as determined in the G protein BRET assay. All data represents mean EC50 ± SEM 
(µM) of at least 2 independent experiments, or EC50 from a single experiment if no error is indicated; observed 
Emax was 100% for all active compounds; "X" indicates inactive or EC50  >100 µM in agonist mode. All 
compounds were inactive at hKOR. Data collected by Madalee Gassaway. 
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displaying the best activity and examined analogs varied only at position 3. Notably, we found 
that increasing the size of the halogen atom at this position induced a considerable increase in 
potency, with activity increasing in the order H ≈ F < Cl < Br < I. This trend held true across 
several different side chain substituents, including acid analogs of tianeptine itself (10b-c), as 
well as the heptanoate esters (8b,n,o,p) and the methoxypropyl ethers (8h,r,s,t,u). The iodo-
substituted analogs thus represent the most potent MOR agonists identified in this scaffold to 
date. Similarly, although the methoxy analog at this position (8z) was less potent than the 
corresponding chloride, switching to thiomethoxy (8aa) reconstituted activity in this series to the 
same level. Thus, increasing the size and polarizability of the atom adjacent to the aryl ring at 
position 3 appears to generally correlate with increased activity in this scaffold. Exploration at 
position 3 also provided evidence indicating that this region of the diarylthiazepine faces towards 
the outside of the pocket, as suggested by our preliminary docking studies. For example, both 
phenoxy (8ab) and phenyl (8ac) substituents were tolerated at this position. Therefore, there 
must be significant available space in this area of the binding pocket. This discovery also renders 
the observed halogen trend surprising, as, if this region is indeed outward facing, it is difficult to 
imagine the molecular interactions that would mediate the potency variation. 
 SAR of Core Region: Other Ring Substituents and Bridge. We also examined the 
effects of substitution at other ring positions (Table 4). As a general trend, substitution at other 
locants markedly decreased activity. This suggests that the other aryl ring (on the amine side of 
the sulfonamide) does indeed project into a deeper region of the pocket where steric bulk is not 
tolerated. However, we were disappointed to find that the phenolic 7-hydroxy analog (8ae) was 
completely inactive. Thus, our prediction regarding the suitability of this position in 





Alternatively, this failure may simply result from distortion of the wing-like bend in the core 
tricyclic system, due to steric strain with the adjacent methyl group. Indeed, we observed 
conformational broadening/splitting in the NMR spectra of the 7-substituted analogs and 
intermediates, indicating a likely effect of this substituent on the ring bend. 
 Increasing the size of the sulfonamide substituent from methyl to ethyl (8y) was also 
poorly tolerated, revealing an intolerance for increased steric bulk in 
this region, or an interference with critical hydrogen bonding 
interactions. To further probe the importance of the bridge region, we 
tested the activity of amineptine (Figure 14), another atypical 
antidepressant with a structure nearly identical to tianeptine, except 
for loss of the chloro substituent and replacement of the sulfonamide 
with  two  methylene  groups.  This  compound  was  found  to  be 
Compound R1 R2 R3 R4 hMOR hDOR 
8w A 2-Cl H Me 16.9 ± 5.22 X 
8x A H 8-Cl Me 17.8 ± 1.32 X 
8v A 3-Cl 9-Br Me 8.01 ± 2.50 30.2 
8y A H H Et 36.0 ± 26.0 X 
8q B H 7-OMe Me 3.00 ± 4.00 X 
8ae B H 7-OH Me X X 
 
Table 4. Ring substitution at other positions is not tolerated. Agonist activity at hMOR and hDOR as determined 
in the G protein BRET assay. All data represents mean EC50 ± SEM (µM) of at least 2 independent experiments, 
or EC50 from a single experiment if no error is indicated; observed Emax was 100% for all active compounds; "X" 
indicates inactive or EC50  >100 µM in agonist mode. All compounds were inactive at hKOR. Data collected by 
Madalee Gassaway. 
Figure 14. Structure of 
amineptine. 
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 completely inactive at the opioid 
receptors, suggesting that the polar 
atoms of the sulfonamide mediate 
hydrogen bonding interactions that 
are critical for opioid activity. 
            SAR of Thiophene Analogs. 
     We also explored several analogs 
where one of the phenyl rings was 
substituted with an isosteric 
thiophene (Table 5). This 
substitution was generally 
tolerated, although the resulting derivatives possesed modestly decreased potency at MOR, and 
no activity at DOR. Notably, the same halogen trend was observed in this series, as the bromo 
analogs were more potent than the corresponding chloro analogs. 
 
Ether Analogs as Leads for Improved Therapeutics 
 Ether Analog 8h Has Improved Pharmacokinetics. Suspecting that our ether analog 
8h might represent a more metabolically stable derivative of tianeptine, we tested this compound 
in a pharmacokinetic study in C57BL/6 mice, using the same dosing (30 mg/kg) and route of 
administration (intraperitoneal) used in our prior behavioral and pharmacokinetic experiments 
with tianeptine. We were pleased to find that 8h exhibited a much longer duration of action in 
comparison to tianeptine, being detectable in plasma at time points up to 24 h, and brain up to 8 
h (t1/2 (plasma) = 2.73 h; t1/2 (brain) = 3.37 h),. Similarly, 8h also showed much larger overall 
Compound R1 R2 hMOR hDOR 
9a A Cl 1.00 ± 0.010 X 
9b A Br 0.372 ± 0.086 X 
9c B Br 0.784 X 
 
Table 5. Thiophene analogs are also active, but with reduced 
potency. Agonist activity at hMOR and hDOR as determined in the 
G protein BRET assay. All data represents mean EC50 ± SEM (µM) 
of at least 2 independent experiments, or EC50 from a single 
experiment if no error is indicated; observed Emax was 100% for all 
active compounds; "X" indicates inactive or EC50  >100 µM in 
agonist mode. All compounds were inactive at hKOR. Data 
collected by Madalee Gassaway. 
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drug exposure in both plasma 
and brain, as quantified by area 
under the curve (Figure 15). In 
contrast, the brain-plasma ratio 
remained nearly identical to 
tianeptine (0.14, based on area 
under the curve). Absorption 
and distribution was also 
slower, with maximum brain 
concentration not reached until 
0.5 h. Accordingly, it can be 
imagined that given its slower 
rise and decline to and from peak effects, 8h would produce a more uniform mood enhancement 
compared to tianeptine. Futher, at higher dosing, this slower distribution profile may be expected 
to blunt any potential euphoric "rush", thus further minimizing tianeptine's already low abuse 
potential. Analog 8h therefore provides a useful proof of concept that the pharmacokinetic 
properties of tianeptine may be significantly improved through structural modification, while 
retaining similar on-target activity. 
 Ether Analog 8h Maintains High Selectivity for MOR. Although we had successfully 
shown that the heptanoic acid side chain is not required for MOR activity in the tianeptine 
scaffold, we were concerned that this moiety might mediate another important feature of this 
compound, its exceptional selectivity over other CNS targets. Thus, we submitted our lead ether 































Figure 15. Brain concentrations (nM) of tianeptine and analog 8h 
following administration to C57BL/6 mice (30 mg/kg, i.p.). Compound 
8h was also detected at 8 h, but this data point is excluded to facilitate 
simpler visual comparison with tianeptine. 
 
 359 
in out initial target indentification efforts with tianeptine. This work showed that 8h was at least 
as selective as tianeptine itself, as no binding affinity or functional activity was observed for any 
of the >60 CNS targets tested. Therefore, with compound 8h we accomplished our primary 
initial development goal of finding a tianeptine analog with similar pharmacological properties to 
tianeptine itself, but having improved pharmacokinetics. This analog also represents a potentially 
useful tool compound to further confirm the mechanism of tianeptine, as it is structurally and 
metabolically distinct, while being nearly equipotent at MOR and inactive at DOR. Thus, were 
the weak DOR activity or other unknown targets important for tianeptine's effects, compound 8h 
would be expected to be inactive. 
 
Conclusion and Outlook 
 Herein we have described the identification of MOR as the likely molecular target for the 
long used and clinically significant antidepressant tianeptine. Using in vitro binding and 
functional assays, we demonstrated the nanomolar activity of tianeptine at both human and 
mouse MOR, and the concomitant lack of activity at >60 other CNS targets. Further, in animal 
models, we showed that the acute antidepressant and anxiolytic effects of tianeptine are 
eliminated in MOR knockout mice and inhibited by the MOR selective antagonist cyprodime. 
Further, we have reviewed the available evidence connecting opioid receptor modulation to the 
known cellular- and circuit-level effects of tianeptine, and suggest mechanisms by which 
tianeptine may ellicit antidepressant effects downstream of MOR activation. Taken together, we 
believe the work presented here represents a compelling argument for activation of MOR as the 
initial molecular event responsible for the beneficial behavioral effects of tianeptine. More 
broadly, the connection of a long used antidepressant to this molecular mechanism suggests 
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MOR agonists as a potential new class of therapeutics for mood disorders. Thus, as an initial 
effort towards new antidepressant medications in this class, we have developed novel tianeptine 
analogs with improved pharmacokinetcs compared to the parent compound. It is our hope that 
these derivatives will provide improved efficacy, tolerability, and reduced potential for abuse, 
while serving as a new options for patients suffering with treatment resistant depression. 
 However, several important questions still remain, in regards to both our fundamental 
understanding, and for assesing the potential therapeutic importance of MOR agonists in mood 
disorders. For one, the studies here also demonstrated a surprising involvement of DOR. 
However, given the low potency of tianeptine at DOR in mice, and even lower potency in 
humans, further studies will be necessary to confirm the potential importance of DOR to 
tianeptine's mechanism of action. Another curious observation made with tianeptine was that a 
dose of naloxone sufficient to blockade its analgesic effects was unable to inhibit its 
antidepressant and anxiolytic effects. This suggests the remarkable possibility that the analgesic 
and antidepressant effects of tianeptine may be mediated by distinct subpopulations of MOR 
with different sensitivities to naloxone inhibition. We also observed that the analgesic and 
antidepressant effects of tianeptine were temporally separated, with the mood enhancement 
persisting beyond the short-lived analgesic and motor stimulating effects of the drug. Therefore, 
it seems that a short pulse of opioid activity is sufficient to initiate longer-lasting changes in 
brain signaling, perhaps through indirect modulation of AMPAR or NMDAR activity. A full 
understanding of the molecular mechanisms involved in tianeptine's action downstream of opioid 
receptors will thus require additional study. For example, brain region-specific knockout of 
MOR and/or DOR will help to localize the specific neural tissues and cell types responsible for 
tianeptine's behavioral effects. At the same time, molecular biological and electrophysiological 
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studies in isolated brain slices or primary neuronal cell cultures, should assist in identification of 
the particular signaling effectors and cascades involved in the cellular- and cirucuit-level 
modulations initiated by MOR activation. 
 In considering the adoption of MOR agonists as a new class of antidepressant 
therapeutics, it is important to also take into account their potential for abuse and perhaps more 
importantly, the development of tolerance. However, as tianeptine has already been used 
extensively in the clinical setting for several decades, and instances of abuse appear to be only 
sporadic, this agent represents a strong argument for the therapeutic benefit and practicality of 
applying MOR agonists in treating mood disorders. Similarly, tianeptine maintains long term 
efficacy as an antidepressant, suggesting that tolerance does not easily develop to its mood-
elevating effects. Further study will be necessary to determine if the apparently unique properties 
of tianeptine are mearly a funciton of its low potency, or instead related to as-yet-unknown 
pharmacological effects.  
 
Experimental 
 General Considerations: Chemistry. Reagents and solvents (including anhydrous 
solvents) were obtained from commercial sources and used without further purification unless 
otherwise stated. All compounds were prepared in racemic form. All reactions were performed in 
flame-dried glassware under an argon atmosphere unless otherwise stated, and monitored by 
TLC using solvent mixtures appropriate to each reaction. All column chromatography was 
performed on silica gel (40-63µm). For compounds containing a basic nitrogen, Et3N was 
sometimes used in the mobile phase in order to provide better resolution. In these cases, TLC 
plates should be pre-soaked in the Et3N containing solvent and then allowed to dry briefly before 
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use in analysis, such that an accurate representation of Rf is obtained. Nuclear magnetic 
resonance spectra were recorded on Bruker 300, 400, or 500 MHz instruments as indicated. 
Chemical shifts are reported as δ values in ppm referenced to CDCl3 (
1
H NMR = 7.26 and 
13
C 
NMR = 77.16), Acetone-d6 (
1
H NMR = 2.05 and 
13
C NMR = 29.84), or Methanol-d4 (
1
H NMR = 
3.31 and 
13
C NMR = 49.00). Multiplicity is indicated as follows: s (singlet); d (doublet); t 
(triplet); q (quartet); p (pentet); h (heptet); dd (doublet of doublets); ddd (doublet of doublet of 
doublets); dt (doublet of triplets); td (triplet of doublets); dq (doublet of quartets); m (multiplet); 
br (broad).  
 For several compounds, spectra are complicated by the presence of conformers, resulting 
in multiple peaks corresponding to the same proton group or carbon atom. Furthermore, 
compounds containing fluorine are subject to F-C coupling, resulting in splitting of some carbon 
peaks. When possible, such peaks are indicated by an "and" joining two peaks or spectral 
regions, or by partial integrals. All carbon peaks are rounded to one decimal place unless such 
rounding would cause two close peaks to become identical. In these cases, two decimal places 
are retained. Low-resolution mass spectra were recorded on a JEOL LCmate (ionization mode: 
APCI+). For compounds 4 and 5, mass spectra are reported for carbocations corresponding to 
loss of OH or Cl respectively. 
 
Preparation of Sulfonyl Chlorides 
 Methyl 4-chloro-2-(chlorosulfonyl)benzoate. A suspension of methyl 2-amino-4-
chlorobenzoate (8.35 g, 45.0 mmol) in 20% aqueous HCl (29 mL) was sonicated for several 
minutes and warmed slightly until all clumps were broken up and the mixture was a uniform 
suspension of fine particles. This mixture was cooled to 0 °C, and a solution of NaNO2 (3.11 g, 
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45.0 mmol) in water (7.5 mL) was added dropwise, maintaining the internal temperature below 5 
°C. The resulting mixture was then stirred for 2 h at 0 °C. A solution of SO2 (23.1 g, 360 mmol) 
in AcOH (36.0 mL) and water (3.75 mL) was then prepared by bubbling the gas though the 
mixed solvents at 0 °C until the mass had increased by the required amount. To this SO2 solution 
was then added CuCl (1.11 g, 11.25 mmol) followed by the diazonium salt solution portionwise 
over 30 minutes at 0 °C. The resulting mixture was then stirred for 1 h at 0 °C and 1 h at room 
temperature, poured into ice water (150 mL), and extracted with CH2Cl2 (3 x 50 mL). The 
combined organics were poured into saturated aqueous NaHCO3 (75 mL), and solid NaHCO3 
was added carefully until effervescence ceased. The organic phase was then separated, washed 
with brine (50 mL), dried over Na2SO4, and concentrated to provide the crude sulfonyl chloride 
as a red-brown oil (3.26 g, 81 mass% product by NMR, 22% yield). This material was used in 
the next step without further purification. 
 Methyl 4-bromo-2-(chlorosulfonyl)benzoate. Prepared from methyl 2-amino-4-
bromobenzoate (10.35 g, 45.0 mmol) according to the procedure described above for methyl 4-
chloro-2-(chlorosulfonyl)benzoate. The crude sulfonyl chloride was obtained as a waxy brown 
solid (5.15 g, 78 mass% product by NMR, 29% yield) and used in the next step without further 
purification. A second trial of this reaction provided the product in similar yield and purity (6.11 
g, 74 mass% product by NMR, 32% yield). 
 Methyl 5-chloro-2-(chlorosulfonyl)benzoate. Prepared from methyl 2-amino-5-
chlorobenzoate (5.00 g, 26.9 mmol) according to the procedure described for methyl 4-chloro-2-
(chlorosulfonyl)benzoate. The crude sulfonyl chloride was obtained as a yellow oil (3.70 g, 36 
mass% product by NMR, 19% yield) and used in the next step without further purification. 
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Preparation of Diarylthiazepinones (from Sulfonyl Chlorides) 
 Methyl 4-chloro-2-(N-(thiophen-3-yl)sulfamoyl)benzoate (1a). To a suspension of 
thiophen-3-amine oxalate (2.01 g, 10.63 mmol) in anhydrous CH2Cl2 (10 mL) at 0 °C under 
argon was added anhydrous pyridine (7.0 mL) followed by a solution of crude methyl 4-chloro-
2-(chlorosulfonyl)benzoate (3.22 g, 81% pure, 9.66 mmol) in anhydrous CH2Cl2 (10 mL) over ~ 
2 min. The resulting dark red-brown solution was then allowed to warm to room temperature and 
stirred for 1 h. The reaction mixture was then diluted with CH2Cl2 (100 mL) and washed with 
3% aqueous HCl (2 x 50 mL), brine (50 mL), saturated aqueous NaHCO3 (50 mL), and brine 
again (50 mL), dried over Na2SO4, and concentrated to give a dark-red oil (3.33 g). This material 
was purified by column chromatography (8:2 hexanes:EtOAc) to provide white crystals 
contaminated with oily brown impurities (2.33 g). These solids were washed 3x with small 
portions of 8:2 hexanes:EtOAc (removing the supernatant each time by pipet, impurities 
dissolve) to provide pure sulfonamide 1a as off-white crystals (2.13 g, 66%). 
1
H NMR (500 
MHz, CDCl3) δ 8.21 (s, 1H), 7.89 (d, J = 2.1 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.55 (dd, J = 8.3, 
2.1 Hz, 1H), 7.18 (dd, J = 5.1, 3.2 Hz, 1H), 6.94 (dd, J = 3.2, 1.3 Hz, 1H), 6.89 (dd, J = 5.2, 1.4 
Hz, 1H), 4.03 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 167.5, 140.3, 138.5, 134.2, 132.7, 132.3, 




 Methyl 4-bromo-2-(N-(thiophen-3-yl)sulfamoyl)benzoate (1b). To a solution of crude 
methyl 4-bromo-2-(chlorosulfonyl)benzoate (5.10 g, 78% pure, 12.72 mmol)  in anhydrous 
pyridine (9.6 mL) was added thiophen-3-amine oxalate (2.65 g, 13.99 mmol) at room 
temperature, and the resulting dark-red solution was stirred for 1 h. The reaction mixture was 
then diluted with CH2Cl2 (100 mL) and washed with 7% aqueous HCl (2 x 50 mL), brine (50 
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mL), saturated aqueous NaHCO3 (50 mL), and brine again (50 mL), dried over Na2SO4, and 
concentrated to give a dark-red oil (2.41 g). This material was purified by column 
chromatography (9:1 hexanes:EtOAc, 2 column volumes → 8:2 hexanes:EtOAc, 2 column 
volumes → 7:3 hexanes:EtOAc, 2 column volumes) to provide off-white crystals contaminated 
with oily brown impurities (1.34 g). These solids were washed 2x with small portions of 7:3 
hexanes:EtOAc (removing the supernatant each time by pipet, impurities dissolve) to provide 
pure sulfonamide 1b as tan crystals (1.16 g, 24%). 
1
H NMR (500 MHz, CDCl3) δ 8.19 (s, 1H), 
8.04 (s, 1H), 7.75 – 7.69 (m, 2H), 7.18 (dd, J = 5.1, 3.2 Hz, 1H), 6.94 (dd, J = 3.2, 1.3 Hz, 1H), 
6.89 (dd, J = 5.1, 1.3 Hz, 1H), 4.02 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 167.6, 140.2, 135.8, 
134.2, 133.5, 132.3, 129.1, 126.6, 125.9, 123.6, 114.7, 53.9; LR-MS calcd. for C12H11BrNO4S2  
[M+H]
+
 375.93, found 376.29. 
 Methyl 4-chloro-2-(N-methyl-N-(thiophen-3-yl)sulfamoyl)benzoate (2a). To a 
suspension of sodium hydride (60% in oil, 506 mg, 12.66 mmol) in anhydrous DMF (9 mL) was 
added a solution of sulfonamide 1a (2.1 g, 6.32 mmol) in anhydrous DMF (9 mL) dropwise over 
5 min., and the resulting mixture was left to stir at room temperature for 1.5 h. Methyl iodide 
(1.79 g, 0.788 mL, 12.66 mmol) was then added, and the resulting mixture was stirred for 2.5 h 
and quenched with ice water (125 mL). The aqueous layer was extracted with CH2Cl2 (2 x 50 
mL, 25 mL) and the combined organics were washed with water (2 x 50 mL), dried over MgSO4, 
and concentrated to yield a dark brown oil. This material was washed with 3 portions of boiling 
hexanes (5 mL), cooling and carefully removing the supernatant by pipet each time, and dried in 
vacuo to yield sulfonamide 2a (1.83 g, 84%). 
1
H NMR (300 MHz, CDCl3) δ 7.50 (dd, J = 8.2, 
2.0 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 2.0 Hz, 1H), 7.24 (dd, J = 3.5, 1.3 Hz, 1H), 
7.01 (s, 1H), 7.00 (dd, J = 3.2, 1.5 Hz, 1H), 3.86 (s, 3H), 3.25 (s, 3H);
 13
C NMR (75 MHz, 
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CDCl3) δ 167.5, 139.2, 136.7, 136.2, 132.7, 131.9, 129.7, 129.7, 125.5, 125.1, 118.6, 53.4, 38.8; 
LR-MS cald. for C13H13ClNO4S2 [M+H]
+
 346.00, found 346.89. 
 Methyl 4-bromo-2-(N-methyl-N-(thiophen-3-yl)sulfamoyl)benzoate (2b). To a 
suspension of sodium hydride (60% in oil, 244 mg, 6.12 mmol) in anhydrous DMF (4.5 mL) at 0 
°C was added a solution of sulfonamide 1b (1.15 g, 3.06 mmol) in anhydrous DMF (4.5 mL) 
dropwise over 5 min., and the resulting mixture was allowed to warm to room temperature and 
stirred for 1.5 h. Methyl iodide (869 mg, 381 µL, 6.12 mmol) was then added dropwise over 2 
minutes and the mixture was stirred for 2 h before quenching with ice water (50 mL) and 
extracting with Et2O (3 x 25 mL). The combined organics were washed with water (2 x 25 mL) 
and brine (25 mL), dried over Na2SO4, and concentrated to provide a biphasic, pale-brown oil 
(1.26 g). The material was washed 3x with small portions of boiling hexanes, cooling and 
carefully removing the supernatant by pipet each time. The residue was then dried in vacuo to 
provide pure sulfonamide 2b as an orange-brown oil (1095 mg, 92%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.69 (dd, J = 8.2, 1.7 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.30 
– 7.27 (m, 1H), 7.04 – 7.01 (m, 2H), 3.88 (s, 3H), 3.26 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 
167.6, 139.2, 136.4, 135.6, 132.5, 132.3, 129.7, 125.5, 125.1, 124.0, 118.7, 53.5, 38.8; LR-MS 
calcd. for C13H13BrNO4S2  [M+H]
+
 389.95, found 390.25. 
 Methyl 2-(N-methyl-N-phenylsulfamoyl)benzoate (2c). Obtained as an impure 
compound en route to 3c (see below) and used without further purification. 
 Methyl 4-bromo-2-(N-methyl-N-phenylsulfamoyl)benzoate (2d). To a solution of 
crude methyl 4-bromo-2-(chlorosulfonyl)benzoate (6.04 g, 74% pure, 14.25 mmol)  in anhydrous 
pyridine (10.7 mL) was added N-methylaniline (1.71 mL, 1.68 g, 15.68 mmol) at room 
temperature, and the resulting mixture was stirred for 1 h. The reaction mixture was then diluted 
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with CH2Cl2 (100 mL) and washed with 7% aqueous HCl (2 x 100 mL), brine (100 mL), 
saturated aqueous NaHCO3 (100 mL), and brine again (100 mL), dried over Na2SO4, and 
concentrated to give a yellow-brown oil (2.41 g). This material was purified by column 
chromatography (9:1 hexanes:EtOAc, 4 column volumes → 8:2 hexanes:EtOAc, 4 column 
volumes) to provide pure sulfonamide 2d as an oil (3.71 g, 68%). 
1
H NMR (500 MHz, CDCl3) δ 
7.69 (dd, J = 8.2, 1.9 Hz, 1H), 7.52 (d, J = 1.9 Hz, 1H), 7.38 – 7.29 (m, 4H), 7.21 – 7.17 (m, 2H), 
3.82 (s, 3H), 3.30 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 167.7, 141.0, 137.1, 135.5, 132.8, 
132.3, 129.8, 129.3, 128.0, 127.4, 123.9, 53.4, 39.0.  
 Methyl 5-chloro-2-(N-methyl-N-phenylsulfamoyl)benzoate (2e). Obtained as an 
impure compound en route to 3e (see below) and used without further purification. 
 Methyl 2-(N-(3-chlorophenyl)-N-methylsulfamoyl)benzoate (2f). To a solution of N-
methyl-3-chloroaniline (643 µL, 743 mg, 5.25 mmol) in anhydrous pyridine (3.8 mL) was added 
methyl 2-(chlorosulfonyl)benzoate (1.17 g, 5.00 mmol), and the resulting mixture was stirred for 
3 h at room temperature. The reaction mixture was then diluted with CH2Cl2 (35 mL), washed 
with 7% aqueous HCl (2 x 35 mL), brine (35 mL), saturated aqueous NaHCO3 (35 mL), and 
brine again (35 mL), dried over Na2SO4, and concentrated to provide pure sulfonamide 2f as a 
viscous yellow oil (1.14 g, 67%). 
1
H NMR (500 MHz, CDCl3) δ 7.60 (ddd, J = 7.7, 6.0, 2.6 Hz, 
1H), 7.49 (d, J = 7.5 Hz, 1H), 7.48 – 7.44 (m, 2H), 7.28 – 7.23 (m, 2H), 7.22 – 7.20 (m, 1H), 
7.14 – 7.09 (m, 1H), 3.84 (s, 3H), 3.28 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 168.2, 142.6, 
134.9, 134.6, 133.8, 132.9, 130.04, 129.99, 129.8, 128.5, 127.7, 127.4, 125.3, 53.3, 38.7; LR-MS 
calcd. for C15H15ClNO4S  [M+H]
+
 340.04, found 339.75. 
 Methyl 2-(N-ethyl-N-phenylsulfamoyl)benzoate (2g). To a solution of N-ethylaniline 
(663 µL, 636 mg, 5.25 mmol) in anhydrous pyridine (3.8 mL) was added methyl 2-
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(chlorosulfonyl)benzoate (1.17 g, 5.00 mmol), and the resulting mixture was stirred for 2 h at 
room temperature. The reaction mixture was then diluted with CH2Cl2 (35 mL), washed with 7% 
aqueous HCl (2 x 35 mL), brine (35 mL), saturated aqueous NaHCO3 (35 mL), and brine again 
(35 mL), dried over Na2SO4, and concentrated to provide pure sulfonamide 2g as a viscous 
yellow-orange oil (1.20 g, 75%). 
1
H NMR (500 MHz, CDCl3) δ 7.54 (td, J = 7.5, 1.4 Hz, 1H), 
7.47 – 7.43 (m, 2H), 7.42 – 7.37 (m, 1H), 7.34 – 7.27 (m, 3H), 7.17 – 7.13 (m, 2H), 3.85 (s, 3H), 
3.75 (q, J = 7.1 Hz, 2H), 1.09 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 168.5, 138.5, 
136.7, 133.3, 132.3, 129.9, 129.8, 129.7, 129.2, 128.2, 128.1, 53.2, 46.3, 14.5; LR-MS calcd. for 
C16H18NO4S  [M+H]
+
 320.10, found 320.50. 
 7-Chloro-4-methylbenzo[f]thieno[3,2-c][1,2]thiazepin-10(4H)-one 5,5-dioxide (3a). 
To a solution of sulfonamide 2a (1.83 g, 5.29 mmol) in MeOH (13 mL) and water (6.5 mL) was 
added sodium hydroxide (396 mg, 15.9 mmol). The resulting mixture was refluxed for 1.5 h after 
which time the reaction was cooled to room temperature and 10% aqueous HCl (10 mL) was 
added. The reaction was concentrated to remove most of the MeOH, and to this aqueous residue 
was added water (10 mL), and the mixture was then extracted with CH2Cl2 (30 mL, 2 x 20 mL). 
The combined organics were dried over Mg2SO4 and concentrated to yield the intermediate 
carboxylic acid as a tan crystalline solid (1.47 g), which was used in the next step without further 
purification. The carboxylic acid (1.47 g, 4.44 mmol) was dissolved in thionyl chloride (8.5 mL) 
and allowed to stir overnight at room temperature. After 14 h, the reaction mixture was 
concentrated to obtain the intermediate acyl chloride as a dark-brown residue. This material was 
dissolved in CHCl3 (19.4 mL), aluminum chloride (1.89 g, 14.21 mmol) was added, and the 
reaction mixture was refluxed for 1 h and then cooled to room temperature and quenched with 
ice water (100 mL). The resulting mixture was extracted with CH2Cl2 (3 x 50 mL), and the 
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combined organics were washed with water (50 mL), dried over MgSO4, and concentrated. The 
crude product was purified by column chromatography (2:1 CH2Cl2:hexanes → CH2Cl2) to 
provide pure ketone 3a as a yellow solid (686 mg, 41% over three steps). 
1
H NMR (400 MHz, 
CDCl3) δ 8.12 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 2.1 Hz, 1H), 7.77 - 7.71 (m, 2H), 7.04 (d, J = 5.4 
Hz, 1H), 3.45 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 181.4, 144.2, 141.3, 139.7, 138.3, 135.5, 
133.7, 133.5, 132.2, 125.9, 122.8, 38.1; LR-MS cald. for C12H9ClNO3S2 [M+H]
+
 313.97, found 
314.81. 
 7-Bromo-4-methylbenzo[f]thieno[3,2-c][1,2]thiazepin-10(4H)-one 5,5-dioxide (3b). 
To a solution of sulfonamide 2b (1085 mg, 2.78 mmol) in MeOH (7.0 mL) was added water (3.5 
mL) and NaOH (334 mg, 8.34 mmol) and the mixture was refluxed for 1 h. The reaction was 
then cooled to room temperature, acidified with 10% aqueous HCl (5 mL), and most of the 
MeOH was removed in vacuo. The remaining aqueous residue was diluted with water (10 mL) 
and extracted with CH2Cl2 (20 mL, 2 x 10 mL). The combined organics were dried over Na2SO4 
and concentrated to provide the carboxylic acid as a tan, crystalline solid (1.00 g), which was 
used in the next step without further purification. The carboxylic acid (990 mg, 2.63 mmol) was 
dissolved in thionyl chloride (5.0 mL) and the solution was stirred for 16 h at room temperature. 
The volatiles were then removed to provide the crude acyl chloride as a brown oil. This material 
was dissolved in CHCl3 (11.5 mL), aluminum chloride (1.12 g, 8.42 mmol) was added, and the 
mixture was refluxed for 1 h. The reaction was then cooled to room temperature, quenched with 
ice water (50 mL), stirred until all the brown sludge had broken up, and then extracted with 
CH2Cl2 (3 x 25 mL). The combined organics were washed with water (25 mL), dried over 
Na2SO4, and concentrated to give a brown solid. This material was purified by column 
chromatography (2:1 CH2Cl2:hexanes, 5 column volumes → CH2Cl2, 3 column volumes) to 
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provide pure ketone 3b as a pale-yellow, crystalline solid (579 mg, 59% over three steps). 
1
H 
NMR (500 MHz, CDCl3) δ 8.20 (d, J = 1.9 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.90 (dd, J = 8.3, 
2.0 Hz, 1H), 7.75 (d, J = 5.4 Hz, 1H), 7.04 (d, J = 5.4 Hz, 1H), 3.46 (s, 3H); 
13
C NMR (126 
MHz, CDCl3) δ 181.6, 141.3, 138.2, 136.8, 135.5, 133.4, 132.6, 131.6, 128.7, 127.8, 122.8, 
38.1; LR-MS calcd. for C12H9BrNO3S2 [M+H]
+
 357.92, found 358.49. 
 6-Methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3c). Ketone 3c was 
prepared from methyl 2-(chlorosulfonyl)benzoate via literature procedure
202
 and obtained as a 
white crystalline solid (870 mg, 64% over 4 steps) with spectral and physical properties in 
agreement with those previously reported. 
1
H NMR (400 MHz, Acetone-d6) δ 8.23 (dd, J = 8.1, 
1.6 Hz, 1H), 8.00 – 7.85 (m, 4H), 7.75 (ddd, J = 8.8, 7.3, 1.7 Hz, 1H), 7.56 (dd, J = 8.2, 0.8 Hz, 
1H), 7.47 – 7.40 (m, 1H), 3.37 (s, 3H). 
 3-Bromo-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3d). To a 
solution of sulfonamide 2d (3.69 g, 9.60 mmol) in MeOH (24 mL) was added water (12 mL) and 
NaOH (1.15 g, 28.80 mmol) and the mixture was refluxed for 1 h. Most of the MeOH was then 
removed in vacuo and the resulting clumpy white mixture was diluted with water (30 mL), 
acidified with 10% aqueous HCl (20 mL), and extracted with CH2Cl2 (50 mL, 2 x 20 mL). The 
combined organics were dried over Na2SO4 and concentrated to provide the carboxylic acid as a 
pale-pink glass (3.46 g), which was used in the next step without further purification. The 
carboxylic acid (3.43 g, 9.26 mmol) was dissolved in thionyl chloride (15 mL) and the solution 
was stirred for 13 h at room temperature. The volatiles were then removed to provide the crude 
acyl chloride as a yellow-orange oil. This material was dissolved in CHCl3 (40 mL), aluminum 
chloride (3.95 g, 29.63 mmol) was added, and the mixture was refluxed for 1 h. The reaction was 
then cooled to room temperature, quenched with ice water (150 mL), and extracted with CH2Cl2 
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(3 x 50 mL). The combined organics were filtered through a silica plug, washing with additional 
CH2Cl2 until all of the product had passed through, and the filtrate was concentrated to provide 
an off-white solid. This material was recrystallized from MeOH (~250 mL) to provide the pure 
ketone 3d as cream colored needles (2.08 g, 62% over 3 steps). 
1
H NMR (500 MHz, CDCl3) δ 
8.30 (dd, J = 8.1, 1.5 Hz, 1H), 8.11 (t, J = 1.0 Hz, 1H), 7.84 (d, J = 1.1 Hz, 2H), 7.68 – 7.62 (m, 
1H), 7.41 – 7.37 (m, 1H), 7.35 (dd, J = 8.1, 0.7 Hz, 1H), 3.36 (s, 3H); 
13
C NMR (126 MHz, 
CDCl3) δ 189.8, 141.5, 138.5, 136.4, 135.1, 135.0, 133.4, 132.3, 131.0, 128.4, 126.9, 126.4, 
124.8, 39.2; LR-MS calcd. for C14H11BrNO3S [M+H]
+
 351.96, found 351.85. 
 2-Chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3e). To a 
solution of N-methylaniline (0.65 mL, 6.0 mmol) and anhydrous pyridine (0.55 mL, 6.5 mmol) 
in anhydrous CH2Cl2 (20 mL) was added a solution of methyl 5-chloro-2-
(chlorosulfonyl)benzoate (3.70 g of crude material, 36 mass% pure = 1.35 g, 5.0 mmol) in 
anhydrous CH2Cl2 (10 mL), and the mixture was allowed to stir at room temperature overnight. 
The reaction was then diluted with water and extracted with CH2Cl2 (3 x 30 mL). The combined 
organics were washed with 1M aqueous HCl (30 mL) and saturated aqueous NaHCO3 (30 mL), 
dried over Na2SO4, and concentrated to provide the crude product. This material was purified by 
column chromatography (hexanes:EtOAc - 3:1) to provide sulfonamide 2e as an orange oil still 
containing impurities (1.30 g), which was used in the next step without further purification. To a 
solution of sulfonamide 2e (1.30 g) in MeOH (20 mL) was added water (10 mL) and NaOH 
(0.66 g, 13.5 mmol), and the resulting mixture was refluxed for 1.5 h. After cooling to room 
temperature, the mixture was made strongly acidic with 10% aqueous HCl and extracted with 
CH2Cl2. The combined organics were dried over Na2SO4 and concentrated. The crude carboxylic 
acid thus obtained was dissolved in anhydrous CH2Cl2 (20 mL), thionyl chloride (2.0 mL, 27.4 
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mmol) was added, and the solution was stirred for 6 h at room temperature before concentrating 
in vacuo. The crude acyl chloride thus obtained was dissolved in CHCl3 (20 mL), aluminum 
chloride (1.50 g, 11.2 mmol) was added, and the resulting mixture was refluxed for 1.5 h. The 
volatiles were then removed in vacuo and the residue was quenched with cold water and 
extracted with CH2Cl2. The combined organics were dried over Na2SO4 and concentrated to 
provide the crude product. This material was purified by column chromatography (1:1 
CH2Cl2:hexanes) followed by recrystallization from methanol to provide the pure ketone 3e as a 
pinkish solid (450 mg, 29% over 4 steps). 
1
H NMR (400 MHz, Acetone-d6) δ 8.21 (dd, J = 8.1, 
1.6 Hz, 1H), 8.00 – 7.95 (m, 1H), 7.93 – 7.88 (m, 2H), 7.77 (ddd, J = 8.3, 7.3, 1.7 Hz, 1H), 7.58 
(dd, J = 8.2, 0.9 Hz, 1H), 7.48 – 7.42 (m, 1H), 3.40 (s, 3H); 
13
C NMR (101 MHz, Acetone-d6) δ 
190.8, 143.0, 140.0, 139.2, 136.2, 136.0, 133.0, 132.2, 131.8, 131.2, 128.0, 126.7, 125.8, 39.4; 
LR-MS calcd. for C14H11ClNO3S [M+H]
+
 308.01, found 308.37. 
 8-Chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3f). To a 
solution of sulfonamide 2f (1.09 g, 3.21 mmol) in MeOH (8.2 mL) was added water (4.1 mL) 
and NaOH (385 mg, 9.63 mmol), and the resulting mixture was refluxed for 45 minutes. The 
solution was diluted with water (50 mL), washed with Et2O (30 mL), made strongly acidic with 
10% aqueous HCl, and extracted with CH2Cl2 (30 mL, 2 x 20 mL). The combined organics were 
washed with water (20 mL), dried over Na2SO4, and concentrated to provide the pure carboxylic 
acid intermediate as a yellow solid (1.04 g). The carboxylic acid (1.00 g, 3.07 mmol) was 
dissolved in thionyl chloride (6.6 mL), and the resulting solution was stirred for 2 h and then 
concentrated in vacuo to provide the intermediate acyl chloride as a tan solid. This material was 
dissolved in CHCl3 (13 mL), aluminum chloride (1.31 g, 9.82 mmol) was added, and the 
resulting mixture was refluxed for 1 h. The reaction was then quenched with ice water (100 mL) 
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and extracted with CH2Cl2 (50 mL, 2 x 25 mL). The combined organics were washed with water 
(50 mL), dried over Na2SO4, and concentrated to give the crude product as a viscous brown oil. 
When a small quantity of MeOH was added to this oil, tan crystals formed. These were crushed 
up and the supernatant was removed by pipet. The crystals were washed with an additional small 
portion of ice-cold MeOH and then recrystallized from MeOH to provide pure ketone 3f as 
glistening tan needles (400 mg, 42% over 3 steps). 
1
H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 
8.6 Hz, 1H), 7.97 – 7.91 (m, 2H), 7.76 – 7.70 (m, 2H), 7.35 – 7.30 (m, 2H), 3.35 (s, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 189.9, 142.8, 140.8, 136.8, 136.3, 133.6, 133.5, 132.3, 131.7, 129.2, 
126.2, 125.3, 124.1, 38.8; LR-MS calcd. for C14H11ClNO3S [M+H]
+
 308.01, found 308.47. 
 6-Ethyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3g). To a solution of 
sulfonamide 2g (1.14 g, 3.58 mmol) in MeOH (9.1 mL) was added water (4.5 mL) and NaOH 
(430 mg, 10.74 mmol), and the resulting mixture was refluxed for 45 minutes. The solution was 
diluted with water (50 mL), made strongly acidic with 10% aqueous HCl, and extracted with 
CH2Cl2 (30 mL, 2 x 20 mL). The combined organics were washed with water (20 mL), dried 
over Na2SO4, and concentrated to provide the pure carboxylic acid intermediate as a viscous 
brown oil (1.09 g). This carboxylic acid (1.06 g, 3.47 mmol) was dissolved in thionyl chloride 
(7.5 mL), stirred for 4 h at room temperature, and then concentrated in vacuo to provide the acyl 
chloride intermediate as a viscous yellow oil. This material was dissolved in CHCl3 (15 mL), 
aluminum chloride (1.48 g, 11.1 mmol) was added, and the resulting mixture was refluxed for 
1.5 h. The reaction was then quenched with ice water (100 mL) and extracted with CH2Cl2 (50 
mL, 2 x 25 mL). The combined organics were washed with water (50 mL), dried over Na2SO4, 
and concentrated to give the crude product as a dark-green glass. This material was purified by 
column chromatography (8:2 CH2Cl2:hexanes) to provide a tan solid (297 mg) still containing 
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some impurities. This crude product then recrystallized from MeOH to provide pure ketone 3g as 
off-white crystals (231 mg, 23% over 3 steps). 
1
H NMR (400 MHz, CDCl3) δ 8.31 – 8.27 (m, 
1H), 8.02 – 7.96 (m, 2H), 7.74 – 7.68 (m, 2H), 7.66 – 7.60 (m, 1H), 7.42 – 7.36 (m, 2H), 3.84 (q, 
J = 7.2 Hz, 2H), 0.98 (t, J = 7.2 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 191.0, 140.1, 139.1, 
136.1, 134.7, 133.2, 132.9, 132.4, 132.2, 131.8, 126.5, 125.5, 125.4, 47.5, 14.1; LR-MS calcd. 
for C15H14NO3S [M+H]
+
 288.07, found 288.08. 
 
Preparation of Diarylthiazepinones (from Advanced Intermediate) 
 3-Chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3h). Ketone 3h 
was purchased from Ark Pharm Inc. (Libertyville, IL) and used without further purification. 
 9-Bromo-3-chloro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3i). N-
bromosuccinimide (187 mg, 1.05 mmol) was added portionwise to a solution of ketone 3h (308 
mg, 1.00 mmol) and FeCl3 (324 mg, 2.00 mmol) in CH2Cl2 (10 mL) and CH3CN (5 mL), and the 
reaction mixture was stirred at room temperature for 3 h. Additional N-bromosuccinimide (187 
mg, 1.05 mmol) was then added and the reaction mixture was stirred at room temperature for a 
further 14 h. The reaction mixture was washed with water and brine, dried over NaSO4, and 
concentrated to provide the crude product. This was purified by column chromatography (2:1 
CH2Cl2:hexanes) followed by crystallization from MeOH to yield pure ketone 3i as a white solid 
(290 mg, 75 %). 
1
H NMR (400 MHz, Acetone-d6) δ 8.31 (d, J = 2.5 Hz, 1H), 8.00 – 7.96 (m, 
1H), 7.95 – 7.90 (m, 3H), 7.58 (d, J = 8.7 Hz, 1H), 3.44 (s, 3H); 
13
C NMR (101 MHz, Acetone-
d6) δ 189.7, 142.0, 139.1, 139.0, 138.4, 135.3, 134.7, 134.3, 132.8, 127.9, 125.8, 119.4, 39.3; 
LR-MS calcd. for C14H10BrClNO3S [M+H]
+
 387.92, found 388.63. 
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 6-Methyl-3-phenyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3j). The 
coupling reaction was conducted according to the procedure of Buchwald.
203
 Ketone 3h (308 
mg, 1.00 mmol), phenylboronic acid (228 mg, 1.50 mmol), K3PO4 (425 mg, 2.00 mmol), 
Pd(OAc)2 (2.2 mg, 1.0 mol%), and 2-(di-tert-butylphosphino)biphenyl (JohnPhos) (6.0 mg, 2 
mol%) were added to a reaction vial and sealed with a screw-cap equipped with a teflon septum. 
The vial was evacuated and backfilled with argon (3x), toluene (3 mL, de-oxygenated before use 
by standard “freeze-pump-thaw” technique) was added via syringe, and the reaction mixture was 
stirred at 100 °C for 18 h. The reaction mixture was diluted with CH2Cl2, washed with water, 
dried over Na2SO4, and concentrated. The crude product was crystallized from MeOH/ethyl 
acetate (~5:1) to provide pure ketone 3j as orange crystals (315 mg, 90%). 
1
H NMR (400 MHz, 
Acetone-d6) δ 8.27 (dd, J = 8.1, 1.7 Hz, 1H), 8.18 (d, J = 1.7 Hz, 1H), 8.15 (dd, J = 8.0, 1.9 Hz, 
1H), 8.06 – 8.01 (m, 1H), 7.88 – 7.84 (m, 2H), 7.76 (ddd, J = 8.2, 7.2, 1.7 Hz, 1H), 7.61 – 7.54 
(m, 3H), 7.53 – 7.48 (m, 1H), 7.45 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 3.42 (s, 3H); 
13
C NMR (101 
MHz, Acetone-d6) δ 191.5, 145.8, 143.1, 139.1, 138.2, 136.0, 135.7, 133.0, 132.4, 132.1, 131.7, 




 6-Methyl-3-(trimethylsilyl)dibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3k). 
Ketone 3k was prepared from the aryl chloride utilizing the trimethylsilylation procedure of 
Buchwald.
204
 Ketone 3h (462 mg, 1.50 mmol), Pd2dba3 (20.6 mg, 0.0225 mmol), t-BuDavePhos 
(2′-(Di-tert-butylphosphino)-N,N-dimethylbiphenyl-2-amine, 46.1 mg, 0.135 mmol), and LiOAc 
(495 mg, 7.50 mmol) were combined under argon. Anhydrous DMF (4.5 mL), water (54 µL, 
3.00 mmol), and hexamethyldisilane (369 µL, 1.80 mmol) were then added, and the resulting 
orange-brown mixture was heated to 100 ºC for 33 h. After cooling to room temperature, the 
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reaction mixture was diluted with water (20 mL) and extracted with Et2O (3 x 10 mL). The 
combined organics were washed with water (10 mL), dried over Na2SO4, and concentrated to 
yield a yellow crystalline solid. This crude material was recrystallized from MeOH to obtain 
pure ketone 3k as fine yellow needles (301 mg, 58%). 
1
H NMR (500 MHz, CDCl3) δ 8.30 (dd, J 
= 8.1, 1.6 Hz, 1H), 8.04 (d, J = 0.8 Hz, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.85 (dd, J = 7.6, 1.1 Hz, 
1H), 7.63 (ddd, J = 8.1, 7.3, 1.7 Hz, 1H), 7.41 – 7.29 (m, 2H), 3.35 (s, 3H), 0.36 (s, 9H); 
13
C 
NMR (126 MHz, CDCl3) δ 191.2, 147.4, 141.9, 138.3, 136.6, 136.0, 134.8, 132.1, 131.2, 130.5, 
129.7, 126.0, 124.6, 39.1, -1.2; LR-MS calcd. for C17H20NO3SSi [M+H]
+
 346.09, found 345.86. 
 3-Fluoro-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3l). Ketone 3h 
(462 mg, 1.50 mmol) and cesium fluoride (684 mg, 4.50 mmol) were combined, anhydrous 
DMSO (3.0 mL) was added, and the mixture was heated to 180 ºC for 20 min. After cooling to 
room temperature, the reaction was diluted with water (60 mL) and extracted with CH2Cl2 (20 
mL, 2 x 15 mL). The combined organics were washed with water (50 mL), dried over Na2SO4, 
and concentrated to give a yellow glass. This was purified by column chromatography (8:2 
CH2Cl2:hexanes) to yield ketone 3l as a white solid (215 mg, 49%). 
1
H NMR (400 MHz, 
CDCl3) (spectrum complicated by F-H coupling) δ 8.32 (dd, J = 8.1, 1.6 Hz, 1H), 8.03 (dd, J = 
8.6, 5.1 Hz, 1H), 7.71 – 7.62 (m, 2H), 7.43 – 7.34 (m, 3H), 3.36 (s, 3H); 
13
C NMR (126 MHz, 
CDCl3) (spectrum complicated by F-C coupling) δ 189.4, 165.2 and 163.2, 141.3, 139.5 and 
139.4, 135.1, 134.84 and 134.77, 132.5, 132.3, 131.2, 126.4, 124.9, 120.5 and 120.3, 113.3 and 
113.1, 39.2; LR-MS calcd. for C14H11FNO3S [M+H]
+
 292.04, found 292.12. 
 3-Methoxy-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3m). To a 
solution of sodium metal (115 mg, 5.00 mmol) in anhydrous MeOH (5.0 mL) was added ketone 
3h (308 mg, 1.00 mmol) and the mixture was heated to 100 ºC for 2 h in a sealed pressure vial. 
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The reaction was then cooled to room temperature, diluted with water (10 mL), and extracted 
with CH2Cl2 (3 x 10 mL). The combined organics were washed with water (2 x 10 mL), dried 
over Na2SO4, and concentrated to yield a yellow crystalline solid. This material was 
recrystallized from MeOH to yield ketone 3m as white prisms (158 mg, 52%). 
1
H NMR (500 
MHz, CDCl3) δ 8.33 (dd, J = 8.1, 1.6 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.63 (ddd, J = 8.0, 7.3, 
1.7 Hz, 1H), 7.46 (d, J = 2.6 Hz, 1H), 7.42 – 7.34 (m, 2H), 7.18 (dd, J = 8.7, 2.6 Hz, 1H), 3.96 (s, 
3H), 3.33 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 189.0, 162.8, 141.2, 139.1, 134.6, 134.5, 
132.4, 128.3, 126.6, 125.5, 118.9, 110.8, 56.3, 39.4; LR-MS calcd. for C15H14NO4S [M+H]
+
 
304.06, found 303.91. 
 6-Methyl-3-phenoxydibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3n). Ketone 
3h (308 mg, 1.00 mmol), phenol (2.82 g, 30.0 mmol), and K2CO3 (691 mg, 5.00 mmol) were 
combined and heated to 150 ºC for 2 h and then to 170 ºC for 3.25 h. The hot reaction mixture 
was then carefully diluted with 10% aqueous NaOH and extracted with Et2O (3 x 30 mL). The 
combined organics were washed with water (30 mL) and brine (30 mL), dried over Na2SO4, and 
concentrated to yield a yellow foam. This material was purified by column chromatography (1:1 
CH2Cl2:hexanes, 3 column volumes → 6:4 CH2Cl2:hexanes, 3 column volumes) to give a pale-
yellow foam still contaminated with impurities. This material was re-dissolved in CH2Cl2 and 
concentrated again to yield a yellow foam. A small quantity of Et2O was then added to this 
material causing complete dissolution followed immediately by crystallization of the product as a 
cake of fine white crystals. After cooling on ice, the supernatant was removed by pipet and the 
mass of crystals was washed with small portions of ice-cold Et2O and hexanes. After drying, the 
pure ketone 3n was obtained as short pale-yellow needles (288 mg, 79%). 
1
H NMR (400 MHz, 
CDCl3) δ 8.32 (dd, J = 8.1, 1.6 Hz, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.63 (ddd, J = 8.0, 7.4, 1.7 Hz, 
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1H), 7.53 (d, J = 2.5 Hz, 1H), 7.47 – 7.41 (m, 2H), 7.40 – 7.33 (m, 2H), 7.29 – 7.24 (m, 1H), 
7.22 (dd, J = 8.6, 2.5 Hz, 1H), 7.14 – 7.09 (m, 2H), 3.33 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
189.3, 161.3, 154.8, 141.2, 139.1, 134.7, 134.4, 132.2, 131.8, 130.5, 129.9, 126.4, 125.6, 125.1, 
121.3, 120.4, 114.2, 39.2; LR-MS calcd. for C20H16NO4S [M+H]
+
 366.08, found 365.84. 
 6-Methyl-3-(methylthio)dibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3o). To a 
solution of sodium thiomethoxide (116 mg, 1.65 mmol) in anhydrous DMF (2.0 mL) was added 
ketone 3h (462 mg, 1.50 mmol) and the resulting yellow suspension was stirred at room 
temperature for 1 h. Additional sodium thiomethoxide (26.3 mg, 0.375 mmol) was then added 
and stirring continued for a further 15 min. The reaction was then quenched with water (10 mL) 
and extracted with CH2Cl2 (10 mL, 2 x 5 mL). The combined organics were washed with water 
(20 mL), dried over Na2SO4, and concentrated to yield a yellow oil containing residual DMF. 
This crude was diluted with Et2O and chilled on ice causing the product to crystallize as pale-
yellow needles. These crystals were washed with several small portions of ice-cold Et2O and 
dried to give the pure ketone 3o (331 mg, 69%). 
1
H NMR (500 MHz, CDCl3) δ 8.31 (dd, J = 
8.1, 1.6 Hz, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 7.62 (ddd, J = 8.0, 7.4, 1.7 
Hz, 1H), 7.48 (dd, J = 8.3, 2.0 Hz, 1H), 7.40 – 7.33 (m, 2H), 3.33 (s, 3H), 2.59 (s, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 189.5, 146.5, 141.4, 137.7, 134.7, 132.4, 132.2, 131.8, 131.7, 129.2, 
126.4, 125.2, 121.4, 39.3, 15.0. LR-MS calcd. for C15H14NO3S2 [M+H]
+
 320.04, found 320.75. 
 3-Iodo-6-methyldibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide (3p). To a solution 
of trimethylsilylketone 3k (108 mg, 0.313 mmol) in anhydrous CH2Cl2 (0.94 mL) at 0 ºC was 
added a solution of iodine monochloride (173 mg, 1.06 mmol) in anhydrous CH2Cl2 (0.63 mL) 
dropwise over 3 min. The resulting dark-brown solution was allowed to warm to room 
temperature, stirred for 35 min (extended reaction times produce polyiodinated byproducts), and 
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quenched with saturated aqueous Na2S2O3 (3 mL). The resulting mixture was diluted with water 
(15 mL) and extracted with CH2Cl2 (2 x 15 mL). The combined organics were washed with 
water (15 mL), dried over Na2SO4, and concentrated to yield a yellow solid. This material was 
purified by column chromatography (1:1 CH2Cl2:hexanes) to yield impure product. This crude 
product was recrystallized from MeOH and the resulting fine-white needles were dissolved in 
CH2Cl2 and concentrated, causing a second crystallization to occur once most of the solvent had 
been removed. The powdery white crystals thus obtained were washed with ice-cold MeOH and 
dried to yield the pure ketone 3p (68.4 mg, 55%). 
1
H NMR (400 MHz, CDCl3) δ 8.32 – 8.27 
(m, 2H), 8.06 (dd, J = 8.1, 1.7 Hz, 1H), 7.69 – 7.62 (m, 2H), 7.38 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 
7.34 (dd, J = 8.1, 0.9 Hz, 1H), 3.35 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 190.1, 142.4, 141.5, 
138.1, 135.6, 135.1, 133.9, 133.1, 132.2, 131.0, 126.3, 124.7, 98.7, 39.2; LR-MS calcd. for 
C14H11INO3S [M+H]
+
 399.95, found 399.78. 
 
Preparation of Diarylthiazepinyl Alcohols 
 General Procedure for Preparation of Diarylthiazepinyl Alcohols (4a-p). Sodium 
borohydride (2 equivalents) was added to an ice-cooled solution (or suspension) of ketone 3 (1 
equivalent) in MeOH (0.143 M based on 3) and the mixture was allowed to warm to room 
temperature and stirred until TLC indicated the complete consumption of starting material. The 
reaction was then quenched with saturated aqueous ammonium chloride (5 mL per mmol 3) and 
saturated aqueous NaHCO3 (5 mL per mmol 3). The MeOH was evaporated and the precipitate 
was filtered, washed with water, and dried (alternatively, the residue was extracted with EtOAc 
and the combined organic layers were washed with water, dried over Na2SO4, filtered, and 
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concentrated). The crude product was crystallized from MeOH/water or used in the next step 
without further purification. 
 7-Chloro-10-hydroxy-4-methyl-4,10-dihydrobenzo[f]thieno[3,2-c][1,2]thiazepine 5,5-
dioxide (4a). The product 4a was prepared according to the general procedure and obtained as a 
tan solid (336 mg, 98%). 
1
H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 2.0 Hz, 1H), 7.68 - 7.60 
(m, 2H), 7.29 (d, J = 5.4 Hz, 1H), 6.84 (d, J = 5.5 Hz, 1H), 6.10 (d, J = 10.0 Hz, 1H), 4.61 (d, J = 
10.1 Hz, 1H), 3.10 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 136.1, 135.8, 135.02, 134.97, 134.2, 





dioxide (4b). The product 4b was prepared according to the general procedure and obtained as a 
yellowish-tan solid (579 mg, 100 %). 
1
H NMR (500 MHz, CDCl3) δ 8.10 (d, J = 2.0 Hz, 1H), 
7.80 (dd, J = 8.1, 2.0 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.31 (d, J = 5.4 Hz, 1H), 6.85 (d, J = 5.5 
Hz, 1H), 6.05 (d, J = 10.6 Hz, 1H), 4.49 (d, J = 10.6 Hz, 1H), 3.11 (s, 3H); 
13
C NMR (126 MHz, 
CDCl3) δ 137.2, 136.4, 136.0, 135.3, 131.5, 130.6, 127.5, 125.4, 124.1, 122.8, 71.3, 39.3; LR-
MS cald. for C12H9BrNO2S2 [M-OH]
+
 341.93, found 342.47. 
 11-Hydroxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (4c). The 
product 4c was prepared according to the general procedure, crystallized from MeOH/water, and 
obtained as a white crystalline solid (290 mg, 96%) with spectral and physical properties in 




H NMR (400 MHz, Acetone-d6) δ 7.97 (d, J = 7.9 
Hz, 1H), 7.85 (dd, J = 7.9, 1.2 Hz, 1H), 7.71 (dd, J = 7.5, 1.7 Hz, 1H), 7.63 (td, J = 7.7, 1.3 Hz, 
1H), 7.54 – 7.45 (m, 2H), 7.42 – 7.31 (m, 2H), 6.48 (d, J = 5.5 Hz, 1H), 5.49 (d, J = 5.7 Hz, 1H), 
3.37 (s, 3H). 
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 3-Bromo-11-hydroxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(4d). The product 4d was prepared according to the general procedure and obtained as a white 
solid (1.85 g, 99%). 
1
H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 2.0 Hz, 1H), 7.73 (dd, J = 8.2, 
2.0 Hz, 1H), 7.61 (dd, J = 7.7, 1.0 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.41 (td, J = 7.6, 1.5 Hz, 
1H), 7.37 – 7.30 (m, 2H), 5.93 (d, J = 9.7 Hz, 1H), 4.16 (d, J = 9.7 Hz, 1H), 3.20 (s, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 138.9, 138.8, 136.9, 136.4, 135.3, 131.8, 131.5, 131.0, 130.1, 127.9, 
127.0, 122.7, 76.2, 39.4; LR-MS calcd. for C14H11BrNO2S [M-OH]
+
 335.97, found 335.89. 
 2-Chloro-11-hydroxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(4e). The product 4e was prepared according to the general procedure and obtained as a white 
solid (195 mg, 95%). 
1
H NMR (400 MHz, Acetone-d6) δ 7.98 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 
8.5 Hz, 1H), 7.73 (dd, J = 7.1, 1.8 Hz, 1H), 7.57 – 7.47 (m, 2H), 7.44 – 7.35 (m, 2H), 6.51 (d, J = 
5.3 Hz, 1H), 5.72 (d, J = 5.4 Hz, 1H), 3.40 (s, 3H); 13C NMR (101 MHz, Acetone-d6) δ 143.6, 
142.8, 138.7, 138.2, 138.1, 130.3, 129.8, 129.0, 128.9, 128.4, 126.8, 126.6, 69.4, 37.7; LR-MS 
calcd. for C14H11ClNO2S [M-OH]
+
 292.02, found 292.38. 
 8-Chloro-11-hydroxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(4f). The product 4f was prepared according to the general procedure and obtained as an off-
white foam (384 mg, 100%). 
1
H NMR (500 MHz, CDCl3) δ 7.96 (dd, J = 7.8, 1.1 Hz, 1H), 7.68 
(d, J = 7.5 Hz, 1H), 7.62 (td, J = 7.5, 1.3 Hz, 1H), 7.58 – 7.55 (m, 1H), 7.52 (td, J = 7.6, 1.2 Hz, 
1H), 7.30 – 7.26 (m, 2H), 5.94 (d, J = 9.0 Hz, 1H), 4.50 (d, J = 9.5 Hz, 1H), 3.14 (s, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 140.2, 137.6, 136.6, 135.0, 134.0, 133.8, 132.8, 130.1, 128.9, 128.1, 
127.7, 126.6, 75.9, 39.1; LR-MS calcd. for C14H11ClNO2S [M-OH]
+
 292.02, found 292.51. 
 6-Ethyl-11-hydroxy-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (4g). The 
product 4g was prepared according to the general procedure and obtained as a pale-yellow glass 
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(226 mg, 100%). 
1
H NMR (500 MHz, CDCl3) δ 7.98 (dd, J = 7.8, 1.1 Hz, 1H), 7.68 (d, J = 7.5 
Hz, 1H), 7.65 – 7.57 (m, 2H), 7.50 (td, J = 7.6, 1.2 Hz, 1H), 7.41 – 7.32 (m, 3H), 5.99 (s, 1H), 
4.22 (d, J = 6.6 Hz, 1H), 3.77 – 3.68 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, 
CDCl3) δ 139.0, 138.1, 137.2, 137.0, 133.3, 131.9, 129.9, 129.8, 128.9, 127.9, 127.8, 127.4, 
76.6, 47.0, 13.9; LR-MS calcd. for C15H14NO2S [M-OH]
+
 272.07, found 271.97. 
 9-Bromo-3-chloro-11-hydroxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (4i). The product 4i was prepared according to the general procedure, recrystallized from 
MeOH/water, and obtained as a white solid (280 mg, 96 %). 
1
H NMR (400 MHz, Acetone-d6) δ 
8.01 (dd, J = 8.5, 0.7 Hz, 1H), 7.89 (dd, J = 2.4, 0.6 Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.70 (dd, J 
= 8.5, 2.2 Hz, 1H), 7.59 (ddd, J = 8.5, 2.4, 0.4 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 6.50 (d, J = 5.4 
Hz, 1H), 5.83 (d, J = 5.6 Hz, 1H), 3.39 (s, 3H); 
13
C NMR (101 MHz, Acetone-d6) δ 144.5, 
140.7, 139.1, 137.7, 134.4, 133.3, 132.8, 130.6, 130.1, 129.2, 127.7, 122.2, 69.2, 38.2; LR-MS 
calcd. for C14H10BrClNO2S  [M-OH]
+
 371.93, found 372.86. 
 11-Hydroxy-6-methyl-3-phenyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(4j). The product 4j was prepared according to the general procedure and obtained as a white 
solid (235 mg, 94 %). 
1
H NMR (400 MHz, Acetone-d6) δ 8.08 – 8.03 (m, 2H), 7.91 (dd, J = 8.2, 
1.9 Hz, 1H), 7.74 (dd, J = 7.3, 1.7 Hz, 1H), 7.72 – 7.66 (m, 2H), 7.54 – 7.46 (m, 3H), 7.45 – 7.34 
(m, 3H), 6.51 (d, J = 5.5 Hz, 1H), 5.55 (d, J = 5.7 Hz, 1H), 3.41 (s, 3H); 
13
C NMR (101 MHz, 
Acetone-d6) δ 142.8, 141.8, 140.0, 139.9, 139.7, 138.6, 131.4, 130.0, 129.7, 129.0, 128.8, 128.4, 
128.0, 127.8, 127.4, 126.4, 70.6, 38.0; LR-MS calcd. for C20H16NO2S [M-OH]
+
 334.09, found 
334.15. 
 3-Fluoro-11-hydroxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(4l). The product 4l was prepared according to the general procedure and obtained as a white 
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crystalline solid (215 mg, 100%). 
1
H NMR (400 MHz, CDCl3) (spectrum complicated by F-H 
coupling) δ 7.71 – 7.66 (m, 2H), 7.61 (dd, J = 7.6, 1.6 Hz, 1H), 7.41 (td, J = 7.6, 1.7 Hz, 1H), 
7.37 – 7.26 (m, 3H), 5.93 (d, J = 9.7 Hz, 1H), 4.25 (d, J = 9.8 Hz, 1H), 3.19 (s, 3H); 
13
C NMR 
(101 MHz, CDCl3) (spectrum complicated by F-C coupling) δ 163.3 and 160.8, 139.0, 138.9, 
135.3, 134.0 and 133.9, 132.63 and 132.55, 131.8, 130.1, 127.9, 127.1, 120.3 and 120.1, 115.9 
and 115.7, 76.4, 39.5; LR-MS calcd. for C14H11FNO2S [M-OH]
+
 276.05, found 276.12. 
 11-Hydroxy-3-methoxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (4m). The product 4m was prepared according to the general procedure and obtained as 
a white crystalline solid (153 mg, 100%). 
1
H NMR (500 MHz, CDCl3) δ 7.60 (dd, J = 7.7, 1.5 
Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 2.7 Hz, 1H), 7.38 (td, J = 7.6, 1.6 Hz, 1H), 7.32 
(td, J = 7.5, 1.4 Hz, 1H), 7.28 (dd, J = 7.9, 1.3 Hz, 1H), 7.09 (dd, J = 8.4, 2.7 Hz, 1H), 5.81 (d, J 
= 10.3 Hz, 1H), 4.43 (d, J = 10.3 Hz, 1H), 3.88 (s, 3H), 3.14 (s, 3H); 
13
C NMR (126 MHz, 
CDCl3) δ 159.7, 139.4, 138.0, 135.1, 132.6, 132.5, 129.9, 129.6, 127.6, 127.1, 119.0, 113.5, 
56.0, 39.8; LR-MS calcd. for C15H14NO3S [M-OH]
+
 288.07, found 287.93. 
 11-Hydroxy-6-methyl-3-phenoxy-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (4n). The product 4n was prepared according to the general procedure and obtained as a 
pale-yellow glass (291 mg, 100%). 
1
H NMR (400 MHz, CDCl3) δ 7.63 – 7.58 (m, 3H), 7.42 – 
7.36 (m, 3H), 7.36 – 7.28 (m, 2H), 7.22 – 7.15 (m, 2H), 7.08 – 7.03 (m, 2H), 5.89 (d, J = 9.5 Hz, 
1H), 4.41 (d, J = 9.8 Hz, 1H), 3.17 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 157.9, 155.8, 139.1, 
138.4, 135.4, 132.4, 132.0, 131.9, 130.3, 129.9, 127.7, 127.1, 124.8, 122.3, 119.8, 117.8, 76.7, 
39.5; LR-MS calcd. for C20H16NO3S [M-OH]
+
 350.09, found 350.01. 
 11-Hydroxy-6-methyl-3-(methylthio)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (4o). The product 4o was prepared according to the general procedure and obtained as a 
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pale-yellow, crystalline solid (323 mg, 100%). 
1
H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 2.0 
Hz, 1H), 7.57 (dd, J = 7.6, 1.3 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.40 – 7.33 (m, J = 9.2, 7.9, 1.9 
Hz, 2H), 7.32 – 7.27 (m, 2H), 5.89 (d, J = 9.4 Hz, 1H), 4.44 (d, J = 9.4 Hz, 1H), 3.16 (s, 3H), 
2.51 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 140.8, 138.8, 137.4, 136.0, 134.0, 131.2, 130.4, 
130.3, 129.7, 127.7, 127.0, 124.8, 75.9, 39.2, 15.4; LR-MS calcd. for C15H14NO2S2 [M-OH]
+
 
304.05, found 304.71. 
 11-Hydroxy-3-iodo-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(4p).  The product 4p was prepared according to the general procedure and obtained as a white 
solid (74.8 mg, 95%). 
1
H NMR (500 MHz, CDCl3) (observed as a ~4:1 ratio of 2 conformers, 
resulting in partial integrals) δ 8.27 (d, J = 1.8 Hz, 1H), 7.99 (dd, J = 7.7, 1.1 Hz, 0.2H), 7.93 
(dd, J = 8.1, 1.8 Hz, 0.8H), 7.68 (d, J = 7.2 Hz, 0.2H), 7.65 – 7.58 (m, 1H), 7.53 (td, J = 7.6, 1.3 
Hz, 0.2H), 7.44 – 7.37 (m, 1.8H), 7.37 – 7.29 (m, 1.8H), 5.92 (s, 1H), 4.40 (d, J = 9.6 Hz, 0.2H), 
4.15 (d, J = 7.5 Hz, 0.8H), 3.20 (s, 2.4H), 3.14 (s, 0.6H); 
13
C NMR (126 MHz, CDCl3) 
(additional peaks due to conformers) δ 142.4, 138.8, 138.7, 137.5, 136.5, 135.4, 133.6, 132.1, 
131.7, 131.4, 130.6, 130.1, 130.0, 128.9, 128.4, 127.9, 127.6, 127.0, 126.9, 93.6, 76.2, 39.3; LR-
MS calcd. for C14H11INO2S [M-OH]
+
 383.96, found 383.71. 
 11-Hydroxy-7-methoxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (4q). To a dark-green suspension of CrCl2 (474 mg, 3.86 mmol) and NiCl2 (50.0 mg, 
0.386 mmol) in anhydrous DMF (4.8 mL) was added a solution of sulfonamide 7 (416 mg, 0.965 
mmol, see below for preparation) in anhydrous DMF (4.8 mL) dropwise over 4 minutes. The 
resulting nearly black mixture was heated to 90 ºC for 1.5 h then quenched with water (50 mL) 
and extracted with Et2O (50 mL, 2 x 25 mL). The combined organics were washed with brine 
(50 mL), dried over Na2SO4, and concentrated to yield a yellow oil. This crude was purified by 
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column chromatography (CH2Cl2, 2 column volumes → 80:1 CH2Cl2:Et2O, 2 column volumes 
→ 40:1 CH2Cl2:Et2O, 2 column volumes → 20:1 CH2Cl2:Et2O, 2 column volumes) to obtain 
impure product as a white foam. On addition of a small quantity of Et2O, crystallization 
occurred. After washing the crystals, this crystallization procedure (concentration from CH2Cl2 
solution followed by addition of Et2O) was repeated to yield the pure alcohol 4q as fine white 
crystals (132 mg, 45%). 
1
H NMR (500 MHz, CDCl3) (significant broadening of some peaks 
was observed due to conformers) δ 7.99 (d, J = 7.8 Hz, 1H), 7.70 (br s, 1H), 7.58 (t, J = 6.9 Hz, 
1H), 7.49 (t, J = 7.7 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.21 (br s, 1H), 6.95 (d, J = 7.7 Hz, 1H), 
6.01 (br s, 1H), 4.10 (br s, 1H), 3.93 (s, 3H), 3.05 (br s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 
156.0, 139.5, 138.4, 137.5, 133.1, 129.1, 128.8, 128.6, 126.7, 121.5, 112.1, 74.9, 56.3, 37.1; LR-
MS calcd. for C15H14NO3S [M-OH]
+
 288.07, found 288.72. 
 N-(2-formyl-6-methoxyphenyl)-2-iodobenzenesulfonamide (6). To a solution of 2-
amino-3-methoxybenzaldehyde (800 mg, 5.29 mmol) in anhydrous pyridine (3.75 mL) was 
added 2-iodobenzenesulfonyl chloride (1.52 g, 5.04 mmol), and the orange-brown solution was 
stirred at room temperature for 1 h. The reaction mixture was then diluted with CH2Cl2 (50 mL), 
washed with 7% aqueous HCl (2 x 50 mL), brine (50 mL), saturated aqueous NaHCO3 (50 mL), 
and brine again (50 mL), dried over Na2SO4, and concentrated to yield an orange-brown oil. This 
crude material was purified by repeated column chromatography (Column 1: CH2Cl2, 4 column 
volumes → 1:1 CH2Cl2:Et2O, 2 column volumes; Column 2: 7:3 hexanes:EtOAc, 2 column 
volumes → 1:1 hexanes:EtOAc, until finished) to obtain pure sulfonamide 6 as a tan crystalline 
solid (668 mg, 32%). 
1
H NMR (400 MHz, CDCl3) δ 10.32 (s, 1H), 8.19 (s, 1H), 8.10 (dd, J = 
7.8, 0.9 Hz, 1H), 7.76 (dd, J = 7.9, 1.5 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.31 (dd, J = 11.1, 4.2 
Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 7.17 (dd, J = 7.7, 1.6 Hz, 1H), 6.91 (dd, J = 8.2, 1.1 Hz, 1H), 
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3.42 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 191.1, 153.1, 142.5, 142.2, 133.5, 132.7, 131.0, 




 N-(2-formyl-6-methoxyphenyl)-2-iodo-N-methylbenzenesulfonamide (7). To a 
suspension of sodium hydride (60% in oil, 120 mg, 3.00 mmol) in anhydrous DMF (2.2 mL) was 
added a solution of sulfonamide 6 (626 mg, 1.50 mmol) in anhydrous DMF (2.2 mL) dropwise 
over 4 min., and the resulting lemon-yellow solution was stirred for 30 minutes at room 
temperature. Methyl iodide (187 µL, 3.00 mmol) was then added, and the mixture was stirred for 
1 h and then quenched with ice water (30 mL). The resulting white precipitate was collected, 
washed with hexanes and Et2O, and dried to yield the first crop of pure sulfonamide 7 as an off-
white crystalline solid (231 mg). The filtrate was then washed with hexanes and extracted with 
4:1 Et2O:CH2Cl2 (2 x 25 mL), adding the CH2Cl2 first to ensure dissolution and then diluting 
with Et2O. The combined organics were washed with water (2 x 50 mL), dried over Na2SO4, and 
concentrated to yield a pale-yellow oily solid. Upon addition of a small quantity of Et2O to this 
material, abundant off-white crystals formed. After removal of the supernatant these crystals 
were washed with three small portions of ice-cold Et2O and dried to obtain a second crop of pure 
sulfonamide 7 (281 mg). Total yield of 7 was 512 mg (79%). 
1
H NMR (400 MHz, CDCl3) δ 
10.36 (d, J = 0.8 Hz, 1H), 8.11 (dd, J = 7.8, 1.2 Hz, 1H), 7.79 (dd, J = 8.0, 1.6 Hz, 1H), 7.56 (dd, 
J = 7.8, 1.4 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.38 – 7.34 (m, 1H), 7.14 (td, J = 7.7, 1.7 Hz, 1H), 
6.99 (dd, J = 8.2, 1.3 Hz, 1H), 3.53 (s, 3H), 3.39 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 190.3, 
157.3, 143.1, 143.0, 136.8, 133.1, 131.9, 130.9, 130.1, 128.0, 119.9, 116.7, 91.9, 55.4, 40.0; LR-
MS calcd. for C15H15INO4S [M+H]
+
 431.98, found 432.66. 
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Preparation of Diarylthiazepinyl Chlorides 
 General Procedure for Preparation of Diarylthiazepinyl Chlorides (5a-q). 
Thionyl chloride (4-6 equivalents) was added dropwise to a solution of the alcohol 4 (1 
equivalent) in anhydrous CH2Cl2 (0.143 M based on 4) (in some cases, neat thionyl chloride was 
used). The reaction mixture was stirred for 2-18 h at room temperature and then concentrated to 
give the chloride 5, which was used directly in the following reactions without further 
purification. 
 7,10-Dichloro-4-methyl-4,10-dihydrobenzo[f]thieno[3,2-c][1,2]thiazepine 5,5-dioxide 
(5a). The product 5a was prepared according to the general procedure and obtained as a dark-
brown solid (371 mg, 100%). 
1
H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 2.1 Hz, 1H), 7.74 (d, J 
= 8.3 Hz, 1H), 7.64 (dd, J = 8.2, 2.2 Hz, 1H), 7.32 (d, J = 5.3 Hz, 1H), 6.89 – 6.81 (m, 2H), 3.13 
(s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 137.3, 137.1, 135.8, 133.9, 131.7, 131.4, 128.1, 126.2, 
125.8, 124.6, 57.6, 39.4; LR-MS cald. for C12H9ClNO2S2 [M-Cl]
+
 297.98, found 298.00. 
 7-Bromo-10-chloro-4-methyl-4,10-dihydrobenzo[f]thieno[3,2-c][1,2]thiazepine 5,5-
dioxide (5b). The product 5b was prepared according to the general procedure and obtained as a 
brown solid containing ~6 mass% starting material by NMR (577 mg, 92% corrected for starting 
material impurity). 
1
H NMR (500 MHz, CDCl3) δ 8.14 (d, J = 2.0 Hz, 1H), 7.80 (dd, J = 8.3, 
2.0 Hz, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 5.5 Hz, 1H), 6.85 (d, J = 6.8 Hz, 1H), 6.84 (s, 
1H), 3.13 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 137.3, 137.04, 137.00, 131.9, 131.8, 130.9, 
126.1, 125.8, 124.6, 123.6, 57.7, 39.4; LR-MS cald. for C12H9BrNO2S2 [M-Cl]
+
 341.93, found 
342.47. 
 11-Chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (5c). The 
product 5c was prepared according to the general procedure and obtained as a white solid (220 
 388 




H NMR (500 MHz, Acetone-d6) δ 7.96 (d, J = 7.3 Hz, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.70 – 
7.62 (m, 4H), 7.57 (t, J = 7.6 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 6.63 (s, 1H), 3.54 (s, 3H). 
 3-Bromo-11-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(5d). The product 5d was prepared according to the general procedure and obtained as a white 
solid (1.92 g, 99%). 
1
H NMR (400 MHz, CDCl3) δ 8.14 (d, J = 2.1 Hz, 1H), 7.66 (dd, J = 8.3, 
2.1 Hz, 1H), 7.55 – 7.49 (m, 2H), 7.45 – 7.40 (m, 2H), 7.39 – 7.33 (m, 1H), 6.10 (s, 1H), 3.58 (s, 
3H); 
13
C NMR (101 MHz, CDCl3) δ 142.0, 139.2, 137.6, 135.6, 134.1, 133.0, 131.7, 131.0, 
130.2, 129.5, 129.0, 124.3, 63.7, 39.3; LR-MS cald. for C14H11BrNO2S [M-Cl]
+
 335.97, found 
335.79. 
 2,11-Dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (5e). The 
product 5e was prepared according to the general procedure and obtained as a white solid (195 
mg, 99%). 
1
H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.5 Hz, 1H), 7.60 – 7.50 (m, 4H), 7.46 (d, 
J = 7.4 Hz, 1H), 7.41 – 7.35 (m, 1H), 6.11 (s, 1H), 3.60 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 
139.1, 138.7, 138.3, 137.3, 136.9, 131.6, 130.9, 130.1, 129.9, 129.6, 129.2, 128.8, 63.1, 38.9; 
LR-MS calcd. for C14H11ClNO2S [M-Cl]
+
 292.02, found 292.38. 
 8,11-Dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (5f). The 
product 5f was prepared according to the general procedure and obtained as an off-white solid 
(390 mg, 100%). 
1
H NMR (500 MHz, CDCl3) δ 8.04 – 7.99 (m, 1H), 7.59 – 7.51 (m, 4H), 7.39 
(d, J = 8.3 Hz, 1H), 7.32 (dd, J = 8.3, 2.0 Hz, 1H), 6.14 (s, 1H), 3.55 (s, 3H); 
13
C NMR (126 
MHz, CDCl3) δ 140.7, 140.2, 136.9, 136.4, 134.8, 132.8, 131.5, 131.1, 130.4, 129.5, 129.0, 
128.1, 63.6, 39.0; LR-MS calcd. for C14H11ClNO2S [M-Cl]
+
 292.02, found 292.56. 
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 11-Chloro-6-ethyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (5g). The 
product 5g was prepared according to the general procedure and obtained as a white solid (230 
mg, 98%). 
1
H NMR (500 MHz, CDCl3) δ 8.04 – 8.00 (m, 1H), 7.59 – 7.45 (m, 6H), 7.37 (td, J = 
7.6, 1.3 Hz, 1H), 6.22 (s, 1H), 4.12 (dq, J = 14.4, 7.2 Hz, 1H), 3.83 (dq, J = 14.2, 7.1 Hz, 1H), 
1.45 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 140.7, 138.4, 138.1, 135.1, 132.5, 
131.4, 131.2, 130.8, 130.4, 130.2, 129.0, 128.3, 64.1, 48.0, 16.3; LR-MS calcd. for C15H14NO2S 
[M-Cl]
+
 272.07, found 271.97. 
 3,11-Dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (5h). 
Chloride 5h was purchased from Ark Pharm Inc. (Libertyville, IL) and used without further 
purification. 
 9-Bromo-3,11-dichloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(5i). The product 5i was prepared according to the general procedure and obtained as an off-
white solid (270 mg, 99 %). 
1
H NMR (400 MHz, Acetone-d6) δ 7.91 (s, 1H), 7.90 (s, 1H), 7.82 
(d, J = 8.4 Hz, 1H), 7.79-7.73 (m, 2H), 7.64 (d, J = 8.5 Hz, 1H), 6.67 (s, 1H), 3.54 (s, 3H); 
13
C 
NMR (101 MHz, Acetone-d6) δ 143.0, 140.4, 139.9, 136.6, 135.2, 135.0, 134.4, 134.0, 133.6, 
132.1, 127.9, 122.1, 62.6, 39.4; LR-MS calcd. for C14H10BrClNO2S  [M-Cl]
+
 371.93, found 
372.84. 
 11-Chloro-6-methyl-3-phenyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(5j). The product 5j was prepared according to the general procedure and obtained as an off-
white solid (235 mg, 99 %). 
1
H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 1.9 Hz, 1H), 7.76 (dd, J 
= 8.1, 2.0 Hz, 1H), 7.65 – 7.59 (m, 3H), 7.56 (dd, J = 7.9, 1.4 Hz, 1H), 7.52 (td, J = 7.9, 7.5, 1.5 
Hz, 1H), 7.49 – 7.44 (m, 3H), 7.44 – 7.38 (m, 1H), 7.36 (td, J = 7.6, 1.5 Hz, 1H), 6.21 (s, 1H), 
3.61 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 143.5, 140.9, 139.5, 138.6, 138.0, 133.7, 132.1, 
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131.5, 130.9, 130.1, 129.5, 129.2, 128.8, 128.7, 127.3, 126.6, 64.3, 39.2; LR-MS calcd. for 
C20H16NO2S [M-Cl]
+
 334.09, found 334.15. 
 11-Chloro-3-fluoro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(5l). The product 5l was prepared according to the general procedure and obtained as a white 
solid (219 mg, 99%). 
1
H NMR (500 MHz, CDCl3) (spectrum complicated by F-H coupling) δ 
7.71 (dd, J = 8.1, 2.7 Hz, 1H), 7.58 – 7.49 (m, 3H), 7.43 (d, J = 7.5 Hz, 1H), 7.39 – 7.34 (m, 1H), 
7.26 – 7.21 (m, 1H), 6.14 (s, 1H), 3.59 (s, 3H); 
13
C NMR (126 MHz, CDCl3) (spectrum 
complicated by F-C coupling) δ 163.9 and 161.8, 142.5, 139.3, 137.8, 133.82 and 133.75, 131.7, 
131.3, 130.1, 129.5, 129.0, 119.8 and 119.7, 115.5 and 115.3, 63.7, 39.3; LR-MS calcd. for 
C14H11FNO2S [M-Cl]
+
 276.05, found 275.78. 
 11-Chloro-3-methoxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(5m). The product 5m was prepared according to the general procedure and obtained as an off-
white solid (158 mg, 99%). 
1
H NMR (500 MHz, CDCl3) δ 7.57 – 7.39 (m, 5H), 7.34 (t, J = 7.4 
Hz, 1H), 7.05 (dd, J = 8.6, 2.6 Hz, 1H), 6.14 (s, 1H), 3.88 (s, 3H), 3.58 (s, 3H); 
13
C NMR (126 
MHz, CDCl3) δ 160.7, 141.6, 139.5, 138.3, 133.4, 131.4, 130.0, 129.5, 128.8, 127.1, 119.3, 
112.0, 64.7, 56.0, 39.3; LR-MS calcd. for C15H14NO3S [M-Cl]
+
 288.07, found 287.94. 
 11-Chloro-6-methyl-3-phenoxy-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(5n). The product 5n was prepared according to the general procedure and obtained as an off-
white solid (283 mg, 97%). 
1
H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 2.6 Hz, 1H), 7.55 – 7.47 
(m, 3H), 7.45 – 7.33 (m, 4H), 7.21 (t, J = 7.4 Hz, 1H), 7.11 (dd, J = 8.6, 2.6 Hz, 1H), 7.09 – 7.03 
(m, 2H), 6.14 (s, 1H), 3.58 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 159.3, 155.3, 142.0, 139.4, 
138.1, 133.5, 131.5, 130.4, 130.0, 129.5, 129.0, 128.9, 125.1, 121.5, 120.2, 116.7, 64.4, 39.3; 
LR-MS calcd. for C20H16NO3S [M-Cl]
+
 350.09, found 349.75. 
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 11-Chloro-6-methyl-3-(methylthio)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (5o). The product 5o was prepared according to the general procedure and obtained as an 
off-white solid (329 mg, 98%) 
1
H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.56 – 7.47 (m, 2H), 
7.45 – 7.40 (m, 2H), 7.38 – 7.32 (m, 2H), 6.12 (s, 1H), 3.58 (s, 3H), 2.53 (s, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 142.9, 140.9, 139.4, 137.9, 131.9, 131.5, 130.9, 130.1, 129.6, 129.5, 128.9, 
124.1, 64.5, 39.3, 15.3; LR-MS calcd. for C15H14NO2S2 [M-Cl]
+
 304.05, found 304.74. 
 11-Chloro-3-iodo-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide (5p). 
The product 5p was prepared according to the general procedure and obtained as a gray solid 
(73.4 mg, 96%). 
1
H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 1.8 Hz, 1H), 7.87 (dd, J = 8.2, 1.8 
Hz, 1H), 7.57 – 7.48 (m, 2H), 7.43 (d, J = 7.1 Hz, 1H), 7.39 – 7.33 (m, 1H), 7.27 (d, J = 7.1 Hz, 
1H), 6.08 (s, 1H), 3.57 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 141.8, 141.5, 139.3, 137.6, 
136.7, 134.7, 132.9, 131.7, 130.1, 129.5, 129.0, 95.4, 63.8, 39.3; LR-MS calcd. for C14H11INO2S 
[M-Cl]
+
 383.96, found 383.70. 
 11-Chloro-7-methoxy-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide 
(5q). The product 5q was prepared according to the general procedure and obtained as a white 
solid (70.4 mg, 100%). 
1
H NMR (400 MHz, CDCl3) δ 8.04 – 7.97 (m, 1H), 7.56 – 7.47 (m, 3H), 
7.31 (t, J = 8.0 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 7.7 Hz, 1H), 6.03 (s, 1H), 3.97 (s, 
3H), 3.54 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 158.4, 141.2, 140.1, 135.1, 132.2, 131.7, 
130.4, 130.0, 128.1, 127.4, 121.3, 114.1, 64.7, 56.4, 38.1; LR-MS calcd. for C15H14NO3S [M-
Cl]
+
 288.07, found 288.07. 
 
Preparation of Diarylthiazepineamines (Tianeptine Analogs) 
General Procedures for Preparation of N-substituted Diarylthiazepinamines (8 and 9). 
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N-substituted 11-amino-6-alkyl-6,11-dihydrodiaryl[c,f][1,2]thiazepine 5,5-dioxides were 
prepared via amination of the corresponding chlorides 5 with amines, according to general 
methods A, B, or C. 
 Method A. An amine (1.3 equivalents) and Et3N (2 equivalents) were added to a solution 
of the chloride 5 (1 equivalent) in nitromethane (0.2 M based on 5) and the reaction heated to 60 
°C until TLC indicated the complete consumption of starting material (typically <30 min.). The 
reaction mixture was then concentrated and purified directly by column chromatography with an 
appropriate solvent mixture, as described below for each compound. 
 Method B. To a suspension of chloride 5 (1 equivalent) in nitromethane (0.5 M based on 
5) was added an amine (2 equivalents), and the mixture was warmed to 60 °C and left to stir until 
TLC indicated that the reaction was complete (typically <30 min.). The reaction mixture was 
concentrated, and the residue partitioned between Et2O (20 mL per mmol 5) and water (20 mL 
per mmol 5). The ethereal layer was separated and the aqueous extracted again with Et2O (20 mL 
per mmol 5). The combined organics were washed with water (20 mL per mmol 5) and 10% 
NH4OH (20 mL per mmol 5), dried over Na2SO4, and concentrated to yield the product. If 
necessary, the product was further purified by column chromatography. Alternatively, in some 
cases, no extraction was performed and the concentrated reaction was purified directly by 
column chromatography. 
 Method C. To a suspension of chloride 5 (1 equivalent) in nitromethane (0.5 M based on 
5) was added an amine hydrochloride (1.2 equivalents) and Et3N (2.4 equivalents) and the 
mixture was warmed to 60 °C and left to stir until TLC indicated that the reaction was complete 
(typically <30 min.). The reaction mixture was concentrated and the residue partitioned between 
Et2O (20 mL per mmol 5) and water (20 mL per mmol 5). The ethereal layer was separated and 
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the aqueous extracted again with Et2O (20 mL per mmol 5). The combined organics were 
washed with water (20 mL per mmol 5) and 10% NH4OH (20 mL per mmol 5), dried over 
Na2SO4, and concentrated to yield the product. If necessary, the product was further purified by 
column chromatography. Alternatively, in some cases, no extraction was performed and the 
concentrated reaction was purified directly by column chromatography. 
 Ethyl 5-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)pentanoate (8a). Method C. The product 8a was purified by column chromatography 
(40:1 CH2Cl2:Et2O) and obtained as a viscous, pale-yellow oil (130 mg, 60%). 
1
H NMR (500 
MHz, CDCl3) δ 7.96 (d, J = 2.1 Hz, 1H), 7.50 – 7.34 (m, 5H), 7.30 (dd, J = 7.2, 1.8 Hz, 1H), 
5.00 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.36 (s, 3H), 2.48 (t, J = 7.0 Hz, 2H), 2.27 (t, J = 7.4 Hz, 
2H), 2.10 (br s, 1H), 1.70 – 1.58 (m, 2H), 1.52 (ddd, J = 11.9, 7.0, 3.7 Hz, 2H), 1.24 (t, J = 7.1 
Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 173.6, 140.4, 138.7, 138.6, 136.8, 134.5, 132.4, 131.4, 
130.3, 129.5, 128.6, 128.2, 128.1, 66.3, 60.4, 47.8, 38.9, 34.2, 29.6, 22.8, 14.4; LR-MS calcd. 
for C21H26ClN2O4S [M+H]
+
 437.13, found 437.51. 
 Ethyl 7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)heptanoate (8b). Method C. The product 8b was purified by column chromatography 
(40:1 CH2Cl2:Et2O, 6 column volumes → 1:1 CH2Cl2:Et2O, 2 column volumes) and obtained as 
a viscous, pale-yellow oil (91 mg, 78%). 
1
H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 2.0 Hz, 
1H), 7.48 – 7.26 (m, 6H), 5.00 (s, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.36 (s, 3H), 2.45 (t, J = 7.1 Hz, 
2H), 2.26 (t, J = 7.5 Hz, 2H), 2.03 (br s, 1H), 1.65 – 1.53 (m, 2H), 1.53 – 1.41 (m, 2H), 1.35 – 
1.26 (m, 4H), 1.23 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 173.8, 140.5, 138.9, 
138.6, 137.0, 134.3, 132.3, 131.3, 130.1, 129.4, 128.5, 128.2, 128.1, 66.2, 60.3, 48.2, 38.8, 34.3, 
30.0, 29.1, 27.0, 24.9, 14.4; LR-MS calcd. for C23H30ClN2O4S [M+H]
+
 465.16, found 465.13. 
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 3-Chloro-6-methyl-11-(propylamino)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (8c). Compound 8c was prepared according to a modified Method B using 10 
equivalents of n-propylamine. The product 8c was obtained as a viscous, pale-yellow oil (169 
mg, 96%). 
1
H NMR (400 MHz, CDCl3) δ 7.98 – 7.93 (m, 1H), 7.48 – 7.26 (m, 6H), 5.01 (s, 
1H), 3.38 (s, 3H), 2.44 (t, J = 7.1 Hz, 2H), 2.02 (br s, 1H), 1.57 – 1.44 (m, 2H), 0.89 (t, J = 7.4 
Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 140.6, 139.1, 138.6, 137.1, 134.3, 132.2, 131.3, 130.1, 
129.4, 128.5, 128.3, 128.2, 66.2, 50.1, 38.8, 23.3, 11.9; LR-MS calcd. for C17H20ClN2O2S 
[M+H]
+
 351.09, found 351.51. 
 3-Chloro-6-methyl-11-(pentylamino)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (8d). Method B. The product 8d was purified by column chromatography (8:2 
CH2Cl2:hexanes, 4 column volumes → CH2Cl2, 3 column volumes) and obtained as a viscous, 
colorless oil (52.9 mg, 28%).  
1
H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 1.7 Hz, 1H), 7.48 – 
7.42 (m, 2H), 7.41 – 7.32 (m, 3H), 7.32 – 7.27 (m, 1H), 5.01 (s, 1H), 3.38 (s, 3H), 2.46 (t, J = 7.2 
Hz, 2H), 2.01 (br s, 1H), 1.57 – 1.37 (m, 2H), 1.35 – 1.20 (m, 4H), 0.86 (t, J = 7.0 Hz, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 140.5, 139.0, 138.6, 137.1, 134.3, 132.3, 131.2, 130.1, 129.4, 128.5, 
128.3, 128.1, 66.2, 48.3, 38.8, 29.9, 29.6, 22.7, 14.1; LR-MS calcd. for C19H24ClN2O2S [M+H]
+
 
379.12, found 378.75. 
 3-Chloro-11-(heptylamino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (8e). Method B. The product 8e was purified by column chromatography (9:1 
hexanes:EtOAc + 2% Et3N) and obtained as viscous, colorless oil (161 mg, 79%). 
1
H NMR (500 
MHz, CDCl3) δ 7.96 (d, J = 1.9 Hz, 1H), 7.47 – 7.42 (m, 2H), 7.41 – 7.33 (m, 3H), 7.29 (td, J = 
7.3, 1.5 Hz, 1H), 5.01 (s, 1H), 3.38 (s, 3H), 2.46 (t, J = 7.1 Hz, 2H), 1.99 (br s, 1H), 1.54 – 1.41 
(m, 2H), 1.32 – 1.17 (m, 8H), 0.86 (t, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 140.6, 
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139.1, 138.6, 137.2, 134.3, 132.3, 131.2, 130.1, 129.4, 128.5, 128.3, 128.1, 66.2, 48.3, 38.7, 31.9, 
30.2, 29.3, 27.4, 22.7, 14.2; LR-MS calcd. for C21H28ClN2O2S [M+H]
+
 407.16, found 406.94. 
 3-Chloro-11-((3-hydroxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8f). Method B. The product 8f was purified by column chromatography 
(1:1 CH2Cl2:Et2O, 3 column volumes → 1:1 CH2Cl2:Et2O + 5% MeOH, 3 column volumes) and 
obtained as a cloudy, colorless glass (27.1 mg, 74%). 
1
H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 
2.2 Hz, 1H), 7.50 (dd, J = 8.2, 2.2 Hz, 1H), 7.45 – 7.40 (m, 2H), 7.38 – 7.31 (m, 2H), 7.31 – 7.27 
(m, 1H), 5.01 (s, 1H), 3.82 – 3.74 (m, 2H), 3.25 (br s, 2H), 3.25 (s, 3H), 2.68 – 2.60 (m, 2H), 
1.75 – 1.63 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 139.9, 139.2, 136.2, 135.6, 134.6, 132.5, 
132.4, 131.5, 129.6, 128.8, 128.1, 127.6, 67.1, 63.7, 47.4, 39.1, 31.2; LR-MS cald. for 
C17H20ClN2O3S [M+H]
+
 367.09, found 367.09. 
 3-Chloro-11-((5-hydroxypentyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8g). Method B. The product 8g was purified by column chromatography 
(6:4 CH2Cl2:Et2O) and obtained as a viscous, pale-yellow oil (317 mg, 80%). 
1
H NMR (500 
MHz, CDCl3) δ 7.96 (s, 1H), 7.51 – 7.26 (m, 6H), 5.00 (s, 1H), 3.63 – 3.54 (m, 2H), 3.36 (s, 
3H), 2.55 – 2.43 (m, 2H), 1.97 (br s, 2H), 1.58 – 1.46 (m, 4H), 1.43 – 1.31 (m, 2H); 
13
C NMR 
(126 MHz, CDCl3) δ 140.4, 138.7, 138.5, 136.9, 134.3, 132.3, 131.5, 130.3, 129.5, 128.5, 128.2, 
128.0, 66.4, 62.6, 48.0, 38.8, 32.5, 29.8, 23.5; LR-MS calcd. for C19H24ClN2O3S [M+H]
+
 
395.12, found 394.85. 
 3-Chloro-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8h). Method B. The product 8h was obtained as a viscous, pale-yellow 
oil (188 mg, 99%). 
1
H NMR (500 MHz, CDCl3) δ 7.94 (t, J = 1.2 Hz, 1H), 7.46 – 7.33  (m, 2H), 
7.41 – 7.37 (m, 2H), 7.37 – 7.33 (m, 1H), 7.28 (td, J = 7.3, 1.6 Hz, 1H), 5.02 (s, 1H), 3.45 – 3.39 
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(m, 2H), 3.37 (s, 3H), 3.29 (s, 3H), 2.64 – 2.52 (m, 2H), 2.18 (br s, 1H), 1.82 – 1.68 (m, 2H); 
13
C 
NMR (126 MHz, CDCl3) δ 140.5, 139.0, 138.6, 137.1, 134.3, 132.3, 131.1, 130.0, 129.4, 128.5, 
128.3, 128.1, 71.3, 66.0, 58.8, 45.8, 38.6, 30.0; LR-MS calcd. for C18H22ClN2O3S [M+H]
+
 
381.10, found 380.79. 
 3-Chloro-11-((3-ethoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8i). Method B. The product 8i was purified by column chromatography 
(1:1 hexanes:EtOAc, 4 column volumes → EtOAc, 2 column volumes) and obtained as a 
viscous, pale-yellow oil (176 mg, 89%). 
1
H NMR (500 MHz, CDCl3) δ 7.93 (s, 1H), 7.51 – 7.23 
(m, 6H), 5.05 (s, 1H), 3.53 – 3.40 (m, 4H), 3.37 (s, 3H), 2.59 (t, J = 6.4 Hz, 2H), 2.35 (br s, 1H), 
1.83 – 1.70 (m, 2H), 1.14 (t, J = 6.9 Hz, 3H);
 13
C NMR (126 MHz, CDCl3) δ 140.5, 139.1, 
138.5, 137.1, 134.2, 132.2, 131.0, 129.8, 129.3, 128.4, 128.2, 128.1, 69.1, 66.3, 65.6, 45.9, 38.6, 
30.0, 15.2; LR-MS calcd. for C19H24ClN2O3S [M+H]
+
 395.12, found 394.49. 
 3-Chloro-11-((3-methoxybutyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8j). Method B. The product 8j was purified by column chromatography 
(1:1 hexanes:EtOAc, 2 column volumes → EtOAc, 2 column volumes) and obtained as a 
viscous, colorless oil (30.4 mg, 77%, 1:1 mixture of diastereomers). 
1
H NMR (400 MHz, 
CDCl3) (partial integrals due to mixture of diastereomers) δ 7.95 (d, J = 1.2 Hz, 1H), 7.49 – 7.32 
(m, 5H), 7.32 – 7.27 (m, 1H), 5.04 (s, 0.5H), 5.02 (s, 0.5H), 3.43 – 3.34 (m, 1H), 3.38 (s, 1.5H), 
3.37 (s, 1.5 H), 3.27 (s, 1.5H), 3.26 (s, 1.5H), 2.64 – 2.51 (m, 2H), 2.36 (br s, 1H), 1.75 – 1.57 
(m, 2H), 1.10 (t, J = 6.0 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) (additional peaks due to mixture 
of diastereomers) δ 140.5, 140.4, 138.6, 137.0, 134.3, 132.3, 131.2, 130.0, 129.5, 128.5, 128.3, 
128.1, 75.7, 75.4, 66.2, 65.9, 56.1, 45.2, 44.9, 38.7, 36.8, 36.7, 19.11, 19.08; LR-MS calcd. for 
C19H24ClN2O3S [M+H]
+
 395.12, found 394.98. 
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 3-Chloro-11-((2-methoxyethyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8k). Method B. The product 8k was obtained as a viscous, pale-yellow 
oil (184 mg, 100%). 
1
H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 2.1 Hz, 1H), 7.49 – 7.33 (m, 
5H), 7.29 (td, J = 7.4, 1.5 Hz, 1H), 5.07 (s, 1H), 3.53 – 3.44 (m, 2H), 3.43 (s, 3H), 3.32 (s, 3H), 
2.73 – 2.59 (m, 2H), 2.43 (br s, 1H); 
13
C NMR (101 MHz, CDCl3) δ 141.0, 139.5, 138.4, 137.1, 
134.4, 132.2, 131.0, 129.6, 129.5, 128.4, 128.4, 128.3, 72.1, 65.6, 58.9, 47.6, 38.4; LR-MS 
calcd. for C17H20ClN2O3S [M+H]
+
 367.09, found 367.50. 
 3-Chloro-6-methyl-11-((3-(methylthio)propyl)amino)-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8l). Method B. The product 8l was obtained as a viscous, pale-yellow oil 
(194 mg, 98%). 
1
H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 2.1 Hz, 1H), 7.50 – 7.27 (m, 6H), 
5.00 (s, 1H), 3.34 (s, 3H), 2.65 – 2.46 (m, 4H), 2.07 (br s, 1H) 2.06 (s, 3H), 1.77 (p, J = 7.0 Hz, 
2H); 
13
C NMR (101 MHz, CDCl3) δ 140.3, 138.8, 138.3, 136.8, 134.4, 132.4, 131.5, 130.5, 
129.5, 128.6, 128.2, 128.0, 66.4, 46.9, 38.9, 32.1, 29.4, 15.7; LR-MS calcd. for C18H22ClN2O2S2 
[M+H]
+
 397.08, found 396.84. 
 3-Chloro-11-((2-(furan-2-yl)ethyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8m). Method B. The product 8m was purified by column 
chromatography (CH2Cl2, 3 column volumes → 20:1 CH2Cl2:Et2O, 4 column volumes) and 
obtained as a pale-brown glass (17.7 mg, 44%). 
1
H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 2.1 
Hz, 1H), 7.45 (dd, J = 8.3, 2.2 Hz, 1H), 7.41 – 7.33 (m, 4H), 7.31 – 7.27 (m, 2H), 6.28 (dd, J = 
3.1, 1.9 Hz, 1H), 6.02 (d, J = 3.1 Hz, 1H), 5.01 (s, 1H), 3.32 (s, 3H), 2.90 – 2.80 (m, 2H), 2.80 – 
2.74 (m, 2H), 2.24 (br s, 1H); 
13
C NMR (126 MHz, CDCl3) δ 153.6, 141.5, 140.7, 138.6, 136.7, 
134.6, 132.3, 131.3, 130.1, 129.6, 128.5, 128.3, 128.2, 110.5, 106.4, 66.1, 46.5, 38.6, 28.8; LR-
MS calcd. for C20H20ClN2O3S [M+H]
+
 403.09, found 402.73. 
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 Ethyl 7-((3-fluoro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)heptanoate (8n). Method C. The product 8n was obtained as a viscous, pale-yellow 
oil (39.0 mg, 87%). 
1
H NMR (400 MHz, CDCl3) (spectrum complicated by F-H couling) δ 7.68 
(dd, J = 8.2, 2.7 Hz, 1H), 7.47 (dd, J = 8.6, 5.2 Hz, 1H), 7.41 – 7.32 (m, 3H), 7.32 – 7.26 (m, 
1H), 7.19 (ddd, J = 8.5, 7.7, 2.7 Hz, 1H), 4.99 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.37 (s, 3H), 2.45 
(t, J = 7.1 Hz, 2H), 2.26 (t, J = 7.5 Hz, 2H), 2.05 (br s, 1H), 1.64 – 1.53 (m, 2H), 1.52 – 1.42 (m, 
2H), 1.35 – 1.26 (m, 4H), 1.24 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) (spectrum 
complicated by F-C coupling) δ 173.8, 163.0 and 160.5, 140.9 and 140.8, 139.0, 138.7, 134.5, 
132.1 and 132.0, 130.3, 129.5, 128.22 and 128.20, 119.3 and 119.1, 116.0 and 115.7, 66.5, 60.3, 





yl)amino)heptanoate (8o). Method C. The product 8o was purified by column chromatography 
(20:1 CH2Cl2:Et2O, 4 column volumes → 7:3 CH2Cl2:Et2O, 2 column volumes) and obtained as 
a viscous, colorless oil (42.0 mg, 82%). 
1
H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 2.1 Hz, 1H), 
7.61 (dd, J = 8.2, 2.1 Hz, 1H), 7.40 – 7.33 (m, 4H), 7.31 – 7.27 (m, 1H), 4.98 (s, 1H), 4.11 (q, J 
= 7.1 Hz, 2H), 3.37 (s, 3H), 2.45 (t, J = 7.1 Hz, 2H), 2.26 (t, J = 7.5 Hz, 2H), 2.03 (br s, 1H), 
1.63 – 1.54 (m, 2H), 1.52 – 1.43 (m, 2H), 1.34 – 1.26 (m, 4H), 1.24 (t, J = 7.1 Hz, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 173.8, 140.6, 138.9, 138.6, 137.6, 135.3, 131.4, 131.3, 130.1, 129.4, 
128.2, 128.1, 122.0, 66.3, 60.3, 48.2, 38.8, 34.4, 30.0, 29.1, 27.0, 25.0, 14.4; LR-MS cald. for 
C23H30BrN2O4S [M+H]
+
 509.11, found 509.92. 
 Ethyl 7-((3-iodo-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)heptanoate (8p). Method C. The product 8p was purified directly by column 
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chromatography (20:1 CH2Cl2:Et2O) and obtained as a viscous, nearly-colorless oil (31.7 mg, 
70%). 
1
H NMR (400 MHz, CDCl3) δ 8.26 (d, J = 1.8 Hz, 1H), 7.81 (dd, J = 8.1, 1.8 Hz, 1H), 
7.41 – 7.32 (m, 3H), 7.31 – 7.26 (m, 1H), 7.21 (d, J = 8.2 Hz, 1H), 4.98 (s, 1H), 4.11 (q, J = 7.1 
Hz, 2H), 3.36 (s, 3H), 2.46 (t, J = 7.1 Hz, 2H), 2.26 (t, J = 7.5 Hz, 2H), 2.05 (br s, 1H), 1.65 – 
1.53 (m, 2H), 1.53 – 1.42 (m, 2H), 1.35 – 1.26 (m, 4H), 1.24 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 
MHz, CDCl3) δ 173.8, 141.3, 140.6, 138.7, 138.1, 136.9, 131.5, 130.1, 129.5, 128.2, 128.1, 92.9, 
66.3, 60.3, 48.2, 38.7, 34.4, 30.0, 29.1, 27.0, 25.0, 14.4; LR-MS calcd. for C23H30IN2O4S 
[M+H]
+
 557.10, found 556.54. 
 Ethyl 7-((7-methoxy-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-
11-yl)amino)heptanoate (8q). Method C. The product 8q was obtained as a viscous, pale-
yellow oil (44.6 mg, 97%). 
1
H NMR (500 MHz, CDCl3) (observed as a ~55:45 ratio of 2 
conformers resulting in partial integrals) δ 7.96 (dd, J = 7.6, 1.6 Hz, 1H), 7.58 (d, J = 7.6 Hz, 
0.45H), 7.52 – 7.33 (m, 2.55H), 7.29 – 7.21 (m, 1H), 7.06 – 6.81 (m, 2H), 5.34 (s, 0.45H), 4.67 
(s, 0.55H), 4.10 (p, J = 7.2 Hz, 2H), 3.93 (s, 1.65H), 3.89 (s, 1.35H), 3.48 (s, 1.65H), 3.22 (s, 
1.35H), 2.65 – 2.33 (m, 2H), 2.31 – 2.20 (m, 2H), 1.87 (br s, 1H), 1.66 – 1.50 (m, 3H), 1.46 – 
1.29 (m, 3H), 1.28 – 1.18 (m, 5H); 
13
C NMR (126 MHz, CDCl3) (spectrum complicated by 
conformers) δ 173.8, 158.2, 156.9, 142.5, 141.8, 138.4, 137.9, 132.3, 131.7, 129.6, 129.3, 129.1, 
128.9, 128.2, 127.9, 126.3, 122.5, 112.6, 111.3, 70.8, 60.3, 56.3, 48.5, 48.2, 38.0, 36.5, 34.3, 
30.0, 29.8, 29.1, 27.1, 25.0, 24.9, 14.4; LR-MS calcd. for C24H33N2O5S [M+H]
+
 461.21, found 
460.98. 
 11-((3-Methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (8r). Method A. The product 8r was purified by column chromatography (1:2 
hexanes:EtOAc) and obtained as a viscous, colorless oil (59 mg, 85 %). 
1
H NMR (400 MHz, 
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Acetone-d6) δ 7.89 (dd, J = 7.8, 1.2 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.60 (td, J = 7.5, 1.3 Hz, 
1H), 7.54 – 7.48 (m, 2H), 7.46 (dd, J = 7.8, 1.2 Hz, 1H), 7.38 (td, J = 7.6, 1.6 Hz, 1H), 7.32 (td, J 
= 7.5, 1.3 Hz, 1H), 5.20 (s, 1H), 3.39 (t, J = 6.3 Hz, 2H), 3.37 (s, 3H), 3.22 (s, 3H), 2.72 (br s, 
1H), 2.63 – 2.52 (m, 2H), 1.73 (p, J = 6.6 Hz, 2H); 13C NMR (101 MHz, Acetone-d6) δ 141.0, 
140.4, 140.1, 139.9, 133.o, 130.8, 130.7, 129.7, 128.9, 128.8, 128.5, 71.6, 66.7, 58.5, 46.1, 38.6, 
30.8, 29.8; LR-MS calcd. for C18H23N2O3S  [M+H]
+
 347.14, found 347.90. 
 3-Fluoro-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8s). Method B. The product 8s was obtained as a viscous, pale-yellow 
oil (33.8 mg, 93%). 
1
H NMR (400 MHz, CDCl3) (spectrum complicated by F-H coupling) δ 
7.68 (dd, J = 8.2, 2.7 Hz, 1H), 7.48 (dd, J = 8.6, 5.2 Hz, 1H), 7.41 – 7.33 (m, 3H), 7.32 – 7.27 
(m, 1H), 7.23 – 7.14 (m, 1H), 5.01 (s, 1H), 3.42 (td, J = 6.2, 2.5 Hz, 2H), 3.38 (s, 3H), 3.29 (s, 
3H), 2.63 – 2.49 (m, 2H), 2.25 (br s, 1H), 1.83 – 1.66 (m, 2H); 
13
C NMR (101 MHz, CDCl3) 
(spectrum complicated by F-C coupling) δ 163.0 and 160.5, 140.9 and 140.8, 139.1, 138.7, 
134.6, 132.0 and 131.9, 130.2, 129.4, 128.3 and 128.2, 119.3 and 119.1, 116.0 and 115.7, 71.3, 
66.3, 58.8, 45.8, 38.8, 30.1; LR-MS calcd. for C18H22FN2O3S [M+H]
+
 365.13, found 365.52. 
 3-Bromo-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8t). Method A. The product 8t was purified by column chromatography 
(1:1 hexanes:EtOAc) and obtained as a colorless oil turning to a white solid (45 mg, 71 %). 
1
H 
NMR (400 MHz, Acetone-d6) δ 7.96 (d, J = 2.1 Hz, 1H), 7.77 (dd, J = 8.3, 2.1 Hz, 1H), 7.65 (d, 
J = 8.3 Hz, 1H), 7.51 (dd, J = 7.6, 1.5 Hz, 1H), 7.49 (dd, J = 7.9, 1.2 Hz, 1H), 7.41 (td, J = 7.6, 
1.6 Hz, 1H), 7.34 (td, J = 7.4, 1.3 Hz, 1H), 5.18 (s, 1H), 3.42 (s, 3H), 3.39 (t, J = 6.2 Hz, 2H), 
3.22 (s, 3H), 2.58 (t, J = 6.8 Hz, 2H), 2.54 (br s, 1H), 1.73 (p, J = 6.6 Hz, 2H); 
13
C NMR (101 
MHz, Acetone-d6) δ 142.7, 140.8, 139.7, 139.1, 135.8, 133.1, 131.0, 130.8, 130.0, 129.4, 128.9, 
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thiazepine 5,5-dioxide (8u). Method B. The product 8u was purified directly by column 
chromatography (1:1 hexanes:EtOAc, 2 column volumes → EtOAc, 2 column volumes) and 
obtained as a viscous, pale-yellow oil (32.2 mg, 84%). 
1
H NMR (400 MHz, CDCl3) δ 8.26 (d, J 
= 1.8 Hz, 1H), 7.81 (dd, J = 8.1, 1.8 Hz, 1H), 7.43 – 7.32 (m, 3H), 7.31 – 7.27 (m, 1H), 7.24 (d, J 
= 8.2 Hz, 1H), 5.02 (s, 1H), 3.46 – 3.39 (m, 2H), 3.37 (s, 3H), 3.29 (s, 3H), 2.65 – 2.52 (m, 2H), 
2.40 (br s, 1H), 1.77 (p, J = 6.3 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 141.3, 140.6, 138.7, 
136.9, 131.4, 130.0, 129.5, 128.3, 128.0, 93.0, 71.3, 66.1, 58.8, 45.9, 38.6, 30.0; LR-MS calcd. 
for C18H22IN2O3S [M+H]
+
 473.04, found 472.79. 
 9-Bromo-3-chloro-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo 
[c,f][1,2]thiazepine 5,5-dioxide (8v). Method A. The product 8v was purified by column 
chromatography (2:1 hexanes:EtOAc) and obtained as a white solid (75 mg, 82 %). 
1
H NMR 
(400 MHz, Acetone-d6) δ 7.83 (d, J = 2.2 Hz, 1H), 7.74 – 7.70 (m, 2H), 7.66 (dd, J = 8.3, 2.2 
Hz, 1H), 7.58 (dd, J = 8.5, 2.4 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 5.23 (s, 1H), 3.42 – 3.38 (m, 
5H), 3.23 (s, 3H), 2.80 (br s, 1H), 2.60 (td, J = 6.8, 2.1 Hz, 2H), 1.79 – 1.69 (m, 2H); 
13
C NMR 
(101 MHz, Methanol-d4) δ 141.8, 141.7, 139.6, 137.5, 135.4, 134.6, 133.6, 133.5, 130.9, 128.9, 
122.4, 101.4, 72.2, 66.5, 58.9, 46.3, 39.0, 30.5; LR-MS calcd. for C18H21BrClN2O3S  [M+H]
+
 
461.01, found 462.07. 
 2-Chloro-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8w). Method A. The product 8w was purified by column 
chromatography (1:1 hexanes:EtOAc - 1:1) and obtained as a viscous colorless oil (72 mg, 95%). 
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1
H NMR (400 MHz, Acetone-d6) δ 7.88 (d, J = 8.5 Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.56 – 
7.47 (m, 3H), 7.41 (td, J = 7.6, 1.7 Hz, 1H), 7.35 (td, J = 7.4, 1.5 Hz, 1H), 5.28 (s, 1H), 3.42 (t, J 
= 6.1 Hz, 2H), 3.41 (s, 3H), 3.24 (s, 3H), 2.81 (br s, 1H), 2.63 (t, J = 6.8 Hz, 2H), 1.77 (dq, J = 
12.2, 6.2 Hz, 2H); 
13
C NMR (101 MHz, Acetone-d6) δ 142.4, 141.0, 139.7, 139.4, 138.3, 130.7, 
130.0, 129.9, 129.8, 129.1, 128.92, 128.86, 71.5, 65.2, 58.6, 46.2, 38.4, 30.8; LR-MS calcd. for 
C18H22ClN2OS [M+H]
+
 381.10, found 381.46. 
 8-Chloro-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8x). Method B. The product 8x was purified by column chromatography 
(1:1 hexanes:EtOAc, 2 column volumes → EtOAc, 3 column volumes) and obtained as a 
viscous, nearly colorless oil (33.8 mg, 89%). 
1
H NMR (500 MHz, CDCl3) δ 7.98 (dd, J = 7.8, 
0.9 Hz, 1H), 7.54 (td, J = 7.6, 1.2 Hz, 1H), 7.52 – 7.41 (m, 3H), 7.33 (d, J = 2.1 Hz, 1H), 7.25 
(dd, J = 8.6, 2.3 Hz, 1H), 5.09 (s, 1H), 3.45 – 3.38 (m, 2H), 3.28 (s, 3H), 3.28 (s, 3H), 3.01 (br s, 
1H), 2.61 (dt, J = 13.2, 6.7 Hz, 1H), 2.53 (dt, J = 11.4, 6.7 Hz, 1H), 1.83 – 1.71 (m, 2H); 
13
C 
NMR (126 MHz, CDCl3) δ 140.5, 138.3, 137.3, 136.2, 134.5, 132.8, 132.1, 130.3, 128.68, 
128.65, 128.0, 127.5, 71.2, 66.4, 58.8, 45.7, 38.6, 29.8; LR-MS calcd. for C18H22ClN2O3S 
[M+H]
+
 381.10, found 380.79. 
 6-Ethyl-11-((3-methoxypropyl)amino)-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-
dioxide (8y). Method B. The product 8y was purified by column chromatography (1:1 
hexanes:EtOAc, 2 column volumes → EtOAc, 3 column volumes) and obtained as a viscous, 
colorless oil (30.6 mg, 85%). 
1
H NMR (500 MHz, CDCl3) δ 7.98 – 7.94 (m, 1H), 7.52 – 7.45 
(m, 2H), 7.43 – 7.38 (m, 3H), 7.35 – 7.27 (m, 2H), 5.16 (s, 1H), 3.96 – 3.77 (m, 2H), 3.50 – 3.39 
(m, 2H), 3.31 (s, 3H), 2.68 – 2.56 (m, 2H), 2.32 (br s, 1H), 1.83 – 1.73 (m, 2H), 1.18 (t, J = 7.2 
Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 140.7, 139.9, 138.7, 136.9, 132.2, 129.3, 129.1, 129.0, 
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128.7, 128.4, 128.3, 71.3, 65.2, 58.8, 46.3, 45.8, 30.1, 14.9; LR-MS calcd. for C19H25N2O3S 
[M+H]
+
 361.16, found 361.06. 
 3-Methoxy-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8z). Method B. The product 8z was purified by column chromatography 
(8:2 CH2Cl2:Et2O, 2 column volumes → 1:1 CH2Cl2:Et2O, 3 column volumes) and obtained as a 
viscous, colorless oil (32.1 mg, 85%). 
1
H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 2.7 Hz, 1H), 
7.42 – 7.36 (m, 3H), 7.34 (td, J = 7.5, 1.6 Hz, 1H), 7.27 (dt, J = 7.5, 1.6 Hz, 1H), 7.01 (dd, J = 
8.5, 2.7 Hz, 1H), 4.92 (s, 1H), 3.84 (s, 3H), 3.40 (pd, J = 9.4, 6.3 Hz, 2H), 3.35 (s, 3H), 3.29 (s, 
3H), 2.55 (t, J = 6.8 Hz, 2H), 2.17 (br s, 1H), 1.80 – 1.67 (m, 2H); 
13
C NMR (126 MHz, CDCl3) 
δ 159.3, 139.9, 139.2, 139.1, 131.8, 130.7, 130.4, 129.2, 128.1, 128.0, 118.7, 112.9, 71.3, 67.0, 
58.8, 55.9, 45.6, 38.9, 30.1; LR-MS calcd. for C19H25N2O4S [M+H]
+
 377.15, found 376.95. 
 11-((3-Methoxypropyl)amino)-6-methyl-3-(methylthio)-6,11-dihydrodibenzo 
[c,f][1,2]thiazepine 5,5-dioxide (8aa). Method B. The product 8aa was purified by column 
chromatography (1:1 hexanes:EtOAc, 2 column volumes → EtOAc, 3 column volumes) and 
obtained as a viscous, pale-yellow oil (31.1 mg, 79%). 
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, J 
= 1.7 Hz, 1H), 7.43 – 7.31 (m, 5H), 7.31 – 7.25 (m, 1H), 4.97 (s, 1H), 3.45 – 3.38 (m, 2H), 3.35 
(s, 3H), 3.29 (s, 3H), 2.57 (t, J = 6.7 Hz, 2H), 2.51 (s, 3H), 2.29 (br s, 1H), 1.82 – 1.68 (m, 2H). 
13
C NMR (101 MHz, CDCl3) δ 140.0, 139.5, 139.1, 138.9, 134.8, 130.41, 130.37, 129.9, 129.3, 
128.1, 128.0, 125.3, 71.3, 66.6, 58.8, 45.7, 38.8, 30.1, 15.6; LR-MS calcd. for C19H25N2O3S2 
[M+H]
+
 393.13, found 392.74. 
 11-((3-Methoxypropyl)amino)-6-methyl-3-phenoxy-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8ab). Method B. The product 8ab was purified by column 
chromatography (9:1 CH2Cl2:Et2O, 2 column volumes, → 8:2 CH2Cl2:Et2O, 2 column volumes) 
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and obtained as a viscous, pale-yellow oil (37.4 mg, 85%). 
1
H NMR (500 MHz, CDCl3) δ 7.59 
(d, J = 2.2 Hz, 1H), 7.47 – 7.33 (m, 6H), 7.29 (t, J = 7.3 Hz, 1H), 7.16 (t, J = 7.1 Hz, 1H), 7.09 
(dd, J = 8.4, 2.3 Hz, 1H), 7.04 – 7.01 (m, 2H), 4.98 (s, 1H), 3.47 – 3.40 (m, 2H), 3.38 (s, 3H), 
3.30 (s, 3H), 2.59 (t, J = 6.7 Hz, 2H), 2.07 (br s, 1H), 1.84 – 1.71 (m, 2H); 
13
C NMR (126 MHz, 
CDCl3) δ 157.5, 156.0, 140.5, 139.3, 138.9, 132.7, 131.7, 130.3, 130.2, 129.3, 128.1, 124.5, 
121.7, 119.7, 117.9, 71.3, 66.6, 58.8, 45.8, 38.7, 30.1; LR-MS calcd. for C24H27N2O4S [M+H]
+
 
439.17, found 438.88. 
 11-((3-Methoxypropyl)amino)-6-methyl-3-phenyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8ac). Method A. The product 8ac was purified by column 
chromatography (1:1 hexanes:EtOAc) and obtained as a colorless oil (75 mg, 89%). 
1
H NMR 
(400 MHz, Acetone-d6) δ 8.11 (d, J = 1.9 Hz, 1H), 7.88 (dd, J = 8.1, 1.9 Hz, 1H), 7.77 (d, J = 
8.1 Hz, 1H), 7.73 – 7.67 (m, 2H), 7.57 – 7.46 (m, 4H), 7.45 – 7.41 (m, 1H), 7.39 (dd, J = 7.7, 1.6 
Hz, 1H), 7.34 (td, J = 7.5, 1.4 Hz, 1H), 5.24 (s, 1H), 3.41 (m, 5H), 3.23 (s, 3H), 2.62 (t, J = 6.8 
Hz, 2H), 2.57 (br s, 1H), 1.75 (p, J = 6.6 Hz, 2H); 
13
C NMR (101 MHz, Acetone-d6) δ 141.7, 
141.1, 140.9, 140.1, 139.7, 138.7, 131.6, 131.1, 130.9, 130.0, 129.8, 129.11, 129.08, 128.6, 





c][1,2]thiazepine 5,5-dioxide (9a). Method B. The product 9a was purified by column 
chromatography (20:1 CH2Cl2:Et2O → 10:1 CH2Cl2:Et2O → 5:1 CH2Cl2:Et2O) and obtained as a 
dark-green solid (24.7 mg, 54%). 
1
H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 2.3 Hz, 1H), 7.61 
(dd, J = 8.2, 2.3 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.19 (d, J = 5.4 Hz, 1H), 6.82 (d, J = 5.5 Hz, 
1H), 5.37 (s, 1H), 3.56 – 3.44 (m, 2H), 3.35 (s, 3H), 3.04 (s, 3H), 2.77 (br s, 1H), 2.76 (t, J = 6.5 
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Hz, 2H), 1.89 – 1.72 (m, 2H); 
13
C NMR (101 MHz, CDCl3) δ 137.2, 135.2, 134.7, 134.0, 133.6, 
130.4, 128.4, 124.5, 124.1, 110.1, 71.2, 60.8, 58.8, 45.3, 39.6, 30.2; LR-MS cald. for 
C16H20ClN2O3S2 [M+H]
+
 387.06, found 387.24. 
 7-Bromo-10-((3-methoxypropyl)amino)-4-methyl-4,10-dihydrobenzo[f]thieno[3,2-
c][1,2]thiazepine 5,5-dioxide (9b). Method B. The product 9b was purified by column 
chromatography (20:1 CH2Cl2:Et2O, 3 column volumes → 10:1 CH2Cl2:Et2O, 3 column volumes 
→ 5:1 CH2Cl2:Et2O, 4 column volumes) and obtained as a beige solid (22.1 mg, 51%). 
1
H NMR 
(400 MHz, CDCl3) δ 8.11 (d, J = 2.0 Hz, 1H), 7.77 (dd, J = 8.2, 2.0 Hz, 1H), 7.39 (d, J = 8.1 Hz, 
1H), 7.21 (d, J = 5.5 Hz, 1H), 6.82 (d, J = 5.5 Hz, 1H), 5.39 (s, 1H), 3.54 – 3.43 (m, 2H), 3.34 (s, 
3H), 3.05 (s, 3H), 2.77 (t, J = 6.4 Hz, 2H), 1.88 – 1.76 (m, 2H); 
13
C NMR (101 MHz, CDCl3) δ 
137.3, 136.7, 131.1, 130.8, 124.5, 124.3, 121.9, 71.2, 60.8, 58.8, 45.4, 39.6, 29.9; LR-MS calcd. 
for C16H20BrN2O3S2 [M+H]
+
 431.01, found 431.92. 
 Ethyl 7-((7-bromo-4-methyl-5,5-dioxido-4,10-dihydrobenzo[f]thieno[3,2-
c][1,2]thiazepin-10-yl)amino)heptanoate (9c). Method C. The product 9c was purified by 
column chromatography (20:1 CH2Cl2:Et2O, 4 column volumes → 10:1 CH2Cl2:Et2O, 4 column 
volumes) and obtained as a dark-brown solid (52.5 mg, 51%). 
1
H NMR (400 MHz, CDCl3) δ 
8.11 (d, J = 2.1 Hz, 1H), 7.76 (dd, J = 8.2, 2.1 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.19 (d, J = 5.5 
Hz, 1H), 6.81 (d, J = 5.5 Hz, 1H), 5.31 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.03 (s, 3H), 2.64 (br s, 
1H), 2.62 (t, J = 6.9 Hz, 2H), 2.27 (t, J = 7.5 Hz, 2H), 1.66 – 1.55 (m, 2H), 1.55 – 1.45 (m, 2H), 
1.40 – 1.27 (m, 4H), 1.24 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 173.9, 137.3, 
136.5, 135.3, 135.0, 131.2, 130.8, 129.6, 124.5, 124.1, 121.7, 60.8, 60.3, 47.7, 39.6, 34.4, 29.9, 
29.0, 26.9, 25.0, 14.4; LR-MS calcd. for C21H28BrN2O4S2 [M+H]
+
 515.07, found 516.24. 
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Synthesis of Additional Diarylthiazepinamines 
 Additional diarylthiazepinamines were prepared via methylation, demethylation, or 
hydrolysis of existing analogs. 
 3-Chloro-11-((5-methoxypentyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8ad). Compound 8ad was prepared by O-methylation of alcohol 8g 
according to the following procedure. To a mixture of 8g (118 mg, 0.300 mmol) and NaH (12.0 
mg of 60% in oil, 0.300 mmol) was added anhydrous THF (0.38 mL, freshly distilled from 
Na/benzophenone), and the yellow-orange mixture was stirred for 1 h at room temperature. 
Dimethyl sulfate (28.6 µL, 0.300 mmol) was then added to the red-orange mixture and the 
reaction was stirred for 1 h at room temperature. The reaction was then quenched with water (10 
mL) and extracted with Et2O (3 x 5 mL). The combined organics were washed with 10% 
NH4OH (5 mL), dried over Na2SO4, and concentrated to yield a thick yellow oil. This crude 
material was purified by column chromatography (6:4 hexanes:EtOAc) to yield the pure product 
8ad as a viscous, pale-yellow oil (29.4 mg, 24%). 
1
H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 
2.0 Hz, 1H), 7.48 – 7.33 (m, 5H), 7.31 – 7.27 (m, 1H), 5.00 (s, 1H), 3.37 (s, 3H), 3.33 (t, J = 6.5 
Hz, 2H), 3.30 (s, 3H), 2.47 (t, J = 7.1 Hz, 2H), 1.95 (br s, 1H), 1.58 – 1.46 (m, 4H), 1.39 – 1.30 
(m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 140.5, 138.8, 138.7, 137.0, 134.4, 132.3, 131.3, 130.2, 
129.5, 128.6, 128.3, 128.1, 72.8, 66.3, 58.7, 48.2, 38.8, 30.0, 29.6, 24.0; LR-MS calcd. for 
C20H26ClN2O3S [M+H]
+
 409.14, found 409.03. 
 7-Hydroxy-11-((3-methoxypropyl)amino)-6-methyl-6,11-dihydrodibenzo[c,f][1,2] 
thiazepine 5,5-dioxide (8ae). Phenol 8ae was prepared according to the following procedure. To 
a solution of compound 8q (29.1 mg, 0.0631 mmol) in anhydrous CH2Cl2 (0.50 mL) at 0 °C was 
added aluminum chloride (50.5 mg, 0.379 mmol) followed by ethanethiol (84.4 µL, 1.14 mmol), 
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and the resulting mixture was allowed to warm to room temperature and stirred for 1.5 h. The 
reaction was then quenched with water (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The 
combined organics were washed with water (5 mL), dried over Na2SO4, and concentrated to give 
a white solid. This material was purified by column chromatography (6:1 CH2Cl2:Et2O, 2 
column volumes → 7:3 CH2Cl2:Et2O, 2 column volumes) to provide the pure product 8ae as a 
white solid (23.3 mg, 83%). 
1
H NMR (500 MHz, CDCl3) (partial integrals due to conformers) δ 
8.00 – 7.94 (m, 1H), 7.63 – 7.36 (m, 3H), 7.23 – 7.15 (m, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.88 (dd, 
J = 17.9, 7.7 Hz, 1H), 6.29 (br s, 1H), 5.24 (s, 0.5H), 4.74 (s, 0.5H), 4.11 (p, J = 7.1 Hz, 2H), 
3.56 (s, 1.5H), 3.17 (s, 1.5H), 2.67 – 2.57 (m, 0.5H), 2.51 (td, J = 13.7, 6.8 Hz, 1H), 2.39 (dt, J = 
11.2, 7.3 Hz, 0.5H), 2.32 – 2.20 (m, 2H), 1.66 – 1.52 (m, 3H), 1.47 – 1.17 (m, 8H); 
13
C NMR 
(126 MHz, CDCl3) (additional peaks due to conformers) δ 174.0, 173.9, 155.2, 153.8, 141.7, 
140.9, 137.7, 132.8, 132.2, 131.8, 130.2, 129.7, 129.3, 128.7, 128.2, 125.0, 122.8, 117.4, 116.0, 
71.2, 60.4, 48.7, 48.2, 39.7, 38.0, 34.4, 34.3, 30.0, 29.8, 29.12, 29.08, 27.10, 27.06, 25.0, 24.9, 
14.4; LR-MS calcd. for C23H31N2O5S [M+H]
+
 447.19, found 447.15. 
 5-((3-Chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)pentanoic acid (10a). Acid 10a (a metabolite of tianeptine) was prepared by 
hydrolysis of ester 8a according to the following procedure. To a solution of 8a (120 mg, 0.275 
mmol) in ethanol (0.75 mL) and water (0.25 mL) was added NaOH (11.8 mg, 0.296 mmol), and 
the resulting solution was refluxed for 1 h. Most of the ethanol was removed in vacuo and the 
mixture was diluted with water (5 mL) and washed with Et2O (2 x 5 mL). It was then carefully 
acidified to pH 4-5 with 10% aqueous HCl, saturated with (NH4)2SO4, and extracted with CHCl3 
(2 x 5 mL). The combined organics were washed with water (3 mL), dried over Na2SO4, and 
concentrated to yield the product 10a as a foamy, off-white solid (105 mg, 94%). 
1
H NMR (500 
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MHz, CDCl3) δ 7.97 (d, J = 1.9 Hz, 1H), 7.56 – 7.46 (m, 3H), 7.44 – 7.38 (m, 1H), 7.36 (dd, J = 
8.0, 1.3 Hz, 1H), 7.30 (td, J = 7.6, 1.4 Hz, 1H), 5.27 (s, 1H), 4.42 (br s, 2H), 3.27 (s, 3H), 2.55 
(dd, J = 11.0, 8.2 Hz, 1H), 2.42 (dd, J = 9.9, 6.9 Hz, 1H), 2.25 (dd, J = 10.9, 5.0 Hz, 2H), 1.71 – 
1.45 (m, 4H); 
13
C NMR (126 MHz, CDCl3) δ 177.3, 140.2, 139.5, 135.3, 134.2, 134.0, 133.2, 
132.9, 132.0, 130.3, 128.6, 128.1, 127.6, 66.3, 46.9, 39.2, 34.2, 28.4, 22.6; LR-MS calcd. for 
C19H22ClN2O4S [M+H]
+
 409.10, found 408.69. 
 7-((3-Bromo-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-
yl)amino)heptanoic acid hydrochloride salt (10b). Ester 8o (20.0 mg, 0.0393 mmol) was 
heated in aqueous HCl (0.5 M, 1.5 mL) at 70 °C for 3 h. The reaction mixture was then 
concentrated and dried thoroughly in vacuo to provide the pure HCl salt of the acid 10b as a 
glassy, white foam (19.9 mg, 98%). 
1
H NMR (500 MHz, Methanol-d4) δ 8.22 (d, J = 2.1 Hz, 
1H), 8.02 (dd, J = 8.2, 2.1 Hz, 1H), 7.86 – 7.81 (m, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.66 – 7.62 (m, 
1H), 7.57 (dd, J = 8.1, 1.1 Hz, 1H), 7.49 (td, J = 7.7, 1.3 Hz, 1H), 5.95 (s, 1H), 3.24 (s, 3H), 2.96 
(ddd, J = 12.1, 10.4, 5.5 Hz, 1H), 2.82 (ddd, J = 12.2, 10.3, 5.9 Hz, 1H), 2.27 (t, J = 7.3 Hz, 2H), 
1.74 – 1.61 (m, 2H), 1.61 – 1.53 (m, 2H), 1.37 – 1.28 (m, 4H); 
13
C NMR (126 MHz, Methanol-
d4) δ 177.4, 142.5, 141.8, 138.3, 137.0, 134.7, 133.4, 132.2, 129.1, 128.7, 128.6, 127.4, 126.5, 





yl)amino)heptanoic acid hydrochloride salt (10c). Ester 8p (25 mg, 0.045 mmol) was heated 
in aqueous HCl (0.5 M, 1.5 mL) at 70 °C for 3 h. The reaction mixture was then concentrated 
and dried thoroughly in vacuo to provide the pure HCl salt of the acid 10c as a yellowish glass 
(25 mg, 100%). 
1
H NMR (400 MHz, Methanol-d4) δ 8.38 (d, J = 1.4 Hz, 1H), 8.22 (d, J = 6.8 
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Hz, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.71 – 7.60 (m, 2H), 7.57 (d, J = 7.8 Hz, 1H), 7.48 (t, J = 7.2 
Hz, 1H), 5.94 (s, 1H), 3.22 (s, 3H), 3.03 – 2.88 (m, 1H), 2.88 – 2.74 (m, 1H), 2.26 (t, J = 7.2 Hz, 
2H), 1.77 – 1.62 (m, 2H), 1.62 – 1.49 (m, 2H), 1.42 – 1.26 (m, 4H); 
13
C NMR (101 MHz, 
Methanol-d4) δ 177.3, 144.6, 142.6, 141.4, 138.0, 136.9, 134.9, 133.5, 129.1, 128.7, 128.5, 
126.3, 97.9, 67.9, 48.6, 39.8, 34.6, 29.4, 27.1, 26.7, 25.6; LR-MS calcd. for C21H26IN2O4S  [M + 
H]
+
 529.07, found, 529.08. 
 BRET Assays. All BRET functional assays were performed by Madalee Gassaway 
(graduate student, Sames Laboratory) with the aid of our collaborators in the laboratory of 
professor Jonathan Javitch at Columbia University Medical Center, according to the procedures 
previously described in Chapters 3 and 4. 
 Receptor Screening and Ki Determination. Receptor screening and Ki determination 
were generously provided by the National Institute of Mental Health's Psychoactive Drug 
Screening Program, Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is 
Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and 
Project Officer Jamie Driscol at NIMH, Bethesda, MD, USA. For experimental details, please 
refer to the PDSP website http://pdsp.med.unc.edu/. Tianeptine was evaluated in a primary 
radioligand binding screen against a panel of 58 CNS receptors, channels, and transporters. The 
primary screen is used to select ligands that show >50% inhibition of binding of a radiolabeled 
reference compound at a single 10 µM test concentration. This primary screen was followed by 
Ki determination where appropriate (>50% inhibition). In all cases, the reported Ki values are the 
average of 2 or more independent experiments, each run with triplicate wells for each 
concentration. The following targets were included in the primary screening panel: serotonin: 5-
HT1A,B,D,E, 5-HT2A,B,C, 5-HT3,5A,6,7; nicotinic: α2β2, α2β4, α3β2, α3β4, α4β2, α4β4, α7; adrenergic: 
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Alpha-1A,B,D, Alpha-2A,B,C, Beta-1,2,3; cannibinoid: CB1,2; dopamine: D1–5; monoamine 
transporters: DAT, NET, SERT; opioid: DOR, KOR, MOR; histamine: H1-4; muscarinic: M1–5; 
glutamate: NMDAR, AMPAR, mGluR5; GABAA; Ca
2+
 channel; BZP rat brain site; peripheral 
benzodiazepine receptor; sigma-1,2. Activity at additional receptors (mGluR1A,2,4,5,6,8 and 
nociceptin receptor) was also determined by the PDSP in primary functional assays (both agonist 
and antagonist) at 10 µM test concentration. Lastly, activity at adenosine A1 receptor was 
determined in primary functional assays (both agonist and antagonist mode) at 10 µM test 
concentration by GenScript USA Inc (Piscataway, NJ) using the FLIPR
®
 Calcium 4 assay kit 
(#R8141; Molecular Devices; Sunnyvale, CA) in CHO-K1 cells stably expressing the A1 
receptor (#M00324; GenScript). 
 Pharmacokinetic Studies. Pharmacokinetic studies of tianeptine and compound 8h were 
conducted by Sai Life Sciences Limited (Hinjewadi, India). Briefly, a group of 48 male C57BL/6 
mice were divided into two groups (Group 1 and Group 2), with each group comprising 24 mice. 
Animals in Group 1 and Group 2 were administered tianeptine or compound 8h as a solution 
formulation in normal saline intraperitoneally at a dose of 30 mg/kg. Blood samples 
(approximately 60 µL) were collected under light isoflurane anesthesia from the retro orbital 
plexus at 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h. Plasma samples were separated by centrifugation of 
whole blood and stored below -70ºC until bioanalysis. Immediately after collection of blood, 
brain samples were collected from each mouse at 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h. Brain 
samples were homogenized using ice-cold phosphate-buffered saline (pH 7.4) and homogenates 
were stored below -70ºC until analysis. Total homogenate volume was three times the tissue 
weight. All samples were processed for analysis by protein precipitation using acetonitrile and 
analyzed by a fit-for-purpose LC/MS/MS method (LLOQ – 2.02 ng/mL in plasma and 1.01 
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ng/mL in brain). Pharmacokinetic parameters were calculated using the non-compartmental 
analysis tool of Phoenix WinNonlin® (Version 6.3). 
 Behavioral Studies. All behavioral studies were conducted by Dr. Benjamin Samuels 
and Marjorie Levinstein according to established procedures in the laboratory of Professor René 
Hen at Columbia University Medical Center. 
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